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FTDP-17 Frontotemporal dementia and parkinsonism linked to chromosome 
17 
FT-ICR  Fourier transform-ion cyclotron resonance 
FWHM  Full width half maximum 
GluFib  [Glu1]-Fibrinopeptide 
gpmdb  Global proteome machine database 
GS1  QTRAP ion gas 1 
GSK-3  Glycogen synthase kinase 3 
GWAS  Genome-wide association study 
H2O  18 MΩ water 
HPLC  High performance liquid chromatography 
IAA  Iodoacetamide 
ICAT  Isotope-coded affinity tag 
ICPL  Isoptope coded protein label 
ID      Identification 
IDA  Information dependent acquisition 
IDE  Insulin-degrading enzyme 
iSRM  Intelligent selected reaction monitoring 
iTRAQ  Isobaric tags for relative and absolute quantitation 
LC  Liquid chromatography 
LINAC  Linearly accelerating 
LOD         Limit of detection 
LOQ         Limit of quantitation 
LRP-1  Lipoprotein receptor-related protein 1 
m/z             Mass-to-charge ratio 
MALDI      Matrix assisted laser desorption/ ionisation 
MCI       Mild cognitive impairment 
MIDAS  Multiple reaction monitoring initiated detection and sequencing 
MMSE      Mini mental state examination 
Mr             Molecular mass 
MRI  Magnetic resonance imaging 
MS              Mass spectrometry 
MS/MS       Tandem mass spectrometry 
NDC         Non-demented control 
NFT        Neurofibrillary tangle 
NINCDS-ADRDA National Institute of Neurological and Communicative Disorders 
and the Alzheimer’s Disease and related Disorders Association 
NSD  No significant difference 
o/c       On column 
OD            Optical density 
PAGE      Polyacrylmide gel electrophoresis 
PAI      Protein abundance index 
PBS       Phosphate buffered saline 
PBS-T  Phosphate buffered saline-Tween 
PD       Parkinson’s disease 
PET  Positron emmision tomography 
pI  Isoelectric point 
PIB       Pittsburg compund B 
PPG           Polypropylene glycol 
ppm  Parts per million 
PSAQ  Protein standard absolute quantitation 
p-tau      Phospho-tau 
PTM       Post-translational modification 
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PHF        Paired helical filaments 
Q0  Quadrupole 0 
Q1      Quadrupole 1 
Q2        Quadrupole 2 
Q3       Quadrupole 3 
QC          Quality control 
RAGE  Receptor for advanced glycation end-products 
RCD         Rapid cognitive decline 
RF  Radiofrequency 
RP            Reversed-phase 
RT            Room temperature 
S/N  Signal-to-noise ratio 
SAP          Serum amyloid P-component 
SCD         Slow cognitive decline 
SCX          Strong cation exchange 
SD              Standard deviation 
SDS             Sodium dodecyl sulphate 
SELDI  Surface enhanced laser desorption/ionisation 
SISCAPA      Stable isotope standards and capture by anti-peptide antibody 
SNP          Single-nucleotide polymorphisms 
SP            Senile plaque 
SRM         Selected reaction monitoring 
SRP       Single-reference point 
ST      Stubby lens 
TCEP       Tris(2-carboxyethyl) phosphine 
TEAB      Triethylammonium bicarbonate 
TFA          Trifuoroacetic acid  
TMT         Tandem mass tag 
Tof            Time of flight 
tR                     Retention time 
t-tau          Total-tau 
WB  Western blotting 
















Biomarker discovery studies in plasma have revealed several proteins which 
may have clinical utility in the diagnosis and prognosis of Alzheimer’s disease. The 
qualification of these proteins as true biomarkers, sensitive and specific to the disease, 
requires rapid, high quality, quantitative assays. Selected reaction monitoring (SRM) 
has emerged as an accurate and precise method for targeted protein selection through 
signature peptide measurement in highly complex mixtures such as plasma. 
Quantitative SRM-based assays are an attractive alternative to immuno-based 
approaches where costs can be high and requisite antibodies unavailable. 
Furthermore, the highly multiplexed nature of SRM allows the quantitation of multiple 
peptides/proteins in one rapid analysis step. Herein, we combine SRM with isotopic 
versions of tandem mass tags (TMT) to provide an internal reference for quantitation, 
an approach termed TMT-SRM, for the validation of prognostic candidate biomarkers 
of Alzheimer’s disease. 
The panel of proteins included clusterin, complement C3, alpha-2-
macroglobulin, gelsolin, fibrinogen gamma-chain, serum amyloid p-component and 
complement factor H. These proteins were previously found to be differentially 
expressed between plasma of Alzheimer’s disease subjects and non-demented 
controls. Additionally, apolipoprotein E4 was included in the panel as possession of the 
apolipoprotein e4 allele is the only unequivocal genetic risk factor for late-onset 
Alzheimer’s disease and the protein expression of this genetic association may 
translate as an Alzheimer’s disease biomarker.  
For technology validation, TMT-SRM was shown to strongly correlate with 
western blot measurements for one of the proteins, gelsolin, in a sample cohort. 
Furthermore, the performance characteristics were determined for each target analyte 
in the assay. For biomarker validation, a cohort of 90 subjects was selected as having 
Alzheimer’s disease (n = 60) or as non-demented controls (n = 30). To monitor disease 
progression, the Alzheimer’s disease group was sub-divided into two groups (n = 30 
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per group), rapid cognitive decliners and slow cognitive decliners, based on decline in 
Mini Mental State Examiniation score per year.  
Plasma alpha-2-macroglobulin expression was found to significantly increase in 
Alzheimer’s disease and the difference correlated with disease progression. No 
significant differences were observed for the remaining proteins in the panel. Western 
blot analysis was performed on the same cohort for alpha-2-macroglobulin and 
gelsolin. In accordance with the mass spectrometry results, gelsolin showed no 
significant differences between disease and controls groups, providing confidence that 
the mass spectrometry-based assay was reflecting the real expression of the protein in 
the cohort. However, in contrast to the mass spectrometry results, alpha-2-
macroglobulin did not show a significant difference between disease and control 
groups, illustrating the fact that the TMT-SRM approach was able to detect more subtle 
changes in peptide/protein expression than western blot. Results were replicated on an 
analogous mass spectrometer with strong correlation, demonstrating the robustness 
and ease-of-transfer of the TMT-SRM assay. Here, we have demonstrated TMT-SRM 
to be a rapid, precise and selective strategy for the quantitation of candidate 








































1.0 Alzheimer’s disease 
1.0.1 Dementia 
Dementia (from Latin de- "apart, away" + mens "mind") is the progressive 
deterioration in cognitive function as a result of damage or disease to the brain. To 
date, many different types of dementia have been described including dementia with 
Lewy bodies (DLB), vascular dementia, frontotemporal dementia and parkinsonism 
linked to chromosome 17 (FTDP-17) and Alzheimer’s disease (AD; Fratiglioni et al., 
2000). The primary risk factor for most dementia is age. The prevalence of the 
condition rises exponentially from approximately 1% at the age of 60 up to 35% at the 
age of 85 years, making it one of the most widespread medical conditions affecting the 
elderly (Ferri et al., 2005). Current estimates suggest that in 2010, 35.6 million people 
globally are living with dementia and the number of new cases will rise to 
approximately 67.5 million in 2030 and approximately 115.4 million by the year 2050 
(www.alz.co.uk/research/files/WorldAlzheimerReport2010.pdf). In the UK, the number 
of people living with dementia today is estimated to be 700,000, at a cost to the 
economy of £17 billion per year (www.alzheimer’s.org.uk).  
AD is the most severe and debilitating type of dementia, accounting for about 
60% of all cases (Van Marum, 2008). In addition, AD in combination with intracerebral 
vascular disease accounts for a further 13 – 17% of cases (Querfurth and LaFerla, 
2010). The disease is a fatal neurodegenerative disorder characterised by the 
progressive loss of cognitive function. A number of changes occur in the AD brain 
leading to clinical manifestations such as memory impairment, disorientation, attention 
deficits, deterioration in language and drawing function, agitation, aggression, and 
impaired gait and movement (Kirk and Kertesz, 1991; Price et al., 1993; Greene et al., 
1996; Karlawish and Clark, 2003; Salzman et al., 2008). 
Many molecular species have been implicated in AD, but the overriding 
hypothesis is that the aging brain accumulates misfolded proteins resulting in oxidative 
and inflammatory damage, which in turn leads to energy depletion, white matter and 
neuronal loss (Querfurth and LaFerla, 2010). Alois Alzheimer, a Bavarian psychiatrist 
18 
 
first described the clinicopathological symptoms of the disease in 1906. His original 
report based on a patient named Auguste D. characterised several features of the 
disorder which are still recognised as the major hallmarks of AD today, i.e., progressive 
memory loss, hallucinations and delusions (Alzheimer et al., 1995; English translation 
from original paper). Upon autopsy, Alzheimer noted the presence of sticky 
proteinaceous plaques and abnormal tangled filaments in the limbic and associated 
cortices. These structures are what we now refer to as amyloid or senile plaques (SP) 
and neurofibrillary tangles (NFT).   
 
1.0.2 The classic neuropathological hallmarks of Alzheimer’s disease 
1.0.2.1 Amyloid plaques  
Amyloid plaques are composed of insoluble 5 – 10 nm thick amyloid fibrils, 
surrounded by a halo of reactive astrocytes, dystrophic neuritis and activated microglia 
(Selkoe, 2001). The principle protein component of these cerebral plaques is the 
amyloid-beta (Aβ) peptide (Masters et al., 1985). Aβ is derived from the cleavage of 
amyloid precursor protein (APP), a single transmembrane spanning glycoprotein of 
unknown function (Kang et al., 1987). In the amyloidogenic pathway, APP is initially 
cleaved by beta-site APP-cleaving enzyme 1 (BACE-1), a β-secretase, releasing the 
majority of the protein into the extracellular matrix (Figure 1.1; Haass et al., 1992; 
Seubert et al., 1992). The remaining 99 amino acid membrane bound stub (C99) is 
cleaved by γ-secretase generating Aβ which can be 38, 40 or 42 amino acids long 
(Aβ1-38, Aβ1-40, Aβ1-42; Walsh and Selkoe, 2007). Excess accumulation of Aβ is 
speculated to be one of the initiating factors in AD. Conversely, a non-amyloidogenic 
pathway occurs with APP cleavage by γ-secretase and α-secretase (Goedert and 
Spillantini, 2006). APP processing has been linked to an association with lipid rafts. 
APP molecules within rafts are cleaved by β-secretase whereas those outside the raft 
are cleaved by the non-amyloidogenic α-secretase (Figure 1.1; Ehehalt et al., 2003). A 
further study has associated γ-secretase within the lipid rafts of Golgi and endosome 




Figure 1.1 Production of Aβ from APP. The membrane spanning APP can be 
differentially cleaved to produce two distinct pathways. In the amyloidogenic 
(pathological) pathway, APP is cleaved by BACE-1 and γ-secretase to produce Aβ 
monomers. Conversely, cleavage of APP by α-sectretase and γ-sectretase produces 
the non-amyloidogenic p3 peptide. APP cleavage is facilitated by an association with 
lipid rafts. If Aβ cleavage occurs within the cell, e.g., within lysome or endosome 
structures, then that Aβ would be intracellular; if cleavage occurs in the secretory 
pathway or at the plasma membrane, then it would be released into the extracellular 
fluid (LaFerla et al., 2007; Figure extracted from Querfurth and LaFerla, 2010). 
 
Considerable genetic and biochemical evidence gives rise to the ‘amyloid 
hypothesis’, suggesting that an increased production or defective clearance of Aβ 
results in excessive accumulation and aggregation of the protein which may instigate 
the disease course (Citron et al., 1992; Carson and Turner, 2002; Nalivaeva et al., 
2008). Monomeric forms of Aβ1-42 can spontaneously self-aggregate into multiple forms, 
i.e., soluble oligomeric species which define intermediate diffuse plaques or the 
compacted, insoluble fibrillised structures of advanced SP (McDonald et al., 2010). 
Several studies have implicated soluble oligomeric forms as the most potent species of 
Aβ, preceding insoluble amyloid deposits and synaptic dysfunction (Enya et al., 1999; 
Walsh and Selkoe, 2007). Interestingly, the severity of neuronal deficits in AD 
correlates with the levels of oligomeric Aβ in the brain but not overall Aβ load (Lue et 
al., 1999). The proteases plasmin, neprylisin and insulin-degrading enzyme (IDE) can 
regulate the steady-state levels of Aβ by degradation of Aβ monomers and oligomers 
(Ledesma et al., 2000; Wang et al., 2010). Reduction in either one of these enzymes 
can result in defective clearance and Aβ accumulation (Iwata et al., 2001; Farris et al., 
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2003). Conversely, neprylisin and IDE overexpression can prevent amyloid plaque 
formation (Leissring et al., 2003). 
The APP gene occurs on chromosome 21 and over 20 missense mutations 
within the gene have been associated with familial cases of AD (Citron et al., 1992). It 
is well recognised that people with Down’s syndrome or Trisomy 21 (due to an extra 
copy of chromosome 21) display amyloid deposits in brain and cerebral vasculature 
well before mid-life. However, mutations in presenelin-1 and presenelin-2 genes are 
the most common cause of familial AD (Goedert and Spillantini, 2006). The protein 
products of these genes are essential components of the γ-secretase catalytic 
complex, acting as diaspartyl proteases, which enable the γ-secretase cleavage of 
APP (Brouwers et al., 2008). This results in an increase in the ratio of the highly 
amyloidogenic Aβ1-42, as compared to Aβ1-40 (Citron et al., 1996; De Strooper et al., 
1998).  
 
1.0.2.2 Neurofibrillary tangles 
Many areas of the AD brain such as the entorhinal cortex, hippocampus, 
amygdala and cerebral cortices contain intracellular neuronal deposits of a normally 
soluble protein called tau (Kosik et al., 1986). Electron microscopy studies reveal that 
in AD, the tau protein is self-aggregated into a helical arrangement termed ‘paired 
helical filaments’ (PHF), the predecessor of NFT formation (Kidd, 1963; Wiśniewski et 
al., 1976). In addition to AD, filamentous tau deposits have been implicated in several 
other types of dementia termed the ‘tauopathies’. These include progressive 
supranuclear palsy and FTDP-17 (Hutton et al., 1998; Lee et al., 2001).  
Six different isoforms of tau exist in the human central nervous system, each 
identified by the regulated inclusion of inserts near the N-terminus and the number of 
imperfect repeat tubulin binding domains near the C-terminus (Figure 1.2; Mulot et al., 
1994). Three isoforms have three highly conserved binding domains (3R) and the 
remaining three have four binding domains (4R; Goedert et al., 1989). Each isoform is 
a result of alternative splicing in exons 2, 3 and 10 of the tau gene, which is located on 
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chromosome 17 (Goedert, 2004; Hanger et al., 2009). In the normal brain, the 4R:3R 
ratio is equally expressed, however in most of the neurodegenerative tauopathies, this 
ratio is increased (Hanger et al., 2009). 
 
Figure 1.2 Alternative splicing results in different isoforms of tau. The tau gene 
undergoes alternative post-transcriptional splicing of exons 2, 3 and 10, producing 
tubulin binding domains. Tau isoforms have three (3R) or four (4R) binding domains. 
Tau can undergo phosphorylation/ dephosphorylation for microtubule organisation and 
stability, key sites are Thr181 and Thr231 (Figure adapted from Brunden et al., 2009). 
 
The primary function of tau is to interact with tubulin for microtubule assembly 
and stabilisation and phosphorylation is thought to be one of the key regulators of this 
(Weingarten et al., 1975; Hanger et al., 2009). In AD, tau becomes hyper-
phosphorylated, resulting in reduced amounts of microtubule binding and increased 
PHF and NFT formation. More than 39 phosphorylation sites have been identified in 
PHF-tau in AD brain and their respective candidate protein kinases and phosphatases 
have been well researched, including glycogen synthase kinase 3 (GSK-3), cyclin-
dependent kinase 5 (CDK-5), casein kinase 1 and protein phosphatase 1 (Anderton et 
al., 2001; Johnson and Stoothoff, 2004; Liu et al., 2005; Hanger et al., 2007). The 
pathway linking Aβ and tau are not clearly understood and there is ongoing debate on 
which molecule, if either, is the causative agent of AD. Recent efforts on tau biology 
have provided new insights into the association of Aβ accumulation and exacerbation 
of NFT formation and neurodegeneration. Overall, the work suggests that abnormalities 
in tau and its aggregation are central to the clinical progression of AD. Studies have 
shown that intermediate aggregated forms of hyperphosphorylated tau can exert 
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pathological effects and induce neurotoxicity (Maeda et al., 2007). Evidence indicates 
that Aβ accumulation precedes and initiates tau aggregation (Gotz et al., 2001). From a 
genetic perspective, there are mutations in the tau-encoding MAPT gene (Kauwe et al., 
2008), in addition to a major tau phosphatase, protein phosphatase B (Cruchaga et al., 
2010) that do not add risk for AD, but affect its progression. Such effects are only 
observed in those people that already present brain Aβ accumulation. Furthermore, it 
has been observed that Aβ-induced neurodegeneration in culture neurons of mice 
requires the presence of tau (Rapoport et al., 2002; Roberson et al., 2007). DYRK1A 
(dual specificity tyrosine-phosphorylation-regulated kinase 1A) primes tau molecules 
for further phosphorylation by GSK-3 and might also be important in linking Aβ and tau, 
as the kinase is upregulated by Aβ (Liu et al., 2008). Thus, the neurodegeneration 
observed in AD may be a result of the pathological effects of Aβ and tau in concert. 
 
1.0.2.3 Blood-brain barrier compromise in Alzheimer’s disease 
The blood-brain barrier (BBB) provides an interface between the brain and the 
peripheral blood system. The BBB is essentially a series of tight junctions in the 
capillary endothelial cells of the cerebral microvasculature, allowing the diffusion of 
small molecules such as O2 or hormones, while restricting larger species such as 
bacteria (Donahue and Johanson, 2008). A combination of pericytes, astrocytes and 
neurons give rise to the ‘microvasculature unit’, the transport and enzymatic processes 
of which maintain BBB integrity and functioning (Hawkins and Davis, 2005). There is a 
growing body of evidence to suggest BBB compromise in AD, especially in those areas 
proximal to Aβ plaques (Blennow et al., 1990; Hampel et al., 1995; Bowman et al., 
2007; Algotsson and Winblad, 2007). Increased permeability of the BBB can result in 
increased deposition of Aβ in the AD brain and this has been confirmed in transgenic 
mouse models of the disease (Pluta et al., 1996; Ujiie et al., 2003). Indeed, the 
principal source of Aβ burden in AD is not clear, however circulating Aβ may contribute 
to Aβ deposition (Zlokovic, 2004). Transport of Aβ from the periphery into the brain via 
the BBB is facilitated by the low density lipoprotein receptor-related protein (LRP)-1 
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and P-glycoprotein receptors and the receptor for advanced glycation end-products 
(RAGE; Shibata et al., 2000; Cirrito et al., 2005; Deane et al., 2008). Thus, in some 
instances, breakdown of BBB integrity and increased transport of Aβ across the 
structure may result in, or at least aggravate, the pathology of the disease. 
 
1.0.2.4 Other neuropathological changes in the Alzheimer’s disease brain  
Findings suggest that there may be converging pathogenic mechanisms 
between amyloid plaque and cerebrovascular pathology (Farkas and Luiten, 2001; 
Mayeux, 2003). The neurovascular hypothesis proposes that dying blood vessels could 
add to cognitive dysfunction by preventing the delivery of nutrients to neurons and by 
reducing Aβ clearance from the brain (Iadecola, 2004). Other hypotheses proposed to 
explicate the pathogenesis of AD include abnormalities in inflammatory processes, 
failure of proteins regulating the cell cycle, reduction in cholinergic activity, oxidative 
stress and mitochondrial dysfunction with disruption in neuronal energy metabolism 
(Geula and Mesulam, 1995; Aisen, 2002; Webber et al., 2005; Gibson and Huang, 
2005; Reddy and Beal, 2005). While each could contribute to disease pathogenesis, to  
what extent they drive the neurodegenerative process remains uncertain. 
 
1.0.3 Diagnosis and treatment of Alzheimer’s disease 
Currently there are several strategies available for the symptomatic treatment of 
AD including the acetylcholinesterase inhibitors donepezil, rivastigmine and 
galantamine (Steele and Glazier, 1999; Jann, 2000; Scott and Goa, 2000). Such 
species reduce the rate of acetylcholine catabolism, thus increasing the concentration 
of the neurotransmitter in the brain and replenishing the loss caused by the death of 
cholinergic neurons (Stahl, 2000). New drug candidates which may be able to reduce 
or slow the progression of the disease are also being produced, e.g., secretase 
inhibitors, Aβ immunotherapy and tau aggregation inhibitors. These aim to prevent or 
reduce the neuropathology of the disease, i.e., amyloid and tau deposition and the 
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inflammatory response. These molecules are now being tested in clinical trials. There 
are currently 50 compounds in Phase II trials for AD and a further ten in Phase III 
(Appendix Table 1.1; Pogacic and Herrling, 2009; Piau et al., 2011). Such therapeutic 
interventions would have the most beneficial effect at the very early stages of the 
disease, before neurodegeneration associated with SP and NFT deposition becomes 
too prevalent and severe. However, so far the clinical trials have produced somewhat 
negative results. In August of 2010, the γ-secretase inhibitor semagacestat was pulled 
from a Phase III trial of over 3000 subjects by Eli Lilly (Samson, 2010). Preliminary 
analysis showed that the drug not only failed to slow the progression of AD, but actually 
worsened cognition and functional ability. Further, the incidence of skin cancer was 
much higher in the treatment group than the placebo group.  
The lack of availability of therapeutic interventions has highlighted the need for 
an early and precise diagnosis of AD. Diagnosis of AD is difficult and currently only 
possible in life using clinical symptoms to rate a tentative diagnosis, with a definitive 
diagnosis made possible only by post mortem analysis of the brain. AD is a 
progressive, neurodegenerative disease and one of the first clinical presentations of 
AD is a gradual and progressive memory loss (Carlesimo and Oscar-Berman, 1992). 
The subtlety of such memory deficits can result in a failure to diagnose the disease at 
the earliest stages, especially as linguistic, motor and sensory functions are relatively 
well preserved (McCarten, 1997). The correlation between clinical symptoms and 
specific stages in the pathological progression of AD was presented by Braak and 
Braak, where neurofibrillary changes in the AD brain were divided into six distinct 
phases of the disease (Braak and Braak, 1991). The first two stages (I-II) are defined 
by a mild or severe alteration in the transentorhinal region. Stages III and IV are 
marked by severe involvement of the entorhinal and transentorhinal (limbic) regions 
and stages V and VI are defined by severe isocortical destruction. Such progression in 
cortical pathology correlates with the gradual deterioration of clinical symptoms. Full-
blown AD is clinically apparent at approximately stage IV. 
25 
 
In an aim to standardise the clinical diagnosis of AD, a working group was 
established in 1984, namely the National Institute of Neurological and Communicative 
Disorders and Stroke and the AD and Related Disorders Association (NINCDS-
ADRDA; McKhann et al., 1984). The NINCDS-ADRDA guidelines classify the diagnosis 
of AD into three distinct groups, which are, possible AD, probable AD and definite AD. 
Additional guidelines for the clinical diagnosis of AD include the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition (DSM-IV; American Psychiatric 
Association). Such guidelines were published up to 30 years ago and may not reflect 
the vast wealth of scientific understanding about AD gained over that time. Recently, 
both guidelines were revised to compensate for this and capture both the earliest 
stages and full spectrum of the illness (Dubois et al., 2007). For a patient to be 
diagnosed as having AD they must have at least two of the following: the presence of 
an early and significant memory complaint, the presence of medial temporal lobe 
atrophy, an abnormal cerebrospinal fluid (CSF) biomarker pattern, a specific pattern on 
functional neuroimaging with positron emission tomography (PET) or an autosomal 
dominant mutation within the immediate family (Table 1.1).  
 
Core diagnostic criteria               
A Presence of an early and significant episodic memory impairment that includes the following features: 
 
1 Gradual and progressive change in memory function reported by patients or informants for more than six months 
2 Objective evidence of significantly impaired episodic memory on testing 
   
3 
The episodic memory impairment can be isolated or associated with other cognitive changes at onset of, 
or during AD   
Supportive features               
B Presence of medial temporal lobe atrophy 
     
 
Volume loss of hippocampi, entorhinal cortex, amygdala evidenced on MRI with qualitative ratings using visual 
scoring or quantitative volumetry of regions of interest  
  C Abnormal cerebrospinal fluid biomarker 
     
 
Low Aβ1–42 concentrations, increased t-tau concentrations, or increased p-tau concentrations, or combinations 
of the three  
  D Specific pattern on functional neuroimaging with PET 
    
 
Reduced glucose metabolism in bilateral temporal parietal regions 
   
 
Other well validated ligands, including those that foreseeably will emerge such as Pittsburg compound B  
 
  E Proven AD autosomal dominant mutation within the immediate family      
 
Table 1.1 Core diagnostic criteria of Alzheimer’s disease and supportive features as 




Several neuropsychological tests are available which aid in the assessment of 
the patient’s cognitive ability as well as emotional, motor and sensory functions. These 
include the AD Assessment Scale - Cognitive Subscale (ADAS-Cog), the Mini Mental 
State Examination (MMSE) and the Clock Draw Test (Rosen et al., 1984; Cockrell and 
Folstein, 1988; Lee et al., 1996).  
While many papers report a moderately accurate rate of clinical diagnosis (80 - 
90%), it must be considered that such values are a result of expert research institutions 
and based on subjects in the final stages of AD, before confirmation at autopsy 
(Galasko et al., 1994; Blennow and Vanmechelen, 2003). Diagnostic accuracy may be 
significantly lower in hospitals or care centres and at the very early stages of AD, when 
symptoms are less apparent. Patients need to be identified during the predementia 
phase (prodromal AD) before symptoms become obvious (preclinical AD). Preclinical 
AD is defined by AD pathology which is not prevalent enough to adversely affect 
episodic memory (Blennow et al., 2010). Recently, interest has focused on the 
transitional period between normal aging and mild AD. Mild cognitive impairment (MCI) 
describes the clinical feature of memory impairment in individuals who have otherwise 
normal functioning and do not meet the clinical criteria for dementia (Petersen et al., 
1999). There is much debate as to whether MCI is a distinct cognitive aetiology or 
represents incipent AD (Arnaiz and Almkvist, 2003). Studies have shown that MCI 
subjects have a 50% higher risk of developing AD than cognitively normal individuals 
and MCI subjects’ progress to AD at a rate of 10 - 15% per year (Petersen et al., 1999; 
Grundman et al., 2004). MCI patients may display diffuse amyloid pathology and 
frequent NFTs (Petersen et al., 2006). Further, magnetic resonance imaging (MRI) 
scanning has demonstrated a progressive loss of grey matter of the brain from MCI to 
full-blown AD (Whitwell et al., 2007). 
Consequently, the availability of a diagnostic test or molecular marker which 
could support clinical measures would be highly desirable. Such tests may enable an 
earlier diagnosis, evaluate disease risk or prognosis and give a better understanding of 
treatment response. A biomarker can be any characteristic that is objectively measured 
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and evaluated as an indicator of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention (Biomarkers Definitions Working 
Group, 2001). According to the 1998 Consensus Report of the Working Group on 
Molecular and Biochemical Markers of AD, the ideal biomarker for AD should be able 
to detect the underlying AD neuropathology with validation in an autopsy confirmed 
examination, precise (with the ability to distinguish AD from other dementias), non-
invasive, inexpensive, reliable and simple to perform (The Ronald And Nancy Reagen 
Research Institute Of The Alzheimer’s Association And The National Institute On Aging 
Working Group, 1998). Further, a biomarker that accurately echoes the progression of 
AD could be used as a surrogate endpoint to complement clinical measures in clinical 
trials. 
 
1.0.4 Neuroimaging markers of Alzheimer’s disease 
Neuroimaging incorporates an array of techniques used for the structural and 
functional imaging of the brain including MRI, functional MRI (fMRI) and PET. 
Structural scanning produces highly detailed images of the brain whereas functional 
scanning enables the analysis of brain activity. Imaging techniques are useful for 
monitoring cognitive and pathological changes at the very earliest stages of AD, in 
addition to monitoring response to clinical interventions (Burggren and Brookheimer, 
2002). Hippocampal volumetry using MRI is currently the most established structural 
biomarker of AD and can predict conversion to the disease with about 80% accuracy 
(Jack et al., 1999; Wang et al., 2006). Several studies have been published comparing 
the temporal rate of change of hippocampal atrophy in AD, where atrophy rates of 3 - 
6% per year have been demonstrated compared to 0.3 - 2.2% in NDCs (Jack et al., 
2003; Kaye et al., 2005; Barnes et al., 2007; Henneman et al., 2009). The diagnostic 
and prognostic value of MRI in AD has resulted in the inclusion of MRI in several 
clinical trials of candidate disease modifiers (Dubois et al., 2007; Jack et al., 2003; 
Gauthier et al., 2009; Frisoni and Delacourte, 2009). fMRI measures the change in 
blood flow associated with neural activity, generating images which reflect which areas 
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of the brain are activated during performance tasks. Studies have been published 
measuring such changes in MCI versus AD subjects, with the aim of finding a 
biomarker for early AD diagnosis (Rombouts et al., 2005; Celone et al., 2006). fMRI 
studies suggest that changes occur in the functional connectivity of visual processing 
areas in MCI subjects and these precede changes in brain activation between MCI and 
NDCs (Horwitz et al., 2005; Bokde et al., 2006). PET in combination with 
18fluorodeoxyglucose (18FDG) can be used to measure cerebral glucose metabolism 
(Bodke et al., 2005). In mild to moderate stages of AD, a reduction in cortical 
metabolism is observed in the temporal and parietal association cortices and these 
predict conversion to AD from MCI with over 80% accuracy (Modrego, 2006). 18FDG-
PET is regarded as the gold standard for the diagnosis of early AD in vivo. Recently, 
novel radiotracer compounds such as Pittsburg Compound B (PIB) have been used in 
combination with PET (Klunk et al., 2004). The molecule binds to Aβ, enabling the 
imaging of amyloid plaques. Studies demonstrate enhanced uptake of PIB in the AD 
brain (Klunk et al., 2004; Drzezga et al., 2008; Grimmer et al., 2009) and the technique 
has been shown to discriminate AD from other types of dementia (Rabinovici et al., 
2007). Although neuroimaging markers have shown great promise, their full potential 
as biomarkers of AD has yet to be fully described. Currently, they do not fulfill the 
requirements of an ideal biomarker of AD as set out by the Working Group on 
Molecular and Biochemical Markers of AD, i.e., the primary limitations associated with 
such techniques are the cost of implementation and the lack of widespread availability. 
Thus, human biological fluids may provide an alternative source of AD biomarkers due 






1.1 Candidate protein biomarkers for the diagnosis and 
prognosis of Alzheimer’s disease  
1.1.1 Cerebrospinal fluid biomarkers of Alzheimer’s disease 
Numerous types of body tissue and fluids have been screened for AD 
biomarkers, including urine, erythrocytes, lymphocytes and skin (Inestrosa et al., 1994; 
Bermajo et al., 2008). The vast majority of AD biomarker studies to-date have focused 
on CSF, the extracellular fluid found circulating within the ventricles and 
subarachnoidal space of the brain. Here it performs several important functions, such 
as maintaining a constant molecular environment for neurons and allowing the 
transport of metabolites between brain regions and the circulatory system. The BBB is 
a single layer endothelium separating both the brain and CSF compartments, and thus, 
it has been hypothesised that a CSF biomarker of AD should echo the pathological 
process in the brain (Thorsell et al., 2010). Protein biomarkers of AD can be separated 
into basic and core biomarkers. Basic biomarkers identify conditions that mirror or co-
exist with AD and include measurement of BBB status and inflammation of the central 
nervous system (Blennow et al., 2010). Core biomarkers measure the pathological 
hallmarks of the disease. For AD, these include markers that reflect neuronal 
degeneration, amyloid deposition in SP’s and the hyperphosphorylation of tau that is 
associated with NFT pathology. The candidate CSF core biomarkers of Aβ1-42, total tau 
(t-tau) and phosphorylated tau (p-tau) have been extensively assessed in numerous 
biomarker programmes.  
 
1.1.1.1 Cerebrospinal fluid Aβ1-42 as a biomarker of Alzheimer’s disease 
As previously described, Aβ1-42 appears to be essential to the amyloid cascade 
hypothesis of AD, by initiating Aβ aggregation and deposition (Hardy and Selkoe, 
2002). Several antibody-based assays such as the ‘‘Innogenetics’’ and ‘’Athena’’ ELISA 
have been developed for the measurement of Aβ1-42 in CSF. These assays have been 
shown to be highly specific for Aβ1-42, with minimal cross-reactivity with other Aβ 
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species (Ida et al., 1996; Tamaoka et al., 1997; Jensen et al., 2000; Mehta et al., 
2000). In many independent research studies, mean CSF Aβ1-42 levels have 
consistently been shown to be markedly reduced in AD, that is, 30 - 50% less than that 
of control levels (Motter et al., 1995; Galasko et al., 1998; Kanai et al., 1998; 
Andreasen et al., 1999; Andreasen et al., 2001; Sunderland et al., 2003, Craig-Shapiro 
et al., 2009; Tapiola et al., 2009). Conversely, one study found an increase in CSF Aβ1-
42 in AD (Jensen et al., 1999). This was likely due to differences in assay specificity, 
methodology or patient sampling. The sensitivity and specificity of CSF Aβ1-42 for 
discriminating between AD and NDCs in the above studies was approximately 85%. 
Interestingly, a recent study has shown a correlation between CSF Aβ1-42 and amyloid 
plaque load post-mortem while a separate study correlated antemortem CSF Aβ1-42 with 
plaque load at autopsy (Strozyk et al., 2003; Tapiola et al., 2009). Further, Aβ1-42 levels 
have been shown to decrease in individuals with MCI or very mild AD (Mattsson et al., 
2009). In 2004, Klunk and colleagues demonstrated a very strong inverse relationship 
between CSF Aβ1-42 and in vivo cortical amyloid load measured by PET-
11C-PIB (Klunk 
et al., 2004). This has since been replicated using the same techniques in other studies 
(Fagan et al., 2006; Fagan et al., 2007). It has been hypothesised that the reduced 
levels of CSF Aβ1-42 observed in AD are due to the increased aggregation of Aβ1-42 in 
SP’s, resulting in lower levels diffusing into the CSF (Blennow and Nellgård, 2004). 
However, decreased levels of CSF Aβ1-42 are also observed in the amyloid plaque-
negative disorder of Creutzfeldt-Jakob disease (Otto et al., 2000).  
 
1.1.1.2 Cerebrospinal fluid t-tau as a biomarker of Alzheimer’s disease 
The total CSF tau level, independent of phosphorylation, can additionally be 
measured using the Innogenetics and Athena ELISA, which detect all isoforms of the 
protein. A consistent observation of increased CSF t-tau (over 300% compared to 
NDCs) has been found by numerous groups (Mecocci et al., 1998; Andreasen et al., 
1999; Molina et al., 1999; Andreasen et al., 2000; Vanmechelen et al., 2000; 
Sunderland et al., 2003; Mattsson et al., 2009; Visser et al., 2009). Both ELISA’s show 
31 
 
variation in performance, with a higher sensitivity observed for the Innogentics test and 
a higher specificity observed for the Athena test. Elevated levels of CSF t-tau have 
been associated with a more rapid progression from MCI to AD and a faster rate of 
cognitive decline in AD (Blom et al., 2009; Wallin et al., 2009). Elevated levels of CSF t-
tau are not specific to AD however, with similar increases found in vascular dementia 
and frontotemporal dementia (Andreasen et al., 1999; Molina et al., 1999). Further, 
elevated levels of CSF t-tau are occasionally observed in other types of dementia such 
as progressive supranuclear palsy and Parkinson’s disease (PD; Molina et al., 1999; 
Urakami et al., 1999). The observation that increased CSF t-tau, which is primarily 
derived from neurons and axons, is correlated to the level of neuronal degeneration 
leads to the theory that CSF t-tau levels are a marker for axonal damage in the brain 
(Bitsch et al., 2002; Blennow and Vanmechelen, 2003). A significant increase is 
observed in Creutzfeldt-Jakob disease where there is rapid and widespread 
degeneration, a moderate increase is observed in AD where there is moderate 
degeneration and no increase is observed in depression, where degeneration is absent  
 (Blennow et al., 1995; Otto et al., 1997; Andreasen et al., 1999). 
 
1.1.1.3 Cerebrospinal fluid p-tau as a biomarker of Alzheimer’s disease 
Hyperphosphorylation of tau is the preceding event to tau aggregation and 
deposition in the AD brain. Such an event is specific to AD and CSF p-tau levels may 
therefore be used to distinguish AD from other types of dementia (Hampel et al., 2004; 
Koopman et al., 2009). Several ELISA’s have been developed for different 
phosphorylation epitopes on tau, including serine 199 (Ishiguro et al., 1999), threonine 
181 and 231 (p-tau181 and p-tau231; Blennow et al., 1995), threonine 231 and serine 235 
(Ishiguro et al., 1999) and threonine 231 (Kohnken et al., 2000; Buerger et al., 2002; 
Buerger et al., 2002). In all studies to-date, an increased level of CSF p-tau was 
observed with a mean sensitivity of 70% and specificity of 94% for discriminating 
between AD and NDCs (Blennow and Vanmechelen, 2003). Correlations have been 
observed between CSF p-tau181 and p-tau231 measurements performed during life and 
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NFT pathology and rate of hippocampal atrophy at autopsy (Buerger et al., 2006; 
Tapiola et al., 2009). Elevated CSF p-tau has been linked with a more rapid 
progression from MCI to AD and a faster rate of cognitive decline in AD (Blom et al., 
2009; Samgard et al., 2010). 
 
1.1.1.4 Combined analysis of cerebrospinal fluid biomarkers 
Many studies have shown that CSF Aβ1-40 levels are unchanged in AD 
(Fukuyama et al., 2000; Mehta et al., 2000; Fagan et al., 2007). However the ratio of 
Aβ1-42: Aβ1-40 has been shown to be a better distinguisher of AD, MCI and NDCs, than 
either marker alone (Lewczuk et al., 2004; Hansson et al., 2007). Furthermore, the 
combination of all three measures, i.e., Aβ1-42, t-tau and p-tau in various ratios has been 
observed to perform better than either alone (Lewczuk et al., 2008; Welge et al., 2009). 
Although promising, the results of CSF biomarker studies in AD are not conclusive. The 
diagnostic performance of CSF biomarkers in distinguishing AD from other types of 
dementia is less than ideal. Consequently, alternative biofluids are currently being 
investigated. 
 
1.1.2 Plasma biomarkers of Alzheimer’s disease 
Recent focus has moved to the analysis of the blood plasma proteome for 
biomarkers of AD diagnosis and prognosis. The extraction of CSF, that is, a lumbar 
puncture or ‘spinal tap’, is the standard method of obtaining CSF for biochemical 
analysis (Peskind, 2005). The procedure is relatively straightforward and recently the 
use of small caliber and blunt-ended needles has reduced discomfort and incidence of 
post-lumbar puncture headache to 1 - 3% (Blennow et al., 1993; Zetterberg et al., 
2010). Nevertheless, obtaining the large volumes of CSF required for biomarker 
analysis on a repeated basis is challenging. The extraction of blood however is 
relatively non-invasive, simple and quick. Approximately 500 mL of CSF is produced 
per day. As the brain can only hold 135 - 150 mL at any one time, the fluid is drained 
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and ‘turned over’ in the peripheral circulatory system at a rate of about 3.7 times daily. 
Consequently, blood proteins may directly reflect pathologic changes in the AD brain. 
Further still, the disruption of the BBB in AD may increase the exchange of proteins 
between the CSF and blood and vice versa (Zipser et al., 2007).  
The human blood plasma proteome is a highly complex mixture, which 
encompasses many classes of proteins including immunoglobulins, secreted proteins, 
hormones, tissue leakage products and foreign proteins, introduced upon bacterial or 
parasitic infection. Current estimates suggest in excess of 1,000 unique plasma 
proteins exist, spanning over ten orders of magnitude from albumin at ~45 mg/mL 
down to cytokines and interleukins at 1 - 10 pg/mL or lower (Figure 1.3; Anderson and 
Anderson, 2002). Due to this large population of proteins, it has been hypothesised that 
human plasma may provide a rich source of novel biomarkers for human disease. 
 
 
Figure 1.3 Abundance intervals for 70 proteins in plasma. The abundance of plasma 
proteins ranges over 12 orders of magnitude, from high mg/mL to low pg/mL. The 
upper and lower limits of abundance are defined by a blunt end interval line; an 
arrowhead represents an unknown value (taken from Anderson and Anderson, 2002). 









Much time and expense has been invested into biomarker discovery and 
validation programmes in plasma but to-date, there are no established protein markers, 
at least in brain diseases, in routine use in the clinic. The inherent properties of plasma 
itself present immense technical and practical challenges. Many possible candidate 
biomarkers occur at very low concentrations in plasma and are ‘masked’ by several 
highly abundant species, namely albumin, transferrin, haptoglobin, IgA, IgG and alpha-
1 antitrypsin (Anderson and Anderson, 2002). These proteins constitute up to 90% of 
the total plasma proteome with a further 12 proteins accounting for 9%. Thus the 
majority of plasma proteins are found in only 1% of the total plasma proteome. Such 
problems may be overcome by extensive fractionation of the sample to remove the 
principal protein components, but this can prove to be costly, time-consuming and 
introduce a level of technical variability. Further, these species may have several 
proteins complexed to them and their removal may result in loss of valuable proteomic 
information.  
 
1.1.2.1 Plasma biomarkers of Alzheimer’s disease related to Aβ and tau  
The pool of Aβ found in the circulatory system is comprised of Aβ produced by 
peripheral tissues and organs as well as that produced by the brain and transported 
across the BBB (Chen et al., 1995; Zlokovic, 2004). Several factors alter circulating Aβ 
levels including age, AD-related pathology, cerebrovascular disease and liver 
metabolism (Lopez et al., 2008). Soluble plasma Aβ is typically measured by sandwich 
ELISA but with more difficulty than CSF due to lipoprotein binding and (~10 fold) lower 
concentrations (Kawarabayashi and Shoji, 2008). The majority of groups investigating 
plasma Aβ1-40, Aβ1-42 and Aβ1-42: Aβ1-40 levels report no statistically significant 
differences between AD, incident MCI and NDCs   (Scheuner et al., 1996; Tamaoka et 
al., 1996; Vanderstichele et al., 2000; Fukumoto et al., 2003; Blasko et al., 2008; Song 
et al., 2009; Roher et al., 2009; Hansson et al., 2010).   
Several studies have reported that high baseline Aβ1-42 levels in non-demented 
elderly were a risk factor for AD (Mayeux et al., 2003; Pomara et al., 2005; Lopez et al., 
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2008, Schupf et al., 2008). Conversely, lower plasma Aβ1-42 and Aβ1-42: Aβ1-40 levels in 
AD and MCI compared to NDC have been reported (van Oijen et al., 2006; Lewczuk et 
al., 2008). This is in agreement with CSF Aβ1-42 and Aβ1-42: Aβ1-40 studies and validates 
the findings by Graff-Radford and colleagues who showed that a low plasma Aβ1-42: 
Aβ1-40 ratio was associated with conversion to MCI or AD (Graff-Radford et al., 2007). In 
a recent longitudinal study, low plasma levels of Aβ1-40, Aβ1-42 and C-reactive protein 
were associated with rapid cognitive decline (Locascio et al., 2008). In another study, 
subjects who were followed for 2.5 years showed that high Aβ1-42 levels were able to 
predict the conversion of NDC to MCI, but not MCI to AD (Blasko et al., 2008). 
However, several further studies suggest that plasma Aβ1-40 or Aβ1-42 does not correlate 
with the progression of AD (Sundelof et al., 2008; Roher et al., 2009). When taken 
together, there is no definitive conclusion whether plasma Aβ levels directly reflect the 
disease. Conflicting results may be due to several reasons including assay 
methodology, differential antibody affinities and sensitivities for Aβ detection, binding of 
Aβ to several plasma proteins including albumin (Kuo et al., 1999) as well as sample 
collection and handling. However, results of longditudinal studies are promising and 
assays of Aβ1-40, Aβ1-42 or Aβ1-42: Aβ1-40 ratio may have future use in stratifying patients 
at risk of MCI or AD (Thambisetty and Lovestone, 2010). 
The measurement of peripheral tau has been somewhat challenging with little 
or no results on t-tau or p-tau plasma levels in AD. However, recently several novel 
sandwich ELISAs have been developed which allow for tau measurements in serum 
and plasma (e.g., Applied Neurosolutions, Vernon Hills, IL, USA; Schneider et al., 
2009). The AD biomarker community eagerly awaits the initial findings from these 
technologies. In summary, the utility of plasma levels of Aβ and tau is not clear and 
attention has moved to the measurement of alternative proteins in plasma, with the 





1.1.2.2 Proteomic discovery of a panel of biomarkers of Alzheimer’s disease in 
blood plasma 
Numerous proteins have emerged as candidate biomarkers of AD from 
discovery studies in plasma by several independent groups. Table 1.2 outlines the 
principal plasma proteins proposed by these studies. Such candidates cover a broad 
range of functionalities, including transport proteins and proteins involved in immune 
regulation, inflammation, coagulation, proteolysis and apoptosis. It is not yet clear 
whether individual proteins may provide an ideal biomarker for the disease, although a 
combination of multiple biomarkers may increase the sensitivity and specificity of AD 
diagnosis and predictive power of prognosis, than single proteins alone (Mor et al., 
2005). In 2007, an elegant study was released in Nature Medicine, where 18 signalling 
proteins in blood plasma were used to classify blinded samples from AD and NDC 
subjects with up to 90% accuracy (Ray et al., 2007). Further, the same multiplexed 
panel of proteins was able to identify MCI patients who progressed to AD 2 - 6 years 
later. However, only 5 out of the 18 proteins have been since validated and additional 
experiments are required to determine the full potential of these candidates 
(Marksteiner et al., 2009). Further, the study used sandwich ELISA’s to determine 
relative expression differences between AD and NDC groups and this approach has 
several disadvantages, i.e., is largely dependent on high quality antibodies which may 
be subject to non-specific responses and thus, inaccuracies in quantitation.  
From proteomic discovery studies in plasma in our laboratory and others, 
several proteins have been identified which have been shown to be differentially 
regulated in AD and which may serve as an ideal panel of biomarkers of AD diagnosis 
and prognosis. From these, a panel of nine proteins (as highlighted in bold in Table 
1.2) were selected for development of a quantitative assay for validation as they were 
considered the most promising, in terms of quantitative differences from discovery and 
relation to AD biology, in providing robust biomarkers of the disease. Complement 
factor H (CFH), fibrinogen gamma-chain (FGG), complement C3, complement C3a, 


















 (Corder et al.,1994; Thambisetty et al., 2010) 
 
P04114 Apolipoprotein B100  
 
Serum ↑ E (German et al., 2007) 
 
P02647 Apolipoprotein A–I  
 
Plasma ↓ G (Ganguli et al., 2004) 
 
P02656 Apolipoprotein C-III 
 
Plasma ↑ A (Thambisetty et al., 2010) 
 




Serum ↑ H (German et al., 2007) 




Plasma ↓ K (Güntert et al., 2010) 
Copper transport P00450 Ceruloplasmin  
 
Plasma ↓ A (Chen et al., 1995) 
Thyroxine transport P02766 Transthyretin  
 
Serum ↑ D (German et al., 2007) 
Oxygen transport P69905 Hemoglobin alpha chain  Serum ↑ E (German et al., 2007) 
Heme transport/ oxidative stress  P02790 Hemopexin  
 
Plasma ↑ B (Ferri et al., 2005) 
Iron carrier protein/ energy  P02787 Transferrin  
 
Plasma ↑ B (Ferri et al., 2005) 
Immune regulation Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 Plasma ↓ A (Chen et al., 1995) 
 
O43866 CD5 antigen-like  
 






Plasma ↑ A (Chen et al., 1995) 
 
P13501 C-C motif chemokine 5 
 
Plasma NA L (Ray et al., 2007) 
 
P80098 C-C motif chemokine 7 
 
Plasma NA L (Ray et al., 2007) 
 
Q16663 C-C motif chemokine 15 
 
Plasma NA L (Ray et al., 2007) 
 
P55774 C-C motif chemokine 18 
 




















Plasma NA L (Ray et al., 2007) 
 
Q9UBN6 TNF-related apoptosis-inducing ligand receptor-4 Plasma NA L (Ray et al., 2007) 
Inflammation P00738 Haptoglobin alpha 2 chain  Serum ↑ I (German et al., 2007) 
 
Table 1.2 Putative plasma biomarkers of AD. The primary function of each candidate is displayed along with the sample and techniques used 
in the biomarker discovery studies (adapted from Song et al., 2009).   
a Candidate biomarkers included in the panel for development of a multiplexed mass spectrometry-based assay 
b 
Found to be decreased in Corder et al., 1994, but unchanged in Thambisetty et al., 2010
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P02763 Alpha 1-acid glycoprotein  Serum ↓ J (German et al., 2007) 
 
Q14624 
Inter-α-trypsin inhibitor family heavy chain-related 
protein 
Plasma ↓ A (Corder et al.,1994) 
 




Plasma NA L (Ray et al., 2007) 
Complement pathway P0C0L4 Complement  C4  
 
Serum ↑ D (German et al., 2007) 
 
P01024 Complement C3/ C3a 
a
 Serum ↑ D (German et al., 2007) 
 
P07360 Complement C8 
 






Plasma ↑ A (Chen et al., 1995; Hye et al., 2006) 
Proteolysis P01009 Alpha-1-antitrypsin  
 






Plasma ↑ A, D (German et al., 2007; Chen et al., 1995; Hye et al., 2006) 
 
P05155 Serpin G1/C1 inhibitor 
 
Plasma ↓ A (Cutler et al., 2008) 
Blood coagulation P04004 Vitronectin  
 
Serum ↑ F (German et al., 2007) 
 
P17612 cAMP-dependent protein kinase catalytic subunit α  Plasma ↓ A (Corder et al.,1994) 
 
P02671 Fibrinogen α-chain 
 
Plasma ↑ A (Hye et al., 2006; Thambisetty et al., 2010) 
 
P02675 Fibrinogen β-chain 
 










Plasma ↓ A (Thambisetty et al., 2010) 
Cell growth P01133 Epidermal growth factor Plasma NA L (Ray et al., 2007) 
 
P24592 Insulin-like growth factor–binding protein-6 Plasma ↑ L (Ray et al., 2007) 
 
P09603 Macrophage colony-stimulating factor Plasma ↓ L (Ray et al., 2007) 
 
P01127 Platelet-derived growth factor BB Plasma ↓ L (Ray et al., 2007) 
 
P39905 Glial-derived neurotrophic factor Plasma NA L (Ray et al., 2007) 
 
Q99062 Granulocyte-colony stimulating factor Plasma NA L (Ray et al., 2007) 
Cell adhesion P05362 Intercellular adhesion molecule-1 Plasma ↑ L (Ray et al., 2007) 
Apoptosis  P47929 Galectin-7  
 
Plasma ↑ A (Chen et al., 1995) 
DNA/Gene regulation P62807 Histone H2B type 1-C/E/F/G/I  Plasma ↓ A (Chen et al., 1995) 
Unknown functions P15924 Desmoplakin  
 
Plasma ↑ A (Chen et al., 1995) 
  P04196 Histidine-rich glycoprotein  Serum ↑ F (German et al., 2007) 
 
Table 1.2 (continued) 
 
A: 2DE LC/MS/MS   B: Glycan affinity chromatography/ MALDI-TOF    C: 2DE/ DNP-immunostaining/ MALDI-TOF     D: DEAE/ 1DE/ MALDI    E: 1DE/ MALDI    F: Heparin/ 





found to have potential in distinguishing AD patients from NDCs using two-dimensional 
gel electrophoresis (2DE; Chen et al., 1995; Hye et al., 2006; Thambisetty et al., 
2010).Further, 2DE and TMT-labeling technologies found clusterin and gelsolin may 
have utility in predicting the progression of the disease (Thambisetty et al., 2010; 
Güntert et al., 2010). Apolipoprotein E (ApoE) is of interest as the the E4 variant of 
ApoE is the largest genetic risk factor for AD (Corder et al., 1993). The E4 variant may 
influence the ApoE protein level and thus, may serve as a good biomarker of the 
disease. The inclusion of the ApoE protein should thus be considered in any biomarker 
panel of AD. These candidate biomarker proteins now require validation, as their 
differential expression in AD may reflect the underlying pathology and course of the 
disease. Thus, the requirement to assess multiple candidate proteins in a single 
measurement results in the need to develop a multiplexed quantitative assay and 
determine whether the protein panel, or indeed a single protein, is a robust and valid 
diagnostic and/or prognostic biomarker of AD. A mass spectrometry (MS)-based 
approach was chosen for assay development as it offers an attractive alternative to 
ELISAs due to the sensitivity and selectivity of the technique, the capacity to multiplex 
and the ability to measure analytes for which no good quality antibodies are available, 
e.g., gelsolin (Section 1.4). The biochemistry and relation of each protein to AD in the 
assay under development will be discussed in detail in the following sections. 
 
1.1.2.3 Clusterin 
The glycoprotein clusterin, also known as apolipoprotein J, is a versatile 
molecular chaperone, so-called due to its ability to ‘cluster’ Sertoli cells involved in 
spermatogenesis (Fritz et al., 1983; Blaschuk et al., 1983; Hermo et al., 1994). 
Clusterin is expressed in all mammalian tissues (Jones and Jomary, 2002) and has 
been implicated in cellular adhesion and aggregation (Silkensen et al., 1995), 
development (French et al., 1993), complement inhibition (Jenne and Tschopp, 1989) 
and transport of lipids (Jenne et al., 1991). The precursor polypeptide chain is 




several molecular domains including amphipathic and α-helical regions. The secondary 
structure of the protein contains three large disordered regions or ‘molten globule 
domains’ common to small heat shock proteins (Bailey et al., 2001; Ganea, 2001). 
These flexible regions can bind to a wide range of molecular ligands involved in AD, 
including Aβ peptides and fibrils, lipids, and complement components (DeMattos et al., 
2001, Calero et al., 2005; Trougakos and Gonas, 2002). Clusterin was first associated 
with AD by Caleb Finch’s group where an increase in its expression was observed in 
the pyramidal neurons and non-pyrimidal cells of the hippocampus and entorhinal 
cortex of AD subjects, compared to NDCs (May et al., 1990). This has been verified by 
several studies (Kida et al., 1995; Calero et al., 2000). Clusterin is highly abundant in 
the amyloid plaques of the AD brain and was first shown to bind to Aβ peptides by 
Ghiso and colleagues (Ghiso et al., 1993). Several studies have demonstrated the 
ability of clusterin to increase Aβ solubility, stabilisation and prevent Aβ aggregation 
(Oda et al., 1995, Matsubara et al., 1996, Wilson et al., 2008). The highly glycosylated 
and sialylated nature of the protein appears to act as a defence mechanism, masking 
fibrillised Aβ peptides and preventing an excessive inflammatory response (Kirszbaum 
et al., 1992). The protein prevents the activation of the complement system and 
facilitates the clearance of amyloid deposits upon neuronal death (Bell et al., 2007). 
Recently, an SNP within the clusterin gene (CLU) was shown to have genome-wide 
significant association with AD in a study of over 16,000 individuals (Harold et al., 
2009). The finding has since been confirmed independently (Lambert et al., 2009, 
Seshadri et al., 2010; Corneveaux et al., 2010; Carrasquillo et al., 2010).  
 
1.1.2.4 Apolipoprotein E 
Numerous studies have reported the apolipoprotein (APOE) genotype to be a 
major risk factor for early and late-onset AD (Corder et al., 1993; Jones et al., 2010). 
The human gene located on chromosome 19 contains several single-nucleotide 
polymorphisms (SNPs) which lead to the production of three common isoforms of 




one or two amino acids results in a high degree of variability within structure and 
function of each isoform (Mahley et al., 2006). The APOE ε4 allelle shows increased 
risk for AD, while the ε2 allelle is protective, by delaying onset and decreasing the risk 
of the disease (Corder et al., 1993; Strittmatter et al., 1993). Human ApoE, a 229 amino 
acid, 34 kDa apolipoprotein is expressed in many organs, with the highest 
concentrations observed in the liver, followed by the brain (Pitas et al., 1987; Cedazo-
Minguez and Cowburn, 2001; Grehan et al., 2001). The primary source of ApoE in the 
latter is from non-neuronal cell types such as astrocytes and microglia. One of the main 
functions of ApoE in the body is the transport and metabolism of cholesterol and 
triglycerides (Cedazo-Minguez and Cowburn, 2001). Although the exact mechanism by 
which ApoE exhibits such effects in AD remains to be determined, evidence suggests 
this is done via interaction with amyloid. ApoE has been shown to bind to Aβ in SP, 
leading to the hypothesis that the protein plays an important role in Aβ transport, 
aggregation and metabolism in the brain (Wisniewski and Frangione, 1992; Naslund et 
al., 1995). Some isoforms are more efficient than others, with studies suggesting that 
the ineffectiveness of the Apo ε4 variant results in increased susceptibility to AD (Jiang 
et al., 2008). Given the importance of APOE alleles on AD risk, numerous studies have 
investigated the association of CSF and plasma ApoE protein levels in AD. The 
majority of results show no major difference in expression of ApoE in AD as compared 
to NDCs (LeFranc et al., 1996, Mulder et al., 1998). Similarly, no significant difference 
was observed in CSF ApoE levels among subjects with different isoforms of the gene 
(Wahrle et al., 2007). Consistent with clusterin, ApoE has been shown to have an anti-
inflammatory role in the AD brain, preventing the induction of cytokines and 
proinflammatory responses (LaDu et al., 2001; Kim et al., 2009). Clusterin and ApoE 
are expressed at similar levels and are the primary chaperones of Aβ in the brain (Harr 
et al., 1996). Using transgenic mouse models, DeMattos and colleagues have shown 
that the two proteins work together at Aβ clearance and deposition in the brain 
(DeMattos et al., 2004). Removal of either protein results in an increase in amyloid 





A2M is a member of a major group of plasma proteins which include 
complement components C3, C4 and C5 (Sottrup-Jensen, 1989). The protein family 
comprises up to 9% of total plasma protein and act as acute-phase pan proteinase 
inhibitors (Kovacs, 2000). Human A2M is a 720 kDa soluble glycoprotein encoded by a 
single copy gene on chromosome 12. The protein is composed of four identical 
subunits, which form two disulphide-linked dimers (Borth, 1992; Andersen et al., 1995). 
The main function of A2M is the entrapment of proteases for subsequent lysosomal 
degradation (Borth, 1992). Each A2M subunit consists of a bait region, a string of 25 
amino acids which is cleaved by aspartic-, cysteine-, serine- and metallo-proteinases. 
This cleavage event results in conformational change in the A2M-proteinase complex, 
inactivation of the proteinase itself and clearance by macrophages (Borth, 1992). A2M 
is an inhibitor of coagulation and fibrinolysis by inhibition of thrombin and plasmin, 
respectively (Marlar and Kressin, 1987; De Boer et al., 1993). A2M was first associated 
with AD by the work done by Bauer in 1991. Here, an increase in A2M 
immunoreactivity was observed in the amyloid plaques of the hippocampus in the AD 
brain (Bauer et al., 1991; Strauss et al., 1992). The Aβ binding site is located within the 
bait region of each A2M subunit, resulting in a very strong affinity for Aβ peptides (Du et 
al., 1997). The principle receptor for A2M in the brain is LRP, which facilitates Aβ 
internalisation in the brain (Narita et al., 1997). Interestingly, LRP itself has been 
associated with late onset familial AD (Hollenbach et al., 1998). In vitro studies in 
cultured neurons have shown A2M to be both neuroprotective and neurotoxic. The 
neurotoxic effect of aggregated Aβ was prevented upon binding of A2M (Du et al., 
1997, Hughes et al., 1998). Conversely, activated A2M increased Aβ25-35 – mediated 
neurotoxicity in neuroblastoma cells (Fabrizi et al., 1999). The absence of LRP in these 
cell types resulted in an interference of A2M with TGF-β neuroprotection. 
Two common polymorphisms within the A2M gene lead to increased risk of AD 
(Matthijs and Marynen, 1991; Blacker et al., 1998; Saunders et al., 2003). Both 




(Myllykangas et al., 1999). However, several other case-control and family-based 
studies indicate no significant association of the gene polymorphisms with AD 
(Rogaeva et al., 1999; Gibson et al., 2000, Poduslo et al., 2002; Bertram et al., 2004).  
 
1.1.2.6 Gelsolin 
Gelsolin is a primary actin-binding protein that is involved in the capping and 
severing of growing and apoptotic cells (Sun et al., 1999). Two monomeric molecules of 
actin bind to a single molecule of gelsolin in a calcium, tyrosine phosphorylation and 
phosphoinositide-dependant fashion (Chauhan et al., 1999; Silacci et al., 2004). 
Gelsolin, a protein of 82 - 84 kDa with six homologous subdomains (S1 - S6) is found 
both intracellularly in the cytosol and mitochondria and as an extracellular isoform in 
plasma and CSF (Kwiatowski et al., 1988; Koya et al., 2000; Qiao et al., 2005). Both 
isoforms are encoded by a single gene on chromosome 9 and are a result of alternative 
splicing events. The secreted protein differs from the cytoplasmic version by inclusion 
of a 25 amino acid signalling peptide and the presence of disulphide bonds between 
Cys 188 and 201 (Kwiatowski et al., 1988; Wen et al., 1996). The protein is expressed 
in a wide variety of cell types indicating several alternative roles besides actin 
polymerisation. Gelsolin has been observed to modulate calcium channel activity and 
N-methyl D-aspartate receptors (Furukawa et al., 1997) and plays a role in apoptosis 
(Kothakota et al., 1997), haemostasis and inflammation (Witke et al., 1995) and tumour 
suppression (Kuzumaki et al., 1997). 
Accumulating evidence has suggested that gelsolin plays an important role in 
AD. The protein is expressed throughout the central nervous system providing 
neuroprotection (Tanaka and Sobue, 1994; Endres et al., 1999). Both cytoplasmic and 
secretory gelsolin have been shown to bind to Aβ (Chauhan et al., 1999). From WB 
analysis and Congo red staining, gelsolin was observed to inhibit Aβ fibrillisation in vitro 
by up to 90% (Chauhan et al., 1999; Ray et al., 2000). In the same study it was 
observed that gelsolin could defibrillise pre-formed Aβ fibrils in a time-dependent 




two independent studies using APP transgenic mouse models of AD (Matsuoka et al., 
2003; Hirko et al., 2007). Increased expression of gelsolin has also been observed 
during periods of oxidative stress (Ji et al., 2010). Interestingly, a mutation in gelsolin at 
Asp187Asn or Asp187Tyr results in a rare hereditary form of amyloidosis. Such 
mutations result in cleavage of the plasma gelsolin molecule and production of an 
amyloidogenic fragment (Maury et al., 1997). 
 
1.1.2.7 Serum amyloid P-component 
SAP is a highly conserved plasma protein which was first identified as a 
component of amyloid plaques in the laboratory of A. S. Cohen (Cathcart et al., 1967). 
SAP is a 25 kDa plasma glycoprotein produced exclusively in the liver and shares 51% 
sequence homology with C-reactive protein, a classical acute phase response plasma 
protein (Kalaria and Grahovac, 1990; Srinivasan et al., 1994). It consists of five identical 
subunits, each consisting of 204 amino acids. SAP has been shown to bind to 
chromatin, DNA and glycosaminoglycans in a calcium dependent manner (Snow and 
Wight, 1989; Stenstad et al., 1993). SAP is a component of amyloid deposits in vivo, 
including plaques in AD and NFTs (Kalaria et al., 1991; Akiyama et al., 1991; Pepys et 
al., 1996). SAP can reversibly bind to Aβ fibrils in vitro in a highly specific and sensitive 
manner and constitutes up to 15% of dry mass deposits of amyloid in vivo (Pepys et al., 
1979). Although the exact physiological role of SAP remains unclear, it has been 
hypothesised that SAP may prevent degradation of fibrillar Aβ species and thus 
contribute to their persistence in vivo (Tennent et al., 1995). Furthermore, human SAP 
has been shown to interact with neurons and rat brain in vivo, causing apoptosis and 
enhanced production of pro-inflammatory cytokines and Aβ (Veerhuis et al., 2003; 
Urbanyi et al., 2007). In contrast, a study using a transgenic mouse model 
overexpressing APP found no endogenous SAP immunoreactivity in the mouse brain 
(Shi et al., 1999). This was in agreement with a finding of no difference in Aβ deposition 
between wild-type and SAP deficient mice (Togashi et al., 1997). Recently, the 




compound CPHPC (R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxohexanoyl] pyrrolidine-2-
carboxylic acid). CPHPC has been shown to deplete circulating SAP in vivo leading to 
the destabilisation of Aβ fibrils in the CSF and AD brain (Kolstoe et al., 2009). Recently, 
CPHPC has been shown to produce sustained depletion of >95% circulating SAP levels 
in 31 patients presenting systemic amyloidosis, with no significant adverse effects of 
either SAP depletion or CPHPC itself (Gillmore et al., 2010). No accumulation of 
amyloid was evident using SAP scintigraphy in any patient on the drug. 
 
1.1.2.8 Fibrinogen gamma chain 
Human fibrinogen is a large blood glycoprotein which is principally synthesised 
by hepatocytes (Wiesel, 2005). Fibrinogen occurs as a dimer, where each monomer is 
composed of three non-identical chains, Aα, Bβ and γ (FGG). Each peptide is encoded 
on chromosome four and mutations in the gene lead to disorders such as 
thrombophilia, dysfibrinogenemia and hypofibrinogenemia. The main Aα chain is 70 
kDa and the Bβ chain 56 kDa (Herrick et al., 1999). Both the charge and size of FGG is 
heterogeneous but the most abundant species is 48 kDa. The whole fibrinogen 
molecule is held together by 29 disulphide bonds between 58 cysteine residues 
(Herrick et al., 1999; Weisel, 2005).  
Inactive fibrinogen is cleaved by thrombin to form active fibrin, the principle 
component of blood clotting (Doolittle, 1984). Fibrinogen additionally functions as a key 
component of cell proliferation, angiogenesis, immunosuppression and cell migration 
(Herrick et al., 1999). FGG has specific roles in initiation of fibrinolysis, interaction with 
platelets and mediating the interaction of thrombin and fibrin (Mosesson et al., 2003). 
As AD pathology has a strong vascular component, it has been suggested that 
cerebrovascular dysfunction may contribute to the disease. Several groups have shown 
that increased concentrations of fibrinogen may result in an increased risk of AD (Lee 
et al., 2007; Cortes-Canteli and Strickland, 2009; Cortes-Canteli, 2010). Upon reduction 
of fibrinogen levels using either a transgenic model of fibrinogen deficient mice or a 




permeability and neuroinflammation was observed (Suh et al., 1995; Paul et al., 2007). 
Interestingly, the same study showed the opposite effect upon reduction of fibrinogen 
levels by plasmin in AD mice, i.e., an increase in neurovascular damage, inflammation 
and BBB permeability was observed. These studies reveal fibrinogen Aα, Bβ and 
indeed, FGG, may play a significant role in the pathophysiology of AD.   
 
1.1.2.9 Complement C3, C3a and Factor H 
The human complement system is the first line of defence against microbial 
infection. The innate immune system comprises over 40 plasma and membrane-
associated proteins which form three activation pathways: the classical, alternative and 
lectin pathways (Rodriguez de Cordoba et al., 2004, Donoso et al., 2010). Human 
complement C3, the principle opsonic protein in the complement system, facilitates the 
activation of all three pathways (Sahu and Lambris, 2001). The protein is 185 kDa in 
weight, formed by a single disulphide bond and non-covalent forces between two 
peptide chains (termed α and β; Sahu and Lambris, 2001). Upon exposure to 
molecules on the surface of pathogens, each pathway leads to the formation of 
unstable protease complexes, the C3-convertases. These species cleave the α-chain of 
complement C3 to form the anaphylotoxin C3a and the active C3b (Figure 1.4; 
Rodriguez de Cordoba et al., 2004). The C3b molecule in turn is cleaved by Factor I to 
form C3c and C3d, the latter of which binds to the invading microorganism, resulting in 
recognition for phagocytosis by neutrophils, macrophages and dentritic cells (Rodriguez 
de Cordoba et al., 2004). This series of reactions is maintained at a relatively low level 
in blood allowing for targeted activation of complement on the surface of pathogens.  
CFH is a key regulator of the alternative pathway, restricting the complement 
cascade to activating surfaces and preventing damage to host tissues. CFH is a large 
soluble glycoprotein of 155 kDa weight which was first identified by Nilsson and Muller-
Eberhard in 1960 (Muller-Eberhard and Nilsson, 1960). The protein is constitutively 
produced by the liver, but also by a wide variety of peripheral cell types including 





Figure 1.4 Inactivation of C3b by CFH. Upon microbial infection, complement C3 is 
cleaved by C3 convertase to form the anaphylotoxin C3a and C3b. C3b is further 
cleaved by Factor I for recognition of the pathogenic cell surface and activation of the 
complement cascade. The system is regulated by the inactivation of C3b by CFH, 
forming iC3b. The lectin pathway is activated by mannose or N-acetyl glucosamine 
surfaces leading to the formation of a membrane attack complex (MAC) on the cell 
surface leading to microbial destruction. 
 
2000). It consists of a single polypeptide chain, composed of 20 highly conserved 
complement control protein modules of 60 amino acids (Ripoche et al., 1988). CFH 
regulates complement activation by providing both cofactor activity for the factor I-
mediated proteolytic inactivation of C3b and accelerating the decay of the alternative 
pathway C3-convertase, C3b/Bb (Weiler et al., 1976; Pangburn et al., 1977).   
Given the importance that CFH plays in the regulation of complement, specific 
mutations or SNPs within the CFH gene, located on chromosome one, can impair the 
release of CFH into circulation. This results in uncontrolled complement activation 
described by several pathologies (Rodriguez de Cordoba et al., 2004). Such instances 
include age-related macular degeneration (AMD), atypical haemolytic uraemic 
syndrome and glomerulonephritis (Hageman et al, 2005; Atkinson and Goodship, 2007; 




and biochemical features (Johnson et al., 2002; Ding et al., 2008) and an AMD-
associated SNP within the CFH gene (the Y402H polymorphism) has been associated 
with increased risk for AD (Thakkinstian et al., 2006; Zetterberg et al., 2008). However, 
the result is not definitive, as prospective and cross-sectional studies from another 
study suggest that the CFH gene polymorphism is not a genetic determinant for AD (Le 
Fur et al., 2010). However, it has been shown that Aβ is present in drusen, the hallmark 
extracellular deposit in AMD (Dentchev et al., 2003). Recently, it has been shown the 
CFH is present in Aβ plaques in AD (Strohmeyer et al., 2002). Here, the co-localisation 
of Aβ, heparin sulphate proteoglycan (agrin) and activated microglia (containing CFH 
receptors) was observed (Strohmeyer et al., 2002). These findings may be of significant 
interest in understanding the roles of complement C3, C3a and CFH in AD. 
 
1.1.3 Statistical tools for biomarker analysis 
Biomarkers may serve several different purposes. These include the ability to 
provide a reliable disease diagnosis and assessment of disease severity. Additionally, 
biomarkers may be used for the prediction of drug treatment effects, monitoring of 
therapeutic interventions and for for risk stratification, i.e., the identification of those 
patients who may experience positive or negative effects upon exposure to a disease 
intervention. For each of these goals, it is imperative to understand the 
pathophysiological processes associated with the biomarker, including the synthesis 
and degradation of the biomarker, its kinetics and its physiologic effects (Ray et al., 
2010). 
The diagnostic performance of a given biomarker is typically estimated by its 
sensitivity and specificity. Sensitivity measures the proportion of actual positives which 
are correctly identified as such (i.e., a true positive), whereas specificity measures the 
proportion of negatives which are correctly identified (i.e., a true negative). The 
calculation of such indices requires prior knowledge of a subjects “true” disease state 
and a prediction based on the biomarker (i.e., disease is predicted to be present or 




Theoretically, optimal prediction aims to achieve 100% sensitivity and 100% specificity. 
The positive predictive value is the proportion of patientss who test positive for a given 
test who are correctly diagnosed (Altman and Bland, 1994). Its value depends on the 
prevalence of the outcome of interest, which can vary from one population to another. 
Similarly, the negative predictive value is the proportion of subjects who test negative 
for a given test who are correctly diagnosed. A further way of describing the prognostic 
or diagnostic value of a biomarker is by calculating the likelihood ratio. This 
corresponds to the ratio of the likelihood of the observed test result in the diseased 
versus non-diseased populations (Ray et al., 2010). Liklihood ratios are not dependant 
on the prevalence of the disease and are therefore considered as a robust global 
measure of the diagnostic properties of a test. 
 
  Disease   
Biomarker Present Absent Total 
Positive a (true positive) b (false positive) a+b  
Negative c (false negative) d (true negative) c+d 
Total a+c b+d a+b+c+d 
 
Table 1.3 Primary diagnostic parameters used in biomarker analysis. Prevalence = (a 
+ c)/( a+b+c+d); sensitivity = a/(a + c);specificity = d/(b + d); positive predictive value = 
a/(a + b);negative predictive value = d/(c + d); accuracy = (a + d)/( a+b+c+d); positive 
likelihood ratio (LHR+) = sensitivity/(1 -specificity); negative likelihood ratio (LHR-) = (1 
- sensitivity)/specificity. Extracted from Ray et al., 2010. 
 
To determine the accuracy of a given biomarker, a receiver operating 
characteristic (ROC), or ROC curve, is a simple graphical plot of the sensitivity, or true 
positive rate versus the false positive rate (1 − specificity; Figure 1.5) of diagnostic 
performance. The area under the receiver operating characteristic curve (AUC) is the 
most frequently used measure of the ability of a biomarker to distinguish between two 
populations, e.g., case and controls. This is equivalent to the probability that the 
biomarker is higher for a diseased patient than a control and, thus, is a measure of 
discrimination (Ray et al., 2010). Sensitivity cannot be interpreted without specificity and 
thus, when reading from the curve, if sensitivity = 0.50, then specificity = 0.50. Similarly, 




considered as having good discriminatory properties when the AUC is > 0.75 and as 
excellent when the AUC is > 0.90. 
 
Figure 1.5 ROC analysis used to characterise the performance of a biomarker. For 
each candidate AD biomarker, Aβ1-42, tau and p-tau, the sensistivity, specificity and 
AUC is extracted from the plot (Welge et al., 2009). 
 
The ROC curve is used to determine a clinical cut-off point to make a clinical 
discrimination (Fan et al., 2006). The calculation of an appropriate cut-off value is 
usually a trade-off between specificity and sensitivity. As both change with each cut-off 
value, it becomes difficult to determine which cut-off point is ideal. Preferably, the the 
most appropriate cut-off value provides the highest sensitivity and the highest 
specificity. Nonetheless, it is infrequent that this ideal is achieved. Thus, one may opt to 
choose a higher sensitivity at the cost of lower specificity. In an effort to avoid providing 
a single cut-off that dichotomises the population, it has been proposed to provide two 
cut-off points surrounding a “grey zone” (Ray et al., 2010). The first cut-off point is 
chosen to exclude the diagnosis with near-certainty, while the second is chosen to 
include the diagnosis with near-certainty. If a value falls into the grey zone between the 
two cutoffs, uncertainty exists, and a diagnosis should be persued by other means. 
Such an approach is more beneficial from a clinical perspective and is therefore more 




Finally, before undertaking any large scale biomarker study, e.g., such as in 
clinical trials, it is imperative to perform an a priori calculation to determine the 
minimum sample size required so that one can be reasonably likely to detect an effect 
of a given cohort. Factors influencing such power calculations include the statistical 
significance measure used in the test, the sample size used to detect an effect and the 

















































1.2 Mass spectrometry for biomarker discovery and validation 
in blood 
1.2.1 Proteomic analysis by mass spectrometry 
Proteomic techniques, incorporating the separation, identification, and 
quantitation of peptides and proteins, are becoming increasingly popular for biomarker 
discovery and validation. It has become apparent that human disorders such as AD are 
largely characterised by their protein complement. This was first noted upon completion 
of a full sequence for the human genome in 2004, where approximately 20,000 - 
25,000 protein-coding genes were identified (International Human Genome 
Sequencing Consortium, 2004). This compares to the estimated 100,000 protein forms 
in man. Alternative-splicing, protein degradation and post-translational modification 
(PTM) events have been proposed to explain such a discrepancy. The term ‘proteome’ 
was first coined by Marc Wilkins in 1994 when describing the protein map of 
Escherichia coli and has since gained widespread popularity for the description of 
protein populations across dynamic biological matrices, none more so than in human 
blood plasma (Wasinger et al., 1995; Wilkins et al., 1996).  
MS is being ever more applied to the proteomic profiling of plasma. Here, it is 
used for the determination of molecular mass and elemental composition of proteins. 
Further, MS-based proteomics allow for the quantitative comparison of proteins 
expression levels in healthy controls and disease-affected individuals. Mass 
spectrometers measure ions according to their mass-to-charge (m/z) ratio. Peptide 
analysis using modern day instruments is typically divided into four distinct phases; 1) 
molecular ionisation 2) mass analysis 3) peptide fragmentation and 4) ion detection.  
1) Molecular ionisation: The principle of ionisation is the generation of gas-
phase ions which can then be separated according to m/z in the mass analyser. 
Several types of ionisation techniques exist of which matrix-assisted laser desorption 
ionisation (MALDI; Karas and Hillenkamp, 1988) and electrospray ionisation (ESI; Fenn 




proteomic analysis in this thesis, and thus, will be described in detail. ESI was first 
described for the ionisation of small molecules by Malcolm Dole in 1968 and was first 
used for ionisation of biological macromolecules in the kDa range by John Fenn in 
1988 (Dole et al., 1968; Fenn et al., 1989). ESI is referred to as a ‘soft’ ionisation as 
very little energy is retained by the molecule after ionisation. The process involves the 
production of ions in the liquid phase at atmospheric pressure (Figure 1.6). Peptides 
and proteins are initially dissolved in water and volatile organic solvents such as 
methanol or acetonitrile (ACN) containing small volumes of acid (e.g., formic acid; FA) 
for increased conductivity.   
 
Figure 1.6 Formation of ESI. A Sample is introduced into the source from a syringe 
pump or HPLC system. As the sample flows through the electrospray needle, a high 
potential difference is applied, producing a spray of charged droplets, which can be 
either positively (as above) or negatively charged, depending on the nature of the 
analysis. The droplets are driven from the needle towards the source cone, aided by a 
nebuliser gas such as nitrogen. As the droplets travel between the needle tip and the 
cone, solvent evaporation occurs. If the applied field is sufficiently high, the solvent 
becomes unstable producing a fine jet of ions known as the ‘Taylor cone’ (Taylor, 
1964). B Continual solvent evaporation forces droplet shrinkage until a point is reached 
where the surface tension can no longer sustain the charge (the Rayleigh limit).  A 
‘Coulombic explosion’ occurs and the droplet falls apart. The process produces smaller 
charged droplets and charged analyte molecules for entry and separation in a mass 




Prior to ESI or MALDI, analysis of large macromolecules such as peptides and 
proteins was problematic, as molecules with masses beyond 1000 Da could not be 
easily transferred into the gas phase and ionised with high efficiency. The advent of 
ESI, however, enabled a series of small multiply charged peptide ions to be produced, 
opening up entirely new areas of research in biochemistry. A further advancement of 
the technique was described by Wilm and Mann in 1996, namely, nanospray ionisation. 
This permits analytes to be introduced into the source at nanolitre flow rates (20 - 40 
nL/min, compared to µL/min flow rates for ESI), which then become ionised within a 
miniaturised electrospray source (Wilm and Mann, 1996). The ionisation process 
produces droplets less than 200 nm, which are between 100 - 1000 times smaller than 
with conventional electrospray sources. The low flow rates associated with nanospray 
ionisation allow for extended sample analysis, enabling the characterisation of proteins 
down to attomole levels (Onisko et al., 2007). 
2) Mass analysers: The function of a mass analyser is to separate ions 
according to m/z. Several types of mass analyser exist that are suited to biological MS, 
including time-of-flight (Tof), quadrupole, ion trap, Fourier transform ion cyclotron 
resonance (FT-ICR) and Orbitrap (Comisarow and Marshall, 1974; Wollnik, 1993; 
Makarov, 2000; Hu et al., 2005). Mass analysers are defined by their ‘upper mass limit’, 
i.e., the highest m/z that they can measure, their mass accuracy and sensitivity, and 
their ability to resolve two distinct ions with a small mass difference (de Hoffmann and 
Stroobant, 2002). As both Tof and quadrupole mass analysers were used for MS 
analysis in this thesis, both shall be described in detail in subsequent sections.  
3) Peptide fragmentation: Collision-induced dissociation (CID) is the most 
widely used technique for molecular ion fragmentation in MS (Wells and McLuckey, 
2005). Here, gas phase peptide/protein cations in positive ionisation mode are 
accelerated by electrical energy to a higher kinetic energy and collide with neutral gas 
atoms (usually helium or argon). A proportion of this energy is converted into internal 
energy which causes fragmentation of the peptide into smaller ions. Fragmentation 




N-terminus and a y-ion series extending from the C-terminus (Figure 1.7). The 
signature ladder of b- and y-ions is diagnostic of the peptide amino acid sequence 
(Roepstorff and Fohlman, 1984).  
 
Figure 1.7 Fragmentation of peptides A Peptide fragment nomenclature is dependent 
on the backbone bond which is cleaved, whether the fragment contains the N- or C- 
terminus and the position along the peptide chain. For example, the b- and y- 
designations correspond to cleavage at the amide bond. Thus, a-, b- and c-ion types 
contain the N-terminus, whereas the x-, y- and z-ion types contain the C-terminus. The 
subscript number is the residue number relative to the terminus that the fragment 
contains. The remaining letters correspond to cleavage at additional bonds. B An 
MS/MS spectrum of doubly protonated IGGIGTVpVGr peptide, where p and r are 
“heavy” proline and arginine residues, respectively. The spectrum is dominated by the 




4) Ion detection: Following separation of ions according to their m/z, a detector 
is necessary to convert the ion signal into visual representation or mass spectrum. 
Typically, detectors record the charge induced or current produced when an ion hits a 
surface (Figure 1.8). To amplify the signal produced by experimental ions in a Tof 
instrument, a microchannel plate is generally used. For quadrupole instruments, this is 
performed by a conversion dynode and electron multiplier. The amplification of current 
provided by an electron multiplier is typically of the order of 105 to 106 for a singly 









Figure 1.8 Ion detectors A Microchannel plate detectors are typically used in Tof 
instruments. Each plate is a continuous-dynode electron multiplier, in which the 
multiplication of electrons (e-) takes place in the presence of a strong electric field 
(http://en.wikipedia.org/wiki/File:Mcp_schematic.gif). B Electron multipliers are found in 
quadrupole instruments. The multiplier is a vacuum-tube structure that multiplies 
incident charges. (http://en.wikipedia.org/wiki/File:Electron_multiplier.svg). 
 
1.2.1.1 Time of flight and quadrupole mass analysers 
The ToF mass analyser was first conceptualised by W.E. Stephens in 1946, 
and the design for the first commercial instrument was proposed by Wiley and McLaren 
in 1955 (Stephens, 1946; Wiley and McClaren, 1955). Advantages of Tof MS are its 
high sensitivity (all ions are transmitted and detected with high efficiency) and speed of 
analysis (full spectra can be obtained in msec and virtually unlimited mass range). Ions 
are accelerated into the Tof tube from the ion source (or other mass analyser) as a 
pulse (Figure 1.9). All ions of the same charge receive the same kinetic energy and so 
their velocity is inversely proportional to their mass. Ions are separated according to 
m/z in a field free drift zone (Figure 1.9). The time taken for each ion to travel along this 
drift zone to a detector of known distance is recorded. Lighter molecules travel faster 
than heavier ones and arrive at the mass detector first. Ions of the same m/z will reach 
the detector at the same time. Inclusion of a reflectron system corrects for differential 
energy distribution between ions of the same m/z. More energetic ions penetrate 
further into the reflectron system than less energetic ones, resulting in all ions of the 





in parallel, increases the length of time taken to reach the detector, allowing for 
improved separation of ions. 
 
Figure 1.9 Principle of ToF mass analysers. Ions are separated according to m/z and 
acceleration in the flight tube (Figure adapted from www.chm.bris.ac.uk/ms/theory/esi-
ionisation.html).  
 
Quadrupole mass analysers consist of four metal rods which are parallel to 
each other. The rods may be cylindrical, or ideally, hyperbolic. The invention of the 
quadrupole is attributed to Wolfgang Paul who shared the Nobel Prize in Physics in 
1989 for this work (Paul and Steinwedel, 1953). The separation of ions in a quadrupole 
is based on their trajectory stability in oscillating electric fields (de Hoffmann and 
Stroobant, 2002). Opposite rods are electrically paired with a fixed direct current (DC) 
and alternating radiofrequency (RF) applied between them. Ions from the source enter 
the quadrupole and are separated according to m/z based on the ratio of a particular 
set of voltages applied (Figure 1.10). Ions which do not complement a pre-defined 
RF/DC ratio will become unstable and collide with the rods. This enables the selection 
of ions of a particular m/z or a full scan of a specified m/z range by varying the voltages 
applied. The advantages of quadrupole mass analysers are their high sensitivity and 
high scan speeds. However, disadvantages include lower mass resolution, i.e., 4,000 
FWHM compared to 10,000 FWHM on Tof instruments and similarly, a lower m/z range 













Figure 1.10 Layout of a quadrupole mass analyser. The system consists of four 
parallel rods which separate ions according to m/z based on the ratio of a particular set 




Several mass analysers can be arranged in tandem, depending on the type of 
analysis required. Two different MS formats were used in this thesis, a QTof and a 
triple quadrupole. QTof consists of a ToF and quadrupole mass analyser (Figure 1.11 
A). Triple quadrupole mass spectrometers consist of a series of three quadrupoles 
(Figure 1.11 B and C). The first (Q1) and third (Q3) quadrupole can operate as mass 
filters, encompassing a central quadrupole ion guide (Q2) which has separate 
functionality such as a collision cell. The Q3 quadrupole can additionally be used for 
ion trapping and MS/MS (McLuckey et al., 1994).  Ions enter Q1 from the source where 
they can be separated by RF and DC according to m/z. Ions of a particular precursor 
m/z can then be selectively filtered to undergo fragmentation by low-energy CID in the 
RF-only Q2. MS/MS fragment ions are then ejected from Q2 for full scanning or 
fragment ion selection by alternate RF and DC voltages in Q3. 
Triple quadrupole mass spectrometers enable a variety of different scan 
functions (Figure 1.12). ‘Product ion scanning’ selects ions of a particular m/z in Q1 to 
undergo fragmentation in Q2. The full range of precursor fragment ions is then scanned 
in Q3. This experiment is useful for providing peptide sequence information. ‘Precursor 
ion scanning’ scans the full m/z range of precursor ions in Q1 and a particular fragment 








Figure 1.11 Layout of utilised mass spectrometers. A Layout of a QTof micro 
instrument consisting of a quadrupole and Tof tube with a reflectron system for 
improved separation of ions B Layout of a 4000 QTRAP® instrument consisting of a 
linear arrangement of three quadrupoles in tandem (Q1, Q2 and Q3). Ions enter Q0 
from the source and are focused between quadrupoles by a series of stubby lenses 
(ST) for detection at the channel electron multiplier (CEM). C Layout of a TSQ Vantage 
instrument. Three quadrupoles are arranged in tandem, enabling a wide variety of scan 
functions. Ions are focused into the instrument via the S-Lens and through quadupoles 
via a series of lenses (e.g., L11, L12). In both 4000 QTRAP® and TSQ Vantage 








Figure 1.12 Primary scan functions of mass analysers.  Scan functions are shown for 
triple quadrupole mass analysers, however, each can additionally be performed on 
QTof instruments (adapted from Hüttenhain et al., 2009). 
 
In a third scan mode, scanning occurs in the Q1 and Q3 mass analysers, but 
with a constant mass offset between both. Here, the exclusive loss of a molecule of 
sought mass, e.g., 18 mass units for H2O, upon fragmentation of a precursor ion is 
specifically measured in Q3. This type of ‘neutral loss scanning’ has particular utility in 
the measurement of peptide PTMs such as phosphorylation or glycosylation (Hager, 
2003). Another scan mode which is commonly used on a triple quadrupole mass 
spectrometer is selected reaction monitoring (SRM). Here, Q1 of a triple quadrupole 
instrument is set to allow only specific precursor ions of a set m/z through. Selectivity 
for this particular ion is further achieved by setting Q3 to measure specific MS/MS 
fragment ions arising from the precursor being measured in Q1 (Figure 1.12). SRM is 
sensitive, selective, fast and quantitative. An added advantage of SRM is that analyses 










1.2.1.2 Reversed phase-high performance liquid chromatography 
The complex and dynamic nature of the human plasma proteome presents an 
enormous technical challenge. The search for potential biomarkers needs a separation 
technique that would enable the analysis of a large number of samples in a relatively 
short time. High-performance liquid chromatography (HPLC) is a technique which 
allows for the separation and purification of complex mixtures of proteins or peptides 
prior to MS analysis, in a feasible time-scale for biomarker studies (Bączek et al., 
2005). Prior to the 1970's, limited reliable chromatographic techniques were available 
to the laboratory scientist and methods which did exist, e.g., open-column and thin 
layer chromatography, were inadequate for robust quantitation of compounds and 
resolution between similar species. The advent of HPLC revolutionised the analysis of 
peptides by MS, enabling faster and more reproducible separation of complex 
biological matrices such as plasma (Gygi et al., 2002). The improvement of LC column 
packing materials and the additional convenience of on-line detectors further 
revolutionised the approach. Peptide analysis by MS typically uses up-front reversed-
phase (RP) chromatography (Washburn et al., 2001; Davis et al., 2001; Horvatovic et 
al., 2010). RP-HPLC separates peptides according to their hydrophobicity over a 
gradient of increasing solvent, e.g., ACN or methanol. Analytes with greater 
hydrophobic surface area (due to C-H or C-C) have longer retention as the molecule's 
non-polar surface area is non-interacting with water. Polar groups (-OH, -NH2, COO
- or 
-NH3
+) reduce retention as they are readily integrated into water. Resolved peptides are 
eluted from the RP column for entry into the mass spectrometer. RP-HPLC is 
compatible with MS as the chromatographic solvent typically contains acid, which aids 
molecular ionisation. Separations can be performed at nanoflow LC rates (i.e., nL/min) 
for nanospray ionisation sources or microflow LC rates (i.e., µL/min) for ESI. 
HPLC retention time (tR), is a chemical structure dependent parameter, which is 
maintained for a given analyte in particular separation conditions including 
temperature, pH, mobile phase and stationary phase composition (Bączek and 




be helpful to improve the confidence of peptide identifications and to increase the 
number of correct peptide identifications. Such knowledge is particularly useful when 
designing SRM experiments, in order to classify which peptides would provide the most 
robust quantitative information: hydrophilic peptides are poorly retained on the 
stationary phase, while very hydrophobic peptides may have tailing effects, will elute 
late, or may even stick on the LC column. Poor chromatographic performance may also 
add to an increased chemical background (Gallien et al., 2011). Several software 
packages have recently become available to aid in tR prediction for LC-MS/MS 
experiments (Petritis et al., 2003; Bączek et al., 2005; Krohin et al., 2006; Gorshkov et 
al., 2006). In one such example, sequence-specific retention calculator (SSRCalc) was 
developed for tR prediction of tryptic peptide digests during RP-HPLC (Krohkin et al., 
2006). The algorithm was applied using a test library of 2,000 peptides and an array of 
biological samples. Good correlation between predicted and experimental tR were 
found. Furthermore, the software helped in significantly reducing the instrument time 
required for a complete analysis of a digest separated by RP-HPLC. 
 
1.2.2 Global mass spectrometry quantitation strategies  
Global quantitation of peptides and proteins is the preferred strategy for the 
initial screening of patient populations in biomarker discovery. Such techniques 
generate extensive lists of candidate proteins for further evaluation by more targeted 
quantitative methods to determine a candidate biomarker’s full diagnostic and 
prognostic utility. Biomarker quantitation strategies can incorporate both relative and 
absolute quantitative techniques. In relative quantitation, a comparison is made 
between changes in protein/peptide abundance in a given sample relative to another 
reference sample, e.g., an untreated control sample. Such methods require the least 
amount of optimisation. For absolute quantitation, quantitation of unknowns is based on 
a known quantity. Initially, a standard curve is created, from which, the quantity of 




accurate value of the standard for which the unknown is being compared, and usually 
requires extensive method optimisation and validation.  
Traditionally, global strategies have incorporated 2DE technology for the 
relative comparison of protein abundance across case and control groups. However, 
2DE is limited due to its low dynamic range, high costs and low throughput. More 
recently, improvements in MS-based methods for the profiling and quantitation of 
complex biological mixtures have resulted in these approaches garnering more 
widespread popularity where biomarker discovery is being pursued. MS-based 
approaches for biomarker discovery encompass LC-MS and LC-MS/MS in conjuction 
with label-free or peptide/protein labeling approaches. Each technology will be 
discussed in the following sections. 
 
1.2.2.1 Two dimensional gel electrophoresis 
2DE allows for the separation of complex mixtures of proteins such as plasma 
based on differences in isoelectric point (pI), in the first dimension, and by molecular 
weight (Mr) in the second dimension. Separated proteins can then be visualised by 
binding to a Commassie or Silver stain (Sasse and Gallagher, 2004). Protein spot 
densities between two samples, e.g., control and disease samples are compared to 
provide relative differences between the two populations. When combined with MS, 
peptide components of a gel spot can be identified. 2DE was first described in 1975 by 
independent studies on E. coli (O’Farrell, 1975) and mouse tissue (Klose and 
Spielmann, 1975). The method was rapidly applied to the separation of plasma, where 
approximately 300 proteins were successfully separated and visualised (Anderson and 
Anderson, 1977). Following this, the same group produced a more comprehensive 
database of plasma proteins, where 727 spots were fully resolved by 2DE, of which 
376 were identified as 49 different proteins (Anderson and Anderson, 1991).  
Since its inception, 2DE has proved popular in biomarker discovery studies in a 
range of biofluids and tissues with a plethora of publications released. 2DE studies in 




cancer and Downs syndrome (Myrick et al., 1990; Cochran et al., 2003; Ahmed et al., 
2004; Davidsson and Sjögren, 2005; Hye et al., 2006; Korolainen et al., 2006; Maarouf 
et al., 2009; Roher et al., 2009). However, 2DE technology is limited to a low dynamic 
range of quantitation and the inability to separate and quantitate highly acidic, basic or 
hydrophobic proteins (Davidsson and Sjögren, 2005). Further, a large number of repeat 
analyses are required to minimise between-gel variances. This can be both costly and 
time-consuming. Differential gel electrophoresis (DIGE) is an extension of 2DE, which 
has addressed some of the problems associated with the technology. Here, the relative 
quantitation across protein populations is provided by differential fluorescence labeling 
(Unlü et al., 1997; Gharbi et al., 2002). DIGE has been used to detect protein 
expression changes in the CSF of neurological disorders such as dementia as well as 
cancer biomarker discovery studies (Maurya et al., 2007; Kondo and Hirohashi, 2009; 
Tumani et al., 2010).  
 
1.2.2.2 LC-MS and LC-MS/MS-based biomarker profiling strategies 
1.2.2.2.1 Label-free  
Label-free quantitation methods are increasingly becoming more popular in 
biomarker discovery studies due to their clean, fast and less complex quantitation 
results (Old et al., 2005; Patel et al., 2009). Quantitation is generally performed by two 
different strategies: relative quantitation by alignment of RP-HPLC traces and 
comparison of peak intensities of MS ions or spectral counting of ions upon MS/MS 
analysis (Washburn et al., 2001; Bondarenko et al., 2002). The general hypothesis for 
peptide quantitation based on LC chromatograms and retention time is that during LC-
MS/MS analysis, an ion of a particular m/z will be detected at a particular intensity and 
at a particular time. Label-free approaches have been used for biomarker discovery 
studies in sera and CSF of schizophrenia patients (Levin et al., 2007; Huang et al., 
2007), Gaucher patients (Vissers et al., 2007) and cancer (Xue et al., 2010; Lengqvist 
et al., 2009). Absolute quantitation between E. coli peptide populations has been 




MSE (Expression) mode (Silva et al., 2005; Levin et al., 2007). Here, the quadrupole 
mass analyser is set to transfer all ions as the collision cell switches from low to high 
collision energy intermittently during the course of the acquisition time. One of the main 
difficulties in label-free quantitation based on the alignment of LC chromatograms is the 
normalisation of the data to allow for the direct comparison of LC-MS/MS runs. There is 
a strict requirement for reproducible sample preparation and upfront fractionation as 
well as high resolution and highly reproducibility in online chromatography (Old et al., 
2005). Further, ion suppression may affect target analytes. This is a result of the 
presence of less volatile compounds that may change the efficiency of droplet 
formation or evaporation, which can alter the amount of charged ion in the gas phase 
that ultimately reaches the detector (Annesley, 2003). Such phenomena could perhaps 
have been compensated for by the inclusion of isotopically-labeled reference peptides.  
There has been a large increase in the number of bioinformatics tools available 
to aid in the comparative analysis of label-free quantitation (Fischer et al., 2006; Finney 
et al., 2008; Haqqani et al., 2008). Indeed, these also have utility in the analysis of 
stable isotope labeled experiments. Over 20 software packages are currently available 
which typically include processing parameters for data normalisation, LC-MS alignment 
for peak detection and matching and statistical packages for quantitation (America and 
Cordewener, 2008; Vandenbogaert et al., 2008). Perhaps the most popular of these 
include the accurate mass tag (AMT) approach and DeCyderTM MS from GE 
Healthcare. AMT was developed in 2000 in response to metabolic labeling studies 
using FT-ICR MS (Conrads et al., 2000). AMT later evolved to allow for label-free 
quantitation on the Micromass Q-Tof (Strittmatter et al., 2003). DeCyderTM MS 
transforms LC-MS/MS data into a virtual 2D gel format, where retention time is 
displayed on the x-axis, m/z on the y-axis and relative abundance on the z-axis. It 
consists of a PepDetect module for peptide detection and a PepMatch module for LC-
MS matching (Johansson et al., 2006). Quantitation is performed by comparing peak 
volumes of equivalent ‘spots’. Experimental ratios of peptides between samples can 




In the spectral counting approach, quantitation is based on the number of 
MS/MS scans per peptide (Washburn et al., 2001). Proteins of higher abundance 
should produce a greater number of proteolytic peptides, which is reflected in an 
increase in protein sequence coverage, an increase in the number of unique MS/MS 
scan events and an increase in the total number of identified peptides. The concept 
has been extended to quantitation of absolute protein levels. The protein abundance 
index (PAI) was devised by Matthias Mann’s group where the total number of all 
possible tryptic peptides of a protein is divided by the number of experimentally 
observed peptides within the m/z range of a given instrument (Rappsilber et al., 2002). 
This was subsequently advanced into an exponentially modified form, emPAI (equal to 
10PAI minus one) for absolute quantitation, which is proportional to protein abundance 
in a mixture (Ishihama et al., 2005). This successfully allowed for the absolute 
quantitation of 46 proteins in a mouse whole cell lysate.  
 
1.2.2.2.2 Peptide labeling using differential isotopic coding 
Peptide and protein quantitation by differential isotopic labeling is perhaps the 
most widespread and frequently used method in current biomarker discovery studies 
(Figure 1.13). Here, peptides are differentially coded by tagging with light or heavy 
versions of stable isotopic reagents, mixed and subsequently analysed together in the 
mass spectrometer. The relative comparison of the mass spectral signals of the 
isotopically-differentiated peptides determines up- or down-regulation of a species, 
when a known amount of internal standard is included. The concept of isotope dilution 
was first introduced in the 1970’s to measure blood calcium and has since been 
applied to quantitate a large range of biological analytes including cholesterol and 
glucose (Moore et al., 1972; Cohen et al., 1980; White et al., 1982). First, a known 
amount of an isotope, e.g., 13C or 15N is added to the sample, altering its isotopic 
composition. Then, by measuring each isotope, the amount of 13C or 15N in the original 




can decrease the error of injection from 5% to 1%. In MS, the isotopic ratio can be 
calculated with precision typically better than 0.25%.  
 
 
Figure 1.13 Overview of coding strategies currently employed to exploit various 
reactive centres in peptides. All reactions shown to occur on the amino terminus also 
apply to the ε-amino group of lysine residues.  
 
Chemical labeling allows for the in vitro labeling of virtually any protein sample. 
The conditions of the labeling reaction and the amount of the label added to a protein 
sample can be strictly controlled. A novel tool for the identification and quantitation of 
cysteine-containing peptides in complex biological mixtures was introduced in 2004 by 
Wisniewski and colleagues (Olsen et al., 2004). The HysTag reagent is a decapeptide 
of the sequence H6ARAC. Activation with 2,2-dipyridiyl disulphide enables the HysTag 
reagent to become reactive toward cysteine side chains. Each tag contains a trypsin 
cleavage site and isoforms of alanine (d0 or d4) for differential coding. The amino-
terminal histidine residues allows for selective isolation of tagged peptides by metal-
affinity or cation-exchange chromatography (Julka and Regnier, 2005). Differentially 
coded proteins are mixed and digested with Lys-C, preserving the tryptic cleavage site 
present in the HysTag reagent. Subsequent digestion of tagged peptides with trypsin 
releases the H6AR portion of the tag from the peptide that is covalently bound via the 
disulphide bridge with the isotope-labeled dipeptide AC. Proof of principle experiments 
were used to identify and quantify plasma membrane proteins from a mouse brain 




quantifiable. The light and heavy HysTag-labeled peptide pairs were shown to co-elute 
by HPLC. However, a large number of non-differentially coded histidine residues will 
also be captured by the system, leading to possible errors in interpreting differential 
regulation between two states. Similar cysteinyl selection strategies that have been 
released include the quanternary amine tag reagent, quantitative cysteinyl enrichment 
technology and fluorinated affinity tags (Ren et al., 2004; Liu et al., 2004 and Brittain et 
al., 2005). 
 Isotope Coded Affinity Tags (ICAT) were first introduced with the pioneering 
work of Gygi and Aebersold in 1999 (Gygi et al., 1999). Here, reduced cysteine 
residues are specifically derivatised with a tag containing either zero or eight deuterium 
atoms, resulting in a mass difference of 8 Da between the two versions. ICAT labeling 
and mixing of samples is performed prior to digestion, minimising the variance which 
may be introduced due to differential digestion of individual samples. The inclusion of a 
biotin group in the tag facilitates the purification of cysteine-labeled tryptic peptides on 
avidin or streptavidin columns. Following elution from the column and LC-MS analysis, 
the relative abundance between light and heavy-labeled peptides can be compared. 
cICAT was produced subsequent to the first generation tag which incorporated nine 13C 
atoms and a biotin moiety, cleavable upon acid treatment (Hansen et al., 2003). 
Removal of the biotin group improved CID spectra, resulting in a larger number of 
protein identifications. Further, cICAT overcame the problems of oxidation and double 
labeling associated with the original tag (Zhang et al., 2002). Further, the new 
generation tags avoided the problems associated with LC retention shifts between 
heavy and light deuterium-containing tags. ICAT technology has been widely used for 
biomarker discovery studies in liver and breast tumour cells in cancer and for candidate 
discovery in serum and plasma (Somiari et al., 2005; Kang et al., 2010; Kang et al., 
2010). Further, the approach has been applied to the analysis of quantitative 
differences between CSF proteins in AD and NDC where APP and cathepsin D were 
proposed as candidate biomarkers of the disease (Zhang et al., 2005). Limitations of 




making the quantitation of peptides without the amino acid, including many with PTMs, 
impossible (Vaughn et al., 2006). Due to the availability of only light and heavy versions 
of ICAT, only two samples or conditions can be compared at any one time. Accurate 
quantitation requires LC-MS analysis for quantitation, with subsequent LC-MS/MS 
analysis for identification. Additionally, protein identifications are usually based on only 
one or two peptides, making quantitation less reliable. 
Isotope-coded protein labels (ICPL) isotopically label the free amino groups of 
proteins (Schmidt et al., 2005). The technique is derived from the work done by James 
and co-workers in 2000, where the N-terminus of a protein is labeled with either H4 of 
D4 versions of nicotinyl-N-hydroxysuccinimide (Munchbach et al., 2000). ICPL regents 
introduce a mass difference of 6 Da between labeled and unlabeled peptides. A 4-plex 
version of the reagent, the Serva ICPL 4plex Kit, was introduced in 2008 (Elliott et al., 
2009). Recently, ICPL allowed for the quantitation of 211 serum proteins in 
combination with LC-MS/MS analysis (Turtoi et al., 2010). Quantitative changes for 
eight of the proteins were validated by SRM. In an effort to increase the number of 
peptides quantitated using the technology, a modified strategy was recently described 
where ICPL reagents are added post-digestion (Fleron et al., 2010; Leroy et al., 2010).  
 
1.2.2.2.3 Peptide labeling using isobaric chemical tags 
Isobaric chemical tags are chemical molecules with identical structures which 
label the free amino group of lysine residues and N-termini of peptides and proteins 
(Thompson et al., 2003; Ross et al., 2004). Labeling is performed post-digestion, 
therefore, theoretically all the peptides in a given sample have the potential to be 
labeled. This results in multiple peptide measurements per protein, which increases the 
confidence of the protein identification and quantitative measurement as compared to 
isotopic labeling approaches. Another benefit of isobaric labeling is the ability to 
multiplex, allowing for several comparisons within a single experiment, i.e., up to eight 
for Isobaric tags for relative and absolute quantitation (iTRAQ) and up to six for tandem 




‘’peptide reactive group’’ for peptide and protein binding; a mass normalisation group 
and a reporter group (Figure 1.14). Introduction of different numbers of ‘’heavy’’ 
isotopes of 13C or 15N in the reporter and mass normalisation groups produced the 
different versions of the tags.  
 
Figure 1.14 Structure of an isobaric chemical tag. Upon fragmentation in MS/MS 
mode, identification and quantitation is obtained from fragmentation of the peptide 
backbone, giving rise to mass reporter ions of m/z 113 - 121 for 8plex iTRAQ and m/z 
126 - 131 for 6plex TMT (Thompson et al., 2003; Pierce et al., 2007; Ye et al., 2010). 
 
For TMT, there are currently three different types of products available, 
TMTzero, TMTduplex and TMTsixplex (Figure 1.15). TMTzero (TMT0-126; 126 refers to 
the m/z of the mass reporter group) consists of the core TMT structure. Due to the lack 
of heavy isotopes, this tag enables peptide labeling during optimisation of sample 
preparation strategies, without the need for the more costly isotope labeled versions of 
the tag. TMTduplex (TMT2-126 and TMT2-127) allows for the relative comparison 
between two samples, which is beneficial in smaller scale experiments. TMTsixplex, as 
the name suggests, has the full set of six tags (TMT6-126 - TMT6 -131). 
For comparative analyses in biomarker discovery, peptide populations are 
differentially labeled and mixed. During MS analysis, samples are indistinguishable 
from each other due to the isobaric nature of the tag. Upon peptide fragmentation by 
CID both identification and relative quantitation of a peptide is achieved with release of 
the reporter group, giving rise to a unique singly-charged ion signature. Peptide 
quantitation is performed by comparing the reporter ion signal intensities between 





Figure 1.15 Structures of TMT labeling reagents. Three different types of TMT 
products are available, allowing for between two and six comparisons in a single 
experiment A TMTzero B TMTduplex C TMTsixplex. 
 
 
peptides. A known amount of a synthetic peptide can be labeled and spiked into 
biological samples for internal standardisation and absolute quantitation. This holds 
particular promise for quantitative biomarker discovery studies. A large number (over 
1,500, as of August 2011) of unique articles using the isobaric peptide tagging concept 
for biomarker discovery have appeared in the literature.  
Isobaric labels have been used for a number of different applications in 
prokaryote and eukaryote samples including bacteria, yeast and human cells and 
biofluids such as serum, plasma, saliva and urine. iTRAQ has been applied to 
biomarker discovery explorations for several human conditions such as cancer, pre-
eclampsia and Down’s syndrome (DeSouza et al., 2005; Chen et al., 2010; Glen et al., 
2010; Auer et al., 2010; Kolla et al., 2010). Interestingly, iTRAQ has been utilised in the 
search for biomarkers of AD and neurodegeneration. In one study, the expression of 
136, 72 and 101 proteins was found to be significantly changing in the CSF of AD, PD 
and DLB, respectively, compared to NDCs (Abdi et al., 2006). Further, iTRAQ has 
revealed proteomic changes in the hippocampal, cortical and vesicular structures of 
triple transgenic AD mice (Martin et al., 2008; Rhein et al., 2009). iTRAQ has also been 










































intravenous immunoglobulin treatment of AD (Abdi et al., 2006; Ogata et al., 2007; 
Choe et al., 2007).  
One of the first studies using TMT sixplex looked at the differential expression 
of CSF proteins using a model of brain injury from post mortem CSF compared to 
healthy ante mortem CSF (Dayon et al., 2008). A total of 78 identified proteins were 
found to be significantly increased in the post mortem CSF using a differential TMT-
labeling strategy. Confirmation of the quantitative TMT approach was confirmed for 
three of the proteins by ELISA. Very recently, TMTsixplex has been used in an AD 
biomarker discovery study (n = 45) in plasma (Güntert et al., 2010). Here, plasma 
gelsolin was found to be decreased and correlated with the rate of cognitive decline in 
AD. Findings were confirmed by WB analysis. TMTsixplex has been also used in a 
biomarker discovery study for staging human African trypanosomiasis (Tiberti et al., 
2010). Here, 73 proteins were found to be overexpressed in the CSF of patients 
presenting the second stage of the disease. Beta-2-microglobulin and osteopontin were 
confirmed as candidate biomarkers for the disease upon validation by WB and ELISA. 
Van Ulsen and colleagues utilised TMTduplex tags to quantitate proteins in cell 
cultures of Neisseria meningitidis which were induced under iron-limiting conditions 
(van Ulsen et al., 2009). TMT enabled the identification and quantitation of 35 proteins 
which were differentially expressed in response to iron limitation. These proteins 
represented both well-known and novel iron-regulated proteins. 
In an effort to improve the quantitative coverage provided by iTRAQ and TMT, a 
novel quantitation concept based on isobaric peptide termini labeling (IPTL) was 
recently presented (Koehler et al., 2009). The approach is based on the crosswise 
chemical labeling of both peptide termini with complementary isotopically-labeled tags. 
This results in every N- and C-terminal fragment ion providing quantitative data for 
each peptide over the course of the MS/MS spectrum upon forming peak pairs during 
fragmentation. Thus, numerous quantitation points in each spectrum will likely increase 
the robustness and quality of the quantitative data. Additionally, the IPTL approach can 




distributed throughout over the entire mass range (Koehler et al., 2011). Further, no 
chromatographic shift is observed between differentially-labeled peptides as both 
contain the same number of deuterium atoms. The IPTL strategy was used to compare 
the proteome of HeLa cells incubated with S-trityl-L-cysteine to induce mitotic arrest 
and apoptosis (Koehler et al., 2011). Over 50 proteins were found to have differential 
quantitation, with the majority previously reported in other proteome analyses of 
apoptotic cells. 
 
1.2.3 Targeted MS quantitation strategies used in biomarker validation 
To determine which candidates from the large numbers of proteins arising from 
discovery have the most potential as sensitive and specific biomarkers of a disease 
state, assays using targeted approaches to protein and peptide quantitation need to be 
employed. SRM in combination with stable isotope dilution is generally recognised by 
chemists as the ‘gold standard’ for the development of MS-based quantitative methods. 
SRM is not a new technique and has been used for over thirty years to characterise 
small molecules including drugs and pesticides in human biofluids such as plasma and 
urine (Baty and Robinson, 1977; Ohya and Sano, 1977; Ervik et al., 1981; Sutherland 
et al., 2001; Koal et al., 2005; Debayle et al., 2008; Yao et al., 2008; Estrela et al., 
2008; Kennedy et al., 2010; Kay and Creaser, 2010). In terms of biomarker validation, 
the highly multiplexed nature of the technique allows for the simultaneous quantitation 
of many signature peptides of candidate biomarker proteins in the time-scale required 
for high throughput analyses. 
In SRM mode on triple quadrupole mass spectrometers, a precursor ion of 
interest is selected in Q1, fragmented in Q2 and fragmentation products of the 
precursor selected in Q3 (Figure 1.16). Here, sensitivity is enhanced as the analysis 
time is dedicated only to the measurement of the ions of interest. The selection of 
suitable SRM precursor-to-product ion transitions is crucial for the approach, but 
predicting the best candidates can be challenging and slow. To alleviate this problem, 







Figure 1.16 Overview of MS-based approaches utilising SRM for biomarker evaluation. 
Two phases of mass selection in SRM produces a selective response for target 
analytes. Advantages of SRM include its speed and high sensitivity. Incorporation of 
heavy-labeled peptides of known amount enables comparison to, and absolute 
quantitation of, experimental peptides. 
 
largely driven by data from public proteomics libraries, including PeptideAtlas and the 
Global Proteome Machine database (gpmdb; Cham et al., 2010). Such tools include 
both public and proprietary software offerings. Commercial packages include Pinpoint, 
and P3 predictor (Thermo Scientific); MRMPilot software and multiple reaction 
monitoring initiated detection and sequencing (MIDAS) Workflow Designer (AB Sciex) 
and VerifyE (Waters). Feely available software packages include PeptideAtlas, MRMer, 
MRMaid MRM Worksheet, Skyline and MaRiMba (Deutsch et al., 2008; Martin et al., 
2008; Mead et al., 2009; Walsh et al., 2009; Prakash et al., 2009; Sherwood et al., 
2009).  
The sensitivity and selectivity of the SRM approach has the capacity to detect 
and quantitate peptides in complex mixtures of wide dynamic range such as plasma 
without prior fractionation (Stahl-Zeng et al., 2007). In SRM, signature peptides unique 
to the protein of interest are measured to provide quantitative information for that 
protein in the sample. Additionally, more accurate quantitation can be achieved, both 
relative quantitation and moving towards absolute quantitation, when isotopically-
labeled versions of the peptide of interest are spiked into the sample at known 
concentrations. This can be achieved in several ways and will be reviewed in the next 
section. 
 
1.2.3.1 AQUA peptides for absolute peptide quantitation 
The concept of isotope dilution to provide a reference point for MS-based 
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deuterium-labeled hydrolysed peptide, unique to the protein apolipoprotein A-1, was 
used for internal standardisation and quantitation of the purified protein by LC-MS (Barr 
et al., 1996). In 2003, Gerber and colleagues introduced the acronym AQUA (Absolute 
QUAntitation) for the determination of protein expression and PTM levels (Gerber et al., 
2003). The AQUA strategy uses synthetic internal standard peptides which can be 
introduced into experimental samples at known amounts during or after proteolysis, 
providing absolute quantitation of target analytes (Kirkpatrick et al., 2005). Stable 
isotopically-labeled (e.g., 2H, 13C, 15N) amino acids are incorporated into the AQUA 
peptide for the mass discrimination (typically by SRM) of endogenous sample peptides 
and synthetic internal standards, which perfectly co-elute by LC-SRM (Figure 1.11). 
Since their inception, AQUA peptides have garnered widespread popularity due to their 
ease of use, rapid incorporation into experimental samples and their commercial 
availability. AQUA peptides can be engineered to suit experimental needs. However, 
problematic chemical synthesis (particularly for those containing PTMs) determine the 
availability of peptides; peptides should be less than 15 amino acids long and ideally be 
absent of any chemically modifiable residues such as cysteine or methionine (Brun et 
al., 2009). Production of AQUA peptides is costly as each peptide undergoes individual 
synthesis, purification and usually, determination of accurate amount. Further, the 
heavy-labeled amino acid adds significant expense. As a result of such financial 
implications, several studies have been published where target proteins have been 
quantitated using just a single AQUA peptide (Cheng et al., 2006; Bondar et al., 2007). 
It is also worth noting that solubilisation and shelf-life properties of AQUA peptides are 
very much sequence-dependent and if not considered, can severely affect the 
quantitative measurement (Brun et al., 2007; Mirzaei et al. 2008).  
 
1.2.3.2 Peptide concatamers 
In 2005, Beynon and Gaskell introduced the concept of QConCAT, that is, 
absolute quantitation based on an artificial concatamer of tryptic peptides, proteotypic 




coli and stable-isotope labeled upon growth in the presence of isotope-labeled 
precursors. QConCAT proteins are subsequently purified, quantitated by amino acid 
analysis (AAA) and spiked into complex mixtures such as plasma at known amounts 
(Pratt et al., 2006). Thus, QConCAT is a biological means of producing AQUA 
standards. Once the QConCAT gene has been initially cloned, the protein product can 
be synthesised repeatedly, without limit. Commercially available QConCAT, or those 
synthesised in-house, are typically added before sample digestion and are released 
upon enzymatic cleavage to provide internal standards for quantitation. In parallel with 
AQUA peptides, it is necessary to assess the completeness of tryptic digestion for each 
target protein for accurate quantitation (Rivers et al., 2007). Further, it is essential to 
determine the proof of equimolar release of the selected peptides (Arsene et al., 2008). 
QConCAT constructs are digested at high rates and this may be proteolytic efficiency 
may be highly variable compared to the native target peptides. In response to this, it 
has been proposed to surround QConCAT peptides with their respective native 
sequences (Kito et al., 2007). The technique is somewhat cheaper than producing 
AQUA peptides synthetically as up to 50 peptides may be included in a single 
construct, providing multiplexed quantitative measurements (Rivers et al., 2007). This 
strategy has been used to quantitate medium to high abundant plasma proteins over 
three orders of magnitude (Anderson and Hunter, 2006).  
 
1.2.3.3 Synthetic protein standards for absolute quantitation  
In an effort to minimise the variation in the quantitative measurement due to 
sample fractionation and digestion procedures, new strategies for peptide quantitation, 
namely Absolute Stabled Isoptope-Labeled Internal Stardards (SILAC; Hanke et al., 
2008) and Protein Standard Absolute Quantitation’ (PSAQ; Brun et al., 2007), have 
been recently described. In such approaches, full length proteins are isotopically-
labeled and introduced into the sample at the very start of the analytical procedure 
(Dupuis et al., 2008). This has advantages, as both the target peptide and internal 




strategy has been shown to be compatible with almost any method of sample 
prefractionation, including SDS-PAGE and immunoaffinity capture (Brun et al., 2007; 
Dupuis et al., 2008). For accurate peptide quantitation, highly purified proteins are 
required and AAA is essential. Other limitations include high costs and difficulty in 
production of the standards.  
 
1.2.3.4 Isotopic peptide labels in combination with SRM 
As described in Section 1.2.2.3.3, the application of isobaric labeling strategies 
such as iTRAQ and TMT have been successful where biomarker discovery in being 
pursued in complex mixtures such as CSF and plasma (DeSouza et al., 2005; Dayon 
et al., 2008; Güntert et al., 2010; Chen et al., 2010). Extending the tags utility for 
biomarker validation purposes, isotopic versions of iTRAQ labels, termed mTRAQ, 
have been introduced. Such tags enable the quantitation of signature peptides of 
candidate biomarker proteins based on iTRAQ in combination with SRM (DeSouza et 
al., 2008; DeSouza et al., 2009). Two versions of mTRAQ labels exist, i.e., light and 
heavy tags which are chemically identical apart from the number of heavy isotopes (13C 
or 15N) in the heavy label (which is identical to the iTRAQ 117 label); the light mTRAQ 
label contains no heavy isotopes. A mass difference of 4 Da per tag is introduced 
between differentially labeled peptides, allowing for the discrimination between species 
in SRM mode. Absolute quantitation can be achieved by referencing a target tryptic 
peptide labeled with for example, the light label, against a known amount of synthetic 
peptide labeled with the heavy label.  
The mTRAQ strategy was initially employed to measure the levels of a 
candidate endometrial cancer biomarker pyruvate kinase for iTRAQ-labeling discovery 
studies in tissue biopsied EmCa homogenates of 20 malignant tissues and non-
malignant controls (DeSouza et al., 2005; DeSouza et al., 2007; DeSouza et al., 2008). 
Here, differential labeling with mTRAQ in combination with SRM, allowed for the 
absolute quantitation and detection of a 4-fold increase in the protein (based on 




(DeSouza et al., 2008). This was independently confirmed by ELISA. Further, the 4-fold 
increase was higher than the 2-fold increase for the discovery study, suggesting a 
compression of the dynamic range in the non-targeted iTRAQ labeling technique. Such 
compression effects have been demonstrated by others, who proposed that ratio 
compression arises from contamination during precursor ion selection, which occurs at 
a consistent proportion within an experiment and thus results in a linear relationship 
between expected and observed ratios (Karp et al., 2010; Ow et al., 2011). 
Very recently, DeSouza and colleagues employed mTRAQ-SRM for the relative 
quantitation of pyruvate kinase and polymeric Ig receptor from endometrial epithelial 
cells in formalin-fixed paraffin-embedded tissues of cases and controls (DeSouza et al., 
2010). In a further advancement of the approach, mTRAQ labels have been used in 
parallel with ICAT for the relative quantitation of colon cancer tissues and plasma 
samples (Kang et al., 2010).  
Similarly, ICPL reagents have been used in combination with SRM (Lange et 
al., 2008). Here, the reliable quantitation of low abundance virulence factors from 
cultures of the human pathogen Streptococcus pyogenes exposed to increasing 
amounts of plasma was performed. Experiemntal samples were labeled with ICPL 
‘light’, and to provide an internal standard, a pool of all samples was labeled with ICPL 
‘heavy’. This enabled the successful identification and quantitation of a subset of 
virulence proteins that is regulated upon exposure to plasma. 
In a similar fashion to mTRAQ, the combination of TMT and SRM may have 
applicability in the quantitation of candidate protein biomarkers of disease states. By 
employing an isotopic labeling scheme, i.e., TMTzero and TMTsixplex versions of TMT, 
a mass difference can be introduced between two species. As the labels differ only by 
their isotopic constitution, differentially TMT-labeled peptides should co-elute during LC 
separation and can be discriminated in SRM mode. This novel approach, termed TMT-
SRM, has potential for the targeted quantitation and validation of signature peptides of 
candidate biomarkers of AD (and other disorders) in complex biological matrices such 




1.3 Biomarker assay development and implementation 
Biomarkers have enormous potential in clinical practice. Biologically-based 
diagnostic and prognostic tests may enable an earlier disease diagnosis, resulting in 
earlier treatments and the possibility to perhaps cure rather than to merely delay further 
injury or death (Carr and Anderson, 2008). Additionally, biomarkers could possibly be 
used for more accurate staging of a disease, identifying those individuals who are likely 
to respond to therapeutic interventions and assisting in the selection of appropriate 
treatments. Biomarkers may also be used for patient stratification and to serve as 
surrogate endpoints in early-phase drug trials, resulting in more targeted drug 
development and generation of more effective treatments.  
A typical biomarker development pipeline as outlined in Figure 1.17 
incorporates several distinct phases; 1) biomarker discovery in low (in the tens) sample 
numbers uses untargeted, semi-quantitative protein profiling approaches such as 2DE 
and isobaric mass tagging to establish protein signatures which are differentially 
expressed between case and control subjects; 2) assay development requires the 
generation and validation of assays for biomarker measurement using more targeted 
means of quantitation such as ELISA or SRM in combination with stable isotope 
dilution; 3) The developed and validated assay is performed for the verification of the 
differential abundance of candidate biomarkers in larger numbers (in the hundreds) of 
samples than that used in discovery. Here, the large panels of candidate biomarkers 
from discovery are refined to include only those candidates which have the most 
potential as providing sensitive and specific biomarkers of a disease state; 4) full 
biomarker validation and qualification, necessitating the evidentiary process of linking a 
biomarker with a clinical endpoint, requiring clinical trials and large population 
screening in thousands of samples (Thambisetty and Lovestone, 2010). The complete 
process can take many years without any guarantee of success. Consequently, there 
remains no qualified biomarker of AD meeting the United States Food and Drug 
Administration (FDA) approval and this may be due in part to poor selection of assay 





Figure 1.17 Overview of the biomarker development pipeline. The workflow consists of 
initial discovery of a panel of candidate biomarkers in low sample numbers followed by 
their verification and qualification in much larger sample cohorts for determination of 
the most sensitive and specific biomarkers of a respective disease state. 
 
In October 2003, a Biomarker Method Validation Workshop was held in an 
effort to standardise the process of ‘fit-for-purpose’ biomarker assay development and 
validation (Lee et al., 2006). A well validated quantitative assay includes full 
characterisation of the reagents and reference materials (plasma and internal 
standards in this case) in terms of matrix effects and the establishment of assay 
sensitivity, i.e., the limit of detection (LOD) for each target analyte, the determination of 
the linear and dynamic range of quantitation, i.e., definition of lower and upper limits of   
quantitation (LOQ), and the accuracy (trueness and precision) of the quantitative 
measurement. Table 1.4 provides a list of definitions commonly used in biomarker 
assay studies. Many different types of quantitative assays exist for biomarkers but to-
date; the majority is based on antibody-based means of detection and quantitation.  
 
1.3.1 Antibody-based assays 
A clinical assay must be sensitive enough to measure target analytes of interest 
and all candidates must be quantitated with high reproducibility, accuracy and in a high 
throughput manner over a large number of patient samples. Despite the ever 
increasing surge in MS-based quantitation of peptides and proteins, antibody-based 
methods remain the ‘gold standard’ for the quantitation of proteins in tissues and 






Closeness of agreement between a quantity value obtained by measurement and the true 
value of the measurand. Accuracy incorporates both trueness and precision. 
Background 
interference 
(1) Analytical interference: presence of entities in samples that causes a difference in the 
measured concentration from the true value. (2) Physicochemical interference (matrix 
interference): a change in measured physical chemical property of the specimen that 
causes a difference between the population mean and an accepted reference value. 
Clinical endpoint A characteristic or variable that reflects how a patient feels, functions, or survives. 
Dynamic range 
The range of the assay that is demonstrated from the pre-study validation experiments to 
be reliable for quantifying the analyte levels with acceptable levels of bias, precision, and 
total error. This can also be referred to as the linear range. 
Limit of detection 
(LOD) 
A concentration resulting in a signal that is significantly different (higher or lower) from that 
of background. LOD is commonly calculated from mean signal at background + 3 SD. This 
is often described as the analytical sensitivity of the assay in a diagnostic kit. 
Limit of quantitation 
(LOQ) 
The lowest concentration of analyte that have been demonstrated to be measurable with 
acceptable levels of bias, precision, and total error. LOQ is commonly calculated from 
mean signal at background + 10 SD.  
Qualification 
This refers to whether the candidate biomarker qualifies for use in a given context. Does it 
meet the standards required to be used in clinical trials as an indicator of drug response? 
Does it have sufficient positive and negative predictive power to act as a diagnostic tool? 
Might it qualify as a surrogate marker? 
Precision 
The closeness of agreement between independent test results obtained under stipulated 
conditions 
Selectivity 
The ability of a method to determine the analyte unequivocally in the presence of 
components that may be expected to be present in the sample. 
Specificity 
The ability of an assay to distinguish between the target analyte, to which the assay is 
intended to detect, and other components. 
Surrogate endpoint 
A biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is 
expected to predict clinical benefit or harm (or lack of benefit or harm) based on 
epidemiologic, therapeutic, pathophysiologic, or other scientific evidence. 
Trueness 
The closeness of agreement between the average value obtained from a large series of 
test results and an accepted reference values 
Verification 
Verification of candidate biomarkers relies upon specific, quantitative assays optimised for 
selective detection of target proteins. The process involves the refinement of the long list 
of candidates from discovery, leaving only the most promising candidates for full 
validation. Thus, it is a critical step in the discovery pipeline that bridges unbiased 
biomarker discovery to preclinical validation. 
 
Assay Validation 
It is the confirmation via extensive laboratory investigations that the performance 
characteristics of an assay are suitable and reliable for its intended analytical use. It 
describes in mathematical and quantifiable terms the performance characteristics of an 
assay. 
Table 1.4 List of definitions for commonly used terms in biomarker assay development 




immunoassay was described in the late 1950’s, immuno-based measurement of 
protein concentrations in clinical samples has revolutionised the face of medicine 
(Yalow and Berson, 1960). The biochemical nature on the test relies on the high 
specificity between an antibody and antigen. A wide range of antibody-based assays 
are currently available for the examination of the human proteome including WB, 




arrays combined with immunohistochemistry (Kartalov et al., 2008; Brennan et al., 
2010). 
ELISA assays are currently the most prominent technology for the validation of 
differential protein expression changes in biofluids, particularly blood plasma. The 
method was initially described by two groups in Sweden and The Netherlands in 1971 
(Engvall and Perlmann, 1971; Van Weemen and Schuurs, 1971). In ELISA, a sample 
containing an unknown amount of antigen of interest is immobilised on a surface, 
usually a well of a microtitre plate, via adsorption to the surface or by capture by a 
primary antibody specific to the antigen (in the case of sandwich ELISA). A detection 
antibody is subsequently added which may be covalently linked to an enzyme (e.g., 
horseradish peroxidise) to produce a detectable signal, e.g., fluorescence. The 
magnitude of signal produced is relative to the amount of antigen in the sample (Figure 
1.18). ELISA assays have been described for the quantitation of proteins in a wide 
variety of diseases such as Aβ and tau in CSF and plasma of AD subjects (as 
described in Sections 1.2.1 and 1.2.2), HIV testing (Hermez et al., 2010), rabies (Moore 
and Hanlon, 2010), tuberculosis (Lalvani, 2007; Lalvani and Pareek, 2010) and cancer 
(Brennan et al., 2010). The technique offers higher sensitivity than MS-based 
approaches for target analyte detection as demonstrated by the accurate quantitation 
of a very low abundant protein in plasma, interleukin-6, by ELISA down to 
concentrations as low as 15 pg/mL (Rifai et al., 2006). Multiplexed assays based on 
traditional methods of ELISA have recently been described for the high throughput 
measurement of several target antigens in parallel, over a wide dynamic range 
(Morgan et al., 2004; Leng et al., 2008). Luminex xMAP technology from Innogenetics 
has been recently described for the multiplexed, immuno-based quantitation of proteins 
(Earley et al., 2002). Luminex uses tiny, colour-coded beads which can be coated with 
a reagent specific to a particular assay, allowing the capture and detection of target 
analytes from a biological sample. Very recently, the technology has been applied to 





Figure 1.18 Overview of sandwich-ELISAs. (1) The ELISA plate is coated with a 
capture antibody. (2) The sample is added and any antigen present binds to the 
capture antibody. (3) The detection antibody is added and binds to the antigen. (4) The 
enzyme-linked secondary antibody is added and binds to the detecting antibody. (5) 
The substrate is added and is converted by enzyme to a detectable form. Figure 
extracted from http://en.wikipedia.org/wiki/File:ELISA-sandwich.svg. 
 
approach enables the multiplexed measurement of up to 100 proteins, although in 
practice, a decline in assay performance as a result of an increase in overall protein 
concentration means that Luminex xMAP assays rarely complex more than 30 proteins 
at any one time (Lovestone and Thambiestty, 2010). Such techniques are very much in 
their infancy and their success and full potential for protein biomarker quantitation in 
other complex matrices such as human serum and plasma are yet to be determined. 
Thus, immuno-based assays in plasma currently remain limited as only one antigen 
can be accurately detected at any one time. It has been demonstrated that there may 
be genetic variability in epitope structure across populations, resulting in variability in 
assay specificity from person to person (Silva et al., 2001). It is extremely challenging 
to develop antibodies which are specific to particular protein isoforms or PTMs. In 
addition, quantitation can be subject to interference from other species within the 
matrix, reducing assay specificity. The cost associated with immuno-assay 
development is generally very high, with usually a very long lead time. Further, and the 
most important drawback of all, is that their success is exclusively dependant on the 
availability of high quality antibodies for antigen detection. Failure to produce suitable 






1.3.2 Mass spectrometry-based assays 
In response to the limitations associated with immuno-based assays for 
biomarker verification and validation, the scientific community has recently shifted 
attention to the development of MS-based assays such as those using SRM, as they 
may provide cheaper, quicker and more robust alternatives. Besides therapeutic 
monitoring of drug immunosuppressants or neonatal screening for inherited metabolic 
disorders, one of the most established SRM-based assays is that for the quantitation of 
25-hydroxyvitamin D3 in serum (Vogeser, 2010). The molecule is accepted as the most 
useful biological marker for assessment of vitamin D status. Due to the unreliability of 
protein binding assays, several methods have been developed for the quantitation of 
the analyte and have since gained widespread and routine implementation in clinical 
and commercial laboratories (Higashi et al., 2001; Vogeser et al., 2004; Tsugawa et al., 
2005; Singh et al., 2006). Differential mass tagging in LC-MS/MS measurement of the 
target analyte and its different forms allows for robust multiplexed quantitation, with 
sufficient throughput for biomarker verification and validation. 
Desiderio and colleagues were the first group to apply similar techniques for the 
quantitation of peptides in complex biological matrices such as CSF and brain extracts 
(Desiderio and Kai, 1983; Desiderio, 1983; Desiderio et al., 1984). More recently, the 
technique has been further advanced to the quantitation of plasma peptides with high 
analytical sensitivity, specificity and accuracy (Anderson and Hunter, 2006; Keshisihian 
et al., 2007; Hüttenhain et al., 2009; Yocum et al., 2010). To-date, numerous studies 
have been published using MS-based assays to quantitate both individual, and panels 
of plasma proteins (Barnidge et al., 2004; Kuhn et al., 2004; Nicol et al., 2008; Kuzyk et 
al., 2009; Whiteaker et al., 2010). 
Proof-of-principal experiments of the application of the SRM approach to the 
targeted quantitation of plasma peptides were published by Anderson and Hunter 
(2006), where SRM experiments were performed on 53 medium to high abundant 
proteins in plasma. Of these, 47 produced acceptable quantitative data, demonstrating 




CVs <10%. Depletion of six high abundance proteins by immuno-subtraction 
significantly improved CVs compared with whole plasma, but analytes could be 
detected and quantitated in both sample types. The analysis of direct plasma digests is 
of a significant advantage as it enables for measurement of a higher throughput of 
samples, while reducing the potential for sample loss that may be introduced during 
sample pre-processing. In this context, an SRM assay in combination with stable 
isotope standards permitted the absolute quantitation of 45 endogenous proteins (31 of 
which are putative candidate biomarkers of cardiovascular disease) in human plasma 
trypsin digests without prior depletion or affinity enrichment (Kuzyk et al., 2009). Due to 
likelihood of plasma background interference and matrix effects however, the LOD, 
LOQ and specificity of an SRM assay may be severely compromised by the complexity 
and large dynamic range of direct plasma digests. Thus several strategies have been 
proposed to reduce overall sample complexity and decrease the aforementioned assay 
parameters including depletion of high abundance plasma proteins, enrichment of 
target analytes or sample prefractionation. The upfront enrichment of target proteins 
before SRM has been demonstrated for the quantitation of plasma peptides in the low 
µg/mL range (Nicol et al., 2008; Berna and Ackerman, 2009). Immuno-extraction of 
proteins by antibodies immobilised on a hydrazide resin, followed by SRM with stable 
isotope-labeled dilution has been used for the quantitation of candidate biomarkers of 
lung cancer in diseased and normal serum (Nicol et al., 2008). Enrichment strategies 
have been proposed to isolate and enhance the detection of sub-proteomes in plasma 
including the selective isolation of N-glycosite peptides and quantitation via SRM 
(Stahl-Zeng et al., 2007). Precise quantitation (CVs ~15%) was accomplished using 
stable isotope dilution by AQUA peptides. Multiplexed SRM assays have been 
developed to quantitate plasma proteins down to the 1 - 10 ng/mL range with CVs of 3 
- 15% without immunoaffinity enrichment of either proteins or peptides, although pre-
fractionation was performed in this case (Keshishian et al., 2007). 
Stable Isotope Standards and Capture by Anti-Peptide Antibody (SISCAPA) 




AQUA peptides are immuno-enriched prior to LC-MS/MS analysis (Anderson et al., 
2004). This has utility for the quantitation of low abundance proteins in plasma and may 
enable for evaluation of an extended population of candidate biomarkers of disease. 
Although the technique is dependent on high antibody affinity, selectivity requirments 
can be relaxed as the mass spectrometer platform is capable of specifically detecting 
and quantitating the signature peptides, even in the presence of a highly complex 
background (Carr and Anderson, 2008). In the initial experiments, rabbit polyclonal 
antibodies were raised against tryptic peptides of hemopexin, α1 antichymotrypsin, 
interleukin-6 and tumour necrosis factor-α. Antibodies were immobilised on POROS 
supports which were fully recyclable. Using SRM MS, a 120-fold enrichment of the 
target peptides was observed. As the internal standard was added prior to 
immunoaffinity step, quantitative variability due to this step was reduced and a 
relatively low CV was observed, i.e., approximately 5% (Anderson et al., 2004). 
Antibodies are very specific, and due to the enrichment process, SISCAPA is well 
suited to the quantitation of low abundant species in complex proteomes like plasma, 
without the need for other sample fractionation. This was demonstrated by Steve Carr’s 
group, where SISCAPA in combination with SRM was used for the enrichment and 
quantitation of the cardiovascular biomarkers troponin I and interleukin-33, typically 
present in plasma in the low ng/mL range (Kuhn et al., 2009). Quantitation was linear in 
the range of 1.2 ng/mL to 5 µg/mL, with CVs <15%. SISCAPA assays have been used 
for the quantitation of a range of target analytes, where up to three peptides per protein 
have been enriched in parallel (Berna et al., 2006; Whiteaker et al., 2007; Hoofnagle et 
al., 2008). Indeed, SISCAPA coupled to SRM has also been demonstrated for the 
enrichment and subsequent quantitation of specific peptide glycoform in human serum 
(Ahn et al., 2009). 
In 2009, Anderson and co-workers further improved the method by introducing 
a simple magnetic bead protocol which formed part of a nanoflow LC-MS/MS system 
(Anderson et al., 2009). The work used antibodies which were conjugated to small 




peptides inside the nanoflow capillary and reducing peptide losses. Peptides of α1-
antitrypsin and lipopolysaccharide-binding protein were enriched up to 18,000 fold in 
the new system (Anderson et al., 2009). This was replicated by Amanda Paulovich’s 
group for the high throughput quantitation of 15 peptides from a murine biomarker 
discovery study (Whiteaker et al., 2007; Whiteaker et al., 2010). The multiplexed 
platform was shown to be precise, with LODs down to ng/mL (using 10 μL of plasma). 
This was extended down to pg/mL using 1 mL of plasma, allowing for the quantitation 
of a broad range of peptide abundances (Whiteaker et al., 2010). However, as with any 
method based on immuno-capture, the success of the technique is only as good as the 
antibody utilised. Monoclonal species have been recently suggested as a better source 
of antibodies compared to their polyclonal counterparts (Schoenherr et al., 2010). In an 
effort to reduce the cost associated with SISCAPA-SRM, a workflow was recently 
described where the multiplexed immunisation of up to five proteotypic peptides from a 
single protein target in individual rabbits was incorporated (Whiteaker et al., 2011). A 
total of 403 proteotypic tryptic peptides representing 89 target proteins were used as 
immunogens, with over half of the developed assays capable of detecting the target 
peptide at concentrations of < 0.5 fmol/μL in human plasma, equivalent to protein 
concentrations of < 100 ng/mL. Thus, it has been proposed that a single laboratory is 
capable of generating hundreds of assays per year using a cost-effective SISCAPA 
approach.  
In conclusion, SRM-based assays have several attractive benefits suited to 
targeted biomarker verification and validation studies in plasma. The technology is 
sensitive, selective and multiplexable. In response to the limitations associated with 
ELISA’s as described within, it is anticipated that MS-based quantitative technologies 
will be increasingly implemented in large scale biomarker studies, where hundreds to 
thousands of patient samples require analysis, within the confines of time and cost. 
The particular niche of SRM-based assays is that they potentially permit the 
quantitation of proteins for which ELISAs of good quality are unavailable, or of those for 




1.4 Aims of this thesis 
The current diagnosis of AD is primarily based on clinical means and, to date, 
there is no reliable diagnostic or prognostic test for the disease. While many studies 
have investigated biomarkers of AD in various fluids such as CSF, the extraction of this 
matrix in the volumes required for routine clinical testing is difficult. Thus, attention has 
shifted to analysis of peripheral markers of AD. There is an urgent need for targeted, 
selective, specific and multiplexed quantitative assays to determine those candidate 
biomarkers of AD from discovery which have the most potential as sensitive and 
specific markers of the disease and which warrant further investigation in large-scale 
biomarker qualification studies. MS-based assays in combination with stable isotope 
dilution strategies have been proposed as advantageous over traditional immuno-
based methods in this regard. This thesis aims to develop a novel MS-based assay for 
the multiplexed measurement of candidate plasma biomarkers of AD and to critically 
assess its quantitative performance. Such an assay would potentially provide a panel 
of biomarkers that would have diagnostic and prognostic utility such as prediction of 
those MCI patients which are likely to progress to AD, for example.  
 
The specific aims of the thesis are: 
 To assess the quantitative performance of utilising isotopic versions of TMT 
tags as a means of introducing an internal standard into an SRM experiment.  
 
 To develop a multiplexed TMT-SRM assay for the measurement of signature 
peptides of nine candidate plasma biomarkers of AD. Specifically, an assay  will 
be designed for the measurement of the candidate AD biomarkers clusterin, 






 To validate the TMT-SRM assay against established biomarker technologies 
and determine the performance characteristics for each target analyte in the 
assay in terms of the dynamic range, LOD, LOQ and the accuracy of 
quantitation. 
 
 To evaluate the performance of each candidate biomarker in cohorts of AD and 
NDC samples to determine if individual, or indeed the full panel of candidate 































Biomarker discovery experiments in plasma have revealed several proteins 
which may be valuable in AD diagnosis and prognosis (Hye et al., 2006; Thambisetty et 
al., 2010; Gϋntert et al., 2010).  These proteins are of medium to high abundance in 
plasma and represent tractable analytes for targeted quantitation strategies. Robust, 
high performance quantitative assays are required to verify these candidate biomarkers 
in clinical sample cohorts. Recently, SRM mass spectrometry, utilising signature 
peptides of proteins, has been given considerable attention for the targeted quantitation 
of plasma proteins (Anderson and Hunter, 2006; Keshishian et al., 2007; Pan et al., 
2009). SRM is an attractive alternative to immuno-based approaches due to its intrinsic 
capacity to multiplex, rapid development times and its ability to target specific protein 
isoforms and PTMs (Kirkpatrick et al., 2005; Anderson and Hunter, 2006; Stahl-Zeng et 
al., 2007). 
SRM has routinely utilised AQUA peptides (heavy isotope-labeled versions of 
the target peptide) as internal standards for improved accuracy of quantitation (Gerber 
et al., 2003; Brun et al., 2009). Alternatively and more recently, internal standardisation 
may be achieved by comparison of target peptides to reference peptides, differentially 
labeled with isotopic versions of chemical tags such as  mTRAQ or ICPL reagents 
(DeSouza et al., 2008; Lange et al., 2008; Kang et al., 2010). This referencing 
approach is advantageous over AQUA peptides as the need for the synthesis of 
expensive heavy isotope-doped standards is avoided in the early stages of protein 
verification and both synthetic and biological reference standards can be utilised. In the 
case of the biological reference approach, an internal reference peptide standard can 
be generated for all endogenous proteins in the sample upon enzymatic digestion. 
Similarly to mTRAQ, isotopic versions of TMT (Figure 1.10; light TMT: TMTzero and 
heavy TMT: TMTsixplex) could be utilised for the internal referencing of target analytes 




Here the performance of TMT-SRM was investigated for its potential to provide 
high quality quantitative measurements which could be later applied to the 
development of robust ‘‘fit for purpose’’ assays for the validation of candidate plasma 
biomarkers of AD. In the first instance, proof of principle experiments were designed for 
the targeted quantitation of high abundant tryptic plasma peptides by TMT-SRM. In this 
experiment, reference peptides were derived from a plasma sample (biological 
reference). These initial investigations were also designed to gain a first impression of 
the accuracy of TMT-SRM quantitation.  
The complexity of the plasma matrix may detrimentally affect the quantitative 
measurement, due to the increased likelihood of contaminating background ions 
contributing to signals measured for target and reference analytes. Additionally, ion 
suppression effects from the plasma may result in reduced detection of target analytes. 
In a further proof of principal experiment, the effect of this interference was assessed 
on the accuracy of TMT-SRM quantitation. In the initial experiment, the plasma matrix 
effect could not be directly assessed as target analytes were endogenous to the 
plasma. A model experiment was therefore designed utilising peptides exogenous to 
plasma. Here, bovine serum albumin (BSA) peptides were spiked into a human plasma 
digest over a range of concentrations and the plasma matrix effects on the trueness 













2.1 Materials and Methods 
2.1.1 Initial assessment of the performance of TMT-SRM as a strategy for 
targeted MS assays in plasma  
2.1.1.1 Estimation of plasma protein concentration by Bradford assay 
The total protein content of a reference plasma sample, prepared from a 
healthy control subject (Dade Behring, Milton Keynes, UK) was determined by the 
Bradford colorimetric assay (Bradford, 1976). Lyophilised plasma was prepared by 
resuspension in 1 mL 18 MΩ water (H2O; NB this water quality was used for all 
experimental procedures here-on-in) followed by gentle shaking for 1 min. Plasma was 
left to stand for 20 min at room temperature (RT) to ensure all proteins were fully 
solubilised whilst minimising proteolytic degradation. The sample was aliquoted into 25 
μL volumes and stored at -80 ˚C until further use. For the determination of protein 
concentration, an aliquot was defrosted and diluted 1:300 (3 µL in 897 µL H2O) in 
accordance with standard operating procedures and stored on ice. Plasma was 
compared to BSA standards (stock solution 2.96 µg/mL; Sigma-Aldrich Company Ltd, 
Dorset, UK) prepared over a concentration range 0 - 0.5 μg/μL in H2O. Protein 
standards (10 μL) or diluted plasma (10 μL) were combined with 200 μL of Bradford 
dye reagent (Sigma-Aldrich) in a Nunc 96-well microplate (Thermo Scientific, Hemel 
Hempstead, UK), mixed, incubated at RT for 5 min and read at 595 nm using a Victor 3 
1420 Multi-label Counter (Perkin Elmer, Cambridge, UK). BSA and experimental 
measurements were performed in triplicate. BSA absorbance at 595 nm (A595) was 
plotted against concentration (µg/µL). The protein concentration of the plasma sample 
was estimated to be 47 μg/μL (Appendix Figure 2.1). 
 
2.1.1.2 Solubilisation, reduction, alkylation and digestion of human plasma  
Plasma was digested and labeled with TMT according to the manufacturer’s 




 μg, 10.6 µL) was diluted to 1µg/µL with 100 mM borate buffer, pH 7.5 (Sigma-Aldrich) 
and 0.1% sodium dodecyl sulphate (SDS; Genomic Solutions, Huntingdon, UK). Borate 
buffer was used to provide an alkaline pH which was necessary for tryptic digestion 
and the TMT-labeling reaction. SDS was used to solubilise the plasma proteins, 
resulting in the loss of all secondary, tertiary and quaternary protein structures. To 
disrupt disulphide bonds between cysteines of the plasma proteins, the sample was 
reduced with 1 mM Tris(2-carboxyethyl) phosphine (TCEP; Sigma-Aldrich, stock 
solution 20 mM TCEP in H2O) for 30 min at RT. Free cysteines were blocked by 
alkylation with 7.5 mM iodoacetamide (IAA; Sigma-Aldrich, stock solution 150 mM IAA 
in ACN; Fisher Scientific UK Ltd., Loughborough, UK), for 1 hr at RT in the dark. The 
digestion efficiencies of bovine and porcine trypsin were compared for the generation 
of plasma peptides. This comparison came about as bovine trypsin was routinely used 
in the London laboratory and porcine trypsin was utilised in the TMT protocol. Bovine 
trypsin (Roche, Welwyn Garden City, UK) and porcine trypsin (Promega, Southampton, 
UK) were solubilised to 400 ng/µL in 100 mM borate buffer pH 7.5 and added to the 
plasma sample (divided into 2 x 200 μg aliquots) to give a trypsin: protein ratio of 1:25. 
Samples were incubated on a Thermomixer (Eppendorf, Cambridge, UK) at 37 oC for 
18 hr.  
 
2.1.1.3 TMT-labeling of digested plasma peptides  
Following digestion, the bovine- and porcine-digested plasma samples were 
divided into two 100 µg aliquots for TMT labeling. One aliquot of each digest was 
labeled with 15 mM light TMT (TMT zero tag) and the other with 15 mM heavy TMT 
(TMT sixplex-127 tag) at RT for 1 hr. The stock solution in both cases was 60 mM TMT 
reagent solubilised in ACN. All TMT labels were manufactured in-house at Proteome 
Sciences R&D GmbH & Co., Frankfurt, Germany. To remove non-specific TMT labeling 
of amino acids other than lysine and the N-terminus, each solution was brought to 
0.25% hydroxylamine (25% stock solution in H2O; Sigma-Aldrich) and incubated for 30 




2.1.1.4 Purification of TMT-labeled peptides by reversed-phase and strong cation 
exchange chromatography  
To remove excess TMT reagents, salts and SDS, TMT-labeled peptides were 
purified using RP and strong cation exchange (SCX) cartridges. The ACN 
concentration of the peptide samples was reduced from 24% to ~5% with 0.1% 
trifluoroacetic acid (TFA; Merck Services Ltd., Hull, UK). Samples were desalted by RP 
using HLB Oasis cartridges (30 mg bed volume, Waters, Hertfordshire, UK). Cartridges 
were prepared by conditioning with 1 ml 95% ACN, 0.1% TFA, followed by equilibration 
with 2 mL 5% ACN, 0.1% TFA. The diluted peptide sample was loaded onto the 
prepared cartridge and bound peptides were washed with 4 mL 5% ACN, 0.1% TFA, 
followed by elution with 3 mL 50% ACN, 0.1% TFA. Peptides from the RP step were 
eluted directly onto self-packed SCX cartridges. Cartridges were prepared using 
Chromabond 15 mL columns (Thames Restek Ltd., High Wycombe, UK) filled with 650 
μL fast flow sepharose slurry (Sigma-Aldrich) and a frit placed on top of the resin bed. 
Prior to peptide loading, cartridges were washed with 2 mL 25% ACN, 0.1% TFA. The 
RP eluant was loaded onto the column and washed with 4 mL of 25% ACN, 0.1% TFA. 
Peptides were eluted from the cartridge with 2 mL of 25% ACN, 400 mM ammonium 
acetate (Fisher Scientific). Both purification procedures were performed with the aid of 
a vacuum manifold (Thames Restek). During loading and elution of the peptides, the 
flow rate of the system was maintained at approximately 1 drop/sec. The samples were 
lyophilised to dryness in a vacuum centrifuge (Savant Speedvac®, Thermo Scientific). 
To ensure the removal of the volatile salt used for SCX, the samples were 
resuspended in 25% ACN, 0.1% TFA and re-lyophilised to dryness. Samples were 
stored at -80 °C until further analysis. 
 
2.1.1.5 LC-MS/MS analysis of plasma labeled with light TMT and heavy TMT on a 
Q-Tof to compare the digestion of plasma by different trypsin species 
To assess the enzymatic efficiencies of both trypsin species for the generation 




LC system (Dionex Ltd., Camberley, UK) coupled to a Q-Tof micro (Waters). 
Specifically, a comparison of the MS survey scan and the peptides identified via 
MS/MS for each sample was made. Further, MS/MS data was used to assess the TMT 
labeling efficiency.  
TMT-labeled plasma samples, digested with bovine or porcine trypsin, were 
resuspended to a final concentration of 1 μg/μL (i.e., 100 μL in each of the four 
samples) in 5% ACN, 0.05% FA (BDH Chemicals, VWR, Leighton Buzzard, UK). 
Aliquots (10 μL) were stored at -80 oC for subsequent MS analysis. Aliquots of light and 
heavy TMT labeled plasma samples from each of the digests were combined in a 1:1 
ratio, vortexed and diluted 20 fold to a final concentration of 0.05 μg/μL in 0.05% FA. 
Sample [20 uL full loop injection with 21 uL sample pick-up, i.e., 1µg total protein load 
on column (o/c), 500 ng of each labeled sample] was loaded via a Famos™ 
autosampler (Dionex) onto a C18 pre-column (PepMap cartridge, 300 μm x 5 mm; 
Dionex) for concentration and further desalting. Washing was performed in loading 
buffer (0.1% FA) for 4 min at 30 µL/min. During washing the pre-column was out of line 
with the analytical column by means of a Switchos™ II microcolumn switching unit 
(Dionex), allowing all eluant to flow to waste. The pre-column was then switched in-line 
with the analytical column (C18 PepMap column, 75 μm x 15 cm; Dionex) and peptides 
were resolved over a gradient of 0 - 32% ACN, delivered by a combination of Buffer A 
(0.05% FA) and Buffer B (80% ACN, 0.05% FA) for 120 min and at a flow rate of 200 
nL/min. Following delivery of the gradient, both columns were washed for 10 min with 
60% Buffer B followed by 20 min with 95% Buffer B. The pre-column and analytical 
column were then equilibrated for 20 min in loading buffer and 95% Buffer A, 
respectively. 
Peptides were ionised by ESI using a Z-spray ion source fitted to a Q-Tof micro. 
For MS/MS analysis of the plasma digest, the instrument was set to run in automated 
switching mode (data dependent acquisition, DDA), selecting precursor ions based on 
their intensity and charge state for sequencing by CID with argon gas. Singly charged 




ions. Furthermore, TMT-labeled peptides are typically multiply charged. A collision 
energy (CE) profile was applied for the fragmentation of peptides, optimised to the 
precursor ions m/z and charge state. For further optimisation, each setting in the CE 
profile was increased by 5 V for the fragmentation of TMT-labeled peptides. The source 
cone voltage was set to 30 V and the capillary voltage to 3500 V. 
Mass calibration of the MS was performed on MS/MS fragment ions of synthetic 
human [Glu1]-fibrinopeptide (GluFib; Sigma-Aldrich) directly infused into the instrument 
at a concentration of 63 fmol/µL in 50% ACN, 0.5% FA and a flow rate of 0.2 µL/min 
using a syringe pump (Harvard Apparatus Ltd, Kent, UK). The accuracy of the 
calibration was ±0.05 amu (50 ppm or ±0.005% at m/z 785.85). Instrument 
performance was benchmarked prior to the analysis of samples using a tryptic digest of 
BSA. LC-MS/MS analysis was performed on 200 fmol BSA digest over a gradient of 0 - 
32% ACN for 60 min. MS and MS/MS sensitivity, resolution, mass accuracy and 
peptide LC retention were assessed. Typically, 200 fmol BSA gave between 600 and 
1000 base peak intensity (BPI) in the MS channel, 100 - 150 in first MS/MS and 50 - 
100 in second MS/MS channel. 
 
2.1.1.6 Database searching for peptide/ protein identification and for the 
determination of TMT-labeling efficiency 
Mass spectral data was processed into peak lists (.pkl files) for database 
searching using ProteinLynx Global Server 2 (v2; Waters). Peak lists contained the 
precursor m/z, intensity and charge state along with MS/MS fragment ion m/z and 
intensity. All .pkl files were searched against the UniProtKB/Swiss-Prot database 
(release 54.0, 24th July 2007) using Mascot (v2.2; Matrix Science, London, UK). 
Parameters were set to identify tryptic peptides with up to three missed cleavages. To 
account for chemical modifications during sample processing, carbamidomethylation of 
cysteines and oxidation of methionines were set as variable modifications within search 
parameters. Similarly, light and heavy TMT-labeling of lysine residues and peptide N-




manually into the in-house version of the software. Peptide identifications were ranked 
according to a scoring system based on the Mowse algorithm (Pappin et. al., 1993). Ion 
score values below 10 were excluded from analysis. For confirmation of single peptide 
identifications of proteins the ion score of the peptide needed to be greater than the 
identity score. 
 
2.1.1.7 LC-MS/MS analysis on a 4000 QTRAP mass spectrometer for peptide and 
transition selection to build the SRM method 
The TMT-SRM method was developed using an UltiMate 3000 nano-LC 
(Dionex) coupled to a 4000 QTRAP triple quadrupole mass spectrometer (QTRAP; AB 
Sciex, Warrington, UK). Initially, information dependent acquisition (IDA, equivalent to 
DDA) was performed to select peptides and transitions representing high abundant 
species in human plasma. Two porcine trypsin digested plasma aliquots (one labeled 
with light TMT and one with heavy TMT) were combined in a 1:1 ratio and diluted as 
described in Section 2.1.1.5. Peptides were resolved by RP chromatography as 
described in Section 2.1.1.5. Peptides were introduced into the mass spectrometer 
using a Nanospray II source at a flow rate of 300 nL/min. Peptides were ionised by ESI 
using source-dependant voltages and gas pressures which had been optimised for 
maximal ion sensitivities using GluFib (m/z 785.852+, infused as described in Section 
2.1.1.5). Specifically, the curtain gas was set to 10 p.s.i., the ion gas 1 (GS1) was 15 
p.s.i. and the ion spray voltage was 3500 V. Peptides were fragmented by CID using 
nitrogen gas.  
The linear ion trap was calibrated on the MS/MS fragment ions of GluFib using 
the conditions as described in Section 2.1.1.5. Instrument quality control checks were 
performed to monitor system performance. Here, LC-MS/MS analysis of a standard 
tryptic digest of BSA (as described in Section 2.1.1.5) was performed between the 
analysis of TMT-labeled samples to check MS sensitivity and to allow for LC column 




generation of raw data .wiff files. Such files are the MS data file format on AB Sciex 
instruments. Following IDA analysis peptides were selected for TMT-SRM quantitation. 
 
2.1.1.8 Development of a TMT-SRM method to assess the co-elution and 
selectivity between light TMT and heavy TMT-labeled peptides 
The performance of Q1 and Q3 of the QTRAP was assessed and corrected for 
mass accuracy, sensitivity, resolution and stability using polypropylene glycol (PPG; 
Agilent Technologies, West Lothian UK). The stock solution was diluted 1:50 with H2O 
(< 0.01 wt %) and directly infused into the instrument at 10 µL/min.  
An SRM method was initially established by inputting all Q1 and Q3 ion m/z for 
the selected peptides. Based on the number of transitions and SRM peak width, 
additional parameters were optimised for maximal SRM sensitivities and sampling over 
the peak. The optimal LC gradient time for separation of the plasma peptides was 
determined. LC-SRM analysis was performed over 30 min, 60 min and 120 min LC 
gradients. The most desirable LC gradient was that which gave smooth SRM peak 
shapes without compromise to SRM sensitivity or selectivity. Furthermore, the optimal 
mass resolution, dwell time and cycle time were determined. Several methods were 
then prepared to determine the approximate CE that gave optimal SRM sensitivities, 
i.e., CE applied for MS/MS fragmentation +/- 5 V.  
TMT-SRM analysis was performed over a 0 - 32% ACN gradient for 30 min. 
The detection of all transitions in the method was analysed using a light TMT and 
heavy TMT-labeled plasma sample combined in a 1:1 ratio. In the first instance, an 
SRM-triggered enhanced product ion (EPI) method was used to confirm the identity of 
each analyte in the method. From this, an accurate retention time (tR) for each peptide 
and interference from the background matrix was extracted. To observe potential 
cross-talk between transitions, light TMT-labeled plasma was analysed over all light 
TMT and heavy TMT transitions (full method). Using accurate tR, the SRM signal in the 




similar analysis was performed on heavy TMT-labeled plasma to observe SRM 
interference in the light TMT channel. 
 
2.1.1.9 TMT-SRM analysis of light TMT and heavy TMT-labeled plasma mixed in 
different ratios to assess the accuracy of quantitation of target peptides 
To gain a first impression of the trueness and precision of TMT-SRM 
quantitation, light TMT and heavy TMT-labeled plasma was combined in ratios of 1:1, 
3:1, 9:1 and 27:1 (light TMT: heavy TMT, L/H), such that the total plasma load o/c 
remained at 1 µg. Each combined sample was analysed in triplicate (analytical repeats) 
using the method developed in Section 2.1.1.8. To minimise carryover from the higher 
amounts of light TMT-labeled peptides used, triplicate samples of each ratio were 
analysed in order of increasing light TMT-labeled peptides, i.e., 1:1, 3:1, 9:1 and finally, 
27:1. A blank sample (5% ACN, 0.05% FA) was analysed before each triplicate ratio 
and at the end of the sample set.  
SRM transitions were visualised through Analyst® SRM quantitation software 
(v1.5; AB Sciex). The quantitation processing parameters were determined using SRM 
data acquired from a representative sample, i.e., the light TMT and heavy TMT-labeled 
peptides combined in a 1:1 ratio. The minimum peak height for detection was set to 50 
cps with minimum peak width of 30 sec. An SRM smoothing width of 3 points was 
applied to all transitions. All peak matching was visually verified and transitions were 
excluded if there was poor peak definition from the background signal. Peak areas 
were exported into Microsoft Excel 2003. The peak area for each light TMT-labeled 
transition was measured relative to the peak area of the corresponding heavy TMT-
labeled transition, i.e., representing the internal standard. The L/H ratio for 
corresponding transition pairs were taken forward for quantitative analysis. The mean 
L/H ratio for all transitions of each peptide was calculated across all repeats and used 
to determine the trueness and precision of TMT-SRM quantitation. Expected L/H ratios 





2.1.2 Assessment of the plasma matrix effects on the accuracy of TMT-
SRM quantitation 
To further investigate the TMT-SRM approach, plasma matrix effects on 
quantitation were explored. To address this, exogenous peptides to human plasma 
(BSA peptides) were spiked into the plasma and the effect of plasma background on 
these peptides was determined. Human plasma was labeled with light TMT and BSA 
peptides were labeled with light TMT and spiked into the light TMT-labeled plasma over 
a range of concentrations. Light TMT-BSA peptides were compared to a constant 
amount of heavy TMT-labeled BSA peptides also spiked into plasma, providing an 
internal standard for quantitation. As a control, the spiked BSA peptides were 
quantitated by the same TMT-SRM method in a buffer-only system. 
 
2.1.2.1 LC-MS/MS analysis of TMT-labeled BSA for peptide and transition 
selection 
BSA (200 µg) was reduced, alkylated, digested with porcine trypsin, divided into 
2 x 100 µg aliquots and labeled with either light TMT or heavy TMT as described in 
Section 2.1.1.3. TMT-labeled peptides underwent RP and SCX purification as 
described in Section 2.1.1.4. BSA was processed in triplicate to provide three technical 
repeats. For peptide selection and method development, light TMT-labeled BSA 
peptides were analysed by LC-MS/MS on the QTRAP as described in Section 2.1.1.7. 
Light TMT-labeled BSA was loaded at 1 µg o/c and IDA analysis was performed over a 
90 min LC gradient (0 - 32% ACN). MS/MS experimental data was searched against 
the sequence for BSA using Mascot with parameters set as described in Section 
2.1.1.6 and peptides selected for TMT-SRM quantitation.  
 
2.1.2.2 Optimisation of MS instrument parameters  
QTRAP compound-dependent parameters were tuned with direct infusion of 
light TMT-labeled BSA peptides (0.9 μg/μL in 45% ACN, 0.25% FA) to achieve optimal 




enhance the ion path of each analyte in the mass spectrometer and are specific for 
each analyte in the method. The compound-dependent parameters optimised in this 
experiment as defined by AB Sciex were: 
 
 Declustering Potential (DP) controls the potential difference between Q0 and the 
orifice plate. It is used to minimise solvent cluster ions which may attach to the 
sample. The higher the voltage, the higher the fragmentation or ‘declustering’. 
 Collision Energy (CE) is the potential difference between Q0 and Q2 for MS/MS-
type scans. It is the amount of energy that the precursor ions receive as they are 
accelerated into the Q2 collision cell, where they collide with gas molecules and 
fragment. 
 Collision Cell Exit Potential (CXP) is used to focus and accelerate ions out of the 
collision cell (Q2). It is important for sensitivity in Q3. 
 
Parameters were optimised by linearly ramping the voltages for each parameter 
(50 – 200 V for DP, 10 – 70 V for CE, 0 - 50 V for CXP) in the order of DP, CE and 
CXP, i.e., the order of voltages applied along the ion path. For each parameter the 
voltage resulting in the maximal ion count over the range was selected as the optimal 
setting. The optimised compound-dependent parameters were added to the method 
along with dwell and cycle times.  
 
2.1.2.3 Detection of BSA peptides in human plasma and determination of the 
effect of plasma background interference on the accuracy of TMT-SRM  
A representative sample of light TMT and heavy TMT-labeled BSA combined in 
a 1:1 ratio and spiked into light TMT-labeled plasma (10 ng BSA peptides to 1 µg 
plasma o/c) was prepared. This was used to determine the optimal LC gradient time for 
quantitation of the spiked BSA peptides. LC-SRM analysis was performed over 30 min, 




Once the TMT-SRM method was established, crosstalk between transitions 
was assessed with analysis of light TMT-labeled BSA peptides only over all light TMT 
and heavy TMT transitions. Similarly, heavy TMT-labeled BSA peptides only were 
analysed over all transitions. To determine if there was any signal contribution from the 
plasma matrix which could effect quantitation of the target analytes, light TMT-labeled 
plasma (1 µg o/c) was combined with light TMT BSA (10 ng o/c) and analysed over all 
light TMT and heavy TMT transitions. An similar analysis was performed using heavy 
TMT-labeled BSA peptides. Plasma background interference on BSA peptides could 
be directly aligned in the heavy TMT channel using exact tR from the light TMT-labeled 
BSA peptides and vice versa. 
Light and heavy TMT-labeled BSA peptides were combined in 0.33:1, 1:1, 3:1, 
9:1 and 27:1 ratios (L/H) and spiked into the light TMT-labeled plasma. One unit 
represented 10 ng BSA. This spiked concentration is equivalent to 800 µg/mL levels in 
plasma. For control purposes, an identical analysis was performed without plasma 
matrix. Three analytical and three technical replicates of BSA digest were analysed in 
the order of 0.33:1 1:1, 3:1, 9:1 and finally 27:1 over a 0 - 32% ACN gradient for 30 
min. A blank sample (5% ACN, 0.05% FA) was analysed before replicate runs of each 
ratio and after the complete sample set. 
 
2.1.2.4 Data processing and analysis 
SRMs were processed using Analyst SRM quantitation software as described in 
Section 2.1.9. All peak matching was visually verified and peak areas were exported 
into Microsoft Excel 2003. The peak area for each light TMT-labeled BSA transition 
was measured relative to the peak area of the corresponding heavy TMT-labeled BSA 
transition. The L/H ratio for each transition was taken forward for quantitative analysis. 
The mean L/H ratios for all transitions of each peptide across all repeats were used to 
determine the trueness and precision of TMT-SRM quantitation. Expected L/H ratios 





2.2.1 Initial assessment of the performance of TMT-SRM as a strategy for 
targeted MS assays in plasma 
2.2.1.1 TMT-labeling of plasma 
A protocol for the digestion and TMT-labeling of plasma first needed to be 
established. To determine the optimal source of trypsin for digestion of plasma, 
equivalent amounts of plasma were digested with bovine and porcine trypsin and 
analysed by LC-MS/MS on the Q-Tof micro. In the first instance, LC-MS/MS 
experiments were performed on the Q-Tof micro due to its higher resolution (as 
compared to the QTRAP), improved mass accuracy and charge state recognition and 
higher quality MS/MS data. Overall, a higher BPI was observed in the MS survey scan 
of the porcine trypsin digested plasma sample than in the bovine trypsin digested 
plasma, with more ions detected in the earlier half of the gradient (Figure 2.1). These 
ions represented the more hydrophilic peptide ions which were potentially more 
amenable for SRM analysis.  
The total number of peptides and proteins identified was compared between 
samples (Table 2.1). A greater number of peptides (218) and proteins (28) were 
identified in plasma digested by porcine trypsin as compared to the bovine trypsin 
digest (101 peptides and 20 proteins). The number of missed cleavages is an 
indication of the incompleteness of proteolytic cleavage by trypsin. An equivalent 
percentage of missed cleavages were observed in both experiments, with 82 - 87% of 
all identified peptides being fully cleaved by both trypsin species (Table 2.1). As plasma 
digested using porcine trypsin gave a much richer BPI and a greater number of peptide 
and protein identifications by LC-MS/MS as compared to bovine trypsin, porcine trypsin 
was used for all subsequent digestions. Of all identified peptides, 99% were fully 
labeled by TMT, demonstrating the high efficiency of the labeling reaction. The 









Figure 2.1 BPI chromatograms of plasma digested with bovine and porcine trypsin. A contaminant is observed at m/z 449 (suspected to be 
dicyclohexyl urea; http://www.waters.com/webassets/cms/support/docs/bkgrnd_ion_mstr_list.pdf) and can be excluded from the comparison. The 







    
 












































Missed cleavages (% of total) 
    
0 1 2 3 
QTof 
Bovine 101 20 88 (87.0) 10 (10.0) 3 (3.0) 0 (0.0) 
Porcine 218 28 176 (81.6) 36 (16.0) 4 (1.8) 2 (0.6) 
QTRAP 
Bovine 105 22 90 (85.7) 12 (11.4) 3 (2.9) 0 (0) 
Porcine 220 29 177 (80.5) 37 (16.8) 4 (1.8) 2 (0.0) 
 
Table 2.1 The total number of peptides and proteins identified by LC-MS/MS on the Q-
Tof micro and QTRAP for plasma digested by bovine or porcine trypsin. The number 
and proportion of missed cleavages for all identified peptides is also displayed. Results 
were comparable across platforms. 
 
peptides and was therefore reasoned to be suitable for the preparation of TMT-labeled 
peptides in plasma for subsequent quantitation studies.  
Equivalent to the QTof MS/MS analysis, MS/MS analysis of the same physical 
digests was performed on a QTRAP (DDA). Results were comparable across mass 
spectrometer platforms (Q-Tof micro and linear ion trap) with equivalent numbers of 
peptide and protein identifications and similar peptide fragmentation patterns observed 
(Table 2.1). This was encouraging as not only were the mass analysers different but 
different gases were used for CID on the two instruments, i.e., argon on the Q-Tof 
micro and nitrogen on the QTRAP. This demonstrated the potential of MS/MS data 
from discovery experiments to be transferred into SRM methods for validation using 
experimental rather than theoretical data. As Q-Tof micro and QTRAP MS platforms 
were comparable, all future work-up and SRM assessment experiments were 
performed on the QTRAP only. 
Q-Tof mass spectra of two representative plasma peptides are displayed in 
Figure 2.2 to demonstrate the mass difference between light TMT and heavy TMT-
labeled versions of the same peptide. The expected mass differences between the 
differentially TMT-labeled versions of 2+ and 3+ peptide ions were observed. This is 
important for the derivation of SRM transitions. This demonstrates that, by applying an 
isotopic TMT-labeling strategy, a mass difference can be introduced between 
experimental sample peptides and internal standards, allowing for the differential 










    
 
 
                                                           
   
 
Figure 2.2 The mass difference observed between differentially labeled peptides by TMT at different charge states. A Structures of light TMT and 
heavy TMT (TMTsixplex – 127 tag). Heavy TMT has five isotopic labels (13C and 15N; denoted *). B Mass spectra of two peptides labeled with light 
TMT and heavy TMT. The peptide LVTDLTK is labeled at the N-terminus and lysine giving a difference of 10 Da between the labeled peptides. The 
doubly charged precursor ions have a m/z difference of 5. The peptide HPDYSVVLLLR is labeled at the N-terminus only, resulting in a mass 
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2.2.1.2 Peptide and transition selection 
Table 2.2 displays a set of peptides representing high abundant plasma 
proteins which were selected for initial TMT-SRM quantitation. Following QTRAP IDA 
analysis of the light and heavy TMT-labeled plasma sample, peptides were taken 
forward as suitable candidates if they were fully hydrolysed with trypsin and had strong, 
high m/z MS/MS fragment ions. Additionally, peptides were selected that had both 
arginine and lysine at the C terminus (i.e., either one or two TMT tags), were doubly or 
triply charged and had varying LC tR. Theoretical m/z values were extracted from 
Mascot or calculated in silico for each light TMT and heavy TMT-labeled peptide. As an 
example, peptide G was doubly charged and had one N-terminal tag attached (Table 
2.2). The Q1 m/z of the light TMT-labeled peptide was 592.90, therefore the m/z of the 
corresponding heavy labeled peptide was 595.40 ( m/z 2.5). The b5 ion (measured in 
Q3) had one tag attached and thus the singly charged fragment ions between the 
labeled versions had an m/z difference of 5 Th (i.e., m/z 798.50 and 803.50). As a 
second Q3 transition the pseudo y-ion was selected. Pseudo-y ions are TMT fragment 
ions common to all TMT-labeled peptides. The m/z of these ions is always the intact 
mass of the labeled peptide minus the reporter ion and carbon monoxide (CO; Figure 
2.3). Pseudo y-ions may serve as Q3 transitions without prior insight into fragmentation 
patterns for peptide detection.  
 
2.2.1.3 LC-TMT-SRM method development for target plasma peptides 
A TMT-SRM method was compiled by first adding the m/z for each Q1 and Q3 
ion representing the thirteen target analytes, resulting in a total of 26 transitions (13 
light and heavy TMT pairs). The shortest LC-SRM gradient (30 min) was determined to 
be optimal for the separation of the peptides in that all target analytes were observed 
without compromise to the sensitivity or selectivity of each transition. Shorter gradients 
were favourable as analysis of the samples could proceed in a timelier manner. The 
dwell time, cycle time, mass resolution and CE were then optimised. The dwell time is 


















    Light TMT      Heavy TMT 
  Mr (Da) Q1 (m/z) Q3 (m/z)   Mr (Da) Q1 (m/z) Q3 (m/z) 
A Alpha-2-macroglobulin 
TMT





 2 12.6 29  1022.58 512.29 653.39 (b4)  1032.58 517.29 658.39 (b4) 
Ci IgG 
TMT
DTLMISR 2 13.5 40  1058.60 530.30 906.60 (p*)  1063.60 532.80 909.60 (p*) 
Cii IgG 
TMT















 2 18.5 34  1236.76 619.38 585.40 (y3)  1246.76 624.38 590.40 (y3) 
Gi Albumin 
TMT
FQNALLR 2 18.9 43  1183.80 592.90 1031.76 (p*)  1188.80 595.40 1034.76 (p*) 
Gii Albumin 
TMT















 2 22.4 43  1596.96 799.48 589.38 (y3)  1606.96 804.48 594.38 (y3) 




 2 26.2 60   1849.10 925.55 581.41 (y3)  1859.10 930.55 586.41 (y3) 
 
Table 2.2 Light and heavy TMT-labeled plasma peptides selected for SRM quantitation. For each peptide (A - J) the position of the TMT label is 
indicated along with the peptide’s precursor ion charge state, molecular mass (Mr) and LC tR. The CE is given for peptide fragmentation. The Q1 and 
Q3 transitions for the detection of both the light and heavy TMT-labeled versions of the peptides are also listed. One Q3 transition was selected per 
peptide with the exception of peptides C, G and I which were measured using two transitions. The Q3 transitions denoted (p*) represent the pseudo 








Figure 2.3 TMT fragment ions formed by CID highlighting the formation of the pseudo-
y ion. A Upon fragmentation of the labeled peptide (with TMTsixplex-127), the TMT 
reporter ion is observed at m/z 127.13. B The tag is observed at m/z 230.17 Th. C The 
pseudo-y ion is observed at m/z 1034.53. This relates to the mass of the TMT-labeled 
peptide minus the reporter ion and a CO group. The m/z of the pseudo y-ion will 
change depending on the tag used within each isobaric set as the distribution of the 
heavy isotopes across the reporter ion and CO moieties differ. 
 
 
to scan all transitions. At a fixed cycle time, dwell time is dependent on the total 
number of transitions in the method. For optimal sampling of the peak, a minimum of 
10 data points at full width half maximum (FWHM) was required. SRM quantitation was 
performed with a dwell time of 100 msec per transition resulting in a total cycle time of 
2.6 sec. 
The peak width was 30 sec at FWHM, resulting in approximately 11 data points 
per SRM. The mass resolution is the mass window around the precursor ion mass in 
Q1 or fragment ion mass in Q3 and the number of ions which are scanned around each 
mass is relative to the size of the window. Although higher sensitivities are achieved 
with a wider window, the selectivity becomes compromised. A balance between 
sensitivity and resolution was therefore needed. 
C Peptide and TMT6-127 with 
neutral loss of 155 (reporter 
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Labeled plasma peptides were analysed using the TMT-SRM method with the 
resolution of Q1 and Q3 set to either low (1 Da ± 0.1 amu FWHM), unit (0.7 Da ± 0.1 
amu FWHM) or high (0.5 Da ± 0.1 amu FWHM) and the data compared. Unit resolution 
gave the highest SRM sensitivity whilst still maintaining selectivity and was therefore 
used for subsequent measurements (data not shown). Finally, the CE was tuned. Here, 
three analyses of TMT-labeled plasma were performed using methods with the CE set 
to the default MS/MS CE voltage and +/-5 V. The higher CE settings (+5 V) resulted in 
the loss of detection of transitions A, Ci, Cii, Gi and Gii. No significant differences in 
SRM sensitivities were observed for the remaining peptides in the method. The lower 
CE settings (-5 V) resulted in reduced (~20%) SRM sensitivities of all target analytes. 
The default CE (calculated depending on precursor ion m and z) was therefore taken 
as the most suitable for the detection of all transitions in the method.  
Once the method was established it was important to define whether light and 
heavy TMT-labeled versions of the same peptide co-eluted following RP 
chromatography. Additionally, it was required that the approach was able to discern 
between light and heavy TMT-labeled transitions of the same peptide, i.e., crosstalk. 
To assess co-elution, light and heavy labeled plasma peptides mixed in a 1:1 ratio 
were analysed using the TMT-SRM method. All peptides were observed by TMT-SRM. 
Figure 2.4 displays the SRM extracted ion chromatogram (XIC) for the target peptides. 
Light and heavy-labeled versions of the same peptide were shown to perfectly co-elute. 
This was crucial for the approach, as it allowed for the direct comparison and relative 
quantitation between different TMT-labeled versions of the same peptide, both here, 
and in subsequent TMT-SRM experiments.  
To assess the selectivity between light TMT and heavy TMT transitions, light 
TMT-labeled plasma and heavy TMT labeled plasma were analysed individually. The 
method was shown to be highly selective and no significant crosstalk (< 1% of total 
SRM signal) was observed for the majority of transitions. However, at this stage it was 
not possible to discern between crosstalk and background interference due to the 




selectivity was achieved (peptide A). Here, the approach discriminated between light 
TMT and heavy TMT transitions with an m/z difference of only 1.66 in Q1, whilst Q3 ion 
m/z were identical. Background interference (>1%) was observed for peptide Gi. Here, 
TMT-SRM quantitation was based on a pseudo y-ion in Q3. Pseudo y-ions would 
therefore be treated with caution in future TMT-SRM experiments, but at this stage 
warranted further consideration due to the benefit these ions provided in the absence 
of other fragmentation information. 
  
 
Figure 2.4 An SRM XIC for light TMT and heavy TMT-labeled peptides A - J spiked in 
a 1:1 ratio. All transitions listed in Table 2.2 are observed. The top right-hand panel 
displays the zoomed SRM XIC showing the lower intensity peptides H and J. For each 
peptide, it can be seen the light TMT and heavy TMT-labeled peptide pairs co-elute.  
 
 
2.2.1.4 Accuracy of TMT-SRM quantitation of target plasma peptides 
The trueness and precision of TMT-SRM quantitation was assessed by 
combining light TMT and heavy TMT-labeled standard plasma in 1:1, 3:1, 9:1 and 27:1 
(L/H) ratios and comparing the observed experimental ratios to that of expected ratios. 
Three analytical repeats were acquired for each ratio. Figure 2.5 A displays the 



































Figure 2.5 The accuracy of TMT-SRM quantitation. A SRM XIC for peptide B mixed in 
1:1, 3:1, 9:1 and 27:1 (L/H) ratios. B Plots of observed versus expected L/H ratios for 
plasma peptides A – J. A linear response was observed for the majority of peptides 
with good precision from replicate runs. Less accurate TMT-SRM quantitation was 














Each ratio appeared to be as expected. Similar patterns were observed for all 
remaining peptides in the TMT-SRM method. 
Good agreement was found between observed and expected ratios for peptides 
A - Iii (Table 2.3, Figure 2.5 B), indicating trueness in TMT-SRM quantitation. Using    
peptide B as the best example, observed mean ratios matched well with expected 
ratios and analytical repeats were precise, with CVs < 1% (Table 2.3).  Peptides H – J 
had higher mean %CVs. This can be explained by the increased hydrophobicity of 
these peptides as they elute later in the LC gradient. These peptides typically have 
poorer elution properties exhibiting peak broadening and jagged peak shapes resulting 
in increased variability in peak area. Poor SRM peak shape may also explain the 
poorer trueness observed for the hydrophobic peptide J, where a mean ratio of 13:1 
was observed for the expected ratio of 27:1. Furthermore, peptides eluting later in the 
LC gradient had the lowest SRM sensitivities and are thus more likely to be affected by 
background interference at the extreme ratios, i.e., 27:1 L/H. Consequently, 
hydrophobic peptides of low SRM sensitivity may be less suitable for TMT-SRM 
quantitation. Considering all peptides however, the approach was shown to be precise, 
with 83% of all CVs < 5%. In summary, the results demonstrate the potential of TMT-




Ratio (L/H) Mean 
Precision 
(%CV) 1:1 3:1 9:1 27:1 
A 0.91 2.87 8.67 23.08 2.60 
B 0.90 2.53 8.60 26.46 0.59 
Ci 0.91 2.61 8.36 25.96 1.18 
Cii 0.78 2.20 7.24 21.91 0.99 
D 0.76 2.11 7.36 23.67 2.23 
E 0.84 2.28 7.96 25.68 2.23 
F 0.96 2.58 8.50 27.39 1.78 
Gi 0.82 2.24 7.54 23.80 2.01 
Gii 0.94 2.55 8.44 27.93 1.72 
H 0.98 2.77 9.50 32.64 8.70 
Ii 0.87 2.51 8.38 25.45 5.43 
Iii 0.87 2.51 8.67 26.84 5.87 
J 0.91 2.68 9.18 13.09 11.39 
Table 2.3 Observed ratios of L/H for plasma peptides A – J. Good agreement between 
observed and expected L/H ratios was shown for the majority of peptides in the TMT-




2.2.2 Assessment of plasma matrix effects on the accuracy of quantitation 
by TMT-SRM 
The previous experiment demonstrated the value of TMT-SRM as an approach 
for peptide quantitation with good accuracy observed. However, as referencing was 
performed between differentially labeled plasma samples, the background signal 
contribution from the plasma in each light TMT and heavy TMT channel could not be 
directly determined. Furthermore, only high abundant plasma peptides were targeted 
where the background matrix was found to have negligible effect on the quantitative 
measurement. To further appreciate the effect of the plasma matrix on the quantitation 
of less abundant molecules, an additional experiment was designed. Here, a protein 
exogenous to plasma (BSA) was spiked into plasma over a range of concentrations 
(µg/mL) representing the same magnitude as the endogenous levels of the candidate 
AD biomarker proteins in the assay required for development. 
 
2.2.2.1 BSA peptide and transition selection 
Following IDA analysis of light TMT-labeled BSA, peptides were selected for 
TMT-SRM quantitation that were proteotypic to BSA, i.e., each peptide uniquely 
identified BSA and did not share any sequence homology with human serum albumin 
peptides (Table 2.4). This was a further advancement in the TMT-SRM workflow as 
peptide proteotypicity was not considered in the initial experiment. Each peptide had no 
known in vivo or in vitro modifications, was fully hydrolysed by trypsin, covered a good 
range of m/z in Q1 to assess selectivity and background interference at low and high 
m/z and had suitable MS/MS fragment ions for Q3 selection. Three transitions per 
peptide were selected (including pseudo y-ion fragments) to provide multiple 
measurements for the quantitation of each peptide. This was to increase the 
confidence in the quantitative measurement and would allow for the determination of 
aberrant transitions. The corresponding Q1 and Q3 masses of heavy TMT-labeled 










Light TMT  Heavy TMT 
DP (V) CE (V) CXP (V) 










2 31 806.52 819.47 (y5)  811.52 824.47 (y5)    
   932.56 (y6)   937.56 (y6) 120 44 13 








2 22 685.92 1217.84 (p)*
b
  690.92 1226.84 (p)    
   799.50 (b5)   804.50 (b5) 75 48 9 










2 30 731.98 938.64 (y6)  736.98 943.64 (y6)    
   830.55 (y5)   830.55 (y5) 120 40 10 








3 21 585.39 711.48 (y4)  588.67 716.48 (y4)    
   818.45 (b5)   823.45 (b5) 75 28 9 
     635.85 (b9++)
b










3 31 779.76 719.42 (y4)  783.09 724.42 (y4)    
   882.48 (y5)   887.48 (y5) 120 36 20 






2 17 457.27 739.42 (b5)  459.77 744.42 (b5)    
   668.38 (b4)   673.38 (b4) 75 36 9 
     760.74 (p)
b








2 529 852.50 1180.65 (y10)  855.00 1180.65 (y10)    
   1017.58 (y9)   1017.58 (y9) 120 50 17 








2 16 529.31 500.32 (y2)
b
  534.31 505.32 (y2)    
   558.30 (b3)
b
   563.30 (b3) 75 40 9 
     904.62 (p)
b








3 18 474.89 639.35 (b4)  478.23 644.35 (b4)    
   518.34 (y2)   523.34 (y2) 75 23 9 
     728.39 (b5)
b
    733.39 (b5)       
Table 2.4 BSA peptides selected for TMT-SRM quantitation. The position of the TMT label is indicated for each peptide along with the peptide’s 
precursor ion charge state and tR. The Q1 and Q3 transitions for the detection of the light TMT and heavy TMT-labeled versions of each peptide are 
also listed. *the Q3 transitions denoted (p) represent the pseudo y-ion fragmentation. Compound-dependent parameter voltages are also given. 
a
 Excluded due to poor endogenous detection in plasma.   
b




attached to the peptide and the charge state of the peptide (Table 2.4).  
 
2.2.2.2 LC-TMT-SRM method development for target BSA peptides spiked into 
plasma digest  
In contrast to the initial experiments, the availability of a BSA protein here-in 
enabled peptides to be generated for infusion into the mass spectrometer and 
optimisation of compound-dependent parameters for each peptide, i.e., the DP, CE and 
CXP. The instrument was linearly ramped over a range of voltages in combination with 
SRM scanning of a representative transition for each BSA peptide in the TMT-SRM 
method. This was not performed for individual transitions of a peptide due to the limited 
sample amounts when using a purified protein as an internal standard. Therefore, it 
was decided to optimise the compound-dependent parameters on one transition for 
each peptide, i.e., the transition which had the median m/z in Q3. 
For each parameter, the voltage resulting in the maximal ion count over the 
range was selected as the optimal setting (Figure 2.6). The optimal DP voltage trace 
was found to plateau over a broad range, whereas for CE and CXP a much more 
defined voltage resulted in the optimal sensitivity for a given transition. The optimisation 
of the compound-dependent parameters resulted in a ~3-fold improvement in SRM 
sensitivities and was thus considered an important part of the SRM development 
process. The final TMT-SRM method was prepared by combining all transitions, dwell 
and cycle times and optimised compound-dependent parameters (Table 2.4). The 
method measured 54 transitions (27 light and heavy TMT pairs) with a dwell time of 50 
msec per transition and a total cycle time of 2.7 sec. The peak width was 25 sec at 
FWHM, resulting in approximately 10 data points per SRM.  
Crosstalk between transitions pairs of each peptide was further assessed with 
analysis of light TMT-labeled BSA peptides only (i.e., no plasma matrix) over all light 
TMT and heavy TMT transitions using a typical 90 min LC gradient. Similarly, heavy 
TMT-labeled BSA peptides only were analysed over all transitions. All transitions were 






Figure 2.6 Voltage traces for DP, CE and CXP optimisation. The optimal DP, CE and 
CXP values of BSA peptide 7 are indicated by the arrow in the diagram. 
 
-ground interference, i.e., only pure peptides can truly measure crosstalk. This level of 
crosstalk or background interference was considered negligible to the overall 
quantitative measurement.  
Following determination of crosstalk between light TMT and heavy TMT 
transitions, BSA peptides were spiked into plasma matrix and analysed by TMT-SRM 
over the same 90 min LC gradient. Spiking the BSA peptides into the light TMT-labeled 
plasma matrix had a detrimental effect on the detection of several peptides. The more 
hydrophobic peptides 1, 3, 5, and 7 were not quantifiable at the 1:1 ratio due to very 
low signal intensity and poor SRM peak shape. This is likely due to the fact that at this 
spike level in plasma these peptides are poorly detected in the complex background 
and also, the matrix may be causing signal suppression (Keshishian et al., 2007). This 
highlighted the necessity of choosing several peptides per protein for TMT-SRM 
quantitation to compensate for the poor performance of certain peptides. Such peptides 
were excluded from further analysis resulting in peptides 2, 4, 6, 8 and 9 remaining for 
quantitation. LC gradient length (30, 60 and 90 min) was then assessed to determine 
the shortest gradient time which provided the best SRM peak profiles without 
compromise to selectivity and data points. Separation of peptides over the 30 min LC 
gradient achieved the highest SRM sensitivity and smoothest SRM peak shape for all 
transitions, whilst accuracy in quantitation was maintained (the 1:1 ratio for the 
combined peptides was observed). Shorter LC gradient lengths were highly desirable 
as the total analysis time was reduced, allowing for a higher throughput of samples. 
CXP CE DP 




Background interference from the plasma was observed in the light TMT and heavy 
TMT channels for seven BSA transitions when analysing either light TMT and heavy 
TMT-labeled BSA peptides spiked into light TMT-labeled plasma. This was found to be 
dependent on the m/z of the Q3 ion. A greater contribution of background SRM signal 
was observed for transitions which had low m/z Q3 fragment ions. For example, high 
plasma background interference was observed for the transitions which measured the 
low mass structural ions of peptide 8 (y2 and b3) and peptide 4 (b9++; Table 2.4). This 
highlights the importance of selecting Q3 ions greater than the m/z of the precursor ion 
where possible as they provide greater selectivity between light TMT and heavy TMT 
transitions. All transitions which measured the pseudo y-ion in Q3 (peptides 2, 6 and 8) 
were significantly affected by background interference. This is demonstrated for 
peptides 2 and 6 in Figure 2.7, where all Q3 transitions based on high mass structural 
ions fall in the expected 1:1 ratio but transitions based on pseudo y-ions deviate from 
that expected. As pseudo y-ions are generated from all TMT-labeled peptides, this 
would result in the likelihood of less specific SRM transitions and less robust TMT-SRM 
quantitation. Consequently, pseudo y-ions will not be considered for future TMT-SRM 
quantitative measurements. Finally, the b5 transition of peptide 9 was adversely 
affected by high plasma background. As this transition represented a Q3 ion with an 
m/z above the Q1 precursor m/z, it is therefore important to select at least three 
transitions per peptide so as such aberrant transitions can be excluded. Further, it 
increases the chance of having transitions which can provide a robust quantitative 
measurement. In the subsequent analysis of the data, all transitions which were shown 
to be affected by the plasma background were removed to avoid inaccuracies in TMT-
SRM quantitation (Table 2.4). All three transitions of peptide 8 were affected by 
background interference and therefore the peptide was excluded from the data 
analysis. Plasma background interference had a greater effect on certain SRM 
transitions in this experiment than was observed in the initial experiments (Section 













concentrations to that described previously, where any background interference would 
have a greater contribution to overall SRM signal.  
 
    A                                                                  B 
 
 
Figure 2.7 TMT-SRM XIC to highlight the varying selectivities of different transitions of 
BSA peptides. High plasma background interference is observed for the transition 
utilising the pseudo-y ion (p) for peptide 2 (A) and peptide 6 (B). For the remaining 
transitions of both peptides, the expected ratio of 1:1 L/H was observed.  
 
 
2.2.2.3 Effects of plasma matrix on the accuracy of TMT-SRM quantitation  
For the determination of accuracy of TMT-SRM quantitation, light TMT-labeled 
BSA was spiked into plasma over a range of concentrations. Heavy TMT-labeled BSA 
was spiked in at a constant amount of 10 ng to act as a reference. The ratios analysed 
were as follows: 0.33:1, 1:1, 3:1, 9:1 and 27:1 (L/H), representing levels in plasma from 
266 µg/mL to 21.6 mg/ml with the reference spiked in at 800 µg/mL levels (12.6 µM). 
An identical analysis was performed without the presence of matrix. Three analytical 
and three technical replicates of each sample ratio were analysed. It was important to 
perform several analytical and technical repeats to characterise the precision of sample 
preparation procedures and QTRAP instrument performance. A linear relationship was 
found between observed and expected ratios for BSA peptides 2, 4, 6 and 9 in the 
presence of plasma matrix (Figure 2.8 A). Accurate TMT-SRM quantitation was 
observed across analytical and technical repeats with, as expected, better statistics for 
analytical over technical repeats (Table 2.5). Analytical repeats had CVs ranging from 

































Figure 2.8 Observed versus expected L/H ratio for BSA peptides 2, 4, 6 and 9. A in plasma matrix and B buffer-only. The mean of three analytical 











T1 T  1, 2, 3 T 1, 2, 3 







0.33:1 0.29 0.35 0.33 0.32 10.20 0.34 7.80 
1:1 0.93 1.14 1.06 1.04 10.10 1.08 7.33 
3:1 2.93 3.07 3.30 3.01 5.94 3.41 9.15 
9:1 9.16 9.05 9.24 9.15 1.30 10.30 10.95 






T1 T  1, 2, 3 T 1, 2, 3 







0.33:1 0.29 0.29 0.32 0.30 6.85 0.30 0.82 
1:1 0.87 0.99 0.86 0.91 8.15 0.95 10.33 
3:1 2.64 2.91 2.92 2.82 5.61 3.25 11.79 
9:1 8.94 9.67 9.11 9.24 4.16 11.10 15.93 






T1 T  1, 2, 3 T 1, 2, 3 







0.33:1 0.35 0.37 0.37 0.36 3.11 0.35 2.11 
1:1 1.08 1.08 1.02 1.06 3.20 1.07 10.15 
3:1 3.40 2.98 2.85 3.08 9.37 3.21 11.45 
9:1 9.53 8.98 8.78 9.10 4.30 9.57 11.60 






T1 T  1, 2, 3 T 1, 2, 3 







0.33:1 0.32 0.35 0.37 0.35 6.85 0.35 0.61 
1:1 1.05 1.14 1.06 1.08 4.67 1.11 4.43 
3:1 3.43 3.42 3.38 3.40 7.41 3.48 3.04 
9:1 9.63 9.37 10.50 9.83 6.01 12.30 17.86 
27:1 31.20 32.60 32.00 31.90 2.08 34.80 12.10 
 
Table 2.5 Accuracy of TMT-SRM for BSA peptides quantitated in the presence of 
human plasma matrix. As an example of the accuracy of analytical repeats, the 
individual and mean trueness (L/H ratio) for all analytical repeats (A1, A2 and A3) of 
technical replicate 1 (T1) is displayed. Furthermore, mean trueness and precision 









17.9% (45% of CVs ≤ 10%, 85% of CVs ≤ 12%). This demonstrated highly precise 
QTRAP instrument performance and in the overall TMT-SRM sample preparation 
workflow. Buffer-only results were found to be comparable to those obtained in the 
presence of matrix, thus confirming that background interference due to the plasma 
matrix did not affect TMT-SRM quantitation of those peptides remaining in the method 
in this range of concentrations (Figure 2.8 B; Appendix Table 2.1). This was reflected in  
the strong correlation observed between corresponding ratios of BSA peptides 
quantitated in each (r = 0.97 for all measurements). Thus, upon removal of problematic 
transitions with high plasma background interference, robust TMT-SRM measurements 
were achieved for BSA peptides 2, 4, 6 and 9 across the spiked concentration range in 



























 Proof-of-principle experiments have demonstrated TMT-SRM as an accurate 
quantitative strategy for the targeted measurement of multiple peptides in 
plasma at levels which represent medium to high abundant proteins. 
 The TMT sample processing workflow has been optimised for plasma including 
the choice of digestion enzyme. 
 By using isotopic versions of TMT’s, biological samples and purified proteins, as 
well as synthetic peptides can be utilised as internal standards for quantitation. 
 Important factors to achieve accurate quantitative measurements include: 
- Selection of multiple proteotypic peptides per protein. This allows for the 
removal of poor performing peptides and adds confidence to the protein 
measurement. 
- Selection of multiple high m/z structural ions in Q3 to build SRM transitions. 
This enables the determination of the most robust transitions for quantitation 
and adds confidence to the quantitative measurement. 
- Optimisation of compound-dependent parameters. This significantly 
improves SRM sensitivity by tuning voltages to the optimal detection of 
target peptides. 
- LC tR of peptides. Later eluting peptides are less suited to the approach as 
they tend to have poorer SRM peak shape and detection. 
- Assessment of the contribution that the background matrix has on the 
quantitative measurement. Such transitions/peptides affected by 
background signal can be excluded from subsequent data analysis. 
- Consideration of analytical and technical repeats to add confidence to the 
measurement. 
 Similar peptide fragmentation patterns were observed on Q-Tof micro and 
QTRAP MS platforms, demonstrating the ease at which MS/MS data from 













Development of a multiplexed TMT-SRM assay for the 
quantitation of candidate Alzheimer’s disease 





From biomarker discovery studies using 2DE and TMT labeling technologies, 
clusterin, complement C3, complement C3a, CFH, A2M, FGG, SAP, and gelsolin have 
emerged as candidate AD biomarkers (Hye et al., 2006; Thambisetty et al., 2010; 
Güntert et al., 2010). Furthermore, possession of the ApoE ɛ4 allele is the only 
unequivocal genetic risk factor known to-date for late-onset AD and the protein 
expression of this genetic association may translate as an AD biomarker (Coon et al., 
2007). The expression levels of these proteins across large AD patient populations 
have yet to be determined.  
Using the TMT-SRM strategy outlined in Chapter 2, this chapter focuses on the 
development of a multiplexed TMT-SRM assay for the quantitation of the AD candidate 
biomarkers in human plasma. This required that target analytes could be quantitated 
accurately, in parallel, and in a time scale which was viable for the analysis of a large 
number of samples. As the candidate proteins represent medium to high abundant 
species in plasma, it was hypothesised that the target analytes could be detected and 
quantitated in unfractionated plasma. This has obvious benefits as minimal sample 
manipulation will limit sample to sample variability, thereby improving accuracy in the 
quantitative measurement. Furthermore, limited sample processing allows for a 
potentialy higher throughput of samples, essential for any clinical assay. This MS assay 
approach relies on the quantitation of proteolytic peptides, which in turn act as a 
surrogate measurement for the level of the target protein in the sample. Robust 
quantitation is therefore dependent on the careful selection of peptides which are 
unique to the protein of interest, unmodified, i.e., free of PTMs and digested in a 
reproducible manner. Also, to ensure accuracy of quantitation, SRM transitions are 
required to be specific for each target analyte. Both peptide choice and transition 
specificity needed to be established during the method development phase for the 
detection and quantitation of the target proteins. Further, a stable and reproducible 
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analytical platform was required to deliver high quality MS assay results and this was 
also considered in the development of the assay.   
In contrast to the proof of principle experiments described in Chapter 2 where 
internal standardisation was performed against both a human plasma reference and 
purified protein (BSA), the choice was taken to utilise synthetic peptides for the AD 
protein panel TMT-SRM assay. This reference approach (as opposed to a biological 
reference) was taken to limit the overall sample complexity, improving the chance of 
detection and quantitation of the target proteins which are present in plasma down to 
low µg/mL levels. An additional advantage of using synthetic peptides is the ability to 
fine-tune instrument compound-dependant parameters during the method development 
process, thus enhancing the final detection of the target analytes in plasma. 


















3.1 Materials and Methods 
3.1.1. Selection of target peptides  
Clusterin (SwissProt accession number P10909), complement C3 (P01024), 
complement C3a (P01024 [formed from cleavage of amino acids 672-748 from full 
length complement C3]), CFH (P08603), A2M (P01023), FGG (P02679), SAP 
(P02743), ApoE (P02649) and gelsolin (P06396) were selected as candidate proteins 
for which AD diagnosis and prognosis may be monitored. In the first instance, an in 
silico-based approach was undertaken to determine the most suitable peptides from 
each target protein for TMT-SRM quantitation. It was crucial that each peptide uniquely 
identified the mature form of the target protein, that is, was proteotypic, with a unique 
sequence in the human proteome (Craig et al., 2005). This was determined using 
custom built in-house software (Proteotype), where the number of occurrences of each 
tryptic peptide of each candidate protein in the human proteome was determined. The 
software is based on a Perl computer programming script, where each peptide 
sequence from an in silico digest of a protein of interest is compared against all 
sequences in the human database. The frequency of occurence of each sequence is 
calculated, generating an output .pl file. To ensure sufficient SRM selectivity, peptides 
with a minimum of six amino acids were selected for TMT-SRM quantitation (Picotti et 
al., 2010). Further, peptides with a maximum of 25 amino acids were selected due to 
the financial burden and effort required to synthesise longer peptides. Additionally, 
such species are generally more hydrophobic, making them less suited for robust TMT-
SRM quantitation (as demonstrated in Chapter 2). Peptides were also chosen that had 
no known PTMs to ensure the quantitative measurement reflected as closely as 
possible to the level of the protein in the sample. To determine this, each peptide was 
manually checked for the presence of known PTMs, e.g., phosphorylation or 
glycosylation, against the annotation information for each accession number in 
SwissProt (release 54.0, 24th July 2007). Despite trypsin being highly specific and 
efficient for protein digestion, peptides with missed cleavage sites are frequently 
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observed. As a consequence, peptides which were not fully hydrolysed with trypsin, 
i.e., had one or more missed cleavages, were not considered. Peptides were also 
checked for the presence of tryptic cleavage sites immediately upstream or 
downstream from the peptide. Peptides containing residues which may be chemically 
modified during sample processing were also excluded. Specifically, methionine and 
tryptophan residues were avoided as their side chains may become oxidised and 
peptides containing cysteine residues were excluded as they may become alkylated 
(Stadtman and Levine, 2003). N-terminal glutamic acid and glutamine residues were 
avoided as they can spontaneously cyclise to become pyroglutamate. Internal lysine, 
arginine (i.e., KP/RP-non tryptic cleavage sites) and histidine residues increase the 
charge state of a peptide and thus, were avoided where possible (Yocum et al., 2009). 
MS/MS data of TMT-labeled and unlabeled plasma datasets from discovery 
studies were mined to determine which proteotypic peptides from the in silico analysis 
were routinely identified in shotgun proteomic experiments. Ideally, peptides that had 
been observed in TMT-labeled studies were taken forward for further consideration. 
However, where this information was limited, unlabeled plasma datasets were also 
considered.  
Based on the criteria described, panels of peptides per candidate protein were 
taken forward for further consideration. In response to the cost and effort required to 
prepare synthetic peptides, the strategy was limited in the number of peptides available 
for TMT-SRM quantitation. However, at least three peptides per protein were 
considered essential to afford a robust quantitative measurement. Therefore, to further 
refine the list to three peptides per protein, peptides were excluded if problems were 
envisaged during synthesis and purification, i.e., the presence of hydrophobic amino 
acids such as leucine, valine, isoleucine, phenylalanine and tryptophan. These 
peptides would difficult to solubilise in aqueous solution or in some cases, may be 
completely insoluble. Further, peptides were excluded which had many neighbouring 
tryptophan, isoleucine, valine, tyrosine, leucine, glutamine, phenylalanine, and 
threonine residues. These amino acids are responsible for beta-sheet formation which 
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can result in deletions and even truncations, resulting in a poor synthetic yield of the 
required product.  
 
3.1.2 Synthesis and TMT-labeling of peptides for internal standardisation 
The 32 peptides selected for TMT-SRM analysis of the candidate AD biomarker 
proteins were synthesised in-house at Proteome Sciences, Frankfurt, Germany. For 
TMT-SRM analysis, synthetic peptides were resuspended in 50% ACN, 0.1% FA to a 
final concentration of 3 nmol/µL (Keshishian et al., 2007). Peptides were aliquoted into 
50 µL and 100 µL volumes in 250 µL glass vials (Chromacol Ltd, Welwyn Garden City, 
UK) and stored at -80 °C until further use. Peptides (500 μg of each) were individually 
processed using the standard protocol for TMT labeling and purification by RP and 
SCX as described in Sections 2.1.1.3 and 2.1.1.4. The following exceptions were 
made: SDS was omitted from the protocol, and as there were no cysteine-containing 
peptides, no reduction was required. To maintain the concentration of all constituents 
to that of the standard TMT-labeling protocol, the volumes added for solubilisation, 
reduction and alkylation were replaced with equivalent volumes of H2O or ACN. As all 
the peptides were tryptic, no digestion was necessary and so the trypsin solution was 
replaced with 100 mM triethylammonium bicarbonate (TEAB; Sigma-Aldrich). For 
method development purposes, individual peptide solutions were labeled with 15 mM 
light TMT (as per the standard protocol). Purified peptides were lyophilised to dryness 
and stored at -80 °C. 
 
3.1.3 Transition selection and optimisation of compound-dependent parameters 
Light TMT-labeled peptides were directly infused into the QTRAP to assess the 
quality of each peptide and to define the SRM parameters. Specifically, a 2 pmol/µL 
solution of each peptide was prepared in 50% ACN, 0.05% FA and infused at 1 µL/min. 
To assess purity, a total ion MS profile of each peptide solution was acquired using a 
Q1 positive ionisation scan at unit mass resolution over the mass range m/z 400 – 
1600. This also enabled the determination of the predominant charge state for each 
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peptide (precursor ion m/z). For the selection of optimal Q3 ions to build the SRM 
method, an Enhanced Resolution (ER) and EPI scan was initially used to confirm 
theoretical m/z values for each peptide precursor and fragment ion. Using observed 
m/z values from ER, each peptide underwent EPI scanning (i.e., MS/MS analysis). To 
improve the specificity and sensitivity of each transition in Q3, the highest intensity 
fragment ions above the m/z of the precursor ion were selected where possible. Three 
transitions per peptide were selected for quantitation. The SRM method was initially 
established by inputting all theoretical precursor and fragment ion masses for each light 
TMT-labeled peptide.  
To enhance the sensitivities of each peptide and give the best chance of 
detecting each target analyte in plasma, the DP, CE and CXP were optimised for each 
individual transition. Peptides were infused into the QTRAP as described above and 
the DP, CE and CXP were optimised using the strategy as described in Section 
2.1.2.2. Optimal values for each transition were then added to the SRM method. 
 
3.1.4 Definition of peptide retention times and assessment of the selectivity and 
specificity of transitions by LC-SRM analysis  
In the first instance, the SRM method containing the light TMT-labeled 
transitions and optimised voltages was used to determine the LC-SRM detection of a 
mixture of the 32 light TMT-labeled peptides. A mixture was prepared with each 
peptide at 5 fmol/µL (i.e., 100 fmol o/c). An LC gradient of 0 - 32% ACN over 85 min 
was delivered for the resolution of the peptides. The LC was operated as described in 
Section 2.1.1.7. Washing and equilibration of the column increased the total analysis 
time to 100 min. Analysis of the peptide mixture was performed in triplicate to obtain a 
mean tR for each light TMT-labeled peptide. Due to the large number of transitions in 
the method (the final method would have 192 transitions; 96 heavy and light TMT 
pairs), SRM scheduling was required to enhance the detection of each transition. Here, 
SRM transitions are monitored only around their expected elution times, reducing the 
number of transitions being monitored at any one time (Stahl-Zeng et al., 2007). This 
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results in increased dwell and reduced cycle times, with enhancement of SRM 
sensitivity. Mean tR for all peptides were used to build the SRM scheduled method. 
Once all peptides were detected within the SRM scheduling window, the method was 
developed further by adding corresponding heavy TMT ion masses for Q1 and Q3 
(calculated in silico). Using the full method containing all 192 transitions, optimal dwell 
and cycle times for each transition could then be determined. An analysis was also 
performed whereby the light TMT-labeled peptides were analysed over the SRM 
scheduled method containing all light and heavy TMT transitions. From this, crosstalk 
between the light and heavy TMT transitions was directly determined.  
The endogenous detection of the peptides in plasma next needed to be 
established. This was assessed with the analysis of light TMT-labeled peptides spiked 
into heavy TMT-labeled plasma (as prepared in Sections 2.1.1.2 - 4). Analysis was 
performed in triplicate. The mean tR for each peptide in the presence of matrix was 
updated in the method. To establish the plasma load for the optimal detection of the 
endogenous peptides, light TMT-labeled peptides and heavy TMT-labeled plasma was 
run over the TMT-SRM method at 1 µg and 2 µg total protein loads o/c. The level of 
carry-over from TMT-labeled plasma samples was determined by running a blank over 
all light TMT and heavy TMT transitions before and after the heavy TMT-labeled 
plasma sample.  
The TMT-SRM quantitation of the candidate biomarker panel will ultimately be 
performed in a large cohort of plasma samples. The composition of plasma samples 
may be largely varied, with different levels of background interference associated with 
each. It was important to determine such background for each transition in the method 
across different plasmas, so that potentially problematical transitions could be 
highlighted. Specifically, Dade Behring plasma (Plasma A) and a pooled plasma 
sample from an AD cohort (Plasma B; see Section 4.1.1) were compared. Plasma B 
was selected to represent the constitution of the clinical samples to be used in the final 
assay. Plasma A and B were labeled with heavy TMT in parallel as described in 
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Sections 2.1.1.2 – 4. Both plasma samples (2 µg o/c) were analysed over all light TMT 
and heavy TMT transitions and the signal in the light TMT channel assessed.  
 
3.1.5 Determination of the precision of TMT-SRM using a nanoflow analytical 
platform  
To assess the precision of TMT-SRM quantitation for each peptide, replicate 
analyses of plasma A spiked with peptides was performed. Specifically, heavy TMT-
labeled plasma was spiked with the light TMT-labeled reference peptides and divided 
into four aliquots, with each aliquot having enough sample for five replicate runs. Each 
set of five replicate samples where run consecutively in a given day and this was 
repeated for each aliquot over a period of four consecutive days. Plasma was loaded at 
2 µg o/c. The L/H ratio was determined for each transition across all replicates as 
described in Section 2.1.1.9.  
 
3.1.6 Validation of microflow LC rates and ESI for TMT-SRM and development of 
assay design 
Higher LC flow rates (i.e., 100 µL/min) and ESI were investigated with the 
objective of improving the robustness of the assay. In parallel, an assay design was 
also developed such that the accuracy, linearity, LOD and LOQ could be derived for 
the assay of each analyte in an efficient and workable manner. To investigate this, a 
simple target analyte not endogenous to plasma was utilised. A synthetic tryptic 
peptide was selected which was available in-house (peptide sequence VATVSLPR) 
and labeled with light and heavy TMT as described in Section 2.1.1.3. The TMT-SRM 
method was developed with the selection of optimal Q1 and Q3 ions and compound-
dependent parameters as described in Section 2.1.2.2.  
TMT-SRM analysis was performed on a QTRAP coupled to an Ultimate 3000 
LC system (Dionex) as described in Section 2.1.1.7. The initial format of the microflow 
LC system was implemented in the laboratory following discussion with the Biomarker 
Research Initiatives in Mass Spectrometry Centre (BRIMS) in Cambridge, 
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Massachusetts, USA. The mass spectrometer was fitted with a micro-ion spray source 
with a 27-gauge needle insert for microlitre flow rates and operated in positive 
ionisation mode. Q1 and Q3 mass resolution was set to unit. To establish optimal ion 
source voltage and gas parameters at the higher flow rate, light and heavy TMT-
labeled peptides were infused into the instrument at 100 µL/min. Optimal detection was 
obtained with an ion spray voltage of 5250 V, interface heater temperature of 475 °C, 
curtain gas of 20 p.s.i and nebuliser gas of 25 p.s.i. For the LC, an in-line filter (0.2 µm; 
Upchurch Scientific, Cambridgeshire, UK) was placed upstream of the analytical 
column (Hypersil gold, 1 mm i.d. x 50 mm; 1.9 μm, Thermo Fisher Scientific), providing 
protection of the column by removing particulates which may be present in LC buffers 
and/or analytical samples. The autosampler was configured to enable sample pick-up 
(20 uL full loop injection with 21 uL sample pick-up) from a microtitre plate format. 
Peptides were resolved by RP-LC, over a 9 min gradient of 5 - 30% ACN, delivered by 
a combination of Buffer A (0.2% FA) and Buffer B (80% ACN, 0.2% FA) at a flow rate 
of 100 μL/min. Washing and equilibration of the column increased the total run time to 
15 min. To prevent contaminants entering the mass spectrometer, all eluant during the 
first minute and final three minutes of each run was diverted to waste. Using stock 
solutions of 5 pmol/µL, light and heavy TMT-labeled VATVSLPR peptides were 
combined in a 1:1 ratio and diluted to 5 fmol/µL in 3% ACN, 0.2% FA. LC-SRM analysis 
of this solution was performed in triplicate to determine the accurate tR.  
To minimise peptide losses due to non-specific binding to plastics, VATVSLPR 
peptides were redissolved in a scavenger protein, glucagon (200 μg/mL in 3% ACN, 
0.2% FA, glucagon solution; Sigma-Aldrich) to provide new stock solutions of 5 
pmol/µL. An 11-point calibration curve was produced by varying the concentration of 
light TMT-labeled peptide whilst keeping the heavy TMT-labeled peptide constant. 
Specifically, a working solution of 5 fmol/µL heavy TMT-labeled VATVSLPR (to provide 
100 fmol o/c) in glucagon solution was prepared from the stock and used as the diluent 
for preparation of the concentration range of light TMT-labeled peptides (0.25, 0.5, 1, 2, 
5, 10, 50, 100, 250, 500 and 1000 fmol o/c) to build the curve. A comparison was made 
135 
 
between curves prepared in the presence and absence of glucagon. Subsequently, 
calibration curves prepared using VATVSLPR peptides resuspended in glucagon 
solution were quantitated in buffer-only (in duplicate) or plasma (one replicate; 
prepared as described in Section 3.1.7, sample C). The process of assay development 
required the evaluation of the accuracy of quantitation. Accuracy incorporates both 
trueness and precision of a measurement. To determine this, triplicate measurements 
(here-in referred to as QCs) of the 5 and 50 fmol o/c dilutions prepared above were 
acquired for each calibration curve, which were performed over two days (buffer-only 
measurements) or within a single day (plasma measurements). From these, the intra-
batch (within day) and inter-batch (across day; i.e., measurement only available for 
buffer-only experiments) variation was determined. Following peak area extraction as 
described in Section 2.1.1.9, standard curves (L/H versus L concentration) were plotted 
in Microsoft Excel 2003. Plots were log10 transformed to better visualise the lower 
points of the curve. The curves were used to interpolate QC amounts for the 
determination of the trueness and precision of TMT-SRM quantitation. The LOD was 
defined as the lowest concentration where the SRM sensitivity for each target analyte 
was three times the S/N. The LOQ was defined as the lowest concentration where 
precision was < 20%. 
 
3.1.7 Upscaling of plasma digestion, TMT-labeling and purification protocols  
Due to the increased amount of protein required for microflow/ESI analysis (30 
µg of plasma protein per analysis), TMT-labeling and sample purification procedures 
were upscaled. To ensure the sample quality was not compromised and the sensitivity 
of the workflow was maintained, several comparisons were performed as outlined in 
Table 3.1. The same digested plasma sample was used across all comparisons.  
In addition to adapting the standard protocol (Section 2.1.1.3) to account for 
higher protein amounts, several formal changes had been made to the standard 
protocol by the developers and manufacturers of TMT. Specifically, borate buffer was 
replaced with TEAB as this is a volatile buffer and easier to prepare. 
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plate (30 µg) 
A 100 µg          
B 100 µg          
C 1.8 mg            
 
Table 3.1 Comparisons made to assess the effect of upscaling the TMT-labeling 
protocol. 
 
Additionally, the time and temperature required for sample reduction was 
increased to 1 hr and 55 °C, respectively. Plasma A (25 μL; 2 mg, Section 3.1.5) was 
diluted to 1 µg/µL in 0.1% SDS, H2O and 100 mM TEAB (pH 8.5). The sample was 
reduced, alkylated, digested and labeled with light TMT using concentrations as per the 
standard protocol. Labeled plasma peptides were diluted with 0.1% TFA to reduce the 
ACN concentration to ~ 5%. From this, 100 µg (1 mL; Sample A) was removed and 
purified by RP and SCX as per the standard protocol (Section 2.1.1.4). The remainder 
(1.9 mg, 19 mL) underwent an up-scaled RP procedure using Hypersep C18 
Cartridges with a 500 mg bed volume (Thermo Fisher Scientific). Column conditioning, 
equilibration, washing and peptide elution was performed using volumes upscaled 
accordingly to the standard protocol. To determine if upscaling of the RP protocol had 
any detrimental effects, 100 µg of protein was taken from the RP eluant and subjected 
to SCX purification via the standard protocol (Sample B). The remaining 1.8 mg 
underwent SCX purification using an upscaled version of the protocol (Sample C). 
Specifically, SCX cartridges were prepared in-house using 2.6 mL sepharose 
suspension (four times the standard protocol). Washing and equilibration volumes were 
upscaled accordingly. Peptides were eluted in 3 mL SCX elution buffer and a further 1 
mL of SCX loading buffer was added to reduce the concentration of salt in the sample. 
An aliquot (100 µg) was removed and lyophilised in an eppendorf as normal. The 
remaining sample was aliquoted into a Thermo-Fast® 96 Robotic PCR Plate (Thermo 
Fisher Scientific) with 30 µg of peptides per well (resulting in approximately 60 wells for 
analysis). Following lyophilisation, each well containing peptides was resuspended in 
SCX loading buffer to 0.5 µg/µL and lyophilised for a second time. Samples A, B and C 
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were analysed in duplicate by LC-MS/MS (1 µg protein load o/c, 60 min 0 - 32% ACN) 
as described in Section 2.1.1.5.  
 
3.1.8 Preparation, TMT-labeling and purification of equimolar mixtures of 
candidate AD peptides of the same protein  
Clinical sample cohorts, comprising large numbers of samples, consume large 
amounts of TMT label. The more cost-effective approach from here-on-in was to label 
plasma with the less expensive light TMT label (due to the lack of heavy isotopes) and 
label the synthetic peptide internal standards with heavy TMT. As a first step to 
minimise the variation in TMT-SRM quantitation between peptides of the same protein, 
the accurate concentration of each peptide was determined. AAA was performed at the 
Protein and Nucleic Acid Chemistry Facility, Department of Biochemistry, Cambridge, 
UK (Norden et al., 2004). Specifically, all aliquots prepared in Section 3.1.2 were re-
combined and the AAA concentration of each peptide solution determined. A suitable 
volume of each peptide stock solution (1.5 nmole/uL) and of L-norleucine internal 
standard was pipetted into a microtube (4 cm  3 mm), which was cleaned beforehand 
by heating to 500°C for 15 hours and lyophilised to dryness. Gas phase acid hydrolysis 
was performed at 115°C for 22 hours. The residue was then dissolved in sodium citrate 
loading buffer (pH 2.2) and filtered by centrifugation through a 0.2 µm filter. An aliquot 
of the filtrate was injected into a loading capsule and placed in a Biochrom 30 Analyser 
© amino acid analyser (Biochrom Ltd., Cambridge, UK). Chromatography performed on 
a sodium system ion exchange resin eluting with buffers over the pH range 3.2 - 6.45. 
Peak detection was achieved by mixing the eluate with ninhydrin at 135°C and 
measuring the absorbance at 570 and 440 nm. 
To further reduce quantitative variability, peptides of the same protein were 
combined in equimolar mixtures and labeled with light TMT (15.5 nmol of each peptide 
per mixture) and heavy TMT (62 nmol of each peptide per mixture) as described in 
Section 2.1.1. Heavy TMT-labeled peptides were used for method development, the 
generation of calibration curves and to act as an internal standard for TMT-SRM 
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quantitation. Light-labeled peptides were required for method development and the 
generation of calibration curves. 
As each synthetic peptide was already in high concentrations of ACN (50%), 
adjustments were made to the standard protocol to ensure the concentration of ACN 
was in the acceptable range for TMT-labeling. TEAB (400 mM) stock solution was 
added to reach a final concentration of 100 mM for TMT-labeling. Solutions of IAA and 
TCEP were replaced with H2O. Trypsin was replaced with 100 mM TEAB. A more 
concentrated stock solution of TMT was prepared (90 mM in 100% ACN) and added to 
reach a final concentration of 15 mM. Post-TMT labeling, 10 µL was removed from 
each equimolar mixture for quality assessment. Both light and heavy TMT-labeled 
equimolar mixtures underwent subsequent purification by RP and SCX as per the 
standard protocol. Post-purification, a 10 µL aliquot was removed from each mixture for 
quality assessment. The remaining volume was lyophilised to dryness and stored at -
80 oC. Labeled and unlabeled equimolar mixtures of each protein were infused into the 
QTRAP. Solutions were diluted in 50% ACN, 0.25% FA and infused at 500 fmol/µL for 
2 min over m/z 400 – 1200 in Q1 positive ionisation mode. All major ions in each 
mixture were assessed. 
 
3.1.9 Modification of the LC-SRM method for the analysis of the AD candidate 
biomarker panel at microflow LC rates 
LC and SRM parameters for the AD candidate biomarker panel using microflow 
LC conditions were determined. Important considerations were the reduction in 
gradient length and decrease in SRM peak widths. To determine whether the SRM 
detection of the target analytes in plasma was altered using microflow as compared to 
nanoflow LC rates, a full method was prepared for the analysis of all 32 original target 
analytes on the new platform. Heavy TMT-labeled equimolar mixtures of each protein 
were combined and diluted in glucagon solution to provide a stock solution of all 
peptides at 5 pmol/µL. This was further diluted to a peptide working solution of 5 
fmol/µL. Light TMT-labeled plasma (30 µg o/c) was resuspended in 25 µL of the 
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working solution, thus providing 100 fmol of each internal standard o/c. To ensure 
sufficient LC separation of all target AD candidate biomarker peptides, the LC gradient 
was increased by 5 min to that used for TMT-SRM analysis of VATVSLPR. Thus, 
peptides were resolved by RP-LC over a 14 min gradient of 5 - 30% ACN at a flow rate 
of 100 μL/min. Washing and equilibration of the column increased the total run time to 
20 min. QTRAP source parameters were as described in Section 3.1.6, with exception 
of the curtain gas which was increased to 30 p.s.i and the nebuliser gas which was 
increased to 30 p.s.i. Instrument performance was benchmarked prior to analyses 
using the TMT-SRM method established for the analysis of VATVSLPR in Section 
3.1.6. Light TMT and heavy TMT-labeled versions of the peptide in glucagon solution 
were combined in a 1:1 ratio (100 fmol of each o/c) and the SRM sensitivity and elution 
profile assessed. Specifically, an SRM sensitivity of > 1.5 e4 and tR of ~ 7.9 min was 
required. This light TMT/ heavy TMT mix was used as a standard for the future 

















3.2.1 Selection of peptides 
Strict criteria were applied to ensure only the most specific peptides were 
selected to build the TMT-SRM method. In the first instance, a list of the frequency of 
occurrence in the human SwissProt database of all tryptic peptides for each candidate 
protein was generated in silico and filtered according to size and presence of 
unfavourable amino acids (Appendix Tables 3.1 – 3.9). Peptides were considered 
unsuitable for the TMT-SRM method if they were not between 6 - 25 amino acids in 
length and if they contained cysteine, methionine, tryptophan, glutamic acid or 
glutamine residues. To avoid peptides of multiple charge states, internal lysine, 
arginine and histidine residues were avoided where possible. Peptides shortlisted for 
TMT-SRM quantitation were proteotypic except for peptides of clusterin, complement 
C3, complement C3a, SAP and gelsolin, which had sequence frequencies in the 
human proteome of two or three. Two isoforms of clusterin exist in blood (isoform 1 and 
2) as a result of alternative splicing, with isoform 2 having an extra 52 amino acids at 
the N-terminus compared to isoform 1. None of the selected peptides were present in 
this sequence and thus, the peptides measured either isoform. Complement C3 
peptides were also specific to the complement C3 β-chain. Both these proteins are 
observed in blood plasma. Shortlisted peptides of complement C3a were also specific 
to the full complement C3 protein and complement C3 β-chain. However, circulating 
C3a is distinguished from other complement species by the C-terminal proteotypic 
peptide ASHLGLA. Upon processing of C3a in vivo, the C-terminal R residue is 
cleaved from the protein. SAP is observed in plasma as two different isoforms which 
differ by a single amino acid at the C-terminus. Thus, peptides selected for SAP 
measured either isoform. Similarly, the gelsolin protein is found as two distinct isoforms 
with isoform 1 having an extra 51 amino acids at the N-terminus compared to isoform 
2. Isoform 1 is found in plasma and isoform 2 is cytoplasmic and thus it was isoform 1 
that would be measured in the method under development. Following these exclusion 
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criteria, the final panel of signature peptides for the TMT-SRM method was selected 
based on experimentally-derived data and whether the peptide could be easily 
synthesised, with a high yield (Table 3.2). Factors considered here included whether 
shortlisted peptides from the in silico analysis were previously observed in MS/MS 
datasets, with focus on LC tR and peptide fragmentation patterns where available. 
Several peptides (Appendix Tables 3.1 - 3.9) were not shortlisted for quantitation in this 
instance, in favour of peptides previously observed. However, these may serve as 
possible target analytes in future studies. Using CFH as an example, all shortlisted 
peptides were observed in TMT-labeled or unlabeled plasma MS/MS datasets. 
Although possessing early to middle LC tR and high MS/MS fragment ions, CFH 
peptides SSNLIILEEHLK and SSIDIENGFISESQYTYALK were estimated to have 
problematic synthesis and produce a low yield. This was due to the presence of 
hydrophobic partial structures and N-terminal serine residues which cause side 
reactions to occur during cleavage of the peptide from the synthesis solid support. 
Thus, three peptides of CFH remained which were considered suitable for synthesis 
and inclusion in the final TMT-SRM panel. However, despite not being observed in 
discovery datasets or having potential problems during synthesis, the Apo E peptides 
LQAEAFQAR, LGPLVEQGR and SELEEQLTPVAEETR were selected for TMT-SRM 
method development over a potentially more suitable peptide (LAVTQAGAR). The first 
peptide was proteotypic in both the mouse and rat plasma database (data not shown), 
thus allowing for potential future application of the assay in these species. The latter 
two peptides were previously synthesised (even though problems were envisaged in 
synthesis here) and thus, the peptides were selected for TMT-SRM analysis of the 
protein. In total, three peptides per protein candidate were selected for quantitation (32 
in the full panel, Table 3.2). This was with exception as for clusterin, six peptides were 
selected for the protein with three each for α- and β-chains. For complement C3a, only 
a single peptide (ASHLGLA) was available to discriminate this target from the full 
complement C3 protein. Further, due to their availability in-house, one extra peptide of 
A2M and three extra peptides of gelsolin were included for TMT-SRM quantition. 
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Protein SwissProt Proteotypic Peptides (6 - 25 aas) Discovery 
In silico 
frequency 
Observed experimentally LC tR* 
Presence of high mass MS/MS 
ions* 
Synthesis 
   
 Human TMT Unlabeled 
  
 
Clusterin α-chain P10909 TLLSNLEEAK Y 2 Y Y early/middle moderate Y 
  
SGSGLVGR  2 Y N NA NA  
  
ASSIIDELFQDR Y 2 N Y late good Y 
  
IDSLLENDR  2 N N NA NA Y 
Clusterin β-chain P10909 VTTVASHTSDSDVPSGVTEVVVK Y 2 Y Y middle good Y 
  
ALQEYR  2 Y N NA NA Y 
  
YNELLK  2 N N NA NA Y 
  
LANLTQGEDQYYLR  2 N N NA NA  
Complement C3 P01024 TIYTPGSTVLYR  2 Y Y middle good Y 
  
IPIEDGSGEVVLSR  2 Y N NA NA  
  
VVLVAVDK  2 Y N NA NA  
  
AEDLVGK  2 Y N NA NA  
  
LLPVGR  2 Y N NA NA  
  
LVAYYTLIGASGQR  2 Y N NA NA Y 
  
FYYIYNEK  2 Y N NA NA Y 
  
GVFVLNK  2 Y N NA NA  
  
VLLDGVQNPR  2 Y N NA NA  
  
ISLPESLK  2 Y N NA NA  
Complement C3a P01024 SVQLTEK  3 Y N NA NA  
  
ASHLGLA  1 N N NA NA Y 
CFH P08603 SPDVINGSPISQK  1 Y Y middle good Y 
  
SSNLIILEEHLK  1 Y Y middle good  
  
VGEVLK  1 Y N NA NA Y 
  
SSIDIENGFISESQYTYALK  1 N Y NA NA  
  
IDVHLVPDR  1 Y N NA NA Y 
A2M P01023 AIGYLNTGYQR  1 Y Y middle good Y 
  
TGTHGLLVK  1 Y Y early poor Y 
  
GEAFTLK  1 Y N NA NA Y 
  
LPPNVVEESAR  1 Y N NA NA  
  
VSVQLEASPAFLAVPVEK  1 Y Y middle good  
 
Table 3.2 Overview of the selection of signature peptides for the TMT-SRM method. Peptides highlighted red were estimated to have problematic 
purification,  those in orange were estimated to have problematic synthesis and those in yellow were estimated to have a low overall yield from 
synthesis. Also included is the proteotypicity, LC tR, fragmentation properties and whether the peptide was selected for synthesis. * from discovery datasets 
NA:
 
this information was not available for the TMT-labeled dataset as the identification was in the Proteome Sciences Frankfurt research facility and the information was not easily retrievable. 
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Analyte Protein SwissProt  Proteotypic Peptides (6 – 25 aas) Discovery In silico frequency Observed experimentally LC tR 
Presence of high mass 
MS/MS ions 
Synthesis 
    Human TMT Unlabeled    
 A2M (continued)   AAQVTIQSSGTFSSK  1 Y N NA NA  
    SLNEEAVK  1 Y N NA NA  
    GPTQEFK  1 Y N NA NA  
    LLIYAVLPTGDVIGDSAK Y 1 Y Y late good Y 
    SDIAPVAR  1 Y N NA NA  
    FEVQVTVPK  1 Y N NA moderate  
    ALLAYAFALAGNQDK  1 Y Y late moderate  
FGG P02679 YLQEIYNSNNQK Y 1 Y Y early/middle good Y 
    LDGSVDFK Y 1 Y Y middle good Y 
    YEASILTHDSSIR  1 N Y NA NA  
    IHLISTQSAIPYALR  1 Y N NA NA  
    VGPEADK Y 1 N N NA NA Y 
SAP P02743 IVLGQEQDSYGGK Y 2 Y Y middle good Y 
    VGEYSLYIGR Y 2 Y Y middle good Y 
    AYSLFSYNTQGR Y 2 Y Y middle good Y 
    DNELLVYK  2 Y N NA NA  
    AYSDLSR  2 N Y NA NA  
    VFVFPR  2 Y N NA NA  
ApoE P02649 LGPLVEQGR  1 Y Y middle good Y 
    LAVYQAGAR  1 Y N NA NA  
    GLSAIR  1 N N NA NA  
    LQAEAFQAR  1 N N NA NA Y 
    AATVGSLAGQPLQER  1 N N NA NA  
    VEQAVETEPEPELR  1 N N NA NA  
    LEEQAQQIR  1 N N NA NA  
    SELEEQLTPVAEETR  1 Y Y NA NA Y 
    DADDLQK  1 N N NA NA  
Gelsolin P06396 QTQVSVLPEGGETPLFK Y 2 Y Y late moderate Y 
    AGALNSNDAFVLK Y 2 Y Y late moderate Y 
    TASDFITK Y 2 Y Y middle good Y 
    AVEVLPK Y 2 Y Y middle good Y 
    HVVPNEVVVQR Y 2 Y Y early good Y 
    EPGLQIWR Y 2 Y Y late moderate Y 
Table 3.2 (continued) 
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From the selected peptides, 16 were observed in biomarker discovery plasma datasets 
(Table 3.2). This was desirable as it enabled the direct transfer of information from 
TMT-labeled discovery. In summary, peptides were selected which fulfilled the 
characteristics required for robust TMT-SRM quantitation, i.e., were between 6 - 25  
amino acids in length, were fully hydrolysed by trypsin, contained no variable 
modifications, either in vivo or in vitro and typically, doubly charged. Further, each 
peptide could be easily synthesised with a high yield expected. 
 
3.2.2 Selection of transitions  
The TMT-SRM method was initially developed with direct infusion of the light 
TMT-labeled synthetic peptides for the assessment of purity and for the selection of 
suitable SRM transitions. An MS spectrum was acquired to assess the purity of the 
TMT-labeled peptide standards. All peptides were free from contaminating ions. 
MS/MS spectra were acquired following fragmentation of the predominant peptide ion 
and three fragment ions were selected as Q3 transitions for each precursor ion (Table 
3.3). The selectivity of SRMs was aimed to be improved by choosing those fragment 
ions with an m/z greater than that of the precursor ion m/z. Further, ions of the highest 
intensity were selected, ensuring high SRM sensitivity. Figure 3.1 displays the MS/MS 
spectrum of peptide 31 to demonstrate fragment ion selection. The unfragmented 
precursor ion is observed along with the selected Q3 fragment ions. Optimal light TMT 
transitions for all 32 peptides were combined to initially build the TMT-SRM method 
(Table 3.3).  
 
3.2.3 Optimisation of compound-dependant parameters and application of SRM 
scheduling 
To give the best chance of detecting each target analyte in undepleted plasma, 
the sensitivity of each transition was optimised with fine-tuning of the DP, CE and CXP. 
In Section 2.1.2.2, optimised values for one transition were taken as 




Figure 3.1 Selection of optimal MS/MS fragment ions for TMT-SRM quantitation. Upon 
CID of the precursor ion (Q1), fragment ions are measured in Q3 (1, 2 and 3) and used 
to build the TMT-SRM method.  
 
 
analyte amount upon utilisation of a purified protein as an internal standard. In contrast 
here, the incorporation of synthetic peptides for internal standardisation provided 
increased amounts of each analyte. This enabled the optimisation of compound-
dependent parameters for individual transitions in the TMT-SRM method. This further 
demonstrates the advantage of using synthetic peptides as an internal standard for 
TMT-SRM quantitation. Appendix Table 3.10 displays the optimised DP, CE and CXP 
voltages for all target analytes which were used to build the TMT-SRM method. For 
transitions of the same peptide, the DP value was identical. Optimal CE and CXP 
values were very defined and could vary greatly between different transitions of the 
same peptide, depending on the m/z of the ion selected in Q3. This underlined the 
necessity of optimising the CE and CXP for each individual transition in future TMT-
SRM methods. Also displayed are the mean tR for each peptide which was used to 
build the SRM scheduled method. A 360 sec SRM scheduling window was applied for 
the measurement of each peptide and all peptides were observed in the centre of each 
window (± 30 sec). Heavy TMT transitions were subsequently added to build the final 
























































 2 1616.92 809.5 940.5 1053.6 1443.7  1621.92 812.0 945.5 1058.6 1448.7 
 3 
TMT
IDSLLENDR 2 1297.76 649.9 766.5 846.5 1124.6  1302.76 652.4 771.5 846.5 1129.6 




 3 2761.65 921.6 898.6 1238.7 1337.8  2771.64 924.9 903.6 1243.7 1342.8 
 5 
TMT





  2 1226.80 614.4 744.4 840.5 857.4  1236.80 619.4 749.4 845.5 862.4 









 2 1587.02 794.5 811.4 890.5 1217.6  1597.02 799.5 816.4 895.5 1222.6 
 9 
TMT
LVAYYTLIGASGQR 2 1735.08 868.5 1228.6 1299.7 1398.7  1740.08 871.0 1228.6 1299.7 1398.7 











 2 1789.14 895.6 1054.6 1167.7 1266.7  1799.14 900.6 1059.6 1172.7 1271.7 
 12 
TMT





 2 1091.82 546.9 609.4 722.5 769.5  1101.82 551.9 614.4 727.5 774.5 
A2M 14 
TMT






























 2 1162.78 582.4 783.5 793.4 840.4  1172.78 587.4 788.5 798.4 845.4 
 
Table 3.3 Tryptic plasma peptides from each candidate AD biomarker selected for TMT-SRM quantitation. For each protein the sequence of each 
peptide is indicated, along with the precursor ion charge state and peptide Mr. The m/z of Q1 and Q3 for the specific detection of the light and heavy 
TMT versions of the peptides are listed.  
a indicates those peptides with poor endogenous detection in plasma by nanoflow LC/ nanospray MS. 
b indicates those peptides which were adversely affected by sample preparation procedures (as described in Section 3.2.8). 














































 2 1841.08 921.5 1107.6 1292.6 1504.8  1851.08 926.5 1112.6 1297.6 1509.8 
 22 
TMT
VGEYSLYIGR 2 1379.78 690.9 871.5 1036.5 1057.5  1384.78 693.4 871.5 1041.5 1057.5 
 23 
TMT
AYSLFSYNTQGR 2 1629.90 816.0 972.5 1172.6 1335.8  1634.90 818.5 972.5 1172.6 1335.8 
ApoE 24 
TMT
LGPLVEQGR 2 1191.66 596.8 704.5 833.5 855.5  1196.66 599.3 709.5 838.5 855.5 
 25 
TMT


































 3 1498.92 500.6 560.4 600.4 729.4  1503.93 502.3 565.4 600.4 729.4 




 2 1221.82 611.9 749.4 862.5 869.5   1226.82 614.4 754.4 867.5 874.5 
 








windows) had a dwell time of 37.8 msec per transition, a cycle time of 2.5 sec with 21 
data points at FWHM. Further, doubling the number of transitions in the method upon 
inclusion of the heavy TMT transitions reduced SRM sensitivities of those target 
analytes which elute during the busiest point in the LC gradient by approximately one 
third. All other target analytes had negligible reductions in SRM sensitivities. 
The incorporation of pure synthetic peptides into the TMT-SRM workflow 
additionally allowed for the direct determination of crosstalk between light TMT and 
heavy TMT transitions, i.e., the signal in the heavy TMT channel in the presence of 
light TMT-labeled peptides only. All transitions were found to be selective, i.e., the 
signal in the heavy TMT channel was < 1%.  
 
3.2.4 Detection of target analytes in human plasma and assessment of plasma 
background interference on SRM transitions  
The endogenous detection of each peptide in plasma was next determined. 
Light TMT-labeled peptides were spiked into heavy TMT-labeled plasma. The presence 
of plasma matrix resulted in a shift in tR for all target analytes and a new SRM 
scheduled method was established to account for this. The 2 µg plasma load was 
determined to be the optimal for the detection of target analytes (as compared to the 1 
µg load) as the majority of peptides were observed with good SRM sensitivities. No 
major carry-over (<1%) was observed from the plasma load in the blank analyses 
between runs. Figure 3.2 displays the detection of light TMT-labeled internal standards 
spiked into heavy TMT-labeled plasma. 
Peptides 2 (clusterin α-chain), 4 (clusterin β-chain), 10 (complement C3a), 11 
(CFH), 18 (FGG), 26 (ApoE) and 32 (gelsolin) were not endogenously detected in 
plasma, indicating that detection was dependent on individual peptide properties rather 
than at the protein level (Table 3.2). The peptide which distinguished complement C3a 
from complement C3 (peptide 10) was not detected in the plasma sample and 
consequently, the protein was excluded at this stage. This was perhaps unsurprising as 
peptide 10 was a short, non-tryptic peptide and was not previously observed in MS/MS 
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datasets. However, it was important to at least initially consider complement C3a in the 
candidate AD biomarker panel. Peptides 2, 4, 10, 11, 18, 26 and 32 were excluded at 
this stage. Therefore, 25 peptides remained for quantitation (150 transitions; 75 light 
TMT and heavy TMT pairs), with at least two peptides per candidate protein. Ten 
peptides now eluted during the busiest point in the gradient. The dwell time was 
increased from 37.8 msec to 45 msec per transition with a cycle time of 2.5 sec and 22 
data points at FWHM.  
 
 
Figure 3.2 An SRM XIC for light TMT-labeled synthetic peptides 1 – 32 spiked into 
heavy TMT-labeled plasma. All light TMT transitions listed in Table 3.3, representing 
the internal standard, were observed in the method. The zoomed panel shows those 
peptides which elute during the busiest part of the LC gradient (i.e., 32 – 42 min). 
 
 
To assess the background interference associated with different sources of 
plasma, heavy TMT-labeled plasmas A and B were analysed over all light TMT and 
heavy TMT transitions. Target peptides were generally detected at similar SRM 
sensitivities in both plasmas (r = 0.95 for all measurements). Those transitions which 
had plasma background effects were generally common to both (Table 3.4). All 
transitions with high background interference were highlighted as potentially less 
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accurate, but remained in the method for further investigation in subsequent TMT-SRM 
quantitation studies.  
 
Protein Peptide ID Candidate peptide 
Light TMT Heavy TMT 
Q1 (m/z) Q3 (m/z) Q1 (m/z) Q3 (m/z) 
Clusterin α-chain 1 TLLSNLEEAK 783.5 995.6 (b7) 788.5 1000.6 (b7) 
 
3 IDSLLENDR 649.9 766.5 (b5) 652.4 771.5 (b5) 




Clusterin β-chain 5 ALQEYR 502.3 666.5 (b4) 502.3 671.5 (b4) 





6 YNELLK 614.4 744.4 (b4) 619.4 749.4 (b4) 








Complement C3 9 LVAYYTLIGASGQR 868.5 1228.6 (y11) 871.0 1228.6 (y11) 
CFH 12 IDVHLVPDR 430.0 552.3 (b3) 431.6 557.3 (b3) 
 
13 VGEVLK 546.9 769.5 (y5) 551.9 774.5 (y5) 
A2M 14 AIGYLNTGYQR 740.4 1014.5 (y8) 742.9 1014.5 (y8) 
SAP 21 IVLGQEQDSYGGK 921.5 1107.6 (b8) 926.5 1112.6 (b8) 









22 VGEYSLYIGR 690.9 1036.5 (b7) 693.4 1041.5 (b7) 




Gelsolin 29 TASDFITK 665.9 1005.5 (y7) 670.9 1010.5 (y7) 
  30 AVEVLPK 602.4 736.5 (b5) 607.4 741.5 (b5) 
Table 3.4 SRM transitions with high plasma background interference in plasma A and 
B. Such transitions remained in the TMT-SRM method for further investigation.  
 
3.2.5 Precision of TMT-SRM quantitation by nanoflow LC-SRM 
Once the TMT-SRM method was refined and good endogenous detection of 
each of the 25 peptides was established, the precision of TMT-SRM quantitation was 
assessed. Light TMT-labeled synthetic peptides were spiked into heavy TMT-labeled 
Plasma A and replicate analyses (n = 5) performed over four days. One run each from  
batch 1 and 2 were excluded due to poor SRM signal intensity. Therefore, a total of 18 
replicate runs were taken forward for data analysis. Figure 3.3 displays the L/H ratio for 
each transition of each peptide across all runs and batches. Each line represents a 
given transition of a peptide and each colour represents all transitions within a peptide. 
Peptides of the same protein are plotted on the same graph. High precision in TMT-
SRM quantitation would be presented as a flat line plotted across replicate runs of each 










Figure 3.3 The accuracy of TMT-SRM quantitation of AD candidate peptides. Replicate 
runs of each peptide (I.D.) of each protein are displayed. Each colour represents a 








































I.D. 19, 20 I.D. 21, 22, 23 
I.D. 24, 25 I.D. 27, 28, 29, 30, 31 
I.D. 7, 8, 9 
I.D. 12, 13 I.D. 14, 15, 16, 17 
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Systematic fluctuations of L/H ratios within a batch were observed and consistent 
between different transitions, peptides and proteins. Different fluctuations were 
observed across batches. The large fluctuations observed indicated that large variation 
existed between measurements of the same analyte across runs and batches. Taking 
peptide 17 as representative of all peptides of A2M, a CV value of 31% was observed 
across batch one. Such high imprecision was in contrast to those results described in 
Section 2.2.1.4, where the majority of target analytes were shown to have precise 
TMT-SRM quantitation. A greater number of replicate runs (n = 18) was performed on 
the same sample in this set of experiments compared to previously (n = 9), providing a 
more extensive characterisation of TMT-SRM precision. Plasma carryover o/c was not 
the reason for the variability observed as the heavy TMT (plasma) peak areas across 
all transitions of all peptides was consistent, i.e., did not increase over the course of a 
batch of samples (Appendix Figure 3.11). 
In this instance, visualisation of the data by means of a line graph allowed for 
further characterisation of aberrant transitions and peptides as they displayed 
deviations from the trend which could be excluded from future analysis, e.g., all 
transitions of A2M peptide 16 and SAP peptide 21. Due to the imprecision observed 
between analytical repeats, an alternative platform to the nanoflow LC needed to be 
considered. 
A comparison was made between amounts expressed for peptides of the same 
protein (Figure 3.3). Variation in amounts recovered was observed for all peptides of 
clusterin, CFH, FGG and ApoE. The variations observed may be due to a number of 
reasons including differential peptide production during plasma digestion and 
differences in the recovery of each synthetic peptide following TMT-labeling and RP 
and SCX purification. Further, non-specific binding of peptides to plastics may have 
resulted in losses, the extent of which being dependant on the properties of individual 
peptides. The storage of the peptide solutions across multiple aliquots of low volume 
may have added to peptide instability. The latter two were likely to be major factors in 
the fluctuations observed and thus, the preparation of the internal standards needed to 
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be addressed. However, at least two peptides of complement C3 (peptides 8 and 9), 
SAP (peptides 22 and 23) and gelsolin (peptides 27, 30 and 31 and peptides 28 and 
29) gave endogenous plasma amounts within the same range. This was very 
encouraging, as it provided the first indication that certain peptides of the same protein 
performed similarly by TMT-SRM. 
 
3.2.6 Assay development for TMT-SRM using microflow LC rates and ESI  
Based on the results in Section 3.2.5, the nanoflow LC system was not robust 
enough for a high quality assay. Imprecise TMT-SRM quantitation was observed for the 
majority of peptides in the AD candidate biomarker panel. For any assay to be 
successful, accurate quantitation is essential. An added disadvantage of nanoflow LC 
flow rates is the requirement of long LC gradients for peptide separation, resulting in a 
lower throughput of samples. To resolve this, the configuration of the LC was changed 
to enable microflow rates. A combination of higher flow rates and decreased elution 
peak widths would potentially allow for more robust TMT-SRM quantitation and sample 
analysis times could be reduced from 100 min to 15 min per sample. Furthermore, an 
ESI probe was used in combination with the microflow LC rates. The robustness of this 
source was a major benefit over the nanospray source, the fused silica of which was 
very fragile, resulting in frequent blockage or damage and thus required regular 
replacement and position optimisation.   
The performance of the microflow LC system was assessed with the 
determination of the assay performance characteristics of a synthetic peptide, 
VATVSLPR. Table 3.5 displays the precursor and fragment ion m/z and compound-
dependent parameters used to build the TMT-SRM method. The final TMT-SRM 
method monitored 10 transitions, had a dwell time of 50 msec per transition, a cycle 
time of 0.5 sec with 20 data points at FWHM. To minimise peptide losses due to non-
specific binding to plastics which may have ultimately affected the peptide quantitative 
amounts described in Section 3.2.5, VATVSLPR was resuspended in the presence of a 
scavenger protein, glucagon. As can be seen in Figure 3.4, the incorporation of  
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Light TMT   Heavy TMT  
DP (V) CE (V)  CXP (V) 




600.5 100 40.6 8.4 
664.5  669.5 100 39.1 9.6 
682.5  687.5 100 39.2 9.6 
743.5*  743.5 100 36.8 11.3 
842.6*   842.6 100 35.0 13.6 
 
Table 3.5 Selected transitions and optimised instrument voltages for the TMT-SRM 
quantitation of VATVSLPR peptide. The peptide was doubly charged and fully TMT-
labeled. The DP was constant for all transitions while the CE and CXP were dependent 
on Q1 and Q3 m/z. 
* removed from the data analysis due to crosstalk between light and heavy TMT transitions 
 
 























Figure 3.4 The effect of glucagon on SRM sensitivities of VATVSLPR peptide. 
VATVSLPR peptides (light and heavy TMT-labeled) were loaded at 50 and 100 fmol 
o/c, respectively and quantitated by TMT-SRM in A the presence of glucagon and B 
the absence of glucagon. Light TMT-SRM transitions are coloured in purple, magenta, 
red and grey and heavy TMT-SRM transitions are coloured in blue, cyan, green and 
yellow. The incorporation of glucagon as a scavenger peptide resulted in at least a 10 
fold improvement in SRM sensitivities. 
 
 
glucagon resulted in a 10 fold improvement in SRM sensitivities at 50 fmol light 
VATVSLPR peptides and 100 fmol heavy TMT-labeled VATVSLPR peptides o/c. Due 
to such significant benefits, all subsequent dilutions were performed in the presence of 
























7.0 8.0 7.0 8.0 
2,165 cps 26,000 cps 
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Calibration curves were prepared for VATVSLPR peptide in buffer-only (in 
duplicate over two days) and plasma (one replicate over one day) and the linearity, 
LOD and LOQ for the target analyte assessed (Section 3.1.6; Figure 3.5 and Table 
3.6). Crosstalk was observed for two transitions (those that had the same Q3 ion m/z; 
Table 3.5) which was revealed by a tailing-off at the lower points of their respective 
calibration curves in buffer-only (data not shown). These transitions were less selective 
as they differed only by Q1 m/z and were removed from the data analysis. For the 
remaining three transitions in buffer-only, linearity in TMT-SRM quantitation was 
observed down to 0.25 fmol light TMT-labeled VATVSLPR peptide o/c. In the presence 
of plasma, linearity was observed down to 2 fmol o/c. This difference to the buffer-only 
results was speculated to be due to the increase in overall background signal and ion 
suppression from the complex matrix during ESI. The LODs and LOQs were < 0.25 
fmol o/c in buffer-only. Once again, an expected increase was observed for equivalent 











Figure 3.5 Calibration curves for VATVSLPR peptide quantitated by TMT-SRM in 
buffer-only and plasma. The curves (based on the mean of three transitions) were used 
to interpolate QC amounts for the determination of the trueness and precision of TMT-
SRM quantitation. Linearity was observed down to 0.25 fmol o/c in buffer-only and 2 
fmol o/c in plasma.  
 
 
To determine the accuracy of TMT-SRM quantitation, triplicate QC measurements of 5 
and 50 fmol o/c light TMT-labeled VATVSLPR peptide were analysed for each 
calibration curve. The trueness for VATVSLPR measurements in buffer-only (mean 
across three replicates) and plasma (mean across three replicates) is displayed in  
 
0.25 fmol o/c 
 






 (fmol o/c) 
LOQ 












< 0.25  < 0.25  
5 4.4 4.62 and  5.21 4.72 
  50 4.02 2.69 and 4.03 3.61 
Plasma  
< 1 < 2 
5 9 7.51 NA 
  50 13.02 7.19 NA 
 
Table 3.6 Performance of TMT-SRM for VATVSLPR peptide in buffer-only and plasma 
using microflow LC rates coupled to ESI. The LOD, LOQ, trueness and intra- and inter-
batch variation of TMT-SRM quantitation in buffer-only and plasma is displayed. 
Accuracy values are based on triplicate QC measurements of 5 and 50 fmol o/c. NA = 
not applicable. * taken from one representative calibration curve. 
 
 
Table 3.6. The trueness observed in buffer-only was better than that in plasma, 
indicated by lower %CVs. This was speculated to be due to the reduced complexity of 
the buffer-only samples in that the background interference from the plasma matrix 
contributes to the signal, resulting in an over-estimation of the actual amount compared 
to the matrix-free result. When evaluating the precision of the method, it was necessary 
to assess the performance of QC replicates within a day (intra-batch variation) and 
over several days (inter-batch variation; buffer-only QCs only). The intra- and inter-
batch variation for buffer-only experiments was comparable, thus confirming the 
stability of the platform over a given time period. The intra-batch variation was slightly 
higher for experiments performed in plasma matrix and this was once again attributed 
to the added complexity of the plasma matrix. However, the overall precision and 
variation of TMT-SRM measurements of VATVSLPR peptides in the presence of 
plasma matrix was considered favourable. Thus, acceptable accuracy was observed 
for both QC amounts in buffer-only and plasma. The SRM peak areas of the internal 
standard (100 fmol o/c) remained constant at ~100,000 cps across samples. The 
microflow LC was very stable with highly reproducible tR (7.43 - 7.47 min, CV of 
0.11%), demonstrating the robustness of the new platform.  
In summary, a TMT-SRM assay format was established using a microflow LC 
platform in combination with ESI, enabling the determination of the linearity, LOD, LOQ 
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and accuracy of TMT-SRM quantitation. As well as significantly reducing individual 
sample analysis times and an increasing sample throughput, the new system had a 
more robust LC. Accuracy in TMT-SRM quantitation was observed at the higher flow 
rates. Further, the introduction of glucagon as a peptide scavenger significantly 
improved SRM sensitivities, as less synthetic peptide was lost due to non-specific 
binding to plastics. The new system was a significant improvement in the overall TMT-
SRM quantitation strategy. This strategy was therefore taken forward for the 
quantitation of candidate AD biomarker peptides in plasma.  
 
3.2.7 Assessment of modified plasma digestion, TMT-labeling and purification 
strategies 
To enable the preparation of the higher protein amounts consumed by 
microflow LC rates, several adjustments to the purification protocol of TMT-labeled 
peptides were performed as outlined in Table 3.1. A larger amount of plasma (2 mg) 
compared to the standard protocol (100 μg) was digested and light TMT-labeled. A 
comparison was made between the TMT-labeled plasma sample which was purified 
using either the standard protocol for RP and SCX, an upscaled RP in combination with 
the standard SCX protocol or both an upscaled RP and SCX protocol. All analyses 
were performed in duplicate. Additionally, the integration of a microtitre plate format for 
the preparation of plasma matrix was assessed using the sample that was purified 
using upscaled RP and SCX protocols. Samples were analysed by LC-MS/MS and 
compared using the number of identified peptides in each (Figure 3.6). Comparable MS 
ion distribution and ion intensities were observed using the standard protocol (A) and 
those purified using an upscaled protocol for RP (B) and upscaled RP and SCX (C). 
Equivalent numbers of peptides and proteins were identified across the three 
purification protocols. Samples lyophilised in a microtitre plate were comparable to 
those lyophilised in the standard way, i.e., in an eppendorf. A significant advantage of 
the microtitre plate format was that it enabled increased sample throughput. Both 





Sample Replicate Peptide IDs Protein IDs 
A 1 225 36 
 2 269 25 
B 1 206 20 
 2 275 30 
C 1 238 26 
 2 246 25 
 
Figure 3.6 Comparison of standard and upscaled sample preparation protocols. A BPI 
chromatograms for plasma digested, TMT-labeled and purified using the standard 
protocol, an upscaled protocol for RP and an upscaled protocol for RP and SCX. B The 
number of plasma peptide and protein IDs for each protocol.  
 
3.2.8 Preparation of equimolar mixtures to minimise quantitative differences 
between peptides of the same protein 
In an effort to minimise the difference observed in endogenous plasma amounts 
of peptides of the same protein (Section 3.2.5), peptides within a protein were 
combined in equimolar mixtures. The full panel of 32 synthetic peptides were included 
in the generation of the mixtures as it was hypothesised the new microflow LC 
configuration may improve the TMT-SRM detection of those peptides previously 
determined to be untraceable in undepleted plasma by nanoflow LC (Section 3.2.4). In 
the first instance, AAA was performed on all synthetic peptide solutions to determine 















Standard protocol (A) 
Upscaled RP (B) 
















concentration of each peptide solution as determined by AAA was lower than the 
estimated concentration upon initial solubilisation (Table 3.7). Possible factors 
explicating the observed differences include the synthetic peptides were not fully 
solubilised during initial resuspension, peptide losses to the sides of the sample vials or 
losses due to long-term sample storage. AAA should therefore be an essential step in 
all TMT-SRM strategies where accurate and absolute quantitation is being pursued. 
Further, sample storage is an important consideration. Initially, peptide stock solutions 
were aliquoted into small volumes across many sample vials which could have 
compounded the peptide losses observed. In an effort to minimise this, aliquots of the 
same peptide were combined into one large volume and stored in a single sample vial. 
Using accurate concentrations from AAA, peptides of the same protein were 
subsequently combined in equimolar mixtures. 
The quality of equimolar mixtures was assessed at each stage of the sample 
preparation workflow. Assessments were performed on the peptide solutions in an 
unlabeled state, post light TMT and heavy TMT-labeling and post RP and SCX 
purification. The majority of peptides across mixtures had strong signal intensities prior 
to TMT-labeling and RP and SCX purification. Taking clusterin peptides as an example, 
a large decrease in the signal intensity of peptide 4 was observed after TMT-labeling 
and a large decrease in the signal intensity of peptide 2 was observed after RP and   
SCX purification (Figure 3.7). Such losses were speculated to be a result of the 
different ionisation properties of unlabeled and TMT-labeled peptides and losses during 
RP and SCX purification. The poor performance of these peptides was in agreement 
with Section 3.2.4, where clusterin peptides 2 and 4 were not endogenously detected in 
plasma and removed from the initial TMT-SRM method. Such problems were further 
highlighted in Table 3.7 where the actual concentration of peptide 4 was significantly 
lower than the estimated concentration of the peptide as determined by AAA. Thus, it 
has been demonstrated here that certain peptides have reduced SRM sensitivies after 
TMT-labeling and purification and this could explain the endogenous detection, i.e., 





















1 3.35 2.93 -13 17 2.29 2.67 17 
2 4.18 3.81 -9 18 4.54 3.12 -31 
3 1.29 1.46 13 19 2.64 2.18 -17 
4 6.95 2.8 -60 20 2.15 1.61 -25 
5 2.34 1.71 -27 21 4.04 3.35 -17 
6 2.34 1.72 -27 22 1.74 1.91 10 
7 4.11 3.39 -18 23 2.53 1.66 -34 
8 3.42 2.7 -21 24 2.91 1.38 -53 
9 4.54 2.74 -40 25 3.1 2.62 -15 
10 2.47 1.58 -36 26 5.19 3.89 -25 
11 4.03 2.32 -42 27 6.86 5.51 -20 
12 3.19 1.73 -46 28 5.33 4.56 -14 
13 1.93 1.5 -22 29 3.99 3.81 -5 
14 3.77 2.75 -27 30 3.64 3.93 8 
15 2.78 2.07 -26 31 2.24 1.81 -19 
16 0.92 0.40 -57 32 3.67 3.15 -14 
 
Table 3.7 Concentration (µg/µL) of peptides 1 - 32 as determined by AAA. A large 
variation was observed for estimated and actual concentrations of each peptide.  
 
 
-tides (1, 3, 5 and 6) were relatively constant at each stage, indicating robust sample 
preparation of these peptides. Due to significant losses in SRM sensitivities at different 
stages of sample preparation, peptides 2, 4, 7, 16, 26, and 28 were not considered for 
future TMT-SRM quantitation (Table 3.3). Such losses in sensitivity were in agreement 
with the fact they weren’t detectable in plasma (peptides 2, 4 and 26) or had 
significantly lower concentrations determined by AAA than expected (peptides 4, 16, 
and 26).                                                                                                                                                                                                                                                                                             
 
 
3.2.9 SRM detection of target analytes in plasma using ESI 
The evolution of the TMT-SRM method to incorporate microflow LC rates and 
ESI resulted in the necessity to re-examine the endogenous detection of the target 
peptides in plasma. Excluding those six peptides which were shown to be affected by 
sample preparation procedures in Section 3.2.8, the method now measured 26 
peptides. Following analysis of plasma using the microflow LC-SRM platform, peptides 


























































Figure 3.7 MS spectra for the equimolar mixture of clusterin peptides at different 
stages of sample preparation. TMT-labeling decreases the MS detection of peptide 4. 
Purification procedures decrease the MS detection of peptide 2. Peptides 1, 3, 5 and 6 
remain relatively constant at each stage. 

































































This was in agreement with the results using the nanoflow LC-SRM platform. 
Additionally, poor detection of peptides 17 and 21 resulted in their exclusion at this 
stage. This is in disagreement with the results using the nanoflow LC platform as 
described in Section 3.2.4, where the endogenous plasma detection of both peptides 
was not problematic. Conversely, peptides 11 and 18, which were initially excluded in 
Section 3.2.4, were detected using the new platform and thus, remained in the TMT-
SRM method. Such discrepancies highlight the differential performance of the two 
platforms for TMT-SRM quantitation, attributed to the different LC column specifications 
or the varying levels of background interference and ion suppression associated with 
individual nanospray/ESI platforms. The results underline the importance of re-
analysing the SRM detection of individual target analytes when moving between 
different LC-SRM platforms. As established for the nano-LC-SRM system in Sections 
3.2.4 and 3.2.5, the presence of background interference on certain SRM transitions 
needed to be ascertained on the new system. This will be addressed in further 
development of the assay in Chapter 4. 
In summary, six peptides had significant losses during preparation of the 
equimolar mixtures (peptides 2, 4, 7, 16, 26, and 28) and a further four peptides had 
poor endogenous detection in plasma by TMT-SRM using ESI (peptides 10, 17, 21 and 
32). These peptides were removed from the method. Therefore, 22 peptides remained 
with importantly, at least two peptides per protein (Table 3.3), for TMT-SRM assay 
















 A TMT-SRM method has been developed for the quantitation of eight medium 
to high abundant proteins in plasma which were proposed from AD biomarker 
discovery studies as providing protein expression signatures of AD diagnosis 
and prognosis. Complement C3a was initially considered in the method but was 
excluded as no endogenous proteotypic peptides could be detected for this 
protein. 
 Synthetic peptides were used for internal standardisation over a biological 
reference or synthetic proteins as they reduced the overall complexity of the 
analysis and enabled tuning of compound-dependant parameters for enhanced 
detection of endogenous target analytes in plasma. Further, synthetic peptides 
allow for absolute quantitative amounts to be determined, provided the accurate 
amount of each peptide is known.  
 Proteotypic peptides were selected which fulfilled criteria for robust TMT-SRM 
quantitation, i.e., were completely hydrolysed by trypsin and fully TMT-labeled, 
contained no known in vivo or experimental modifications. Further, peptides 
between 6 - 25 amino acids were chosen to ensure sufficient SRM selectivity, 
whilst minimising the cost and effort required for their synthesis.  Weight was 
gived to the selection of peptides which had been previously identified. Here, 
the MS detection of the peptide had already been ascertained and LC-MS and 
LC-MS/MS properties defined. 
 In total, 32 peptides were selected for TMT-SRM quantitation, with at least three 
peptides per protein. Three SRM transitions were selected for each target 
peptide. Both factors improved the quantitative statistics and added confidence 
to the result.  
 From the selected peptides, 16 were observed in biomarker discovery plasma 
datasets, enabling the rapid transfer of such data into methods for biomarker 
verification and validation. 
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 A stable and reproducible analytical platform was essential for delivering high 
quality MS assay results. The TMT-SRM assay was initially developed using 
nanoflow LC in combination with nanospray ionisation. However, this LC-SRM 
platform was shown to be imprecise and unstable for the quantitation of the 
target analytes. Accordingly, an alternative assay design was developed for the 
TMT-SRM method. This incorporated:  
- Microflow LC rates in combination with ESI. This resulted in a significant 
improvement in assay accuracy and stability. Analysis times were reduced 
from 2.5 h to 15 min, enabling high sample throughput which is essential for 
a robust clinical assay.  
- A scavenger peptide (glucagon) was used for the preparation of all peptide 
stock and working solutions. This resulted in a significant improvement in 
SRM signal intensities and stability. 
- An assay design was developed which enabled the determination of the 
LOQ, LOQ, linear range and a measurement of the accuracy of TMT-SRM 
quantitation for the target analytes of interest. 
 Losses were observed for several peptides upon TMT-labeling. Further, the RP 
and SCX purification resulted in significant losses for several other peptides. 
Thus, AAA is essential at each stage of the TMT-SRM workflow, i.e., pre- and 
post-TMT-labeling, to compensate for this and accurately measure the amount 
of internal standard peptides at each point in the process. Only then can 
absolute TMT-SRM quantitation truly be determined. 
 The TMT-SRM method quantitated 22 peptides, with at least two peptides for 
each of the eight proteins remaining in the panel, and could now be applied for 
TMT-SRM assay validation and to determine the TMT-SRM assay performance 
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For the TMT-SRM approach to be used or shown to be useful as an alternative 
technology for peptide and protein quantitation, it was required that the assay was 
validated against more traditional methods. The current gold standard for the 
quantitation of protein biomarkers in plasma is by antibody-based assays such as 
ELISA (Engvall and Perlman, 1971). Further, WB is commonly used in candidate 
biomarker verification (Hye et al., 2006; Rifai and Gerszten, 2006; Güntert et al., 2010; 
Haverland et al., 2010). Such techniques are problematic however, as their success is 
primarily dependent on the availability of high quality antibodies. Further, it is very 
difficult to accurately quantitate several target analytes in one fluid volume. It was 
hypothesised that the multiplexed TMT-SRM assay developed here may overcome 
such limitations. The primary goal of this chapter was to perform a direct comparison 
between quantitative values of a sample cohort, measured using an antibody-based 
approach and TMT-SRM. To achieve this, a subset of samples (n = 20) was selected 
from a discovery cohort of AD and NDC subjects (n = 90) where one of the candidate 
AD biomarkers, gelsolin, was found to be differentially expressed between groups by 
WB (Güntert et al., 2010). Here, signature peptides of gelsolin (as refined in Chapter 3) 
were measured by TMT-SRM between disease and control groups. Agreement 
between WB and TMT-SRM measurements for gelsolin would confirm the validity of 
TMT-SRM assay for the quantitation of signature peptides of the candidate proteins in 
undepleted plasma. Further, the TMT-SRM quantitation of the remaining peptides in 
the panel provided an initial insight into their performance in terms of robustness in 
clinical sample cohorts and agreement between peptides within a protein.  
Once the TMT-SRM assay was validated for suitability and refined to include 
only the most robust signature peptides of a protein, the assay performance 
characteristics were determined for each target analyte in undepleted plasma. Here, 
each candidate AD biomarker peptide was defined in terms of linearity, LOD, LOQ and 
the accuracy of TMT-SRM quantitation (Whiteaker et al., 2010). To demonstrate the 
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robustness and portability of the TMT-SRM assay across MS platforms, the assay 
performance characteristics were additionally defined for the target analytes on a 









































4.1 Materials and Methods 
4.1.1 Sample selection based on western blot measurements of gelsolin 
Samples were collected from a largely community-based population of subjects 
with AD and aged people, funded by the Alzheimer’s Research Trust (ART). All 
subjects were white UK citizens with grandparents born in the UK and were assessed 
annually by cognitive measures including the MMSE and the Clinical Dementia Rating. 
A demographic and medical assessment was also performed. Cases with probable AD 
(NINCDS-ADRDA criteria) were identified using methods shown to have a high 
diagnostic validity (Foy et al., 2007). NDCs, defined as having no evidence of cognitive 
impairment, were collected from primary care patient lists. The study was approved by 
the relevant research ethics committees. Blood was extracted from each subject 
according to standardised operating guidelines and collected in 10 mL 
ethylenediaminetetraacetic acid (EDTA) coated glass tubes (Sigma-Aldrich). Upon 
arrival at the laboratory, each blood sample was centrifuged at 3000 rpm using a 
Clinispin Horizon 853VES centrifuge (Woodley Equipment Company Ltd., Bolton, UK) 
at 4 °C for 8 min to isolate the plasma fraction from white and red blood cells. Plasma 
was aliquoted into 0.5 mL volumes and stored at -80 °C. Gelsolin was quantitated by 
WB in 140 plasma samples representing AD and NDCs (Güntert et al., 2010). A sub-
set of these were selected for TMT-SRM quantitation which showed the greatest 
difference in gelsolin levels between AD and NDC samples (n = 10 per group, Table 
4.1). 
 
4.1.2 Light TMT labeling of AD and NDC plasma samples  
An aliquot of each plasma sample was removed from the freezer and brought to 
RT on ice. An equal volume (25 µL) of each was diluted 10-fold with H2O. From this, 
12.5 µL was removed, providing approximately 100 µg of protein per digest (based on 
a theoretical plasma concentration of 80 mg/mL). This strategy, based on equal 
volumes as opposed to equal protein amounts, was equivalent to that used in the WB 
169 
 
studies. In parallel, a pool of all samples (100 µg per sample, 2 mg total protein) was 
prepared to provide the sample matrix for calibration curves and to assess instrument 
performance. 
AD   NDC 
ART ID 
Gelsolin 
relative OD  
ART ID 
Gelsolin 

































Table 4.1 Gelsolin measurements for AD and NDC groups by WB. The samples 
displayed are those which gave the greatest difference in mean relative optical density 
(OD) for gelsolin between groups (n = 10 per group) and thus, selected for validation of 




Experimental samples were solubilised with SDS, reduced, alkylated and 
digested with trypsin as described in Section 2.1.1.2. Tryptic plasma peptides were 
labeled with light TMT and purified by RP and SCX as described in Sections 2.1.1.3 - 
4. All experimental samples were processed in triplicate (technical repeats). Each 
plasma was aliquoted across three microtitre plates (60 µL per sample; 30 μg per well) 
to provide three analytical repeats. Each microtitre plate was lyophilised to dryness. To 
further remove the high ammonium acetate content introduced during SCX elution, 
samples were resuspended in 100 µL SCX loading buffer and lyophilised to dryness for 
a second time. The pooled plasma sample was prepared using the upscaled version of 
the TMT-labeling and purification protocols as described in Section 3.1.7, aliquoted into 
a single microtitre plate and lyophilised twice as above. All microtitre plates were stored 
at -80°C until further use. 
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4.1.3 TMT-SRM analysis of the sample cohort 
TMT-SRM analysis of the cohort was performed on a QTRAP mass 
spectrometer as described in Section 3.1.9. For internal standardisation, all heavy 
TMT-labeled equimolar mixtures representing the eight candidate proteins as prepared 
in Section 3.1.8 were combined and diluted in glucagon solution to provide a stock 
solution of 5 pmol/µL of each peptide. This was further diluted in glucagon solution to 
provide a working solution of 5 fmol/μL. Immediately prior to analysis, plasma samples 
were resuspended in 25 μL of the internal standard working solution, resulting in 100 
fmol of each peptide standard being injected o/c (20 µL injection). This concentration of 
sample ensured good detection of the peptide analytes with no carry-over taken into 
subsequent runs. The run order of each set of analytical repeats (60 samples, i.e., 20 
samples, 3 technical repeats) was randomised to exclude run time and run order bias. 
LC-SRM performance was benchmarked prior to analyses using light and heavy TMT-
labeled VATVSLPR peptides as described in Section 3.1.9. 
TMT-SRM quantitation was performed with the aid of calibration curves. In the 
‘normal’ curve approach, curves are constructed using a constant amount of heavy 
peptide against a varying amount of light peptide, spiked into plasma matrix. This was 
demonstrated in Chapter 3 for the determination of the performance characteristics for 
VATVSLPR peptide. However, this approach is problematic for the assay described 
within, as the presence of endogenous analyte excludes the possibility of determining 
the linear range and the LOD and LOQ. To overcome this, a ‘reverse’ calibration curve 
approach was undertaken to determine the performance characteristics for the AD 
candidate peptides in plasma. Here, a constant amount of light TMT-labeled peptide 
and a varying amount of heavy TMT-labeled peptide are spiked onto light TMT-labeled 
plasma matrix. As there is no contribution to heavy signal from the endogenous 
analyte, it is possible to measure the equivalent of a blank sample and determine both 
LOD and LOQ (Figure 4.1). 
A 12-point reverse calibration curve was produced by combining light and 
heavy TMT-labeled peptides (internal standard of light TMT-labeled peptides constant 
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at 100 fmol o/c and heavy TMT-labeled peptides, varied 1, 100, 200, 300, 400, 500, 
600, 700, 800, 900, 1000 and 6,000 fmol o/c). For the purposes of the curve, additional 
to the heavy TMT-labeled peptide stock solution prepared as above, a stock solution of 
light TMT-labeled peptides (5 pmol/µL) was prepared as described above. In the first  
 
Figure 4.1 Overview of the ‘reverse’ calibration curve approach to provide TMT-SRM 
quantitation. A When constructing the reverse curve, the peak area corresponding to 
the light peptide internal standard (L) is contributed to by the endogenous amount of 
light peptide. The varying amounts of heavy peptide spikes (H) are free of endogenous 
analyte so the curve crosses the origin. B Correcting the reverse curve for the 
endogenous analyte contributing to the internal standard peak area requires a rotation 
of the curve about the intercept. This is the equivalent of increasing each curve point by 
an amount proportional to the ratio of the amounts of endogenous light peptide to the 
spiked light peptide (Campbell et al., 2011). 
 
instance, an analysis was performed to ensure that light and heavy TMT solutions were 
comparable in SRM sensitivity, i.e., equivalent signal of light and heavy TMT peptides 
when combined in a 1:1 ratio and loaded at 100 fmol each o/c. Each point on the curve 
was generated by employing a similar dilution strategy as described in Section 3.1.7. 
The pooled plasma sample (30 µg per well) was resuspended in combined light TMT 
and heavy TMT-labeled peptides at each calibration concentration, gently vortexed and 
spun down in a Speedvac to collect the sample into one volume. A rubber seal (Thistle 
Scientific Ltd., Uddingston, UK) was placed on the plate to protect the contents of the 
wells from particulates such as dust and to avoid evaporation. Prior to, and upon 
completion of a set of 60 samples, samples were analysed for the preparation of a 
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calibration curve. Immediately before the analysis of the sample set, system checks 
were undertaken using VATVSLPR peptides to ensure the LC-SRM system was 
performing with optimal sensitivity, mass accuracy, calibration and ion stability. During 
the analysis of the sample set, light TMT-labeled pooled plasma spiked with internal 
standard was acquired after every 20 samples to ensure LC-SRM performance was 
maintained across the entire sample set (Section 3.1.9). 
 
4.1.4 Data processing for TMT-SRM assay validation 
LC-SRM data on the QTRAP was visualised through Analyst’s quantitation 
wizard as described in Section 2.1.1.9. All peak matching was visually verified and 
peak areas were exported into Microsoft Excel 2003. Transitions were excluded if there 
was poor peak definition from the background signal. For generation of calibration 
curves, the peak area for each heavy TMT transition across the concentration range 
was measured relative to each light TMT transition, representing the endogenous 
target analyte in plasma and the internal standard spiked on top (100 fmol o/c). For 
TMT-SRM assay validation, the peak area of each light TMT transition, representing 
the endogenous target analyte in plasma, was measured relative to the peak area of 
the corresponding heavy TMT transition (constant synthetic peptide internal standard). 
The amount (fmol o/c) of individual transitions of each target peptide across analytical 
and technical repeats in AD and NDC samples were interpolated from the respective 
reverse calibration curves, i.e., each transition had a calibration curve. The presence of 
the internal standard, as well as the endogenous signal in the light TMT channel, 
results in an overestimation of experimental values when reading from the curve 
(Figure 4.1). To account for this, the peak area of the internal standard (100 fmol o/c) is 
subtracted from the total peak area to leave the peak area representing the 
endogenous signal only. To achieve this, it is assumed that the light and heavy TMT 
signals give the same response. Thus, for further confidence in the accuracy of the 
measurement, light TMT and heavy TMT-labeled peptides were combined at 100 fmol 
each o/c to ensure they give a ratio of 1:1. Single-reference point (SRP) calibration was 
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performed upon the relative comparison of the L/H ratio for each transition, i.e., 
measurement of the endogenous plasma amount (L) relative to the internal standard at 
100 fmol o/c (H). 
 
4.1.5 Statistical analysis for TMT-SRM assay validation 
Using values calculated from the calibration curve and SRP, the absolute 
amount (µg/mL) of each transition was calculated using the Mr of the respective 
protein. A grand mean concentration was then calculated for each peptide in each 
sample using combined transitions of a peptide and compared between AD and NDC 
groups. Error bars were plotted using the 95% confidence interval (CI) associated with 
each mean value.  
TMT-SRM quantitation of each peptide was compared between AD and NDC 
groups using SPSS (v12.0, SPSS Ltd., Surrey, UK). The experimental design resulted 
in pseudo-replication of the data, i.e., three transitions per peptide, three analytical 
repeats, three technical repeats and case (Appendix Figure 4.1). Thus, hierarchical 
three-way analysis of variance (ANOVA) was used to maintain the appropriate degrees 
of freedom. Appendix Figure 4.2 displays the syntax script used to perform the 
statistical analysis in SPSS. The approach was used to separate and estimate the 
different sources of variation and these were then recombined to give an estimate of 
the variance of the mean. A method was chosen for analysis that would give a realistic 
estimate of the 95% CI, taking into account the variance attributable to all factors in the 
hierarchy. The variance of the mean was used to estimate the standard error and this, 
together with a value from the t-distribution, was used to estimate the 95% CI around 
the mean difference between the AD and NDC groups. Further, to estimate the 
contribution of variance associated with each level in the hierarchy (case, technical 
repeat, analytical repeat or transition), a variance components analysis was performed. 
The mean concentration of each gelsolin peptide in AD and NDC samples was 
used to directly compare the difference in gelsolin levels between groups. A student’s t-
test was performed to determine if this difference was statistically significant. 
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Spearman correlation coefficients were calculated to determine the agreement 
between the TMT-SRM measurement of each gelsolin peptide across experimental 
samples and the corresponding WB measurement. 
 
4.1.6 Determination of TMT-SRM assay performance characteristics on a QTRAP 
mass spectrometer 
To determine the TMT-SRM assay performance characteristics, 16-point 
reverse calibration curves were produced. Here, the internal standard peptides (light 
TMT-labeled) constant at 100 fmol o/c were combined with heavy TMT-labeled 
peptides (varied from 0.5, 1, 2.5, 5, 10, 25, 50, 75, 100, 250, 500, 1000, 2500, 5000, 
7500 and 10,000 fmol o/c). Each calibration mix was generated by employing a similar 
dilution strategy as described in Section 3.1.7. The pooled plasma sample (30 µg per 
well; prepared in Section 4.1.2) was resuspended in the light TMT and heavy TMT-
labeled peptides across the concentration range, as described in Section 4.1.3. All 
curves were measured in triplicate over three independent days. LODs and LOQs were 
determined by measuring 12 replicates of a blank sample of light TMT-labeled peptide 
and light TMT-labeled plasma only, i.e., less the heavy TMT-labeled peptide 
(Whiteaker et al., 2010). To assess the trueness and precision of TMT-SRM 
quantitation, replicate samples were analysed between curves. Specifically, the pooled 
plasma sample (30 µg) was resuspended in combined light TMT-labeled internal 
standards at 100 fmol o/c and heavy TMT-labeled peptides (at 5 fmol or 50 fmol o/c; 
QCs). Replicate analyses (n = 5) were performed at each amount for each curve. All 
data was processed for construction of the curves as described in Section 4.1.4. 
 
4.1.7 Statistical analysis for determination of TMT-SRM assay performance 
Linear regression was performed using Prism software v5.0 (Graphpad 
Software Inc., CA, USA) using 1/SD2 weighting to construct calibration curves. Axes 
were log10 transformed to better visualise the lower points on the plot. Evidence for 
non-linearity was tested using second and third order polynomial best-fits. Absolute 
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values for each transition of each peptide in each QC sample were interpolated from 
the curves as described in Section 4.1.4. Trueness and precision values for each 
transition of each peptide were determined by calculating the %CV across all QC 
replicates. The LOD was calculated from the mean heavy TMT signal (noise) in the 12 
blank replicates plus three times the SD of the noise in the blank (response at the time 
of peptide elution). Similarly, the LOQ was calculated from the mean heavy TMT signal 
in the 12 blank replicates plus ten times the SD of the noise in the blank. 
 
4.1.8 TMT-SRM assay development on a TSQ Vantage mass spectrometer 
To demonstrate the portability of the TMT-SRM assay across MS platforms, a 
method was developed for quantitation of the AD candidate biomarker panel on a TSQ 
Vantage triple quadrupole mass spectrometer (Thermo Fisher Scientific). For 
confirmation of QTRAP transition selection and optimisation of instrument voltages for 
each transition, equimolar mixtures as prepared in Section 3.1.8 were infused into the 
TSQ Vantage. Specifically, mixtures were prepared in 50% ACN, 0.2% FA and 
introduced into the instrument via a Nanospray-1 ion source (Thermo Fisher Scientific) 
at 500 nL/min. For each transition, the CE and S-Lens voltages were optimised to 
enhance the detection of target analytes in light TMT-labeled plasma. The S-Lens is 
specific to Thermo Fisher Scientific instruments, improving SRM sensitivities by 
focusing ionised peptides into a tight beam before introduction to the mass analyser. 
Instrument voltages were optimised by linearly ramping the voltage over an instrument-
defined range. The maximal voltage over the ramping trace was selected as the 
optimal CE and S-Lens value. 
On-line LC analysis was performed on a Finnigan Surveyor MS Pump Plus LC 
system (Thermo Fisher Scientific). Peptides were resolved using an identical LC 
column, ACN gradient and flow rate as for that on the QTRAP (as described in Section 
3.1.9). However, the slower injection speed of the Finnigan Surveyor MS Pump Plus 
LC system increased the total analysis time to 22 min. Peptides were introduced into 
the instrument using a heated-electrospray ionisation (HESI)-II probe in positive 
176 
 
ionisation mode. Peptides were ionised by ESI and source-dependant voltages and 
gases were optimised for maximal ion sensitivities. Specifically, the entrance pressure 
of nitrogen (used for sheath and auxiliary gas) was ~6 bars, the ion spray voltage was 
4000 V, the vaporising temperature was 200 °C, the sheath gas pressure was 60 bar, 
the auxiliary gas pressure was 15 bar and the capillary temperature was 230 °C. 
Peptides were fragmented by CID using argon gas at 1 mTorr. Mass calibration of the 
TSQ Vantage was performed on MS/MS fragment ions of polytyrosine - 1, 3, 6 
standard [(Tyr)1-6; Thermo Fisher Scientific]. Specifically, a solution of 4 – 24 ng/µL 
(Tyr)1-6 was prepared in 0.1% FA, 50% methanol and infused into the instrument at 1.5 
µL/min using a syringe pump as described in Section 2.1.1.5. LC-SRM performance 
was benchmarked prior to analyses using light and heavy TMT-labeled VATVSLPR 
peptides as described in Section 3.1.9. The determination of accurate tR for application 
of SRM scheduling to the method was performed using a mixture of all heavy TMT-
labeled peptides (100 fmol each o/c) spiked into 30 µg of the light TMT-labeled plasma 
pool sample. The mean tR of three replicates was used to build the SRM scheduled 
method. For determination of TMT-SRM assay performance characteristics, calibration 
curves were constructed using an identical experimental design as described in 
Sections 4.1.7. 
 
4.1.9 Data processing and determination of TMT-SRM assay performance 
characteristics on the TSQ Vantage  
LC-SRM data on the TSQ Vantage was processed using Pinpoint Software 
(v1.0, Thermo Fisher Scientific). Processing parameters included an SRM smoothing of 
7 points, an SRM peak width of 1 min and a minimum signal intensity of 20 cps. All 
peak matching was visually verified. Peak areas were exported into Microsoft Excel 
2003. Transitions were excluded if there was poor peak definition from the background 
signal. Calibration curves were constructed as described in Section 4.1.6. To determine 
the assay performance characteristics, statistical analysis was performed as described 




4.2.1 Validation of the multiplexed TMT-SRM assay 
 
4.2.1.1 Assessment of SRM transitions 
The TMT-SRM assay was validated for suitability to measure the AD candidate 
protein biomarkers in plasma by comparison to measurements obtained using a widely 
established immuno-based platform. Here, the TMT-SRM method as optimised in 
Section 3.2.9 containing 22 peptides and all SRM transitions for these peptides was 
applied to a cohort of 10 AD and 10 NDC samples, previously shown to have a 
difference in plasma geslolin levels between groups. A reverse calibration curve 
strategy was incorporated here which was expanded over the range measured in 
Chapter 3, i.e., 1 – 6000 fmol o/c to ensure TMT-SRM quantitation covered the range 
of endogenous levels of the target analytes in plasma, from low (21.4 – 44.2 µg/mL) 
SAP levels (Nybo et al., 1998; Pepys et al., 2002) to high (2,000 – 2,400 µg/mL) A2M 
levels (Barrett, 1981). Transitions were removed from the data analysis if they 
possessed high plasma background (Figure 4.2). Taking only those peptides which 
remained in the TMT-SRM method up to this stage, plasma background interference 
was observed for transitions of peptides 1, 5, 9, 12, 13, 14, 22 and 30 (Appendix Figure 
4.3). This was in agreement with the results in Section 3.2.4, with all transitions 
highlighted in Table 3.4 having comparable plasma background interference in this 
sample set.  
 
4.2.1.2 Measurement of gelsolin by TMT-SRM  
Figure 4.3 A displays a representative calibration curve for gelsolin peptide 31. 
The normal human plasma concentration of the protein is 180 – 200 µg/mL (Osborn et 
al., 2008). However, the actual amounts measured here for gelsolin were ~10 fold 




Figure 4.2 An XIC of the light TMT and heavy TMT for peptide 13. One transition has 
been affected by high plasma background (coloured in pink; heavy TMT-labeled) and 
subsequently, this transition and its corresponding light-TMT partner were removed 
from the analysis. 
 
 
(although these levels fall within the linear range of quantitation). Therefore, a future 
advancement to the strategy was needed, i.e., it was necessary to expand the linear 
range down to lower concentrations. This was essential to account for potential 
reductions in the endogenous amounts measured by the TMT-SRM assay, as 
compared to theoretical endogenous amounts. 
Figure 4.3 B displays the bar chart of the endogenous plasma amounts of all 
peptides of gelsolin in AD and NDC samples as quantitated by TMT-SRM. Visualisation 
of the data in this manner was advantageous as the difference in the expression of 
each peptide between groups could be readily ascertained. Further, it enabled the 
characterisation of the most robust signature peptides of a protein across sample sets. 
Considering all gelsolin target analytes, peptide 27 had the lowest SRM sensitivity 
across samples and replicate measurements for this peptide were less robust than for 
peptides 29, 30 and 31, i.e., peptide 27 had a CV of 27.14% across technical repeats 
compared to a CV of 7.57% for peptide 31. Peptide 27 was therefore excluded from the 
data analysis and no longer considered for TMT-SRM quantitation. Peptides 29, 30 and 
31 performed similarly, with equivalent absolute amounts quantitated in the plasma, 
e.g., the mean gelsolin level of each signature peptide in AD samples was 16.1 µg/mL 




Figure 4.3 TMT-SRM quantitation of gelsolin in AD and NDC samples. A Reverse calibration curve for gelsolin peptide 31 (displaying 100 – 1000 
fmol o/c). Each of the three TMT-SRM transitions for the peptide are plotted on the curve B Bar charts displaying the difference in the amounts of 
gelsolin peptides between AD (blue) and NDC (red) samples, as measured by TMT-SRM. Peptides with less robust TMT-SRM quantitation are 




















Gelsolin 29  




11.0 18.4 0.60 0.0021  0.68 
  31 
 
16.9 25.1 0.67 0.0001  0.73 
Table 4.2 Comparison of TMT-SRM and WB of gelsolin for TMT-SRM assay validation. Plasma amounts (µg/mL) of each gelsolin peptide in AD 
and NDC samples, as determined by the TMT-SRM assay are displayed. Equivalent amounts of each peptide and similar fold changes were 
observed across the three gelsolin peptides selected for data analysis. Strong correlation (i.e., > 0.5) was observed between each gelsolin peptide 
























Similarly, for NDC samples, endogenous plasma gelsolin levels were calculated to be 
24.9 µg/mL for peptide 29, 18.4 µg/mL for peptide 30 and 25.1 µg/mL for peptide 31. 
Such agreement between signature peptides demonstrated the robustness of the TMT-
SRM workflow and gave confidence to the quantitative result. 
 
4.2.1.3 Correlation of TMT-SRM and WB measurements for gelsolin  
Previous TMT discovery studies in our laboratory have shown plasma gelsolin 
levels to be decreased in AD subjects as compared to NDCs, with strong correlation to 
the rate of cognitive decline (gelsolin decreases as cognitive ability decreases). 
Findings were validated by WB (Güntert et al., 2010). In-line with the WB results, a 
statistically significant (p < 0.0021) difference in plasma gelsolin levels was observed 
for all peptides between AD and NDC groups. Fold changes of 0.65, 0.60 and 0.67 
were observed between AD and NDC groups for peptides 29, 30 and 31, respectively 
(Figure 4.3 B, Table 4.2). The calculation of Spearman correlation coefficients was 
selected as a suitable method to compare the TMT-SRM and WB platforms. A strong 
correlation (0.65, 0.68 and 0.73; Cohen, 1988) was observed for gelsolin peptides 29, 
30 and 31 in each sample, as compared to the corresponding WB measurement (Table 
4.2). Excellent agreement with the established immuno-based platform thus validated 
the TMT-SRM assay as fit-for-purpose for the targeted measurement of gelsolin in 
undepleted plasma.  
 
4.2.1.4 Quantitation of the remaining peptides in the TMT-SRM assay 
In addition to gelsolin, the endogenous levels of the signature peptides of the 
seven other proteins could be quantitated between AD and NDC samples in the 
multiplexed TMT-SRM assay, giving an initial insight into their performance in clinical 
samples (Figure 4.4). Due to the small subject numbers utilised however, it was unwise 
to draw definitive conclusions regarding the expression of each signature peptide 









Figure 4.4 Assessment of the TMT-SRM performance of peptides of the same protein across AD and NDC groups. Peptides of the same protein 






























































































































Clusterin α chain 35 - 105 1 8.3 7.5 1.10 
 
7.6 6.7 1.14 
Clusterin β-chain  5 22.3 24.5 0.91 
 
24.8 27.2 0.91 
Complement C3 670 - 1290 8 321.1 243.8 1.32 
 
316.8 241.6 1.31 
 
 9 477.0 380.3 1.25 
 
457.8 365.9 1.25 
CFH 400 - 800 12 44.7 38.8 1.15 
 
45.7 39.5 1.16 
 
 13 24.6 21.2 1.16 
 
24.3 20.8 1.17 
A2M 2000 - 2400 14 204.6 207.5 0.99 
 
199.7 202.4 0.99 
 
 15 154.0 169.4 0.91 
 
141.6 155.5 0.91 
FGG 80 - 500 19 14.7 12.7 1.16 
 
14.7 12.3 1.19 
 
 20 4.9 4.7 1.04 
 
3.6 3.4 1.06 
SAP 21 – 44 22 5.4 4.2 1.29 
 
5.4 4.6 1.29 
 
 23 5.4 4.5 1.19 
 
4.6 3.5 1.32 
ApoE 34 - 74 24 6.2 6.1 1.00 
 
6.0 6.0 1.00 
 
 25 5.6 6.1 0.91 
 
4.8 5.5 0.88 
Gelsolin 179 - 200 29 16.1 24.9 0.65 
 
16.3 25.5 0.64 
 
 30 11.0 18.4 0.60 
 
11.3 17.7 0.64 
   31 16.9 25.1 0.67  16.8 25.7 0.65 
Table 4.3 Plasma amounts (µg/mL) of target peptides in AD and NDC samples, as determined by the TMT-SRM assay using calibration curves 
and SRP quantitation. Only those peptides included in the final data analysis are displayed. Equivalent amounts of each peptide and similar fold 
changes were observed between both calibration approaches. 
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4.3 were therefore considered as purely representative of the level of agreement 
between peptides of the same protein. 
In addition to gelsolin peptide 27, all transitions of four other peptides (3, 6, 11 
and 18; Figure 4.4, greyed out) were removed from the analysis as the endogenous 
detection was poor in the majority of samples or a high variance was observed for all 
measurements across all samples. Clusterin peptides 3 and 6 were not consistently 
detected in all samples and thus, considered less robust for TMT-SRM quantitation and 
removed from the method. Importantly however, one peptide remained for each of the 
different clusterin chains to be measured. Peptide 11, measuring CFH, was of weak 
SRM sensitivity compared to the other peptides (peptides 12 and 13) within the protein 
and was not consistently detected across all samples. This was reflected in a CV 
across technical replicates of 24.35%, compared to 9.45% for peptide 12. A high 
variance was observed for FGG peptide 18 for all measurements across all samples. 
This peptide was deemed less robust compared to other peptides (peptides 19 and 20) 
within the FGG protein. Therefore, five peptides were removed from the TMT-SRM 
method at this assay validation stage (peptides 3, 6, 11, 18 and 27) with 17 peptides 
remaining for quantitation, and importantly, at least two peptides per protein. 
It can be clearly seen from Figure 4.4 that the endogenous plasma amounts 
between peptides of the same protein were not in agreement in several cases, i.e., 
peptides of clusterin, complement C3, CFH, A2M and FGG. Taking clusterin as an 
example, a large difference was observed, i.e., peptides 1 and 5 had mean amounts of 
8.3 and 22.3 µg/mL in AD and 7.5 and 24.5 µg/mL in NDC, respectively (Table 4.3). 
This was speculated to be due to several factors including the unique clusterin chains 
measured and the different susceptibilities of each peptide to trypsin cleavage. Further, 
peptide losses during TMT-labeling or purification stages may have compounded the 
observed difference. Such factors may additionally explicate the lower absolute 
amounts quantitated for the clusterin peptides as compared to theoretical amounts. A 
lower amount compared to theoretical amounts was a trend observed for all signature 
peptides in the TMT-SRM method. Conversely, peptides of the same protein were 
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equivalent in several cases (peptides of SAP and ApoE), e.g., equivalent absolute 
amounts in plasma were observed for Apo E peptides 24 and 25, which had mean 
amounts of 6.2 and 5.6 µg/mL in AD and 6.1 and 6.1 µg/mL in NDC (Table 4.3).  
Despite discrepancies in the peptide amounts for a number of the proteins, it 
was very encouraging to observe equivalent performance for peptides of the same 
protein, which added confidence to the quantitative result. The most important factor for 
any quantitative biomarker technology is the ability to determine relative differences 
between disease and control groups, rather than absolute amounts. Taking 
complement C3 peptides 8 and 9 for example, excellent agreement in TMT-SRM 
quantitation for the two peptides was indicated by similar fold changes between AD and 
NDC groups, i.e., 1.32 for peptide 8 and 1.25 for peptide 9 (Table 4.3).   
 
4.2.1.5 TMT-SRM quantitation by single reference point quantitation 
To surpass the need for calibration curves, SRP calibration was assessed for 
the quantitation of peptide amounts in AD and NDC groups. Here, quantitation is based 
on relating the endogenous analyte to the known amount (100 fmol o/c) of spiked 
heavy TMT-labeled internal standard (Campbell et al., 2011). This spiked amount fell 
well within the linear range of quantitation (as determined by the calibration curves) for 
all target analytes and could therefore be used for accurate quantitation. The benefits 
of SRP calibration compared to the calibration curve approach are its simplicity and the 
ability to achieve a higher throughput of samples. SRP quantitation was performed by 
calculating the endogenous plasma amount relative to the known amount of internal 
standard spiked in at 100 fmol o/c. 
 It can be seen from Table 4.3 that there was excellent agreement between the 
TMT-SRM quantitation determined by interpolation from the calibration curve and SRP 
calibration. Equivalent absolute plasma amounts were quantitated for each target 
analyte and similar fold changes between AD and NDC groups were observed for all 
peptides. When taking gelsolin peptides in the NDC grouping as an example, 
endogenous plasma amounts determined for peptides 29, 30 and 31 using the 
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calibration curve approach were 16.1, 11.0 and 16.9 µg/mL in AD and 24.9, 18.4 and 
25.1 µg/mL in NDC. The amounts determined for the same peptides by the SRP 
approach were 16.3, 11.3 and 16.8 µg/mL in AD and 25.5, 17.7 and 25.7 µg/mL in 
NDC, respectively. The three gelsolin peptides had fold changes of 0.65, 0.60 and 0.67 
between AD and NDC using the calibration curve approach and 0.64, 0.64 and 0.65 
using SRP calibration. The goal of the calibration curve approach was for assay 
performance characteristic definition and to ensure that linearity was achieved across 
the range required for the measurement of endogenous analytes. Once these 
performance characteristics have been established, TMT-SRM quantitation could then 
proceed by SRP calibration. 
 
4.2.1.6 Variance associated with technical and analytical repeats 
To understand the contribution of variance introduced by technical and 
analytical procedures, the variance was assessed between technical repeats of each 
sample (in triplicate) and analytical repeats of each digest (also in triplicate). Table 4.4 
displays the results for the variance components analysis for the TMT-SRM of the 17 
peptides remaining in the TMT-SRM assay (upon exclusion of five peptides during 
TMT-SRM assay validation; Sections 4.2.1.3 and 4.2.1.4). For A2M peptide 15, some 
variance was explained by transition, i.e., different transitions of this peptide had 
differences in TMT-SRM quantitation. However, when averaging all transitions of this 
peptide as in Section 4.2.1.4, equivalent fold changes were observed for this peptide 
compared to its sister peptide (14). Overall, up to 99.99% of the variance in the 
samples was explained by case (either AD or NDC grouping). As expected, more 
variance was attributed to technical rather than analytical repeats. Such variation may 
be explained by the variable enzymatic efficiency of trypsin, resulting in varying rates at 
which the tryptic peptide is generated across multiple digests. However, both technical 
and analytical repeats had minimal contribution to any variance observed and the 
majority was explained by the factor of case. Thus, for the TMT-SRM quantitation of 
future cohorts, only one technical and one analytical repeat was considered sufficient. 
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It was observed here that this won’t impact the results and prevent the identification of 
differences between AD or NDC groups. Further, this has major benefits as doing 











1 99.99 0.00 0.01 NA 
5 99.99 0.00 0.01 NA 
8 94.11 1.98 0.00 3.91 
9 97.61 2.39 0.00 0.00 
12 97.78 2.22 0.00 0.00 
13 99.13 0.87 0.00 0.00 
14 99.98 0.02 0.00 0.00 
15 54.71 13.05 0.00 32.23 
19 89.38 10.62 0.00 0.00 
20 99.69 0.31 0.00 0.00 
22 98.37 1.63 0.00 NA 
23 99.57 0.43 0.00 0.00 
24 94.03 5.97 0.00 0.00 
25 99.77 0.23 0.00 0.00 
29 99.89 0.11 0.00 0.00 
30 99.57 0.43 0.00 0.00 
31 99.88 0.12 0.00 0.00 
 
Table 4.4 Variance components analysis for target analytes in the TMT-SRM assay 
validation experiments. For those peptides included in the data analysis, any variance 




4.2.2 Assessment of TMT-SRM assay performance on the QTRAP and TSQ 
Vantage platforms 
4.2.2.1 Final TMT-SRM method on the QTRAP 
From the 22 peptides which were brought forward from Chapter 3, five peptides 
were excluded after the TMT-SRM assay validation stage due to their poor quantitative 
performance across a sample set. Therefore, a total of 17 peptides remained in the 
final TMT-SRM assay, with a least two signature peptides for each protein. As different 
plasma samples in different cohorts may have varying levels of plasma background 
interference associated with them, all TMT-SRM transitions for the 17 peptides were 
included in the final method, including those which were shown to be problematic in 
Sections 3.2.4 and 4.2.1.1. However, such transitions may still be filtered out at the 
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data analysis stage. The TMT-SRM method on the QTRAP was updated accordingly. 
Figure 4.5 displays the SRM XIC of the final TMT-SRM assay. The method monitored 
102 transitions (51 light TMT heavy TMT pairs) and had a scheduling window of 45 
sec, 1 sec cycle time, 20.8 msec dwell time per transition with ~8 data points at FWHM. 
 
Figure 4.5 SRM XIC of the 17 target analytes remaining in the final TMT-SRM assay. 
Light TMT-labeled plasma was spiked with heavy TMT-labeled peptides and analysed 
by TMT-SRM.  
 
4.2.2.2 Performance characteristics of the multiplexed TMT-SRM assay on the 
QTRAP  
Once the most robust peptides for TMT-SRM were defined in terms of 
quantitation in clinical sample cohorts, i.e., upon validation of the assay, it was 
necessary to determine the assay performance characteristics for each target analyte 
remaining in the refined method. This enabled the comparison of assay performance to 
more established methods of peptide/ protein quantitation such as ELISA. During TMT-
SRM assay validation experiments as described in Section 4.1.3, 12-point calibration 
curves were utilised, measuring the range of 1 - 6,000 fmol heavy TMT-labeled 
peptides o/c. Such a range confirmed linearity in quantitation but was unable to define 
the lower and upper points of linearity. To determine this, 16-point reverse calibration 
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curves were constructed here to expand over the range which was achieved. Further, 
as opposed to the equal spacing of concentration points in the strategy previously 
utilised, more points were acquired at lower concentrations and less points acquired at 
higher concentrations. This was done to ensure full characterisation at the lower limits 
of the curve. TMT-labeled peptides were varied over 0.5 - 10,000 fmol o/c, whilst light 
TMT-labeled peptides (100 fmol o/c) were spiked on top of the light TMT-labeled 
endogenous analyte in plasma. A blank sample was integrated, enabling the 
determination of definitive LODs and LOQs for each target analyte in plasma. Definition 
of exact LODs and LOQs here was advancement to the strategy as described in 
Section 3.2.6, where LODs and LOQs were based on the lowest concentration points 
measured on the curve which were within acceptable precision levels, i.e., where the 
%CV was < 20. A complete calibration curve was performed each day for three days to 
assess precision. Figure 4.6 displays examples of the calibration curves of peptides of 
CFH, A2M and ApoE. Transitions of the same peptide and peptides of the same 
protein plotted similar curves, adding confidence to the quantitative measurement. The 
linear range of quantitation was defined as the lowest and highest concentration of 
heavy TMT-labeled peptides at which linearity was still observed (Table 4.5). The 
determination of this parameter was essential to confirm that quantitation was being 
performed within the linear range of the endogenous levels of the target analytes in 
plasma. The dynamic range of response was over three orders of magnitude with 
excellent linearity (R2 > 0.99). Taking complement C3 peptide 8 as an example, the 
dynamic range of the TMT-SRM assay was 5.78 - 2311.68 µg/mL in plasma, when 
taking the best transition as representative of the peptide. This range ensured that 
linear TMT-SRM quantitation was observed for this peptide within the levels expected 
for the protein in plasma (670 - 1290 µg/mL). 
To assess the trueness and precision for each target analyte in plasma, 
replicate analyses were performed at 5 fmol o/c and 50 fmol o/c of heavy TMT-labeled 
peptides combined with 100 fmol o/c light TMT-labeled peptide internal standards and 








Figure 4.6 Calibration curves on the QTRAP mass spectrometer. A CFH, B A2M and C ApoE. Comparable performance was observed for 
transitions of the same peptide. The lowest point of linearity is circled on each calibration curve. All curves were acquired in the presence of 
plasma.
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13.96 625.58 17.5 2 






9.73 625.58 1.4 2.7 






14.23 2311.68 8.8 3 
 






18.89 2311.68 1.6 5.1 
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15.68 2009.74 2.7 3.2 
 






11.56 2009.74 1.3 2.7 






10.99 605.83 13.7 5.1 
 






8.93 605.83 1.3 1.2 






14.45 290.51 0.3 15.9 
 






17.57 290.51 9.1 8.9 






12.09 427.74 2.8 1.8 
 






12.91 427.74 0.8 2.6 






11.02 1036.79 5.9 6.1 
 






9.43 1036.79 7.6 5.4 
  31 1274.8 83 0.005 0.33  0.015 0.99  0.001 0.05  15.93 1036.79 0.7 2.4 
 
Table 4.5 Assay performance characteristics of the TMT-SRM method on the QTRAP. For each target analyte, the LOD, LOQ, linearity, trueness 
and precision is displayed. Protein concentrations (in µg/mL) represent the amount of protein corresponding to a given spike amount of the peptide, 
assuming 100% recovery. 
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performed on three days for each calibration curve. All target peptides could not be 
detected and accurately quantitated by TMT-SRM at the 5 fmol heavy TMT-labeled 
peptide QC, which reflected endogenous plasma levels below the LOQ for several 
target analytes, e.g., peptide 9, and so trueness and precision values were calculated 
for the 50 fmol QC measurements only. The accuracy for the QTRAP is displayed in 
Table 4.5. Overall, the accuracy was favourable, with a mean CV of trueness across all 
target analytes of 4.6% and mean CV of precision of 4.5%. 
LODs and LOQs were calculated from the mean response measured in the 
blank runs plus three times the SD (LOD) and 10 times the SD (LOQ). LODs and LOQs 
were determined at both the peptide and protein level, as ultimately, TMT-SRM 
quantitation was performed at the peptide level which was used as a surrogate to 
reflect the endogenous protein level. The calculated LODs and LOQs for the best 
transition of each target peptide are displayed in Table 4.5. Peptide quantitation was 
observed at low ng/mL levels, which was equivalent to low µg/mL protein levels, 
assuming complete digestion by trypsin (e.g., peptide 20). LODs ranged from 0.001 - 
0.036 μg /mL for peptides and 0.04 - 3.66 μg/mL for proteins (Table 4.5). LOQs ranged 
from 0.001 - 0.109 μg /mL for peptides and 0.05 - 11.10 μg/mL for proteins. All LOD 
and LOQ values were well within the physiologically relevant range in plasma. 
 
4.2.3 Portability of the TMT-SRM assay across MS platforms 
 
4.2.3.1 Method development 
Once the TMT-SRM assay performance characteristics were determined for the 
QTRAP, experiments were replicated on an analogous triple quadrupole instrument, a 
TSQ Vantage. The assessment of assay portability was considered an essential 
process, giving an indication of the overall robustness of the TMT-SRM assay across 
MS platforms. A robust, fit-for-purpose assay is particularly crucial if it is to be 
implemented in independent laboratories. Heavy TMT-labeled equimolar mixtures of 
each protein were infused into the TSQ Vantage and MS/MS analysis performed to 
192 
 
confirm those transitions determined as optimal for the TMT-SRM assay on the 
QTRAP. Excellent accordance of fragmentation patterns and thus, transitions, was 
observed across platforms and all three transitions for each of the 17 peptides 
remaining in the method were included (Table 3.3). In addition, a fourth transition of 
peptides 14, 15, 22, 25 and 29 was selected for the TSQ Vantage. This instrument had 
faster scanning capabilities and thus, enabled the assessment of more transitions 
(Table 4.6). Figure 4.7 displays representative voltage traces for CE and S-Lens 
optimisation. S-lens values were optimised for the detection of each precursor ion. As 
with CE values on the QTRAP, the CE values on the TSQ Vantage were specific to 
individual transitions and thus needed to be optimised accordingly (Appendix Table 
4.1). In general, less CE was needed for optimal detection of fragment ions on the TSQ 
Vantage as compared to the QTRAP, e.g., transition 1 of peptide 1 had a CE of 48 V 
on the QTRAP and 34 V on the TSQ Vantage.  
The TSQ Vantage facilitates the division of SRM scheduling windows into 
several segments in order to maximise the number of data points of each transition at 
FWHM. A segmented SRM scheduling scheme was implemented as outlined in 
Appendix Table 4.2 using the mean tR of triplicate measurements of each peptide. All 
light TMT and heavy TMT transitions were combined to build the final method. Figure 
4.8 displays the SRM XIC for heavy TMT-labeled internal standards (100 fmol o/c) 
spiked into light TMT-labeled plasma (30 µg o/c). Similar peptide tR and relative 
intensities were observed for all target analytes on the TSQ Vantage as compared to 
the QTRAP. TMT-SRM quantitation was performed at unit resolution of 0.7 Da ± 0.1 
amu FWHM for both Q1 and Q3, a scan time of 0.02 sec, a scan width of 0.02 Da, with 
a minimal SRM scheduling window of 1 min per peptide. This resulted in a maximal 


























A2M 14 AIGYLNTGYQR 2 1478.88 740.4 1014.6 
 
1483.88 742.9 1019.6 
 
15 TGTHGLLVK 2 1372.84 687.4 791.5 
 
1382.84 692.4 796.5 
SAP 22 VGEYSLYIGR 2 1379.78 690.9 873.5 
 
1384.78 693.4 878.5 
ApoE 25 LQAEAFQAR 2 1256.74 629.4 920.5 
 
1261.74 631.9 920.5 
Gelsolin 29 TASDFITK 2 1329.8 665.9 746.4 
 
1339.8 670.9 751.4 
 
30 AVEVLPK 2 1202.78 602.4 623.4 
 
1212.78 607.4 628.4 
 
Table 4.6 Additional transitions for the TMT-SRM quantitation of the AD candidate 
biomarker panel on the TSQ Vantage. In addition to the three transitions common to 
both instruments, an extra transition was utilised for peptides 14, 15, 22, 25, 29 and 30.  
                             
 




Figure 4.7 Optimisation of TSQ Vantage S-Lens and CE values. Optimal values for the 
S-Lens were those where the SRM voltage ramping trace was maximal (● in panel A). 





Figure 4.8 SRM XIC of the TMT-SRM method on the TSQ Vantage mass 
spectrometer. Light TMT-labeled plasma was spiked with heavy TMT-labeled peptides 
and analysed by TMT-SRM.  
 
4.2.3.2 Performance characteristics of the multiplexed TMT-SRM assay on the 
TSQ Vantage 
As with the QTRAP, 16-point reverse calibration curves were performed on the 
TSQ Vantage over three independent days. To demonstrate the agreement across 
mass spectrometer platforms, the calibration curves on the QTRAP and TSQ Vantage 
for three target analytes (peptides 1, 20 and 31) in the multiplexed TMT-SRM assay 
are displayed in Figure 4.9. All transitions of the same peptide plotted equivalent 
curves and corresponding curves on QTRAP and TSQ Vantage instruments were 
comparable. As with the QTRAP, the dynamic range of response was over three orders 
of magnitude with excellent linearity (R2 > 0.99) on the TSQ Vantage. Using 
complement C3 peptide 8 as an example, an equivalent dynamic range was observed 
as on the QTRAP, where the dynamic range of the TMT-SRM assay was 2.31 – 
2311.68 µg/mL, when taking the best transition as representative of this peptide (Table 
4.7). This pattern was repeated for all peptides across the two LC-SRM platforms. 
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The calculated LODs and LOQs for target peptides on the TSQ Vantage are displayed 
in Table 4.7. In agreement with the QTRAP, peptide quantitation was observed at low 
ng/mL levels, e.g., peptide 20. LODs on the TSQ Vantage ranged from 0.001 - 0.47 μg 
/mL for peptides and 0.07 - 57.70 μg/mL for proteins. LOQs ranged from 0.003 - 1.65 
μg /mL for peptides and 0.11 - 202.02 μg/mL for proteins. 
TMT-SRM assay performance characteristics varied greatly for several peptides 
between the QTRAP and TSQ Vantage instruments, e.g., for peptide 9 and peptide 23 
the truness (%CV) was much higher as measured on the TSQ compared to the 
QTRAP (39.4 and 41.4% on the TSQ and 1.6 and 9.1% on the QTRAP; Tables 4.5 and 
4.7). Such species had robust TMT-SRM quantitation in the assay validation 
experiments, i.e., followed the same trend as corresponding peptides within a protein, 
although these experiments were performed on the QTRAP only. Nevertheless, the 
peptides remained in the assay to allow for continued comparison of TMT-SRM 
quantitation between these peptides and those within the same protein. 
Trueness and precision on the TSQ Vantage was determined as for the QTRAP 
using the 50 fmol QC measurements only (Section 4.2.2.2). Table 4.7 displays the 
accuracy for TSQ Vantage. Overall, the mean CV of trueness was 8.9% on the TSQ 
Vantage. The higher mean CV of trueness on the TSQ Vantage compared to the 
QTRAP was attributed to higher values for peptides 9 and 23. However, mean 
precision CV values on both instruments were considered favourable in the context of 
quantitative biomarker assays. When looking at precision, a mean CV of 6.1% was 
observed across all target analytes on the TSQ Vantage. In summary, the accuracy of 
the TMT-SRM assay on both LC-SRM platforms was comparable and the assay was 









Figure 4.9 Calibration curves for peptides clusterin α-chain, FGG and gelsolin. A Calibration curves on the QTRAP. B Calibration curves on the 
TSQ Vantage. Curves were used to determine the TMT-SRM assay performance characterisitics for all target analytes in the method. Excellent 
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Table 4.7 Assay performance characteristics of the TMT-SRM method on the TSQ Vantage. For each target analyte, the LOD, LOQ, linearity and 
trueness and precision is displayed for comparison to the corresponding performance characteristics on the QTRAP (Table 4.5). Protein 




• The TMT-SRM assay was validated as fit-for-purpose for the measurement of 
signature peptides of candidate AD biomarkers in plasma. A strong correlation 
was observed between quantitation provided by TMT-SRM and an immuno-
based approach for one of the candidate biomarkers, gelsolin, in AD and NDC 
samples (n = 10 per group). 
• The TMT-SRM assay enabled quantitation of all target analytes in plasma, with 
all measurements within the linear range of quantitation for all peptides. 
• Peptides of the same protein performed similarly by TMT-SRM in terms of 
expression. Equivalent fold changes were observed between AD and NDC 
groups for peptides of the same protein, demonstrating the robustness of the 
quantitative measurement. 
• Target peptides for the measurement of SAP, ApoE and gelsolin gave 
equivalent absolute amounts by TMT-SRM. For all other proteins, differences 
were observed and attributed to differential tryptic digestion of each peptide 
and/or differential peptide losses during sample preparation. 
• Equivalent TMT-SRM quantitation was provided by interpolation from reverse 
calibration curves and SRP calibration. Thus, in a further improvement to the 
assay, the more simplified SRP approach will be used in all future TMT-SRM 
analyses. This significantly reduces data analysis times, resulting in a higher 
throughput of samples. 
• One technical digest is sufficient for each experimental sample in future TMT-
SRM analyses. This results in a significant reduction in sample preparation 
times with the benefit of higher throughput.  
• The determination of assay performance is essential to enable comparison to 
related biomarker quantitative technologies, e.g., ELISA. A workflow was 
designed to determine the TMT-SRM assay performance for each target 
analyte in plasma in terms of linearity, accuracy and the LOD and LOQ.  
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• The TMT-SRM assay was portable across LC-SRM platforms. Here, the 
method was transferred to a TSQ Vantage triple quadrupole mass 
spectrometer. The fragmentation, tR and relative intensities between target 
peptides were equivalent for all target analytes across MS platforms, 
demonstrating the robustness of the TMT-SRM assay. Further, equivalent 











































Implementation of a multiplexed TMT-SRM assay for the 














Once the TMT-SRM assay was validated as fit-for-purpose using assay 
performance criteria for each target analyte in undepleted plasma, the assay was 
applied for the evaluation of the candidate AD biomarkers in a clinical cohort (n = 90). 
The primary goal of this chapter was to determine if the TMT-SRM assay could validate 
any of the candidate proteins as prognostic and/or diagnostic markers of AD. Several 
of the plasma proteins were shown in discovery studies to have utility in predicting the 
progression rate of AD. A prognostic biomarker of the disease would be extremely 
beneficial, potentially allowing for treatments at the earliest stages of the disease. 
Further, prognostic markers may facilitate the development of targeted drugs and 
enable the monitoring of their therapeutic actions. Specifically, plasma levels of gelsolin 
have been shown to be decreased in AD subjects as compared to NDC, with strong 
correlation to the rate of cognitive decline (Güntert et al., 2010). Plasma clusterin was 
shown to be associated with the pathology, severity and progression rate of AD 
(Thambisetty et al., 2010). However, the protein was not shown to have potential for 
AD diagnosis as no change in plasma clusterin levels was observed when directly 
comparing AD and NDC samples. Plasma concentrations of complement C3, CFH, 
A2M, FGG and SAP have all been shown to be elevated in AD (Tennent et al., 1995; 
Hye et al., 2006; Lee et al., 2007; Maier et al., 2008). Results for ApoE are conflicting; 
however the majority of studies find no changes in plasma concentrations of this 
protein in AD (Romas et al., 1999; Scacchi et al., 1999). It was hypothesised that these 
results may be validated using the novel, multiplexed TMT-SRM assay. TMT-SRM 
quantitation was performed on both QTRAP and TSQ Vantage instruments to confirm 
the findings between both. TMT-SRM quantitation was confirmed by WB for selected 





5.1 Materials and Methods 
5.1.1 Validation of Alzheimer’s disease candidate biomarkers by TMT-SRM 
5.1.1.1 Modification of the TMT-SRM purification protocol to increase sample 
throughput 
To enable the analysis of a larger number of samples in an appropriate 
timescale required for biomarker validation and qualification studies, a modification to 
the TMT-SRM sample preparation workflow was assessed where the RP step of TMT-
labeled peptide purification was removed. As the purification of TMT-labeled peptides 
has been thus far the most rate-limiting step in the overall workflow, such a 
simplification would be highly desirable. The purpose of RP in the standard protocol 
was to reduce the salt content of TMT-labeled peptide samples, thus maximising the 
efficiency of SCX purification for the removal of SDS and excess TMT-labeling 
reagents. It was hypothesised that removal of the RP step here may have negligible 
effects on TMT-SRM quantitation. A pooled plasma sample (600 µg) from the 20 AD 
and NDC subjects as described in Section 4.1.2, was reduced, alkylated, digested with 
trypsin and labeled with light TMT as described in Sections 2.1.1.2 to 2.1.1.3. The light 
TMT-labeled plasma digest was split into six aliquots of 100 µg. Three aliquots were 
purified using an SCX-only approach. Here, each aliquot was diluted with 3 mL RP 
elution buffer to maintain the conditions of the standard protocol prior to SCX 
purification. Peptides were then purified using the standard SCX protocol as described 
in Section 2.1.1.4. As a control experiment, the remaining three aliquots of light TMT-
labeled plasma peptide digest underwent individual RP and SCX purification 
procedures using the standard protocol. All samples were aliquoted into a microtitre 
plate (60 µL per sample; 30 µg per well) and underwent two stages of lyophilisation as 
described in Section 4.1.1.2. TMT-SRM quantitation was performed for each of the 17 
peptides in the TMT-SRM method on the TSQ Vantage, with each light TMT-labeled 
plasma sample referenced against heavy TMT-labeled synthetic peptides (100 fmol 
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o/c). In the first instance, the detection and relative levels of all target analytes by SRM 
upon purification by the SCX-only and standard RP + SCX purification strategies was 
assessed. Comparison between the two approaches was performed using the mean 
L/H ratios of a subset of peptides, selected to incorporate a range of tR over the course 
of the LC gradient (peptides 1, 5, 12, 14, 15, 22, 23 and 25). Due to pseudo-replication 
(i.e., multiple replicates of each purification protocol), the experimental design was 
hierarchical to maintain the appropriate degrees of freedom, with peptide nested within 
protocol. Two-way ANOVA was used to separate and estimate the different sources of 
variation, which were combined to give an estimate of the variance of the mean. All 
data analysis was performed in SPSS as described in Section 4.1.1.8. 
 
5.1.1.2 Selection of a large cohort of subjects from multi-centre sites for 
validation of the candidate Alzheimer’s disease biomarkers 
Samples were collected from a European-wide population of subjects with AD 
and aged people (AddNeuroMed cohort; Lovestone et al., 2009). Samples were 
selected from six centres across Europe located in London (UK), Toulouse (France), 
Kuopio (Finland), Perugia (Italy), Thessaloniki (Greece) and Lodz (Poland). Ethical 
approval was obtained in each of the participating countries. All subjects were 
assessed at baseline and every three months thereafter for one year (five visits in total) 
by cognitive measures including MMSE, ADAS-cog and the Clinical Dementia Rating 
scale. Blood from each subject at each time point was collected in EDTA coated tubes, 
processed for the extraction of plasma as described in Section 4.1.1.1, aliquoted and 
stored at -80 oC according to standardised protocols. To determine the minimum 
sample size required for the cohort selected here-in, an a priori power analysis 
(Shappiro-Wilks method) was performed in G*Power using the mean amounts of each 
target analyte between AD and NDC groups as described in Section 4.2.1 (Appendix 
Table 5.1; Faul et al., 2007). A total of 90 subjects at baseline were selected for TMT-
SRM analysis (60 AD and 30 NDC subjects). To determine if any of the candidate 
biomarkers could predict the progression rate of the disease, within the AD group, 
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samples were sub-divided into rapid cognitive decliner (RCD) and slow cognitive 
decliner (SCD) groups based on MMSE decline per year. RCD, SCD and NDC groups 
(n = 30 per group) were matched for age and sex.  
 
5.1.1.3 Implementation of the TMT-SRM assay on the QTRAP for the validation of 
the Alzheimer’s disease candidate biomarkers 
An aliquot of each plasma sample was removed from the freezer and brought to 
RT. An equal volume (25 µL) from each aliquot was diluted 10-fold with H2O. As 
described in Section 4.1.2, this strategy was in-line with the biomarker discovery 
studies where an equal volume of each sample as opposed to an equal protein amount 
was used for comparison (Hye et al., 2006; Güntert et al., 2010). From this, 12.5 µL 
was removed, providing approximately 100 µg of protein per digest. Plasma samples 
were reduced, alkylated, digested with trypsin and light TMT-labeled (Sections 2.1.1.2 
and 2.1.1.3) and then SCX-purified as described in Section 5.1.1.1. Each experimental 
plasma sample was resuspended in 25% ACN, 0.1% FA and aliquoted in triplicate 
across three microtitre plates (30 μg per well) as described in Section 4.1.1.2. This 
gave a total of 90 samples per plate with one plate for TMT-SRM analysis on the 
QTRAP, one for the TSQ Vantage and a ‘spare’ microtitre plate if a repeat analysis of 
any sample was needed on either instrument. To allow for instrument performance 
checks, a pool of all samples (2 mg total protein) was digested, TMT-labeled and SCX 
purified using the up-scaled procedures as described in Section 3.1.7. Purified peptides 
of the pooled sample were aliquoted on a separate microtitre plate. All microtitre plates 
were lyophilised to dryness and stored at -80 °C. Immediately prior to analysis, 
samples were resuspended in 25 μL of a 5 fmol/µL solution of heavy TMT-labeled 
peptide internal standards, providing 100 fmol of each o/c. TMT-SRM analysis was 
performed on the QTRAP as described in Section 3.1.6. One analytical repeat of each 
sample was acquired with RCD, SCD and NDC groups randomised to exclude run-time 
and run order bias. The plasma pool was acquired every 15 samples to ensure LC-
SRM performance was maintained over the course of the sample set. SRMs were 
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processed and peak areas extracted using Analyst’s quantitation wizard as described 
in Section 2.1.1.9.  
 
5.1.1.4 Implementation of the TMT-SRM assay on the TSQ Vantage  
TMT-SRM analysis was performed on the TSQ Vantage as described in 
Section 4.1.7. Mirroring the TMT-SRM analysis on the QTRAP, one analytical repeat 
was acquired for each sample in a randomised run order (the same order as that on 
the QTRAP) and the plasma pool acquired every 15 samples to ensure consistent LC-
SRM performance. To minimise the variation in TMT-SRM quantitation between the 
QTRAP and TSQ Vantage, the same heavy TMT-labeled peptide solution was used for 
internal standardisation on both instruments. SRMs were processed and peak areas 
extracted using Pinpoint software as described in Section 4.1.9. 
 
5.1.1.5 Data Analysis for candidate biomarker validation 
SRP calibration was performed by calculating the L/H ratio for individual 
transitions of each peptide in each sample. Two-way ANOVA was used to separate 
and estimate the different sources of variation and these were then recombined to give 
an estimate of the variance of the mean. Appendix Figure 5.1 displays the syntax script 
used to perform the statistical analysis in SPSS. The grand mean concentration 
calculated from all transitions of each sample was calculated for each peptide in RCD, 
SCD and NDC groups. Error bars were plotted using the 95% CI associated with each 
mean value. For biomarkers of AD prognosis, the mean concentration was used to 
directly compare the difference in plasma protein levels between RCD, SCD and NDC 
groups. For biomarkers of AD diagnosis, a direct comparison was performed between 
AD and NDC groups. All measurements from the RCD and SCD groups were 
combined into a single AD group and compared to NDC. A student’s t-test was 
calculated to determine if the difference in the mean concentrations between RCD, 




5.1.2 Validation of TMT-SRM results 
5.1.2.1 Western blotting of A2M and gelsolin 
For confirmation of TMT-SRM results, WB analysis was performed for A2M and 
gelsolin on the same cohort of 90 AD and NDC subjects. Plasma samples (3 μL) were 
diluted in 97 μL phosphate buffered saline (PBS) containing protease inhibitor cocktail 
(Complete®, Roche) and 100 µL of 2x Laemmli buffer (Sigma-Aldrich), heated to 100 
°C for 5 min and clarified at 15,500 g. Plasma proteins were separated for 45 min by 
one-dimensional SDS polyacrylmide gel electrophoresis on 26 well NuPAGE® Novex 4 
- 12% Bis-Tris Midi Gels, (Invitrogen Ltd., Paisley, UK) using the NuPAGE® 
Electrophoresis System (Invitrogen). All samples were equally loaded (10 µL). To 
account for intra-gel variability, samples were run in duplicate across eight gels and 
standardised against a pool of all 90 samples (as prepared in Section 5.1.1.3) which 
was run in duplicate on each gel. Separated proteins were transferred to 0.2 µm 
nitrocellulose membranes (Schleicher & Schuell, NH, USA). Wet transfer was at 80 V 
for 1 hr at RT. The success of transfer was determined by visualising the membrane-
bound proteins with Ponceau S solution for 1 min. Ponceau S was removed by two 
washes of H2O for 5 min. A2M and gelsolin analyses were performed on the same blot. 
Blots were blocked for 2 h with 5% non-fat milk in 0.1% PBS-Tween (PBS-T) and 
probed with antibodies to A2M (diluted 1:5,000, goat monoclonal, M5649, Sigma-
Aldrich) and gelsolin (diluted 1:500, mouse monoclonal, ab55070, Abcam plc, 
Cambridge, UK) for 16 h at 4 °C. Excess primary antibodies were removed with three 
washes of PBS-T for 5 min. A2M primary antibodies were incubated for 1 h with rabbit 
anti-goat secondary antibodies (diluted 1:5,000). Similarly, gelsolin primary antibodies 
were incubated for 1 h with donkey anti-mouse secondary antibodies (diluted 
1:10,000). All dilutions of both primary and secondary antibodies were previously 
optimised by Andreas Güntert and Mirsada Causevic at the MRC Centre for 
Neurodegeneration Research, King’s College London. Excess secondary antibodies 
were removed with three washes of  PBS-T for 5 min. Secondary antibodies were 
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conjugated to fluorophors, emitting at wavelengths of either 680 or 800 nm, using a 
near infrared Odyssey imager (Licor, Lincoln, NE, USA). Densitometric analysis was 
performed using the Odyssey software v2.1.  
 
5.1.2.2 Data analysis of WB 
The ODs of each sample were standardised against the mean OD of the pooled 
plasma sample separated on the same gel. Duplicate measurements for each of the 90 
samples were averaged and the mean value was used to directly compare the 
difference in plasma A2M and gelsolin levels between RCD, SCD and NDC groups. A 
student’s t-test was calculated to determine if the difference in the mean ODs between 
groups was statistically significant as described in Section 5.1.1.5. In accordance with 
the TMT-SRM analysis of the cohort, a single AD group of combined RCD and SCD 
groups was also compared to NDCs. Furthermore, the precision of WB quantitation 
between replicate blots was assessed. Pearson correlation coefficients were calculated 
to determine the agreement between the TMT-SRM measurement of each A2M and 










5.2.1 Validation of AD candidate biomarkers by TMT-SRM 
5.2.1.1 Modified purification strategy for higher throughput of TMT-labeled 
plasma samples 
In each of the experiments described so far, the purification of TMT-labeled 
peptides for TMT-SRM quantitation incorporated both RP and SCX purification. Here, 
both were performed separately and on each sample. This resulted in sample 
preparation timescales which were unfavourable for the high throughput analyses 
required for biomarker validation across large numbers of samples. In response to this 
and to decrease peptide purification times by approximately half, an experiment was 
designed to assess the TMT-SRM quantitation of light TMT-labeled plasma peptides 
purified by SCX only. Using aliquots of the same plasma digest, light TMT-labeled 
peptides were purified by SCX-only and as a control, the standard protocol of RP and 
SCX. All peptides were detected by SRM at equivalent relative intensities in those 
samples purified by SCX-only and by RP followed by SCX. A comparison was made by 
analysing the variance in the TMT-SRM quantitation of a subset of peptides across all 
replicate measurements between each purification strategy. There was no significant 
difference in the L/H ratios when directly comparing the same peptide between the two 
strategies and a very strong correlation was observed when comparing all 
measurements (p = 0.9). Further, the effect of RP removal was similar for peptides of 
varying tR. As there was no difference to the TMT-SRM quantitation of peptides purified 
by SCX-only, this strategy was used to purify the light TMT-labeled plasmas of the 90 
AD and NDC subjects, resulting in significantly reduced sample preparation times.  
 
5.2.1.2 Sample selection and classification into RCD, SCD and NDC groups 
A total of 90 subjects were selected for validation of the AD candidate 
biomarkers. This comprised 60 AD subjects and 30 NDC subjects. Samples were 
selected at baseline to determine which proteins tracked with decline in cognitive 
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ability. Here, the AD group was further divided into RCD and SCD groups depending 
on MMSE decline per year (Table 5.1; Appendix Table 5.2). MMSE testing is used by 
clinicians to estimate the degree of cognitive impairment in an individual at a given 
point in time or to follow the decline in cognitive ability over time (Folstein et al., 1975). 
The RCD group had an MMSE decline of > 2 points per year over the three to five 
years of follow-up data available (median of 3.8 points). The SCD group had an MMSE 
decline of 0 - 2 points per year (median of 0.8 points). There was no change in MMSE 
scores per year within the NDC group. RCD, SCD and NDC groups were age and sex-
matched, with a higher representation of females to males. Furthermore, a higher 
proportion of APOE ε4 carriers were observed in RCD and SCD groups, as compared 
to NDC (Table 5.1). 
  RCD SCD NDC 
Number 30 30 30 
Mean Age (yrs) 75.2 75.2 73.2 
% Female 77 73 73 
% APOE ε4/' 50 60 29 
% APOE ε4/4 13 20 3 
Mean MMSE decline  
per year (median) 
3.8 0.8 0 
      
 
Table 5.1 Subject characteristics of RCD, SCD and NDC groups. All subjects were age 
and sex-matched. Subjects were either heterozygous (ε4/’) or homozygous (ε4/4) for 
the APOE e4 allelle. RCD, SCD and NDC groups were separated according to MMSE 
decline per year. 
 
5.2.1.3 TMT-SRM analysis of RCD, SCD and NDC on the QTRAP 
Using the higher throughput, multiplexed TMT-SRM assay, the quantitation of 
eight candidate biomarkers of AD in a clinical sample cohort of  RCD, SCD and NDC 
subjects (n = 30 per group) was performed. For two of the peptides (5 and 20), variable 
tR combined with a narrow SRM scheduling window resulted in a failure to capture a 
complete SRM peak in 25 of the samples. A repeat analysis was performed in such 
cases, ensuring a complete dataset. Absolute amounts of endogenous signature 
peptides were determined using the SRP approach. To visualise the data and allow for 
ease of comparison between groups, bar charts were plotted, comparing the mean 









Figure 5.1 Bar charts displaying the difference between RCD, SCD and NDC for all peptides in the multiplexed TMT-SRM assay. Peptides of the 




















































































































Generally, patterns of TMT-SRM quantitation and fold changes between RCD, SCD 
and NDC groups were similar for peptides of the same protein (Figure 5.1, Table 5.2). 
Further, the endogenous plasma concentrations of each targeted peptide were in the 
same range as those in the assay validation experiments described in Section 4.2.2. 
For example, peptide 5 had mean concentrations of 24.5 µg/mL and 21.8 µg/mL in the 
NDC grouping across the TMT-SRM assay validation and biomarker validation cohorts, 
respectively. This was very encouraging as it demonstrated the robustness of the TMT-
SRM workflow across different sample sets. This was essential as ultimately if the 
assay is to have widespread implementation in independant laboratories, target analyte 
concentrations should be generally consistent across cohorts. The result confirmed the 
suitability of the TMT-SRM assay to quantitate the AD candidate biomarkers in 
independant studies.  
 
5.2.1.4 A2M is increased predicts the rate of cognitive decline in Alzheimer’s 
disease  
Both A2M peptides quantitated by the TMT-SRM assay (peptides 14 and 15) 
performed congruently, showing a statistically significant difference (p = 0.0146 and 
0.0293, respectively) between RCD, SCD and NDC subjects (Table 5.2). The observed 
difference tracked with AD progression, i.e., A2M concentrations increased as the rate 
of cognitive decline increased. A small but statistically significant negative correlation 
was observed between A2M concentrations and MMSE decline per year, i.e., an 
increase in A2M concentration correlated with a decline in MMSE score.  
A statistically significant difference (p = 0.0173) was observed between RCD, 
SCD and NDC groups for FGG peptide 20. However, this result was not given much 
importance as it was primarily based on the difference between RCD and SCD 
groupings, which flanked the mean concentration of the NDC group, i.e., a consistent 
increase or decrease for the peptide was not observed across the three groups (Table 
5.2).  Further, the statistical result was not in-line with the second FGG peptide in the 






Theoretical amounts in 
plasma (µg/mL) 
Mean RCD Mean SCD Mean NDC Fold change 
p-value 
(µg/mL) (µg/mL) (µg/mL) RCD v SCD RCD v NDC SCD v NDC 
Clusterin α-chain 35 - 105 4.9 4.7 4.8 1.04 1.02 0.98 0.8971 
Clusterin β-chain 22.4 21.1 21.8 1.06 1.03 0.97 0.473 
Complement C3 670 - 1290 400.4 395.3 412.6 1.01 0.97 0.96 0.9278 
 
 
371.2 349.3 369.9 1.06 1.00 0.94 0.5542 
CFH 400 - 800 36.0 35.4 35.0 1.02 1.03 1.01 0.9428 
 
 
18.6 18.2 18.2 1.02 1.02 1.00 0.7481 
A2M 2000 - 2400 216.7 203.0 189.1 1.07 1.15 1.07 0.0146 
 
 
120.8 114.8 108.4 1.05 1.11 1.06 0.0293 
FGG 80 - 500 4.9 4.3 4.7 1.14 1.04 0.91 0.1643 
 
 
1.5 1.3 1.4 1.15 1.07 0.93 0.0173 
SAP 21 – 44 3.0 2.8 3.1 1.07 0.97 0.9 0.145 
 
 
2.4 2.2 2.3 1.09 1.04 0.96 0.9567 
ApoE 34 - 74 5.2 4.6 4.9 1.13 1.06 0.94 0.1488 
 
 
2.7 2.5 2.7 1.08 1.00 0.93 0.402 
Gelsolin 179 - 200 18.1 17.6 18.6 1.03 0.97 0.95 0.7005 
 
 
14.4 14.8 14.7 0.97 0.98 1.01 0.8382 
   19.7 19.3 19.6 1.02 1.01 0.98 0.9027 
 
Table 5.2 Plasma amounts (µg/mL) of each peptide in RCD, SCD and NDC groups as determined by the multiplexed TMT-SRM assay on the 
QTRAP. For each peptide, the protein from which it is derived is indicated along with biomarker discovery results. It can be seen that peptides of 
A2M showed a statistically significant (p < 0.05) difference between RCD, SCD and NDC groups.  
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peptides included in the TMT-SRM assay showed no significant differences between 
RCD, SCD and NDC groups. 
Baseline plasma samples were selected for analysis in this study to evaluate 
the potential of each candidate biomarker as a prognostic marker of AD. In addition to 
this, the diagnostic utility of each could be determined, even though this may be weak 
in the chosen cohort, i.e, samples were taken at baseline, rather than taken later in the 
pathology of the disease, where differences between groups are likely to be greater. 
Nevertheless, to determine if any of the target analytes had utility as a diagnositic 
biomarker of AD, both RCD and SCD groups were combined to create one AD group. 
This was used to directly compare disease and control groups (Figure 5.2). Both A2M 
peptides showed a statistically significant increase in AD (Table 5.3), validating the 
original discovery study where an increased plasma A2M levels were observed in AD 
subjects as compared to NDC (Hye et al., 2006). All other peptides showed no 
statistically significant difference between AD and NDC groups. For clusterin and 
ApoE, this was in-line with discovery, where no differential expression was observed 
for these proteins between AD and NDC groups (Scacchi et al., 1999; Thambisetty et 
al., 2010). 
 
5.2.1.5 TMT-SRM analysis on the TSQ Vantage 
TMT-SRM quantitation of the experimental sample cohort was replicated on the 
TSQ Vantage to validate the results on the QTRAP and to confirm the portability of the 
assay across different MS platforms. In accordance with the QTRAP results, peptides 
of the same protein had equivalent patterns of expression between RCD, SCD and 
NDC groups (Table 5.4). The endogenous plasma amounts of each peptide were 
highly comparable to TMT-SRM on the QTRAP in the majority of cases. However, 
deviations did occur with, peptides 9, 24 and 25 being ~ 40% lower on the TSQ 
Vantage. Indeed, as determined in Chapter 4, peptide 9 had poorer trueness on the 








Figure 5.2 Bar charts displaying the difference between AD and NDC for all peptides of each candidate AD biomarker. Peptides of the same 








































































































































Clusterin α-chain 1 4.8 4.8 0.99 NSD NSD 0.9368 
Clusterin β-chain 5 21.8 21.8 1.00 NSD NSD 0.9550 
Complement C3 8 397.9 412.6 0.96 ↑AD NSD 0.7623 
 9 360.3 369.9 0.97 ↑AD NSD 0.6885 
CFH 12 35.7 35.0 1.02 ↑AD NSD 0.8281 
 13 18.4 18.2 1.01 ↑AD NSD 0.7757 
A2M 14 209.8 189.1 1.11 ↑AD ↑AD 0.0069 
 15 117.8 108.4 1.09 ↑AD ↑AD 0.0434 
FGG 19 4.6 4.7 0.97 ↑AD NSD 0.6342 
 20 1.4 1.4 0.99 ↑AD NSD 0.6641 
SAP 22 2.9 3.1 0.93 ↑AD NSD 0.7720 
 23 2.3 2.3 0.99 ↑AD NSD 0.9658 
ApoE 24 4.9 4.9 1.00 NSD NSD 0.9781 
 25 2.6 2.7 0.97 NSD NSD 0.6416 
Gelsolin 29 17.9 18.6 0.96 ↓AD NSD 0.5401 
 30 14.6 14.7 1.00 ↓AD NSD 0.9388 
 31 19.5 19.6 0.99 ↓AD NSD 0.8715 
 
Table 5.3 Plasma amounts (µg/mL) of each peptide in AD and NDC samples as determined by the multiplexed TMT-SRM assay on the QTRAP. It 
can be seen that peptides of A2M showed a statistically significant (p < 0.05) difference between AD and NDC groups, which was expected based 
on the previous results. For the remainder of the peptides, no significant difference (NSD) was observed. Results are in agreement with the RCD, 

















Fold change  
p-value 
RCD v SCD RCD v NDC SCD v NDC 
Clusterin α-chain 1 3.7 3.5 3.7 1.06 1.00 0.95 0.997 
Clusterin β-chain 5 21.5 21 21.6 1.02 1.00 0.97 0.781 
Complement  C3 8 377 365 401.7 1.03 0.94 0.91 0.878 
 
9 220.6 214.6 219.2 1.03 1.01 0.98 0.996 
CFH 12 31.7 31 30.7 1.02 1.03 1.01 0.836 
 
13 19.1 18.8 18.9 1.02 1.01 0.99 0.881 
A2M 14 224.2 211.6 194.2 1.06 1.15 1.09 0.006 
 
15 142 130.4 124.1 1.09 1.14 1.05 0.031 
FGG 19 4.1 3.6 4.0 1.14 1.03 0.90 0.044 
 
20 1.3 1.2 1.2 1.08 1.08 1.00 0.451 
SAP 22 3.1 2.8 3.0 1.11 1.03 0.93 0.243 
 
23 2.1 1.9 2.2 1.11 0.95 0.86 0.152 
ApoE 24 3.1 2.9 3.1 1.07 1.00 0.94 0.988 
 
25 4.8 4.3 4.6 1.12 1.04 0.93 0.416 
Gelsolin 29 17.4 16.8 17.0 1.04 1.02 0.99 0.538 
 
30 16.2 16.4 16.1 0.99 1.01 1.02 0.955 
  31 20.6 20.1 20.2 1.02 1.02 1.00 0.863 
 
Table 5.4 Absolute amounts for each candidate biomarker peptide in RCD, SCD and NDC groups by TMT-SRM on the TSQ Vantage. For each 
peptide, the protein from which it is derived is indicated along with biomarker discovery results. It can be seen that peptides of A2M showed a 




and reduced SRM sensitivities for this peptide on the TSQ Vantage may account for 
this. However, the performance of peptides 24 and 25 was comparable across LC-
SRM platforms, despite differences in absolute amounts. 
When comparing RCD, SCD and NDC groups for A2M on the TSQ Vantage, a 
statistically significant increase was observed for peptides 14 and 15 across the three 
groups and this difference tracked with disease progression (Table 5.4). This was in 
agreement with the finding on the QTRAP (Figure 5.3, Table 5.5). A statistically 
significant difference (p = 0.0440) was observed between RCD, SCD and NDC groups 
for FGG peptide 19. However, as for FGG peptide 20 on the QTRAP, a consistent 
increase or decrease for the peptide was not observed across the three groups (Table 
5.2). Further, the statistical result was not in-line with the second FGG peptide, in this 
case, peptide 20 and thus, confirmation of its validity was not possible. For the 
remaining peptides in the assay, no significant differences were observed between 
RCD, SCD and NDC groups, which is in-line with the previous finding on the QTRAP.  
When comparing TMT-SRM quantitation of a single AD group against NDC on 
the TSQ Vantage, excellent agreement was observed with the results on the QTRAP 
(Table 5.3; Table 5.6). Both A2M peptides demonstrated a statistically significant 
increase in AD, confirming the protein as a diagnostic biomarker of AD in plasma. 
Gelsolin peptide 29 had a statistically significant decrease in AD (p = 0.0200). 
However, this was not in-line with the other gelsolin peptides in the assay or the TMT-
SRM results from the QTRAP. Thus, confirmation of the validity of this result was not 
possible. The remaining peptides in the TMT-SRM assay had no statistically significant 
differences between AD and NDC groups. 
Equivalent TMT-SRM measurements between instruments were visualised and 
the agreement between all measurements on the two instruments assessed (Bland and 
Altman, 1986). The difference between the equivalent samples on each instrument was 
plotted against the mean of both. This is displayed in Figure 5.4 where different 





               
 
    
Figure 5.3 Expression of A2M between RCD, SCD and NDC on the QTRAP and TSQ 
Vantage. Equivalent patterns of expression were observed for both A2M peptides (14 
and 15) between RCD (blue), SCD (red) and NDC (green) groups across MS 


























216.7 203.0 189.1 1.07 1.15 1.07 0.0146 
TSQ 224.2 211.6 194.2 1.06 1.15 1.09 0.0060 
QTRAP 
15 
120.8 114.8 108.4 1.05 1.11 1.06 0.0293 
TSQ 142.0 130.4 124.1 1.09 1.14 1.05 0.0316 
Table 5.5 Absolute amounts of A2M on the QTRAP and TSQ Vantage. A statistically 
significant (p < 0.05) difference was observed between RCD, SCD and NDC groups for 
peptides 14 and 15 on the QTRAP and TSQ Vantage. 
 
 
Excellent agreement was observed between corresponding TMT-SRM measurements 
on both instruments as the majority of measurements cluster around the mean and are 
within 2 SD of the mean. An example of this agreement is demonstrated by the CFH 
peptide 12 and A2M peptide 14 (blue and purple in the centre of the plot), which are 
clustered tightly around the mean. Several peptides show greater variation across the 
two instruments (e.g., peptide 1, coloured pink). However, as this was the only 
signature peptide remaining for clusterin α-chain, its continued inclusion in the assay 
was essential. 
 


















Clusterin α-chain 1 3.6 3.7 0.98 NSD NSD 0.9810 
Clusterin β-chain 5 21.3 21.6 0.98 NSD NSD 0.6920 
Complement C3 8 371.1 401.7 0.92 ↑AD NSD 0.6920 
 9 217.7 219.2 0.99 ↑AD NSD 0.9840 
CFH 12 31.3 30.7 1.02 ↑AD NSD 0.7300 
 13 19.0 18.9 1.00 ↑AD NSD 0.9910 
A2M 14 218.0 194.2 1.12 ↑AD ↑AD 0.0001 
 15 136.3 124.1 1.10 ↑AD ↑AD 0.0327 
FGG 19 3.8 4.0 0.95 ↑AD NSD 0.3570 
 20 1.3 1.2 1.01 ↑AD NSD 0.9070 
SAP 22 3.0 3.1 0.95 ↑AD NSD 0.4510 
 23 2.0 2.2 0.90 ↑AD NSD 0.0680 
ApoE 24 3.1 3.2 0.99 NSD NSD 0.9250 
 25 4.6 4.6 0.99 NSD NSD 0.9250 
Gelsolin 29 17.1 17.9 0.96 ↓AD ↓AD 0.0200 
 30 16.2 17.0 0.95 ↓AD NSD 0.1210 
  31 20.4 20.2 1.01 ↓AD NSD 0.8560 
 
Table 5.6 Absolute amounts for each candidate biomarker peptide in AD and NDC groups by TMT-SRM on the TSQ Vantage. It can be seen that 












Figure 5.4 Comparison of all TMT-SRM measurements on the QTRAP and TSQ Vantage. The difference between the equivalent samples on each 
instrument was plotted against the mean of both. All data was log2 transformed. The mean and mean +/- 2 SD are plotted with dashed lines. Each 
point represents an individual sample. Points are coloured according to the peptides they represent. A2M peptides are coloured purple (peptide 14) 
and brown (peptide 15) and are plotted in the centre of the figure, indicating excellent agreement across MS platforms. 
Peptide 1 = dark cyan  Peptide 14 = purple  Peptide 24 = magenta 
Peptide 5 = black  Peptide 15 = brown  Peptide 25 = light red 
Peptide 8 = light yellow  Peptide 19 = light cyan  Peptide 29 = dark blue 
Peptide 9 = green  Ppetide 20 = dark red  Peptide 30 = dark brown 
Peptide 12 = dark yellow  Peptide 22 = light grey  Peptide 31 = light blue 
Peptide 13 = dark grey  Peptide 23 = light pink 
    




























5.2.2 Validation of TMT-SRM results 
5.2.2.1 Western blotting of A2M and gelsolin 
To confirm the findings of the mass spectrometry-based TMT-SRM assay, 
quantitation of A2M and gelsolin levels was performed on the sample cohort using the 
standard immuno-based technique of WB. A2M was selected as it was the only protein 
found to be significantly changing between AD and NDC groups by TMT-SRM. Gelsolin 
was selected as a decrease was observed for the protein across RCD, SCD and NDC 
groups in discovery studies which predicted the rate of cognitive decline (Güntert et al., 
2010). Further, it was hypothesised that if no significant differences were observed for 
gelsolin by WB, this would confirm the findings for all target analytes which showed no 
differential expression by TMT-SRM. SDS-PAGE separation and immuno-based 
detection of A2M and gelsolin is displayed in Figure 5.5 A. For both A2M and gelsolin, 
no statistically significant difference was observed between RCD, SCD and NDC 
groups (Figure 5.5 B and C). The gelsolin result confirms the validity of the TMT-SRM 
result for each peptide where no significant differential expression was observed 
between the three groups in the cohort utilised here. This is not in-line with discovery 
studies for the protein, where a statistically significant decrease was observed across 
RCD, SCD and NDC groups by WB. Also, when looking at AD and NDC groups only, 
no statistically significant differences were determined between groups. It was perhaps 
surprising to find no significant increase in A2M levels between RCD, SCD and NDC or 
AD and NDC groups by WB. However, the result demonstrated the superior 
performance of the mass spectrometry-based TMT-SRM assay over the immuno-
based approach, i.e., the absolute quantitation provided by the TMT-SRM assay was 
more sensitive to expression changes between groups than the relative quantitation 
provided by the WB. This is further demonstrated by ROC analyses in Figure 5.6 where 
















Protein RCD SCD NDC 
Fold change 






A2M 1.08 1.09 1.03 0.99 1.05 0.95 0.534 
Gelsolin 0.86 0.85 0.9 1.01 0.96 1.05 0.658 
Figure 5.5 Western blot results for A2M and gelsolin across the sample cohort. A A 
representative blot showing the detection of A2M and gelsolin in the plasma of AD and 
NDC subjects. Denatured plasma samples were separated by SDS-PAGE and 
transferred to nitrocellulose membranes. Blots were probed with antibodies against 
A2M and gelsolin. The Mr (kDa) of the marker is displayed on the left.  B Expression of 
A2M and gelsolin between RCD, SCD and NDC by WB. Similar expression of each 
protein was observed between groups. Error bars indicate the 95% CI.C Relative ratios 
of A2M and gelsolin between RCD, SCD and NDC groups. The fold change between 































































Figure 5.6 ROC analyses for A2M by TMT-SRM and WB. A For the TMT-SRM results, 
a ROC curve is plotted for each transition of each peptide as well as the mean over all 
transitions/peptides B ROC analysis of the A2M WB. For each curve, the AUC is also 
displayed. A higher AUC is observed for the TMT-SRM results than WB, demonstrating 


























5.2.2.2 Correlation of QTRAP, TSQ Vantage and WB results 
A comparison was made between the MS- and immuno-based platforms for all 
A2M and gelsolin measurements. More precisely, agreement between values of the 
same sample obtained by TMT-SRM and WB was assessed. Several analyses were 
performed, i.e., QTRAP versus WB, TSQ Vantage versus WB, QTRAP versus TSQ 
Vantage and WB versus WB (replicates 1 and 2). For the MS measurements, all 13 
transitions of A2M and gelsolin included in the final data analysis were compared to the 
WB measurement for that protein. The Pearson correlation coefficient was calculated 
for each comparison. When comparing either QTRAP or TSQ Vantage against WB, a 
strong correlation was observed for A2M and gelsolin values across MS and WB 
platforms, with Pearson correlation coefficients ranging from 0.51 – 0.70. Figure 5.7 A 
and B displays data for the transitions which gave the highest and lowest correlation 
coefficients on either the QTRAP or TSQ Vantage as compared to WB. The results 
demonstrate the high agreement between both MS and immuno-based approaches. 
Very strong correlation was observed when comparing the measurements on the 
QTRAP to the TSQ Vantage (Pearson correlation coefficients ranged from 0.75 – 0.95, 
Figure 5.7 C and D), further demonstrating the excellent agreement between TMT-
SRM quantitation across both instruments. In general, a weaker correlation was 
observed between the two WB replicates (Pearson correlation coefficients of 0.43 – 
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Figure 5.7 Correlation of QTRAP, TSQ Vantage and WB measurements for A2M and 
gelsolin. A Highest correlation (A2M peptide 14, transition 2) of MS (QTRAP) v WB B 
Lowest correlation (A2M peptide 15, transition 1) of MS (TSQ Vantage) v WB C 
Highest correlation (A2M peptide 14, transition 3) of QTRAP v TSQ Vantage D Lowest 
correlation (A2M peptide 15, transition 2) of QTRAP v TSQ Vantage E WB1 v WB2 of 




 The utility of a TMT-SRM assay was demonstrated for the rapid, selective and 
multiplexed quantitation of a panel of candidate biomarkers of AD across a 
clinical cohort.  
 In-line with discovery, plasma A2M was found to increase in AD and correlated 
with the rate of cognitive decline in the disease, thus confirming the protein as a 
diagnostic and prognostic biomarker of AD. 
 The prognostic utility of plasma clusterin as demonstrated in discovery was not 
confirmed by TMT-SRM. In the same context, the result confirmed discovery 
studies which showed that the protein did not have use as a diagnostic 
biomarker of the disease. Further, several groups have demonstrated that 
plasma ApoE is unchanged in AD and this is in agreement with the TMT-SRM 
results described here-in. 
 The remaining proteins in the panel were not confirmed as prognostic or 
diagnostic biomarkers of AD in this instance. 
 Equivalent absolute amounts were observed for each plasma peptide to those 
described in the assay validation experiments in Chapter 4, demonstrating the 
robustness of the TMT-SRM workflow for peptide quantitation across 
independent sample cohorts.  
 TMT-SRM results were equivalent on analogous MS instruments and 
quantitation provided by the novel MS-based assay was in strong agreement 






































6.0 The pressing need for sensitive and specific biomarkers of AD 
AD is the most prevalent type of dementia. The availability of new treatments 
for common illnesses and an all-round improvement in healthcare is reflected in a 
continually aging population, resulting in a recent explosion in the number of people 
diagnosed with the disease. In addition to the obvious personal strain on both the 
sufferer and their families, this has major implications in terms of financial burden and 
effort on healthcare institutions. The current annual cost to the UK economy for 
treatment of AD is estimated to be £17 billion. Consequently, there is an urgent need 
for new technologies which can aid in an earlier diagnosis, slow the progression or 
indeed, improve the symptomatic treatment of AD. Several drug candidates are 
currently in Phase II and Phase III trials including secretase inhibitors and tau 
aggregation inhibitors (Pogacic and Herrling, 2009). The beneficial action of such 
species would have the greatest impact at the very earliest stages of the disease 
course, before the manifestation of AD pathology and progressive decline in cognitive 
function become insurmountable.  
Currently, AD can only be definitively diagnosed by brain biopsy or upon 
autopsy after the death of a patient (Davinelli et al., 2011). However, in the clinical 
setting, brain biopsy is rarely performed and diagnosis of MCI and AD states in living 
subjects is dependant on clinical evaluation using a battery of neuropsychological tests. 
Such measures may have inherent inaccuracies as they are subject to individual 
interpretation in the clinic. Changes in peptide and protein levels in human body fluids 
such as urine, CSF and plasma may reflect the physiological state of healthy or 
diseased individuals and thus have been proposed as providing a more definitive 
source of diagnostic and prognostic biomarkers of AD (Blennow et al., 2010). As 
detailed in the 1998 Consensus Report of the Working Group on Molecular and 
Biochemical Markers of Alzheimer’s Disease, the perfect biological markers of AD 
would be able to distinguish those people at risk of the disease and would identify AD 
at its very earliest stages. Further, biomarkers which could reflect changes at the 
molecular level could enable the stratification between MCI subjects who convert to AD 
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and those who do not, the characterisation of disease progression and assignment of 
patients for targeted treatments and the monitoring of treatment response. Further, 
biomarkers should be specific enough to distinguish AD from other dementias, non-
invasive, inexpensive, reliable and simple to perform (The Ronald And Nancy Reagen 
Research Institute Of The Alzheimer’s Association And The National Institute On Aging 
Working Group, 1998). 
Due to its proximity and solubility with the brain via the BBB, CSF is an obvious 
source of sample matrix when looking at biomarkers of neurodegenerative diseases 
such as AD. Indeed, many studies utilising antibody-based approaches have been 
published comparing CSF levels of Aβ and tau peptides at different stages of the 
disease course (Sunderland et al., 2003; Craig-Shapiro et al., 2009; Tapiola et al., 
2009; Mattson et al., 2009; Visser et al., 2009). It has been consistently reported that a 
marked decrease in Aβ1-42 and increase in both t-tau and p-tau is observed in the CSF 
of AD subjects. However, it is very difficult to obtain ethical approval for lumbar 
puncture extraction of CSF in many countries, including the United Kingdom. Although 
techniques are improving, CSF sample extraction remains somewhat invasive and 
difficulty in obtaining large volumes of the fluid makes it unsuitable for routine 
application. Attention has recently shifted to blood as molecular changes in the AD 
brain may be reflected in the periphery or indeed, physiological responses to AD may 
be occurring in the blood itself. The repeatability of venepuncture for blood extraction is 
relatively easy, quick and inexpensive compared to CSF and thus, blood plasma or 
serum represent an ideal sample matrix for clinical proteomic studies of the disease. In 
a similar context, blood tests measuring cholesterol and APOE genotype are currently 
available for assessment of AD risk (Mayeux et al., 1998). Such 'susceptibility' or 'risk 
factor' testing indicates whether there is a likelihood of developing late onset AD, but 
unfortunately, does not provide a diagnostic or prognostic measure of the disease.  
Proteomic investigations in plasma by several independent groups have 
revealed an extensive list of candidate biomarkers of AD (Corder et al., 1994; Chen et 
al., 1995; Farlow et al., 2004; Ferri et al., 2005; Hye et al., 2006; German et al., 2007; 
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Cutler et al., 2008; Thambisetty et al., 2010; Güntert et al., 2010). In this thesis, a 
subset of these proteins was selected for assay development as they showed the most 
promise from discovery and had confirmed associations with disease pathology. Using 
2DE and TMT peptide-labeling technologies, complement C3/C3a, CFH, A2M, FGG, 
SAP and gelsolin were previously described as differentially expressed in AD patients 
and may prove to be valuable indicators of AD diagnosis (Hye et al., 2006; Lee et al., 
2007; Maier et al., 2008; Thambisetty et al., 2010; Güntert et al., 2010). Further, 
clusterin and gelsolin may have utility in predicting the progression of the disease. 
ApoE is of interest as the ApoE ε4 allele has been shown to cause increased 
susceptibility to AD and this genetic trait may translate at the protein level (Scacchi et 
al., 1999).  
The next stage requires the verification of such species as true biomarkers, 
sensitive and specific for the disease. The majority of the selected candidate proteins 
are already associated with other degenerative diseases, e.g., CFH with AMD and 
clusterin with Huntington’s disease (Thakkinstian et al., 2006; Dalrymple et al., 2007). It 
is therefore expected that a combined panel of proteins may be used and result in 
enhanced diagnostic and prognostic sensitivity and specificity, than either alone (Mor et 
al., 2005). Biomarker verification requires the development of rapid, high quality, fit-for-
purpose, multiplexed assays to measure target analytes in a sufficient throughput of 
samples necessary for such analyses. This process ensures only the best candidates 
are taken through to biomarker validation and qualification stages and to determine if 
the changes in protein abundance observed in discovery are real (Jaffe et al., 2008). 
Traditional assay development schemes for peptide and protein quantitation have 
utilised the highly selective and specific response of antibodies, e.g., ELISA assays 
(Engvall and Perlman, 1971; Brennan et al., 2010). There are several advantages 
associated with this technique including the highly specific nature of the antibody-
antigen interaction and the high sensitivity of the approach, permitting the quantitation 
of proteins in plasma down to < ng/mL levels. However, quantitation may be subject to 
interference from other species within the matrix and the absolute amounts of target 
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analytes cannot be ascertained (Preissner et al., 2003). ELISA assays in plasma 
currently remain limited as only one antigen can be robustly and accurately detected at 
any one time (Leng et al., 2008). This is changing and recently, multiplexed immuno- 
assays have become available (Ray et al., 2007). However, such techniques are very 
much in their infancy and their full potential as accurate and specific quantitation 
strategies has yet to be comprehensively described. The cost associated with immuno-
assay development is generally very high, with usually a very long lead time, i.e., 
usually over one year (Hüttenhain et al., 2009). Ultimately, the success of such assays 
is exclusively dependent on the availability of high quality antibodies for antigen 
detection. Unfortunately, the production of requisite antibodies frequently fails. There is 
thus an urgent need for novel, highly reproducible, high throughput peptide and protein 
quantitation strategies to improve the success rate of approved biomarkers (Anderson, 
2005). Unfortunately, the limited availability of such techniques, capable of testing 
panels of biomarkers in even moderate sample numbers has created a significant 
bottleneck in the biomarker pipeline (Rifai et al., 2006; Paulovich et al., 2008).  
 
6.1 Moving from the protein antibody to the peptide autograph 
The major difficulty in the analysis of blood-based biomarkers is the huge 
complexity and vast dynamic range of protein concentrations in human plasma 
(Anderson and Anderson, 2002). Despite the effort and vast investment to generate 
lists of candidate biomarkers in discovery studies, there is currently no plasma 
biomarker of AD routinely used in a clinical setting and this is in part due to the 
immense technical requirements for their verification and validation. A possible 
resolution to this problem is the recruitment of more targeted, candidate-based 
proteomic strategies such as SRM for biomarker assay development. The technique 
relies on the detection and quantitation of selected surrogate peptides, unique to the 
candidate biomarker protein of interest (Mallick et al., 2007). In this context, SRM-
based assays for biomarker measurement can be directed towards specific protein 
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isoforms and PTMs, an additional shortfall of immuno-based means. SRM is sensitive 
(down to low attomolar amounts) and its dynamic range covers over five orders of 
magnitude (Anderson and Hunter, 2006; Domon and Aebersold, 2006; Stahl-Zeng, 
2007). Moreover, the technique is suitable in providing highly precise measurements 
across independent laboratories, a requisite feature of any robust quantitative assay 
(Addona et al., 2009). SRM in combination with stable isotope dilution has become 
increasingly popular where targeted, multiplexed, absolute quantitative amounts of 
peptides are being pursued (Gerber et al., 2003; Kirkpatrick et al., 2006; Pratt et al., 
2006). In an effort to reduce the inherent cost associated with production of heavy 
isotope-labeled peptides for internal standardisation in such studies, methods utilising 
isotopic versions of iTRAQ and ICPL in combination with SRM have been recently 
developed, namely mTRAQ (Lange et al., 2008; DeSouza et al., 2008; DeSouza et al., 
2009; DeSouza et al., 2010). In a similar vain, SRM in combination with TMT has been 
proposed as a comparable strategy for the targeted, multiplexed quantitation of 
peptides in complex background matrices such as plasma.  
There is compelling evidence that medium to high abundant proteins in plasma 
have value as clinical biomarkers of AD (Hye et al., 2006; Akkufo et al., 2008; Song et 
al., 2009; Thambisetty and Lovestone, 2010). The feasibility of SRM for the 
measurement of such medium to high abundant species was first demonstrated by 
Anderson and Hunter in 2006. As the candidate proteins discussed in this thesis 
represent plasma species in the same range of abundance as described by the 
aforementioned study (present down to low µg/mL levels), it was hypothesised that the 
target analytes could be detected and quantitated in unfractionated plasma by SRM, 
without the need for prior enrichment such as that using SISCAPA or high abundant 
protein (e.g., albumin or immunoglobulin G) depletion strategies. This has obvious 
benefits as the overall workflow is less complex and less prone to errors and minimal 
sample manipulation will increase throughput and limit sample to sample variability, 
thereby improving the accuracy of the quantitative measurement. Additionally, 
immunoaffinity-SRM approaches are dependent on the availability of requisite 
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antibodies, which additionally has time and cost considerations. To date, no study has 
been published utilising targeted MS-based methods to validate panels of candidate 
biomarkers of AD in plasma. 
 
6.2 Developing novel strategies for candidate biomarker verification in plasma 
In the first instance, it was important to assess the quantitative performance of 
utilising isotopic versions of TMT tags as a means of introducing an internal standard 
into an SRM experiment. In Chapter 2, the TMT-SRM approach was successfully 
demonstrated as an accurate quantitative strategy for the targeted and parallel 
measurement of multiple peptides endogenous to plasma at medium to high 
abundance. Here, a sample preparation workflow was optimised for the production of 
suitable target peptides of plasma proteins, including the choice of enzyme for 
digestion, TMT-labeling of proteolytic peptides and sample clean-up using RP and SCX 
chromatography. All experiments were performed once. Trypsin was selected as an 
appropriate enzyme for peptide production due to its well-recognised high specificity, 
i.e., trypsin cleaves protein peptide bonds specifically on the carboxylic side of basic 
lysine and arginine residues. This cleavage specificity results in protein digestion 
products of the appropriate size range and charge for MS analysis in positive ionisation 
mode. In addition to the high efficiency of the TMT-labeling reaction, the data 
suggested that RP and SCX chromatography were competent for eliminating MS 
interfering compounds.  
The mass difference of 5 Da between light TMT and heavy TMT tags allowed 
distinguishing between differentially labeled versions of the same peptide. This was 
true for peptides of multiple charge states and which had varying numbers of TMT 
attached. This compares to 4 Da per tag and 6 Da per tag in the mTRAQ and ICPL 
strategies, respectively (Julka and Regnier, 2005; Schmidt et al., 2005; DeSouza et al., 
2008). Such differences are important for crosstalk between transitions, i.e., the greater 
the mass difference introduced, the less chance of crosstalk. This needed to be 
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assessed in that transitions were selective even when the ion measured in Q3 was of 
the same m/z and the precursor was triply charged. Further, by applying an isotopic 
TMT-labeling strategy, a mass difference could be introduced between experimental 
sample peptides and internal standards, allowing for the differential detection of both by 
SRM. Additionally, light and heavy TMT-labeled versions of the same peptide were 
shown to perfectly co-elute by LC-SRM. This was crucial, as it allowed for the direct 
comparison and relative quantitation between different TMT-labeled versions of the 
same peptide, both here, and in subsequent TMT-SRM experiments. The accuracy 
achieved was encouraging and comparable to %CV’s required for assays (Anderson 
and Hunter, 2006). Therefore, based on these initial proof-of-principle experiments, an 
assay was developed for a panel of candidate plasma biomarkers of AD. 
By using isotopic versions of TMT, both purified biological sample proteins as 
well as synthetic peptides can be utilised as internal standards. As described in 
Chapter 2, tryptic peptides of biological and synthetic proteins provide relatively quick 
and inexpensive references for TMT-SRM quantitation. During the course of this thesis, 
TMT-SRM was successfully implemented for the verification of candidate biomarkers of 
iron regulation in N. meningitidis (Byers et al., 2009). Here, a biological pool was 
utilised for TMT-SRM internal standardisation. This was highly beneficial as it provided 
an internal standard for all target peptides under consideration and allowed for the 
determination of the most robust SRM transitions for quantitation. However, the 
strategy was somewhat limited by the fact that matrix interference on SRM transitions 
could not truly be deciphered and assay performance characteristics could not be 
determined. Thus, synthetic peptides were prepared for use as internal standards in 
the assay under development in this thesis. This resulted in an overall reduction in 
sample complexity and in so doing, improved the chance of detection and quantitation 
of the target proteins in undepleted plasma. An added benefit of using synthetic 
peptides is the ability to fine-tune compound-dependent parameters for individual SRM 
transitions during the method development process, thus enhancing the final detection 
of the all target analytes in plasma (Keshishian et al., 2007). Furthermore, on condition 
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that accurate concentrations are determined by AAA, synthetic peptides enable 
absolute quantitative amounts to be determined, allowing the comparison of target 
peptide abundance across experiments and independent sample cohorts. The 
provision of absolute amounts assumes the efficiency of the trypsin digestion reaction 
is 100% and the internal standard remains at a constant (known) amount throughout 
the workflow. Further, it was assumed (and confirmed here-in) that light TMT- and 
heavy TMT-labeling of the same peptide gives equal SRM sensitivies. 
Important determinants in achieving sensitive, specific and accurate quantitative 
measurements included the selection of peptides which were proteotypic and of an 
appropriate length (6 - 25 amino acids), fully hydrolysed by trypsin and absent of 
known PTMs such as phosphorylation and glycosylation (Kitteringham et al., 2007; 
Picotti et al., 2010). The most important consideration for peptide selection was peptide 
proteotypicity within the human plasma proteome (Craig et al., 2005). However, due to 
the overlap between different isoforms of a protein, this was not always possible, e.g., 
two isoforms of clusterin exist in blood (isoform 1 and 2) as a result of alternative 
splicing. None of the selected peptides were present in this sequence and thus, the 
peptides measured either isoform. However, all selected peptides were specific to the 
respective protein of interest. The reasoning behind such stringent peptide length was 
that longer peptides are generally more hydrophobic and have a higher overall charge 
(Steen and Mann, 2004). In the same context, peptides with internal RP/KP and 
histidine residues were avoided, where possible. As demonstrated within this thesis, 
more hydrophobic peptides can introduce uncertainty and less accuracy in the 
quantitative measurement. In the same context, a preference for peptides of 2+ (more 
favourable) and 3+ (less favourable, due to charge splitting and reduction in sensitivity) 
charge states was taken during the development of the TMT-SRM assay. Furthermore, 
longer peptides are more expensive to synthesise, whilst shorter peptides (< 6 amino 
acids) do not provide the required specificity as they are less likely to be proteotypic. 
Peptides were required to be free of amino acids which may undergo in vitro 
modifications, e.g., cysteine, tryptophan or methionine, although peptides containing 
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such species may be considered for TMT-SRM only if the choice of suitable peptides is 
low, as often, such modifications are complete. 
As different peptides are subject to differential ionisation efficiencies and 
fragmentation properties by CID, this can dramatically affect the quality of the TMT-
SRM measurement. An approach was taken to select multiple peptides, as opposed to 
a single peptide, per protein candidate. There are advantages and disadvantages to 
both strategies. Using a single signature peptide as representative of a target protein 
has been successfully demonstrated for the quantitation of candidate biomarkers in first 
trimester Trisomy 21 maternal serum (Lopez et al., 2011). The rationale for this was 
that multiple peptides might quantify different isoforms of the same protein, thereby 
producing conflicting results. Further, lower numbers of peptides results in a lower 
overall complexity of the analytical system. Production of single peptides per protein 
would additionally minimise costs. However, caution must be taken when limiting oneslf 
in such a manner as the optimal peptide (in terms of detection, robustness and 
accuracy) may not be selected at an early enough stage during the analysis. The 
selection of multiple signature peptides per candidate biomarker protein was therefore 
chosen for this multi-protein assay to compensate for the fact that different peptides of 
a protein may give different quantitative amounts depending on the region of the 
protein from which each species arises, e.g., due to the presence of splice variants or 
truncations and such biological variances need to be considered (Duncan et al., 2009). 
In total, 32 peptides were selected for TMT-SRM quantitation, with at least three 
peptides per protein. From the selected peptides, 16 were observed in biomarker 
discovery plasma datasets, establishing a link between biomarker discovery using 
isobaric TMT-labeling and subsequent validation by TMT-SRM (Byers et al., 2009). 
Multiple measurements for each candidate protein increased the confidence in the 
TMT-SRM quantitation and enabled the determination of those peptides which provide 
the most robust quantitative measurements in terms of SRM sensitivity and specificity 
(Yocum and Chinnaiyan, 2009). As a result, poorly performing peptides were removed 
at several stages during assay development and validation, with only the most robust 
237 
 
signature peptides of a protein remaining for quantitation in the final TMT-SRM assay. 
Peptides were removed due to significantly decreased sensitivities upon TMT-labeling 
or purification, due to poor endogenous detection in plasma or those peptides which 
had poor accuracy during assay validation. In future studies, experiments could be 
undertaken in an effort to address the variability in peptide recovery at the various 
different stages of the TMT-labeling workflow. To assess the effects of TMT-labeling on 
peptide amounts, a TMT-SRM method may be prepared to measure a plasma sample 
which has remains unlabeled, to that which has been TMT-labeled. If both samples are 
combined in a 1:1 ratio, then the % differences in SRM sensitivities, i.e., deviation from 
the expected ratio, could give an estimation of any peptide losses which are due to the 
TMT-labeling reaction. To quantitate the peptide losses occurring over the complete 
workflow (and primarily at the RP and SCX purification stage), a known amount amount 
of peptide standard could be spiked in at the beginning of the process and quantitated 
by SRM at each stage of the process. To study the effects of storage of plasma 
proteins over long periods of time, a plasma sample could be stored at - 80ºC for, e.g., 
t = 0, 1, 2, 4, 8, 12, 16, 32, 64 weeks and assessed by comparing endogenous plasma 
peptides to synthetic peptide internal standards spiked-in immediately before analysis 
by the developed TMT-SRM method. This analysis could be extended to storage of the 
plasma sample in several different types of sample vial, e.g., glass vials, standard 
eppendorfs and low adsorption eppendorfs to assess the effects of storage in each 
(Kraut et al., 2009). 
A total of 17 peptides demonstrated good endogenous detection in plasma and 
accurate and robust TMT-SRM measurements and thus were included in the final 
quantitative assay. Importantly, at least two peptides per protein remained, which 
enabled continued comparison for peptides within a protein. 
The complexity and huge dynamic range of proteins in plasma increases the 
likelihood of analyte-on-analyte suppression and background matrix effects which can 
detrimentally influence SRM detection and specificity (Keshishian et al., 2007; 
Sherman et al., 2009; Abbatiello et al., 2010). As is often the case, many tryptic plasma 
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peptides share similar m/z and tR properties, which cannot be fully discriminated using 
current low resolving triple quadrupole instruments. In an effort to combat these 
deleterious effects, multiple transitions of a peptide were targeted for quantitation. This 
resulted in a more specific TMT-SRM assay as aberrant transitions affected by non-
specific plasma background could be highlighted and removed from the data analysis, 
or indeed, the method as a whole. The strategy developed in this thesis to determine 
less specific transitions was based on the overlap of calibration curves for different 
transitions of the same peptide. Aberrant transitions were highlighted as less specific. 
Due to this robust way to identify spurious transitions, it was therefore decided not to 
remove such transitions from the method completely here, as it was demonstrated that 
different plasma types are subject to varying levels of background interference, i.e., 
what is true for one plasma species is not necessarily true for all and thus, valuable 
proteomic information may be lost if such analytes are completely ignored. Further, 
selection of multiple SRM transitions per peptide added further confidence to the 
quantitative measurement. In agreement with the literature, the importance of selecting 
Q3 ions greater than the m/z of the precursor ion where possible was highlighted as 
they provide better selectivity between light TMT and heavy TMT transitions 
(Kirkpatrick et al., 2005; Lange et al., 2008; Kuzyk et al, 2009). A common feature of all 
TMT-labeled peptides is the presence of high m/z pseudo-y ions. Such ions are TMT 
fragment ions whose m/z is always the intact mass of the labeled peptide minus the 
reporter ion and CO. It was hypothesised that pseudo-y ions may serve as appropriate 
Q3 SRM transitions ions where no other fragmentation is available. However, as 
demonstrated here, pseudo y-ions are generated from all TMT-labeled peptides, 
resulting in less specific SRM transitions and less robust TMT-SRM quantitation.  
The TMT-SRM assay for the quantitation of the selected AD candidate 
biomarkers in human plasma required that target analytes could be quantitated 
accurately, in parallel, and in a time scale which was viable for the analysis of a large 
number of samples, on a stable and reproducible analytical platform. The combination 
of nanoflow LC and nanospray MS was not a robust enough platform for the assay 
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described here-in, with imprecise TMT-SRM quantitation observed for all target 
peptides in the AD candidate biomarker panel. An added disadvantage of nanoflow LC 
flow rates is the requirement of longer analysis times for peptide separation, resulting in 
a lower throughput of samples. To resolve this, the configuration of the upfront LC was 
changed to enable microflow rates in combination with ESI. The new analytical platform 
was confirmed for suitability using a simple target analyte not endogenous to human 
plasma, namely VATVSLPR peptide. An initial assay design was developed such that 
the accuracy, linearity, LOD and LOQ were derived for the assay of each analyte in an 
efficient and workable manner. Upscaled digestion, TMT-labeling and RP and SCX 
purification protocols allowed for the preparation of the larger protein amounts 
consumed by microflow LC rates with no compromise to MS sensitivity. As well as 
significantly reducing individual sample analysis times (from 100 min to 15 min per 
sample), thus increasing sample throughput, the new system had a more robust LC 
and mass spectrometer source. Further, sample throughput was additionally increased 
with the incorporation of a microtitre plate format (as all samples could be lyophilised in 
parallel prior to SRM analysis) and made for easier sample handling. High accuracy in 
TMT-SRM quantitation was observed at the higher flow rates and the introduction of 
glucagon as a peptide scavenger significantly enhanced SRM sensitivities. The new 
system was deemed a substantial improvement in the overall TMT-SRM quantitation 
strategy.  
 
6.3 Validation and performance characterisation defines if an assay is fit-for-
purpose 
The novel, multiplexed assay was successfully validated by comparison of 
TMT-SRM measurements of plasma gelsolin to those using a traditional biomarker 
quantitation strategy using antibodies, i.e., WB. The TMT-SRM quantitation of the 
remaining peptides in the panel provided an initial insight into their performance in 
terms of robustness in clinical sample cohorts and agreement between peptides within 
a protein. Absolute quantitation of all target analytes in plasma was acheived by TMT-
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SRM, with all measurements within the linear range of quantitation for all peptides. 
Overall, transitions of the same peptide and peptides of the same protein demonstrated 
equivalent TMT-SRM performance and patterns of expression between AD and NDC 
groups. Deviations in the amounts recovered were observed between peptides of the 
same protein however. This was speculated to be due to the different susceptibilities of 
each peptide to trypsin cleavage. Further, peptide losses during TMT-labeling or 
purification stages may have contributed to the observed differences. 
It was demonstrated here-in that accurate and equivalent TMT-SRM 
quantitation could be achieved using SRP as compared to interpolation from the 
reverse calibration curve strategy. SRP was considered the more favourable approach 
due to its simplicity and potential for a higher throughput of samples, provided linearity 
in quantitation was confirmed (Campbell et al., 2011). In another significant advantage 
to the developed workflow, it was established that technical and analytical repeats had 
minimal contribution to any observed quantitative variance and thus, only one technical 
and one analytical repeat could be performed. This has major benefits as doing 
multiple technical repeats severely impacts on sample throughput. 
The performance of each individual target analyte in a quantitative proteomic 
assay should be comprehensively validated before routine application (Lee et al., 
2006). Assay performance was defined for each signature peptide in terms of the 
dynamic range and linearity of quantitation, LOD, LOQ and accuracy for confirmation of 
robust quantitative performance. This is quite a challenging but essential undertaking, 
as a failure to properly define the limits of an assay can result in misguided quantitative 
interpretation. Moreover, such parameters permit the comparison to established assay 
technologies such as ELISA and make clear the relevance and clinical applicability of 
TMT-SRM assays. Peptides of the same protein performed similarly, once again 
demonstrating the robustness of the TMT-SRM workflow for the preparation of 
signature tryptic plasma peptides of each candidate AD biomarker. Peptide quantitation 
was observed at pg/mL levels, which was equivalent to ng/mL protein levels, well within 
the physiologically relevant range of each target analyte in plasma. Taking clusterin as 
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an example, a commercial available ELISA kit (as used in the discovery of the 
candidate marker) is capable of quantitating over two orders of magnitude with a 
precision of 7.8% (Thambisetty et al., 2010). The developed TMT-SRM assay 
measured over three orders of magnitude with a precision of 2.7%, thus confirming the 
superior performance of the MS-based assay compared to the immuno-based 
approach.  
The assessment of assay portability was considered an essential process, 
giving an indication of the overall robustness of the TMT-SRM assay across MS 
platforms. A robust, fit-for-purpose assay is particularly crucial if it is to be implemented 
in independent laboratories. Excellent accordance of fragmentation patterns and thus, 
transitions, was observed across QTRAP and TSQ Vantage platforms. All transitions of 
the same peptide plotted equivalent curves and corresponding curves on both triple 
quadrupole instruments were comparable. Further, equivalent accuracy, LODs, LOQs, 
linearity and dynamic range was observed for all target analytes and in considered 
acceptable for a robust, fit-for-purpose assay. 
 
6.4 Plasma A2M is increased and correlates with the rate of decline in AD 
A biomarker can be any characteristic that is objectively measured and 
evaluated as an indicator of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention (Biomarkers Definitions Working 
Group, 2001). Here, signature peptides of A2M confirmed the protein as both a 
diagnostic and prognostic biomarker of AD. A statistically significant increase was 
observed in plasma levels of the protein in AD and this confirmed the original discovery 
findings (Hye et al., 2006). Further, the ability of A2M in predicting the rate of cognitive 
decline and ultimately progression of the disease as shown by the multiplexed TMT-
SRM assay was in agreement with a separate study where an association of plasma 
A2M and hippocampal N-acetylaspartate/myo-inositol ratio had utility in predicting 
disease progression in early AD (Thambisetty et al., 2008). The role of A2M in AD is of 
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particular interest as the protein has been shown to have very strong affinity for Aβ 
peptides, with increased A2M immunoreactivity in the amyloid plaques of the 
hippocampus in the AD brain (Bauer et al., 1991; Strauss et al., 1992; Du et al., 1997). 
Further, A2M levels were found to be elevated by ELISA in temporal cortices of AD 
compared to NDCs (Wood et al., 1993).The principle receptor for A2M in the brain is 
LRP. Activated A2M facilitates Aβ internalisation in the brain via the binding to LRP 
(Narita et al., 1997). Thus, overexpression of A2M in human tissue such as plasma 
may result in increased amyloid load resulting in plaque pathology associated with AD. 
Interestingly, the LRP itself has been associated with late onset familial AD 
(Hollenbach et al., 1998). In vitro studies in cultured neurons have shown A2M to be 
both neuroprotective and neurotoxic. The neurotoxic effect of aggregated Aβ was 
prevented upon binding of A2M (Du et al., 1997; Hughes et al., 1998). Conversely, 
activated A2M increased Aβ25-35-mediated neurotoxicity in neuroblastoma cells (Fabrizi 
et al., 1999). The absence of LRP in these cell types resulted in an interference of A2M 
with TGF-β neuroprotection. Two common polymorphisms within the A2M gene lead to 
increased risk of AD (Matthijs and Marynen, 1991; Blacker et al., 1998; Saunders et al., 
2003). Both polymorphisms are associated with an increase in Aβ deposition in the 
brain (Myllykangas et al., 1999). However, several other case-control and family-based 
studies indicate no significant association of the gene polymorphisms with AD 
(Rogaeva et al., 1999; Gibson et al., 2000, Poduslo et al., 2002; Bertram et al., 2004).  
The remaining proteins in the TMT-SRM assay did not show any significant 
differences between RCD, SCD and NDC groups. Further, AD and NDC groups were 
compared and no significant differences were observed. The simplest explanation for 
these results was that there were no expression differences for these proteins between 
case and control in the cohort utilised. Here, case and control subjects at baseline were 
matched for age and sex, with MMSE decline described over five timepoints within the 
space of a year. In the cohort used for the discovery of A2M and CFH for example, AD 
subjects were on average 6.8 years older than NDCs (Hye et al., 2006). Such 
differences in selected cohorts may have compounded the diagnostic potential initially 
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observed in discovery and explain why such differences could not be replicated in the 
verification phase. In contrast and the more likely, was that the complexity of sample 
collection across different European centres may have adversely affected the cohort. 
All of the discovery exercises were performed using the ART cohort, a single centre 
collection of samples based in the UK. While multi-centre studies are subject to strict 
sample collection and processing guidelines, potential variations may introduce sample 
heterogeneity. For biofluids such as plasma, significant attention must be given to 
potential sources of variation, including the length of sample storage and the number of 
freeze-thaw cycles. Neglect for such factors may have detrimental effects on the quality 
of the proteomic data generated (Rogers et al., 2003). The determinent criteria for the 
selection of the cohort under investigation here was age, sex and the clinical measure 
of MMSE. This resulted in a cohort which was unbalanced in sample numbers for 
centre. This may have resulted in a ‘cancelling out’ effect between the six collection 
centres when looking at the combined expression differences across centres. This was 
hinted at when looking at gelsolin peptides 29, 30 and 31 in individual centres (Figure 
6.1 A, B and C). When taking peptide 29 for example, no significant differences were 
observed between groups within the Kuopio (n = 17 AD and 5 NDCs) and Perugia  (n = 
17 AD and 6 NDCs) sample collection centres, repectively. However, a statistically 
significant decrease was observed for the peptide between groups in the London 
collection centre (n = 6 AD and 11 NDCs) and this was in-line with discovery (Güntert 
et al., 2010). This result was replicated for gelsolin peptide 30. When looking at peptide 
31 (the most robust signature peptide of the protein in terms of TMT-SRM assay 
performance), a statistically significant decrease was observed between groups within 
Kuopio and London sample collection centres, with no significant differences observed 
between groups within the Perugia collection centre. Nevertheless, when taking the 
gelsolin protein as a whole, no statistically significant differences were observed 
between groups. Despite such conflicting results for at least gelsolin, the increased 
expression observed for A2M between RCD, SCD and NDC and AD and NDC groups 




                  RCD < SCD < NDC    0.229* ↓ 
                  AD < NDC                    0.149 ↓ 
                  RCD < SCD < NDC     0.236 ↓ 
                  AD < NDC                    0.492 ↓ 
            RCD < SCD < NDC     0.006 ↓ 
            AD < NDC                    0.004 ↓ 
 
 
           RCD < SCD < NDC     0.184 ↑ 
           AD < NDC                    0.116 ↑ 
                 RCD < SCD < NDC      0.413 ↑ 
                 AD < NDC                     0.383 ↑ 
            RCD < SCD < NDC     0.593 ↑ 
            AD < NDC                    0.827 ↑ 
 
 
           RCD < SCD < NDC    < 0.001 ↓ 
           AD < NDC                      0.003 ↓ 
              RCD < SCD < NDC     0.035 ↓ 
              AD < NDC                    0.053 ↓ 
            RCD < SCD < NDC       0.022 ↓ 
            AD < NDC                      0.038 ↓ 
 
Figure 6.1 Gelsolin peptide measurements within Kuopio, Perugia and London sample 
collection centres. For each sample collection centre, differential expression across 
RCD, SCD and NDC or AD and NDC groups (data not plotted) was observed. 
Statistically significant (p < 0.05) decreases were observed for certain gelsolin 
peptides, e.g., peptide 31 in Kuopio, but this result was not replicated across all 
sampling centres. 
* indicates the p-value 
Peptide 29 Peptide 30 Peptide 31 
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6.5 Improving the TMT-SRM assay pipeline 
A well characterised ELISA can be configured to run approximately 1000 
samples over a period of two days (Whiteaker et al., 2010). The current TMT-SRM 
protocol requires upfront sample preparation including overnight digestion, TMT-
labeling and purification.  The rate-limiting factor in the workflow was the purification of 
TMT-labeled peptides, primarily due to the in-house preparation of SCX columns and 
the low flow-rate used in the chromatographic separation (approximately 1 drop of 
RP/SCX buffer per second). Purification of approximately 50 samples per day was 
achievable. In this context, an alternative strategy adopting pre-made SCX cartridges 
was investigated (data not shown). However, significantly reduced SRM sensitivities 
were observed for several target peptides (primarily those of a hydrophobic nature) 
meant such columns were unsatisfactory for the TMT-SRM workflow described here-in. 
A further way to expediate this process would be to automate sample handling 
processes to enhance the sample throughput (Kronkvist et al., 1998) and preserve or 
perhaps improve TMT-SRM assay precision. An added suggestion to maximise the 
throughput of the TMT-SRM assay would be to use several LC-SRM platforms.  
Additionally, advances in plasma digestion strategies have been recently published 
which may significant reduces proteolysis times (Slysz and Schreimer, 2005; Freije et 
al., 2005; Lopez-Ferrer et al., 2008). 
It was observed here-in that there were losses in peptide amounts at several 
stages of the TMT-SRM workflow, which ultimately affects the quality and accuracy of 
TMT-SRM data. The main point at which the most significant losses were observed 
was during the SCX clean-up of TMT-labeled peptides. An SCX LC step was 
necessary here to remove the SDS that was initially required to fully solubilise the 
protein content of the sample of interest (Timperman and Aebersold, 2000). Thus, it is 
essential that alternative approaches be considered to avoid such detrimental losses to 
the workflow. These could include avoiding the use of SDS completely or implementing 
a different SDS-removal strategy. As an substitute to SDS, several MS-compatible 
coumpounds have been developed and are being introduced commercially, including 
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RapiGest from Waters, Invitrosol from Invitrogen and 3-[3-(1,1-
bisalkyloxyethyl)pyridine-1-yl]propane-1-sulfonate from Protein Discovery (Imre et al., 
2005, Wu et al., 2011). Traditionally, urea and guanidine hydrochloride have been used 
for protein denaturation, although both have distinct disadvantages (Chen et al., 2007). 
Alternatives to SCX for SDS removal include dialysis and ultrafiltration devices such as 
filter-aided sample preparation or ‘FASP’ (Hixson et al., 2002; Manza et al., 2005; 
Wisniewski et al., 2009; Bereman et al., 2011).  
The addition of synthetic peptide internal standards can be added either pre- or 
post-digestion and there is still much debate as to which approach is best. Typically, it 
is best to add internal standards as early on as possible in the workflow to account for 
any variation which may be introduced during sample preparation. In spite of this, it has 
been demonstrated that when internal standard peptides are added prior to digestion, 
this can lead to elevated and unpredictable results, compared to those added post-
digestion (Kuzyk et al., 2009). Such variation was also peptide dependent. Possible 
reasons for this include degradation or chemical modification of the internal standard 
peptides during the digestion reaction. Further, peptides are liberated from their parent 
protein upon trypsin cleavage at different rates and spiked internal standard synthetic 
peptides may be subject to degradation effects which the endogenous peptides are not 
exposed to. This would therefore lead to inaccuracies in TMT-SRM quantitation. To 
avoid this, in is more common practice (and performed here-in) to add internal standard 
peptides post-digestion so that any losses experienced during sample preparation 
procedures would affect both synthetic and endogenous peptides equally (Ong and 
Mann, 2005). An added advantage of such a strategy is that much less synthetic 
peptides are required as only the amount of sample that is necessary for LC-TMT-SRM 
needs to be prepared. However, the possibility of adding internal standard peptides 
pre-digestion should not be excluded and an informative future experiment could 
compare both pre and post-digestion strategies in relation to the TMT-SRM workflow. 
To fully realise absolute TMT-SRM quantitation, it is essential to determine the 
efficiency of the trypsin enzyme reaction, i.e., has the reaction gone to completion and 
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is it equal for all peptides? Failure to achieve full proteolyic activity for the production of 
tryptic peptides may lead to substantial variatiability in the TMT-SRM quantitation of 
peptides of the same protein and an underestimation of endogenous protein amounts 
(Brun et al., 2007). This could partially explain the underestimation of protein amounts 
as observed in this study. An experiment to resolve such questions would be a useful 
inclusion in future work. This may be achieved by adding a known amount of 
recombinant protein not endogenous to human plasma, at the beginning of the TMT-
SRM workflow and determining the amount of tryptic peptides of the protein remaining 
post-digestion by SRM (Zhen et al., 2007; Mirzaei et al., 2008).   
A significant, but crucial, amount of time was dedicated to the selection of 
suitable target peptides for SRM measurement. This incorporated the manual 
searching of MS/MS discovery datasets for the determination of those peptides that 
were routinely observed during data dependent acquisition and to provide an initial 
insight into the hydrophobicity of each candidate peptide. Further, shortlisted 
candidates were manually inspected for the presence of unfavourable amino acids and 
PTMs which may ultimately affect the accuracy of TMT-SRM quantitation. During the 
course of this thesis, several new software packages have become available which can 
streamline such analysis and may significantly reduce the time required for SRM assay 
development. Assay libraries such as MRMAtlas provide a repository of candidate 
SRM transitions that have been previously identified (Picotti et al., 2008; Anderson, 
2010). Further, the software packages are capable of designing SRM transitions based 
solely on archived data from previous research efforts, through integration of database 
information from gpmdb or PeptideAtlas (Walsh et al., 2009). This allows for a 
significiantly larger amount of experimental data to be accessible for the design of SRM 
transitions.  
To enhance the detection of SRM transitions, compound-dependent parameters 
were optimised using synthetic peptides manually infused into the instrument. In an 
effort to streamline such processes, LC-SRM experiments ran over a range of 
compound-dependent instrument voltages within a single analysis have been 
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demonstrated (Sherwood et al., 2009). Thus, optimal DP, CE and CXP values may be 
more rapidly ascertained than the approach used here-in. Similarly, computational 
algorithms can be applied to predict such parameters although thus far, optimisation 
using empirical means remains the best method for such goals (Maclean et al., 2010). 
Skyline is a recently developed software package for targeted proteomics method 
creation and quantitative SRM data analysis (Maclean et al., 2010). It is open source 
and available without cost for academic and commercial use. The software uses 
MS/MS spectral libraries to optimise SRM parameters and verify results based on data 
previously observed on triple quadrupole instrumentation, including both QTRAP and 
TSQ Vantage mass spectrometers. Pinpoint software (Thermo Scientific) aids in the in 
silico selection of target proteins for SRM assay development and the determination of 
suitable proteotypic peptides to act as surrogates for SRM quantitation. Further, the 
software predicts which SRM transitions may provide the most robust quantitation and 
provide numerical and graphical tools for verification at each stage of the development 
process. However, it must be considered that in silico software packages may be 
subject to errors and although can be generally in good agreement, cannot surpass the 
power of selecting target peptides and transitions for SRM quantitation based on 
experimentally-derived data.  
As previously described, three pieces of information are essential for the 
generation of SRM assays; 1) a list of candidate biomarker target proteins, 2) signature 
proteotypic peptides need to be defined and 3) selective and specific SRM transitions 
and their compound-dependent parameters need to be determined (Lange et al., 
2008). Selection of peptides and SRM transitions is traditionally derived using empirical 
data from data dependent acquisition experiments. However, the approach is 
unsuitable for assay generation of peptides that have not been previously detected or 
have poor MS sensitivities. Two recent strategies could be incorporated into the TMT-
SRM assay development workflow which may ultimately provide a more sensitive and 
cost-effective assay, including the use of crudely synthesised peptides, e.g., SPOT-
synthesis technology and ‘intelligent’ SRM (iSRM). A method has been recently 
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described for the rapid generation of SRM assays where crude synthetic peptides are 
used for internal standardisation (Frank, 2002; Picotti et al., 2010). The cost of 
generating crude peptides using the SPOT-synthesis technology has been estimated to 
be £3-8 per target analyte. This compares favourably to the on average £300 price tag 
associated with the synthesis of a pure synthetic peptide. Such technologies would be 
of benefit for the TMT-SRM assay development process described here, where several 
peptides were removed at various stages of the development process. Using crude, 
low-cost synthetic peptide libraries, the most suitable peptides and transitions could be 
defined in terms of ionisation efficiency, LC-MS properties, instrument parameters and 
endogenous plasma detection in a rapid and multiplexed manner, at the very earliest 
stages of the development process. Such prior knowledge would have avoided the cost 
and effort associated with the synthesis of purer, higher quality peptides (as in the case 
of this thesis) which ultimately did not provide a robust quantitative measurement. 
Furthermore, following determination of the best target peptides from the crude peptide 
set, such peptides could be subsequently synthesised to a high quality for more 
accurate and absolute quantitation. 
The measurement of multiple fragment ions of a peptide has been proven to 
afford sufficient information for confirmation of target peptide identity (Kiyonami et al., 
2011). This intelligent SRM or ‘’iSRM’’ approach utilises a small subset of SRM 
transitions to trigger a full list of transitions of a peptide, enabling the simultaneous 
qualitative and quantitative measurement of a species. This could be beneficial to the 
TMT-SRM strategy described here-in as the best SRM transitions could be more 
quickly and readily deciphered. Further, iSRM has the potential to measure over 
10,000 individual transitions, representing up to 1,000 target peptides in a single 
experiment. Such a method would have major benefits to the TMT-SRM workflow as 
the time associated with SRM transition selection would be reduced. Further, prior 
knowledge of the most sensitive, selective and specific transitions of a target analyte 




6.6 Conclusions and Future Work 
Here, a novel assay has been developed for the targeted, multiplexed 
quantitation of candidate plasma biomarkers of AD. The TMT-SRM approach takes 
advantage of the selectivity and sensitivity of SRM MS in combination with the 
quantitative capabilities of isotopic versions of TMT. Utilising surrogate peptides as 
representative of candidate proteins, the TMT-SRM assay was fully validated as fit-for-
purpose to measure each target analyte in undepleted plasma. Further, the assay was 
fully characterised in terms of performance, with highly favourable statistics. A2M was 
confirmed as both a diagnostic and prognostic biomarker of AD and this was in 
agreement with discovery studies. In comparison to standard immuno-based assays for 
biomarker quantitation, TMT-SRM assays have relatively short lead times for 
development, with significantly reduced costs and low patient sample consumption. 
The approach enables absolute quantitative amounts to be described in a rapid and 
accurate manner, with the necessary throughput required for biomarker verification. 
TMT-SRM provides a link between biomarker discovery (using isobaric TMT tagging) 
and biomarker verification. The definitive nature of the assay means it is universally 
applicable to other researchers in independent laboratories. TMT-SRM has potential to 
substitute or at the very least, compliment, antibody-based quantitation of biomarkers 
in AD and other human disorders in an array of biological fluids not counting plasma, 
including CSF, urine and saliva.  
Even though these initial findings are encouraging for at least A2M, a cohort of 
90 samples is relatively small. The study should now be extended and replicated in 
significantly larger (hundreds to thousands) cohorts of AD samples, as well as those 
from other dementia types, to determine the full clinical validity of each protein as 
sensitive and specific biomarkers of AD. The TMT-SRM assay is currently being 
implemented in a significantly larger cohort (n = 1000 from the AddNeuroMed cohort) 
of AD, MCI and NDC plasma samples to determine the full clinical validity of the panel 
of biomarkers in AD diagnosis and prognosis. This is being performed in parallel with a 
newly established multiplexed antibody-based approach, namely the Luminex xMAP® 
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system and the agreement between the two platforms will be assessed. This is the first 
time such a study is being undertaken in such extensive sample numbers and has vast 
potential and reward for the AD community. Further, the novel TMT-SRM technology is 
viable for the targeted measurement of potentially any protein in the human proteome, 
provided sufficient detection by SRM. On condition that SRMs do not cluster 
significantly around the same elution time, the assay could be expanded, or indeed 
new assays developed, to allow significantly more SRMs to be measured in a single 
LC-SRM analysis. The developed TMT-SRM assay measures eight candidate plasma 
biomarkers of AD. Using the TMT-SRM strategy developed here, it is both theoretically 
and practically possible to construct further assays for the multiplexed measurement of 
protein markers in AD and other diseases, in an accurate, sensitive, rapid and cost-
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Intervention  Study phase Company Reference 
    
Anti-amyloid agents 
   
Active immunisation with CAD106 II Novartis Weissner et al., 2011 
Active immunisation with ACC-001 II Wyeth Pride et al., 2008 
Passive immunisation with PF-04360365 II Pfizer Poduslo et al., 2007 
Passive immunisation with AAB-001 (Bapineuzumab) III Elan Pharmaceuticals Black et al., 2010 
Gamma secretase inhibitor MPC-7869 (Flurizan) III Myriad Pharmaceuticals Hendrix and Wilcock, 2009 
Gamma secretase inhibitor LY450139 III Eli Lilly and Company Fleisher et al., 2008 
Protein Kinase C stimulator: Bryostatin-1 II Rockefeller Neurosciences Institute Hongpaisan et al., 2011 
Beta amyloid synthesis inhibitor : Tarenflurbil (Flurbiprofen)  III Myriad Pharmaceuticals Green et al., 2009 
Plasminogen activator inhibitor: PAZ 417 III Wyeth Jacobsen et al., 2008 
Anti-aggregation agent: tramiprosate (3APS) III Neurochem/Bellus Health Inc Gervais et al., 2007 
Chelating agent: PBT-2 II Prana Biotechnology Ltd Frisardi et al., 2010 
Anti-aggregation/fibrillisation agents ELND005 (AZD-103) II Elan Pharmaceuticals Piau et al., 2011 
Cholesterol lowering agent: simvastatin (CLASP study) III National Institute on Aging Piau et al., 2011 
Cholesterol lowering agent: atorvastatin (LEADe study) III Pfizer Feldman et al., 2010 
RAGE inhibitor: TTP488 (PF 04494700) II Pfizer Piau et al., 2011 
Tau aggregation inhibitor 
   
TRx0014 II TauRx Therapeutics Ltd Piau et al., 2011 
Neuroprotective agents 
   
Vitamin E and Memantine (TEAM-AD) III Department of Veterans Affairs Geldmacher et al., 2011 
Docosahexaenoic acid (DHA) III National Institute on Aging Quinn et al., 2010 
Fish oil vs Fish oil and Alpha lipoic acid II National Institute on Aging Piau et al., 2011 
EGB 761 (Ginkgo Biloba extract) II Ipsen Christen, 2004 
Isoflavones (Novasoy) II University of Wisconsin Piau et al., 2011 
T-817MA (Benzothiophene derivative)  II Toyama chemical Co Ltd Fukushima et al., 2011 
DCB-AD1 (Herbal Medicine) II Development Center dor biotechnology Piau et al., 2011 
Anti-inflammatory agent: IFN-alpha2A (in addition to donepezil) II National Center for Research Resources  Piau et al., 2011 
Resveratrol supplement III Medical College of Wisconsin Piau et al., 2011 
Curcumin II John Douglas French Foundation Piau et al., 2011 
Protection of dopaminergic neurons: Arundic acid (ONO-25-06)  II Ono Pharmaceutical Mori et al., 2006 
Neuroprotectant agent derived from herbal medicine: DCB-AD1  II National Taiwan University Hospital Piau et al., 2011 
Neramexane III Forest laboratories Piau et al., 2011 
 




Intervention  Study phase Company Reference 
 
 
  Neurorestorative factors  
  Neurotrophic growth factor : SR57667B (Paliroden) II Sanofi-Aventis Labie et al., 2006 
Neurotrophic growth factor: CERE-110 II Ceregene Bishop et al., 2008 
Neurotrophic growth factor : SR57746A (Xaliproden)  III Sanofi-Aventis Douillet and Orgogozo, 2009 
Cholinergic agents  
  Acetyl cholinesterase inhibitor: Huperzine A II National Institute on Aging Piau et al., 2011 
Acetyl cholinesterase inhibitor: ZT-1 II Debiopharm S.A. Piau et al., 2011 
Salvia officinalis III National Center for Comp. and Alt. Med. Piau et al., 2011 
Nicotinic partial agonist: ABT-089  II Abbott Apostol et al., 2011 
Nicotinic agonist: GTS-21 (DMXA) II CoMentis Piau et al., 2011 
Nicotinic modulator: MEM-3454 II Memory Pharmaceuticals Mazurov et al., 2007 
Nicotinic partial agonist : SSR-180711C II Sanofi-Aventis Piau et al., 2011 
Nicotinic partial agonist : Varenicicline II Pfizer Piau et al., 2011 
Nicotinic agonist: AZD3480  II AstraZeneca Frölich et al., 2011 
Thiazolidinediones and insulin  
  SNIFF 120 study: insulin administered as a "nasal spray"  II National Institute on Aging Piau et al., 2011 
NIC5-15 (natural product with mild insuline sensitizing effects) II Department of Veterans Affairs Piau et al., 2011 
Thiazolidinedione: Rosiglitazone III GlaxoSmithKline Gold et al., 2010 
Ketone bodies: AC-1202 (Ketasyn™)  III Accera Inc Piau et al., 2011 
Hormonal therapy  
  SERMs: Raloxifene II National Institute on Aging Piau et al., 2011 
Testosterone (Androgel 1%) II Solvay Pharmaceuticals Piau et al., 2011 
Glucocorticoid receptor antagonist: Mifepristone II Institute for the Study of Aging /Corcept  Piau et al., 2011 
7-hydroxysteroid pathway modulator: HF0220 II Hunter-Fleming Ltd Piau et al., 2011 
 











Intervention  Study phase Company Reference 
 
 
  Other treatments  
  5-HT 1a antagonist: Lecozotan SR (SRA-333) III Wyeth Raje et al., 2008 
5-HT 1a agonist: Xaliprodene III Sanofi-Aventis Piau et al., 2011 
5-HT 6 receptor antagonist: SB-742457 II GlaxoSmithKline Maher-Edwards et al., 2010 
5-HT 6 receptor antagonist: SAM-531 II Wyeth Pogacic and Herrling, 2007 
5-HT 4 agonist: PRX-03140 II Epix Pharmaceuticals, Inc Shen et al., 2011 
Anti Histamine Agent: Dimebon  III Medivation Doody et al., 2008 
Mono amine oxydase inhibitor: Rasagiline II Eisai Medical Research Inc Piau et al., 2011 
Monoamine uptake inhibitor: Tesofensine  II Boehringer Ingelheim Pharmaceuticals Piau et al., 2011 
Enantiomer of a dihydro pyridine: MEM 1003  II Memory Pharmaceuticals Rose et al., 2007 
GABA receptor antagonist: SGS742 II Saegis Pharmaceuticals Bullock, 2005 
Benzodiazepin inverse agonist: AC-3933 II Danippon Sumitomo Pharma America Mise et al., 2004 
Cannabinoid CB1 antagonist: AVE-1625  II Sanofi-Aventis Piau et al., 2011 
Dopamine modulator/ neuronal growth factor agonist: PYM50028 II Phytopharm Piau et al., 2011 
Neurotransmitter modulator: Tesofensine (NS2330) II Boehringer Ingelheim Pharmaceuticals Lehr et al., 2007 
Oleonic glycosides saponins: SK-PC-B70M  II SK Chemicals Co., Ltd Han et al., 2007 
Nicotinamide II University of California Green et al., 2008 
CNS modulator: MK-0249  II Merck Brioni et al., 2011 
CNS modulator: MK-0952 II Merck Gallant et al., 2010 
 
















Appendix Figure 2.1 Standard Bradford protein assay to estimate the protein amount 
in a standard plasma sample. Each point on the curve is the mean of three replicates. 




































R² = 0.9969 






















BSA Concentration (µg/µL) 







T 1 T  1, 2, 3 T 1, 2, 3 






0.33:1 0.41 0.45 0.34 0.4 13.5 0.43 4.34 
1:1 1.1 1.25 1.35 1.24 10.4 1.2 7.68 
3:1 3 3.44 3.41 3.28 7.51 3.46 4.44 
9:1 9.75 9.23 11.2 10.4 9.95 11.1 8.78 
27:1 32 31.5 35.3 32.9 6.32 34.3 9.34 
                
Peptide 
4 
T 1 T  1, 2, 3 T 1, 2, 3 






0.33:1 0.43 0.45 0.48 0.46 6.02 0.42 11.14 
1:1 1.04 1.24 1.33 1.2 12.1 1.14 7.7 
3:1 2.46 2.7 2.98 2.71 9.5 3.42 20.6 
9:1 8.34 10.5 9.53 9.45 11.3 11.5 15.58 
27:1 30.6 37.3 38.5 35.5 12 36 3.11 
                
Peptide 
6 
T 1 T  1, 2, 3 T 1, 2, 3 






0.33:1 0.41 0.4 0.36 0.39 8 0.37 6.69 
1:1 1.17 1.05 9.12 1.04 12.3 1.06 11.39 
3:1 3.3 3.06 2.68 3.01 10.4 3.17 7.45 
9:1 9.08 7.96 8.49 8.51 6.58 8.73 7.12 
27:1 31 25.2 27.4 27.9 10.5 29.1 9.71 
                
Peptide 
9 
T 1 T  1, 2, 3 T 1, 2, 3 






0.33:1 0.37 0.42 0.41 0.4 5.71 0.44 9.78 
1:1 1.11 1.19 1.26 1.19 6.36 1.32 8.96 
3:1 3.33 3.61 3.29 3.41 6.04 3.59 4.82 
9:1 11.7 10.7 11.2 11.2 4.37 11.9 7.23 
27:1 36.2 33.3 37.5 35.6 5.9 35.7 3.54 
 
Appendix Table 2.1 Accuracy of TMT-SRM for BSA peptides quantitated in the 
presence of buffer-only. As an example of the  accuracy of analytical repeats, the 
individual trueness (L/H ratio) for all analytical repeats (A 1, A 2 and A 3) of technical 
replicate 1 (T 1) is displayed. Furthermore, mean trueness and precision values across 












Protein SwissProt  Peptide sequence Frequency 
Clusterin P10909  IDSLLENDR 2 
 
 DQTVSDNELQEMSNQGSK 2 
Not proteotypic  EPQDTYHYLPFSLPHR 2 
Containing C, M or W  ALQEYR 2 
≠ 6 - 25 amino acids  SLMPFSPYEPLNFHAMFQPFLEMIHEAQQAMDIHFHSPAFQHPPTEFIR 2 
Internal R, K or H   EILSVDCSTNNPSQAK 2 
N-terminal E or Q  ELDESLQVAER 2 
Shortlisted for TMT-SRM  ELPGVCNETMMALWEECKPCLK 2 
  
 FMETVAEK 2 
  
 RPHFFFPK 2 
  
 TNEER 2 
  
 EDALNETR 2 
  
 DQCDK 2 
  
 YNELLK 2 
  
 SGSGLVGR 2 
  
 EIQNAVNGVK 2 
  
 VTTVASHTSDSDVPSGVTEVVVK 2 
  
 EGDDDR 2 
  
 MLNTSSLLEQLNEQFNWVSR 2 
  






 QLEEFLNQSSPFYFWMNGDR 2 
  
 ASSIIDELFQDR 2 
  
 LANLTQGEDQYYLR 2 
  
 HNSTGCLR 2 
  
 QTCMK 2 
  
 TLLSNLEEAK 2 
  
 SYQWK 2 
  
 ESETK 3 
  
 TLIEK 5 
  
 FYAR 5 
  
 TVCR 6 
  
 FFTR 7 
  
 YVNK 10 
  
 EE 14 
  
 VCR 88 
  
 IVR 136 
  
 QIK 160 
  
 NPK 166 
  
 EIR 263 
  
 LTR 272 
  
 CR 1190 
  
 HR 1777 
  
 MK 2058 
  
 SR 3579 
  
 LK 4679 
  
 LR 4729 
  
 K 15378 
  
 
 R 15485 
 
Appendix Table 3.1 Clusterin in silico peptide selection for TMT-SRM. 
a














Protein SwissProt  Peptide sequence Frequency 
Complement C3 P01024  AELQCPQPAAR 1 
  
 TMQALPYSTVGNSNNYLHLSVLR 2 
Not proteotypic  GLEVTITAR
a
 2 
Containing C, M or W  QDSLSSQNQLGVLPLSWDIPELVNMGQWK 2 
≠ 6 - 25 amino acids  LESEETMVLEAHDAQGDVPVTVTVHDFPGK 2 
Internal R, K or H   LLPVGR 2 
N-terminal E or Q  ADIGCTPGSGK 2 
Shortlisted for TMT-SRM  EVVADSVWVDVK 2 
  
 TVMVNIENPEGIPVK 2 
  
 AYYENSPQQVFSTEFEVK 2 
  
 FLYGK 2 
  
 IEGDHGAR 2 
  
 VVLVSLQSGYLFIQTDK 2 
  
 SPMYSIITPNILR 2 
  
 IFTVNHK 2 
  
 VLLDGVQNPR 2 
  
 VPVAVQGEDTVQSLTQGDGVAK 2 
  
 YYTYLIMNK 2 
  
 QPVPGQQMTLK 2 
  
 TIYTPGSTVLYR 2 
  
 SGQSEDR 2 
  
 ISLPESLK 2 
  
 EYVLPSFEVIVEPTEK 2 
  
 VEGTAFVIFGIQDGEQR 2 
  
 GVFVLNK 2 
  
 IPIEDGSGEVVLSR 2 
  
 DSCVGSLVVK 2 
  
 QELSEAEQATR 2 
  
 YFKPGMPFDLMVFVTNPDGSPAYR 2 
  
 IWDVVEK 2 
  
 VVLVAVDK 2 
  
 TELRPGETLNVNFLLR 2 
  
 SLYVSATVILHSGSDMVQAER 2 
  
 EPGQDLVVLPLSITTDFIPSFR 2 
  
 FYYIYNEK 2 
  
 TVLTPATNHMGNVTFTIPANR 2 
  
 SGIPIVTSPYQIHFTK 2 
  
 DYAGVFSDAGLTFTSSSGQQTAQR 2 
  
 FVTVQATFGTQVVEK 2 
  
 AEDLVGK 2 
  
 LVAYYTLIGASGQR 2 
  
 LSINTHPSQKPLSITVR 2 
  
 FSCQR 3 
  
 CCEDGMR 3 
  
 VFLDCCNYITELR 3 
  
 FISLGEACK 3 
  
 ASHLGLAR 3 
  
 IHWESASLLR 3 
  
 AHEAK 3 
  
 SVQLTEK 3 
  
 LVLSSEK 3 
   * 4 
 
Appendix Table 3.2 Complement C3 in silico peptide selection for TMT-SRM. * 113 
peptide sequences with a frequency > 4. 
a
 those peptides which are not highlighted were not shortlisted for quantitation in this instance. However, they did satisfy 
the criteria for TMT-SRM target analyte selection, i.e., proteotypicity, suitable length and absence of charged or 





Protein SwissProt  Peptide sequence Frequency 
Complement C3a P01024  ASHLGLA 1 
  
 FSCQR 3 
Not proteotypic  SVQLTEK 3 
Containing C, M or W  VFLDCCNYITELR 3 
≠ 6 - 25 amino acids  FISLGEACK 3 
Internal R, K or H   CCEDGMR 3 
N-terminal E or Q  ENPMR 4 
Shortlisted for TMT-SRM  QHAR 11 
  
 YPK 74 
  
 MDK 107 
  
 VGK 170 
  
 ELR 591 
  
 TR 2394 
  
 K 15378 
     R 15485 
 








Protein SwissProt  Peptide sequence Frequency 
CFH P08603  VSVLCQENYLIQEGEEITCK 1 
  
 WSSPPQCEGLPCK 1 
Not proteotypic  CVEISCK 1 
Containing C, M or W  EGWIHTVCINGR 1 
≠ 6 - 25 amino acids  NGFYPATR
a
 1 
Internal R, K or H   HGGLYHENMR 1 
N-terminal E or Q  TGESVEFVCK 1 
Shortlisted for TMT-SRM  GEWVALNPLR 1 
  
 LGYVTADGETSGSITCGK 1 
  
 VGEVLK 1 
  
 AVYTCNEGYQLLGEINYR 1 
  
 EQVQSCGPPPELLNGNVK 1 
  
 LNDTLDYECHDGYESNTGSTTGSIVCGYNGWSDLPICYER 1 
  
 SIDVACHPGYALPK 1 
  
 EEYGHSEVVEYYCNPR 1 
  
 FVCNSGYK 1 
  
 CLGEK 1 
  
 NTEILTGSWSDQTYPEGTQAIYK 1 
  
 ECELPK 1 
  
 SSNLIILEEHLK 1 
  
 CRPGYR 1 
  
 ISEENETTCYMGK 1 
  
 WDPEVNCSMAQIQLCPPPPQIPNSHNMTTTLNYR 1 
  
 RPCGHPGDTPFGTFTLTGGNVFEYGVK 1 
 
Appendix Table 3.4 CFH in silico peptide selection for TMT-SRM. * 40 peptide 
sequences with a frequency > 3. 
a
 those peptides which are not highlighted were not shortlisted for quantitation in this instance. However, they did satisfy 
the criteria for TMT-SRM target analyte selection, i.e., proteotypicity, suitable length and absence of charged or 






Protein SwissProt  Peptide sequence Frequency 
CFH P08603  GDAVCTESGWRPLPSCEEK 1 
   CLPVTAPENGK 1 
Not proteotypic  CTSTGWIPAPR 1 
Containing C, M or W  NDFTWFK 1 
≠ 6 - 25 amino acids  SPDVINGSPISQK 1 
Internal R, K or H   IEGDEEMHCSDDGFWSK 1 
N-terminal E or Q  ECDTDGWTNDIPICEVVK 1 
Shortlisted for TMT-SRM  AQTTVTCMENGWSPTPR 1 
   WSHPPSCIK 1 
   DTSCVNPPTVQNAYIVSR 1 
   WQSIPLCVEK 1 
   TDCLSLPSFENAIPMGEK 1 
   IDVHLVPDR 1 
   SCDNPYIPNGDYSPLR 1 
   CFEGFGIDGPAIAK 1 
   EFDHNSNIR 1 
   WTGRPTCR 1 
   EYHFGQAVR 1 
   DGWSAQPTCIK 1 
   AGEQVTYTCATYYK 1 
   SITCIHGVWTQLPQCVAIDK 1 
   YYSYYCDEHFETPSGSYWDHIHCTQDGWSPAVPCLR 1 
   TGDEITYQCR 1 
   SCDIPVFMNAR 1 
   MDGASNVTCINSR 1 
   FSCKPGFTIVGPNSVQCYHFGLSPDLPICK 1 
   CTLKPCDYPDIK 1 
   IPCSQPPQIEHGTINSSR 1 
   SSIDIENGFISESQYTYALK 1 
   SSQESYAHGTK 1 
   IQCVDGEWTTLPVCIVEESTCGDIPELEHGWAQLSSPPYYYGDSVEFNCSESFTMIGHR 1 
   SLGNVIMVCR 1 
   EDCNELPPR 1 
   SPPEISHGVVAHMSDSYQYGEEVTYK 1 
   CNMGYEYSER 1 
   IVSSAMEPDR 1 
   LSYTCEGGFR 1 
   GNTAK 2 
   CYFPYLENGYNQNYGR 2 
   TTCWDGK 2 
   CLHPCVISR 2 
   LEYPTCAK 2 
   CGPPPPIDNGDITSFPLSVYAPASSVEYQCQNLYQLEGNK 2 
   RPYFPVAVGK 2 
   EIMENYNIALR 2 
   SHTLR 2 
   SPYEMFGDEEVMCLNGNWTEPPQCK 2 
   YPSGER 2 
   * 3 
 





Protein SwissProt  Peptide sequence Frequency 
A2M P01023  TEVSSNHVLIYLDK 1 
  
 GCVLLSYLNETVTVSASLESVR 1 
Not proteotypic  FEVQVTVPK 1 
Containing C, M or W  VGFYESDVMGR 1 
≠ 6 - 25 amino acids  DLKPAIVK 1 
Internal R, K or H   VIFIR 1 
N-terminal E or Q  MCPQLQQYEMHGPEGLR 1 
Shortlisted for TMT-SRM  YFPETWIWDLVVVNSAGVAEVGVTVPDTITEWK 1 
  
 GGVEDEVTLSAYITIALLEIPLTVTHPVVR 1 
  
 TGTHGLLVK 1 
  
 EQAPHCICANGR 1 
  






 FSGQLNSHGCFYQQVK 1 
  
 QEDMK 1 
  
 GEAFTLK 1 
  
 DLGNA 1 
  
 QQNAQGGFSSTQDTVVALHALSK 1 
  
 EEFPFALGVQTLPQTCDEPK 1 
  
 AIGYLNTGYQR 1 
  
 SSSNEEVMFLTVQVK 1 
  
 TEHPFTVEEFVLPK 1 
  
 DTVIKPLLVEPEGLEK 1 
  
 YSDASDCHGEDSQAFCEK 1 
  
 QSSEITR 1 
  
 LVHVEEPHTETVR 1 
  
 AHTSFQISLSVSYTGSR 1 
  
 AVDQSVLLMKPDAELSASSVYNLLPEK 1 
  
 GNEANYYSNATTDEHGLVQFSINTTNVMGTSLTVR 1 
  
 VFQLK 1 
  
 DLTGFPGPLNDQDDEDCINR 1 
  
 AAQVTIQSSGTFSSK 1 
  
 QGIPFFGQVR 1 
  
 LVDGK 1 
  
 LHTEAQIQEEGTVVELTGR 1 
  
 VSVQLEASPAFLAVPVEK 1 
  
 LPPNVVEESAR 1 
  
 SASNMAIVDVK 1 
  
 QFSFPLSSEPFQGSYK 1 
  
 IITILEEEMNVSVCGLYTYGKPVPGHVTVSICR 1 
  
 NALFCLESAWK 1 
  
 NEDSLVFVQTDK 1 
  
 SLFTDLEAENDVLHCVAFAVPK 1 
  
 GPTQEFK 1 
  
 VDLSFSPSQSLPASHAHLR 1 
  
 SLNEEAVK 1 
  
 LSFYYLIMAK 1 
  
 SNHVSR 1 
  
 SFVHLEPMSHELPCGHTQTVQAHYILNGGTLLGLK 1 
 
Appendix Table 3.5 A2M in silico peptide selection for TMT-SRM. * 20 peptide 
sequences with a frequency > 3. 
a
 those peptides which are not highlighted were not shortlisted for quantitation in this instance. However, they did satisfy 
the criteria for TMT-SRM target analyte selection, i.e., proteotypicity, suitable length and absence of charged or 




Protein SwissProt  Peptide sequence Frequency 
A2M P01023  LSFVK 1 
  
 GGIVR 1 
Not proteotypic  IAQWQSFQLEGGLK 1 
Containing C, M or W  SVSGKPQYMVLVPSLLHTETTEK 1 
≠ 6 - 25 amino acids  VSNQTLSLFFTVLQDVPVR 1 
Internal R, K or H   VTGEGCVYLQTSLK 1 
N-terminal E or Q  ALLAYAFALAGNQDK 1 
Shortlisted for TMT-SRM  GHFSISIPVK 1 
  
 ASVSVLGDILGSAMQNTQNLLQMPYGCGEQNMVLFAPNIYVLDYLNETQQLTPEVK 1 
  
 ETTFNSLLCPSGGEVSEELSLK 1 
  
 LLLQQVSLPELPGEYSMK 1 
  
 VYDYYETDEFAIAEYNAPCSK 1 
  
 DNSVHWERPK 1 
  
 SDIAPVAR 1 
  
 TAQEGDHGSHVYTK 1 
  
 HYDGSYSTFGER 1 
  
 HNVYINGITYTPVSSTNEK 1 
  
 VVSMDENFHPLNELIPLVYIQDPK 1 
  
 LLIYAVLPTGDVIGDSAK 1 
  
 SLGNVNFTVSAEALESQELCGTEVPSVPEHGR 1 
  
 QTVSWAVTPK 1 
  
 VTAAPQSVCALR 1 
  
 YDVENCLANK 1 
  
 TTVMVK 1 
  
 SPCYGYQWVSEEHEEAHHTAYLVFSPSK 1 
  
 APVGHFYEPQAPSAEVEMTSYVLLAYLTAQPAPTSEDLTSATNIVK 1 
  
 AYIFIDEAHITQALIWLSQR 1 
  
 DMYSFLEDMGLK 1 
  
 QLNYK 2 
  
 AFTNSK 2 
  
 AFQPFFVELTMPYSVIR 2 
  
 NQGNTWLTAFVLK 2 
  
 VDSHFR 2 
  
 SSGSLLNNAIK 2 
  
 MVSGFIPLKPTVK 2 
  
 YGAATFTR 2 
  
 VVVQK 2 
  
 TFAQAR 2 
  
 YNILPEK 2 
  
 EYEMK 2 
  
 DNGCFR 2 
  
 GVPIPNK 2 
  
 AGAFCLSEDAGLGISSTASLR 2 
  
 ATVLNYLPK 2 
  
 * 3 
 











Protein SwissProt  Peptide sequence Frequency 
FGG P02679  LTIGEGQQHHLGGAK 1 
   YLQEIYNSNNQK
a
 1 
Not proteotypic  FEGNCAEQDGSGWWMNK 1 
Containing C, M or W  FGSYCPTTCGIADFLSTYQTK 1 
≠ 6 - 25 amino acids  NWIQYK 1 
Internal R, K or H   TSEVK 1 
N-terminal E or Q  DNCCILDER 1 
Shortlisted for TMT-SRM  ANQQFLVYCEIDGSGNGWTVFQK 1 
  
 VAQLEAQCQEPCK 1 
  
 VELEDWNGR 1 
  
 IVNLK 1 
  
 LDGSVDFK 1 
  
 WYSMK 1 
  
 K.I]HLISTQSAIPYALR.V 1 
  
 ASTPNGYDNGIIWATWK 1 
  
 DLQSLEDILHQVENK 1 
  
 LTYAYFAGGDAGDAFDGFDFGDDPSDK 1 
  
 YVATR 1 
  
 DCQDIANK 1 
  
 VGPEADK 1 
  
 QVRPEHPAETEYDSLYPEDDL 1 
  
 CHAGHLNGVYYQGGTYSK 1 
  
 TSTADYAMFK 1 
  
 EGFGHLSPTGTTEFWLGNEK 1 
  
 MLEEIMK 1 
  
 AIQLTYNPDESSKPNMIDAATLK 1 
  
 FFTSHNGMQFSTWDNDNDK 1 
  
 QSGLYFIKPLK 1 
  
 IIPFNR 1 
  
 YEASILTHDSSIR 1 
  
 IHLISTQSAIPYALR 1 
  
 DTVQIHDITGK 1 
  
 TTMK 3 
  
 QLIK 14 
  
 VDK 156 
  
 GAK 217 
  
 YR 1540 
  
 TR 2394 
  
 SR 3579 
  
 EK 4547 
  
 K 15378 
     R 15485 
 
Appendix Table 3.6 FGG in silico peptide selection for TMT-SRM. 
a
 those peptides which are not highlighted were not shortlisted for quantitation in this instance. However, they did satisfy 
the criteria for TMT-SRM target analyte selection, i.e., proteotypicity, suitable length and absence of charged or 















Protein SwissProt  Peptide sequence Frequency 
SAP P02743  GYVIIKPLVWV 1 
  
 DNELLVYK 2 
Not proteotypic  VGEYSLYIGR 2 
Containing C, M or W  IVLGQEQDSYGGK 2 
≠ 6 - 25 amino acids  FPAPVHICVSWESSSGIAEFWINGTPLVK 2 
Internal R, K or H   SQSFVGEIGDLYMWDSVLPPENILSAYQGTPLPANILDWQALNYEIR 2 
N-terminal E or Q  ESVTDHVNLITPLEKPLQNFTLCFR 2 
Shortlisted for TMT-SRM  AYSDLSR 2 
  
 AYSLFSYNTQGR 2 
  
 HTDLSGK 2 
  
 VFVFPR 2 
  
 QGYFVEAQPK 2 
  
 VTSK 12 
  
 VIEK 19 
  
 FDR 70 
  
 GLR 362 
  
 HK 1558 
  
 ER 3797 
     K 15378 
 





































Protein SwissProt  Peptide sequence Frequency 
ApoE P02649  SWFEPLVEDMQR 1 
  
 WVQTLSEQVQEELLSSQVTQELR 1 
Not proteotypic  QWAGLVEK 1 
Containing C, M or W  VQAAVGTSAAPVPSDNH 1 
≠ 6 - 25 amino acids  LDEVK 1 
Internal R, K or H   LQAEAFQAR 1 
N-terminal E or Q  WELALGR 1 
Shortlisted for TMT-SRM  VEQAVETEPEPELR 1 
  
 LGADMEDVCGR 1 
  
 QQTEWQSGQR 1 
  
 SELEEQLTPVAEETR 1 
  
 GEVQAMLGQSTEELR 1 
  
 LAVYQAGAR 1 
  
 EQVAEVR 1 
  
 AQAWGER 1 
  
 LGPLVEQGR 1 
  
 GLSAIR 1 
  
 FWDYLR 1 
  
 DADDLQK 1 
  
 ELQAAQAR 1 
  
 ALMDETMK 1 
  
 AATVGSLAGQPLQER 1 
  
 LASHLR 1 
  
 MEEMGSR 1 
  
 LEEQAQQIR 1 
  
 EGAER 2 
  
 LVQYR 2 
  
 * 90 
Appendix Table 3.8 ApoE in silico peptide selection for TMT-SRM. * 14 peptide 












































≠ 6 - 25 amino acids 
 
MVVEHPEFLK 1 
Internal R, K or H  
 
VVQGK 2 
N-terminal E or Q 
 
EDAANR 2 
Shortlisted for TMT-SRM 
 
EPAHLMSLFGGKPMIIYK 2 
   
EPAHLMSLFGGKPMIIYK 2 
   
TASDFITK 2 
   
FVIEEVPGELMQEDLATDDVMLLDTWDQVFVWVGK 2 
   
YIETDPANR 2 
   
EPGLQIWR 2 
   
MDAHPPR 2 
   
AGALNSNDAFVLK 2 
   
QANTEER 2 
   
QTQVSVLPEGGETPLFK 2 
   
LFACSNK 2 
   
VSNGAGTMSVSLVADENPFAQGALK 2 
   
ATQVSK 2 
   
VPVDPATYGQFYGGDSYIILYNYR 2 
   
ANSAGATR 2 
   
GGVASGFK 2 
   
DSQEEEK 2 
   
ATQVSK 2 
   
TPITVVK 2 
   
FDLVPVPTNLYGDFFTGDAYVILK 2 
   
DSQEEEK 2 
   
QANTEER 2 
   
SEDCFILDHGK 2 
   
QGFEPPSFVGWFLGWDDDYWSVDPLDR 2 
   
GGVASGFK 2 
   
VHVSEEGTEPEAMLQVLGPKPALPAGTEDTAK 2 
   
VPFDAATLHTSTAMAAQHGMDDDGTGQK 2 
   
TPITVVK 2 
   
LFACSNK 2 
   
FDLVPVPTNLYGDFFTGDAYVILK 2 
   
IFVWK 2 
   
AMAELAA 2 
   
AQPVQVAEGSEPDGFWEALGGK 2 
   
AVEVLPK 2 
   
TEALTSAK 2 
   
VHVSEEGTEPEAMLQVLGPKPALPAGTEDTAK 2 
   
DPDQTDGLGLSYLSSHIANVER 2 
   
HVVPNEVVVQR 2 
   
AGALNSNDAFVLK 2 
   
LFQVK 2 
   
QIWR 2 
   
VPVDPATYGQFYGGDSYIILYNYR 2 
 
Appendix Table 3.9 Gelsolin in silico peptide selection for TMT-SRM. * 78 peptide 
sequences with a frequency > 4. 
a
 those peptides which are not highlighted were not shortlisted for quantitation in this instance. However, they did satisfy 
the criteria for TMT-SRM target analyte selection, i.e., proteotypicity, suitable length and absence of charged or 














Containing C, M or W 
 
TPSAAYLWVGTGASEAEK 2 
≠ 6 - 25 amino acids 
 
ATEVPVSWESFNNGDCFILDLGNNIHQWCGSNSNR 2 
Internal R, K or H  
 
QGQIIYNWQGAQSTQDEVAASAILTAQLDEELGGTPVQSR 2 
N-terminal E or Q 
 
AMAELAA 2 
Shortlisted for TMT-SRM 
 
DPDQTDGLGLSYLSSHIANVER 2 
   
TGAQELLR 2 
   
FVIEEVPGELMQEDLATDDVMLLDTWDQVFVWVGK 2 
   
VVQGK 2 
   
LFQVK 2 
   
QGFEPPSFVGWFLGWDDDYWSVDPLDR 2 
   
AQPVQVAEGSEPDGFWEALGGK 2 
   
QIWR 2 
   
IFVWK 2 
   
IEGSNK 2 
   
YIETDPANR 2 
   
QTQVSVLPEGGETPLFK 2 
   
EVQGFESATFLGYFK 2 
   
QGQIIYNWQGAQSTQDEVAASAILTAQLDEELGGTPVQSR 2 
   
TEALTSAK 2 
   
EDAANR 2 
   
NGNLQYDLHYWLGNECSQDESGAAAIFTVQLDDYLNGR 2 
   
ATEVPVSWESFNNGDCFILDLGNNIHQWCGSNSNR 2 
   
MDAHPPR 2 
   
EPGLQIWR 2 
   
EGGQTAPASTR 2 
   
ANSAGATR 2 
   
NGNLQYDLHYWLGNECSQDESGAAAIFTVQLDDYLNGR 2 
   
EGGQTAPASTR 2 
   
TPSAAYLWVGTGASEAEK 2 
   
VPFDAATLHTSTAMAAQHGMDDDGTGQK 2 
      * 4 
 



























DP (V) CE (V) CXP (V) 
Q3 (1) Q3 (2) Q3 (3) Q3 (1) Q3 (2) Q3 (3) Q3 (1) Q3 (2) Q3 (3) 
1 47.5 120 120 120 48.4 48.1 48.3 16.2 18.3 16.5 
2 64.5 120 120 120 52.8 48.4 42.7 15.6 18.8 25.9 
3 41.8 90 90 90 43.2 42.2 37.8 12.1 13.1 18.2 
4 37.5 90 90 90 52.8 45 44.2 19.9 20.4 22.2 
5 20 90 90 90 36.3 30.1 31.8 7.2 9.7 13.9 
6 36 100 100 100 44.8 41.9 41.5 11.3 13.5 14 
7 39 80 80 80 22 29.8 24.2 11 12.8 14.8 
8 46.5 100 100 100 47.9 46.9 45.7 13 15.1 21.7 
9 55 130 130 130 53.4 52.1 52.2 22.8 22.8 24.3 
10 23.2 80 80 80 37.8 30 23.9 6.8 6.9 9.7 
11 31.3 110 110 110 54.5 53.3 50 18.6 20.3 21.1 
12 34.2 80 80 80 28.2 25.6 26.6 7.8 8.4 11.2 
13 31.5 100 100 100 42.6 36.3 36.8 8.9 10.9 12.1 
14 33.5 100 100 100 44.9 45 44.2 17.9 18.7 19.5 
15 26 120 120 120 47.6 45.3 42.7 11.3 14.4 18.1 
16 72.7 80 80 80 33.3 31.9 30.1 13.5 17.5 21.6 
17 36 90 90 90 41.4 40 40 11.3 12.8 13.2 
18 39.3 130 130 130 55.1 55 54.4 22.9 21.9 21.5 
19 38.5 120 120 120 42.8 39.1 39 12.9 15 17.3 
20 19.8 90 90 90 41.2 39.9 37.1 12.5 13 13.9 
21 35.8 120 120 120 54.9 52 51 18.1 21 27.1 
22 41.9 120 120 120 46 42.8 42.1 14.7 17.3 18 
23 43.5 110 110 110 48.8 48.5 48.9 16.1 20.1 22.6 
24 34 100 100 100 40.7 38 39.2 10.3 12.3 13.4 
25 29.3 110 110 110 43.9 41.9 42 11.6 15 18.4 
26 71 140 140 140 59.9 59 58.1 18.8 20.2 24 
27 50.3 80 80 80 35.6 31 26.9 13.5 16 21.7 
28 44 140 140 140 59.8 57.1 50 21.9 21 22.4 
29 33.7 100 100 100 44.6 44.5 44 11.1 14.5 17.2 
30 33.1 110 110 110 41.5 38.8 37.9 12 12.4 16.9 
31 22.5 70 70 70 23.9 28.5 29.1 7.8 8.7 11.5 
32 75.5 100 100 100 41.8 37.1 37.3 11.3 14.6 14 
 
Appendix Table 3.10 Optimisation of the TMT-SRM method for the enhanced 
detection of each candidate AD peptide in plasma. For each transition of peptides 1 - 
32, the optimised DP, CE and CXP are given. Also displayed is the tR for SRM 






Appendix Figure 3.1 Stability of plasma peak areas during TMT-SRM reproducibility 
experiments. The mean heavy TMT (plasma) peak area for all transitions of all 
peptides is plotted over the course of four runs, i.e., a batch, within the TMT-SRM 
reproducibility experiments on the nano-LC platform. No increase in area was observed 









Appendix Figure 4.1 Overview of the TMT-SRM assay validation experiment. Ten 
disease and ten control samples were selected for each protein. Three digests were 
performed on each sample (technical digests) followed by three analytical 
measurements of each digest. Each protein had approximately three peptides for 
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Clusterin α-chain 1 13.42 189 34 33 29 NA 
Clusterin β-chain 5 5.34 155 24 21 19 NA 
Complement C3 8 12.85 192 32 30 30 NA 
 
9 14.55 188 36 36 36 NA 
CFH 12 11.16 127 19 16 17 NA 
 
13 10.57 170 27 26 24 NA 
A2M 14 10.38 178 30 30 30 31 
 
15 9.74 193 30 31 25 32 
FGG 19 11.54 174 27 28 28 NA 
 
20 6.31 177 26 25 26 NA 
SAP 22 11.90 193 30 30 30 31 
 
23 11.97 198 33 33 34 NA 
ApoE 24 9.63 190 26 25 26 NA 
 
25 10.64 190 30 32 27 26 
Gelsolin 29 10.53 188 25 28 27 33 
 
30 11.09 198 25 25 25 28 
 
31 8.51 122 16 19 19 NA 
 
Appendix Table 4.1 Determination of tR and TSQ Vantage instrument voltages for 
TMT-SRM method development. Mean tR values used to apply SRM scheduling and 
the optimal S-Lens for each peptide ion and CE for each transition of each target 
analyte are displayed. NA = not applicable. 
 
UNIANOV 
peak.area.ratio BY case digest analysis transition 
/RANDOM = digest analysis transition 
/METHOD = SSTYPE(3) 
/INTERCEPT = INCLUDE 
/EMMEANS = TABLES(OVERALL) 
/EMMEANS = TABLES(case) 
/EMMEANS = TABLES(digest) 
/EMMEANS = TABLES(analysis) 
/EMMEANS = TABLES(transition) 
/CRITERIA = ALPHA (0.05) 







 SEG1 SEG2 SEG3 SEG4 SEG5 SEG6 SEG7 
Time (min) 0.00-9.07 9.07-10.07 10.07-10.24 10.24-10.88 10.88-11.14 11.14-12.92 12.92-22.00 
Δ Time (min) 9.07 1.00 0.17 0.64 0.26 1.78 9.08 
Peptide ID 
5 25 25 14 29 30 8 
20 15 15 29 13 12 9 
31 14 14 13 24 19 1 
 29 29 24 30 22  
  13 30 12 23  
  24 12 19 8  
No. of 
Transitions 
18 24 36 36 36 36 18 
Cycle time 
(sec) 
0.36 0.48 0.72 0.72 0.72 0.72 0.36 
Appendix Table 4.2 SRM scheduling scheme for TMT-SRM analysis of candidate AD 
peptides on a TSQ Vantage. Peptides were separated into a segmented scheduling 
scheme to increase the number of data points for each transition. A minimal 1 min 
SRM scheduling window was applied to all transitions, with a maximal cycle time of 


































































Appendix Figure 4.3 TMT-SRM transitions affected by plasma background 
interference. The transitions which were detrimentally affected by plasma background 
and thus, removed from the analysis are indicated by an arrow. 
 
Peptide 1 Peptide 5 
Peptide 9 Peptide 12 






Protein Peptide 95% CI 80% CI 
Clusterin α-chain 1 23* 15 
Clusterin β-chain 5 19 12 
Complement C3 8 4 3 
 
9 5 4 
CFH 12 5 4 
 
13 4 3 
A2M 14 638 386 
 
15 17 11 
FGG 19 20 13 
 
20 198 120 
SAP 22 8 6 
 
23 7 5 
ApoE 24 35607 21507 
  25 16 10 
 
Appendix Table 5.1 A priori power analysis to determine minimum number of 
samples required for biomarker validation experiments. Based on the fold 
changes observed between AD and NDC samples in Section 4.2.1, low sample 
numbers were projected to have sufficient power in achieving equivalent fold 
changes for the majority of peptides.  




peak.area.ratio BY case transition 
/RANDOM = transition 
/METHOD = SSTYPE(3) 
/INTERCEPT = INCLUDE 
/EMMEANS = TABLES(OVERALL) 
/EMMEANS = TABLES(case) 
/EMMEANS = TABLES(transition) 
/CRITERIA = ALPHA (0.05) 
/DESIGN = case case(transition)  
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No. Description Diagnosis Gender ApoE Age Of Onset (yrs) Disease duration (yrs) MMSE V1 MMSE V2 MMSE V3 MMSE V4 MMSE V5 MMSE decline regression 
1 KPOADC004        RCD F 34 62 4.7 26 25 24 25 22 -3.20 
2 KPOADC002        SCD F 44 66 2.3 26 25 25 24 25 -1.20 
3 KPOCTL008        NDC F 34 NA NA 30 NA NA NA 30 0.00 
4 KPOADC005        RCD F 33 78 5.1 17 13 9 5 1 -16.00 
5 KPOADC006        SCD M 33 69 10.5 27 26 27 25 NA -2.00 
6 KPOCTL011        NDC F 33 NA NA 30 NA NA NA 30 0.00 
7 KPOADC008        RCD F 33 82 0.8 21 13 19 16 17 -2.00 
8 KPOADC007        SCD F 34 68 3.4 25 24 25 28 24 0.80 
9 KPOCTL023        NDC M 33 NA NA 30 NA NA NA 30 0.00 
10 KPOADC009        RCD F 44 71 5.0 15 10 9 6 5 -9.60 
11 KPOADC011        SCD M 34 79 2.2 24 27 26 27 NA 3.20 
12 LNDCTL004        NDC F 33 NA NA 30 NA NA NA 30 0.00 
13 KPOADC010        RCD M 33 80 7.8 25 24 22 14 6 -19.20 
14 KPOADC013        SCD M 44 71 2.3 28 25 30 28 26 -0.40 
15 LNDCTL005        NDC M 23 NA NA 30 NA NA NA 30 0.00 
16 KPOADC012        RCD F 34 62 4.6 25 20 21 20 19 -4.80 
17 KPOADC017        SCD F 33 75 2.5 26 22 23 24 25 0.00 
18 LNDCTL006        NDC F 34 NA NA 30 NA NA NA 30 0.00 
19 KPOADC034        RCD M 44 72 6.6 12 6 9 NA 6 -6.00 
20 KPOADC018        SCD F 34 68 4.4 24 24 22 25 22 -1.20 
21 LNDCTL043        NDC M 33 NA NA 30 NA NA NA 30 0.00 
22 LDZADC008        RCD F 33 55 3.6 22 19 16 13 10 -12.00 
23 KPOADC031        SCD M 33 81 1.7 26 26 29 28 25 0.00 
24 LNDCTL044        NDC F 33 NA NA 30 NA NA NA 30 0.00 
25 LNDADC006        RCD M 33 83 5.5 20 22 17 21 17 -2.80 
26 KPOADC039        SCD F 34 70 5.8 25 26 25 24 25 -0.80 
27 LNDCTL061        NDC F 34 NA NA 30 NA NA NA 30 0.00 
28 THSADC029        RCD F 33 80 2.2 23 19 18 21 NA -2.80 
29 LDZADC014        SCD F 34 70 1.1 27 NA 26 NA 27 0.00 
30 LNDCTL062        NDC F 33 NA NA 30 NA NA NA 30 0.00 
 
Appendix Table 5.2 Selection criteria for TMT-SRM biomarker validation. For each sample, the collection centre description, diagnosis, gender, 
APOE genotype, age and disease duration is indicated. Also displayed are the MMSE scores over five visits (V1 – V5) and a regression index 





No. Description Diagnosis Gender ApoE Age Of Onset (yrs) Disease duration (yrs) MMSE V1 MMSE V2 MMSE V3 MMSE V4 MMSE V5 MMSE decline regression 
31 LNDADC017        1 F 23 78 1.4 26 24 20 24 20 -4.80 
32 LNDADC020        1 M 34 78 0.5 26 26 27 26 27 0.80 
33 LNDCTL056        0 F 44 NA NA 27 NA NA NA 27 0.00 
34 LNDADC029        1 F 34 68 7.3 30 27 27 27 25 -4.00 
35 LNDADC030        1 F 33 77 2.4 30 30 30 29 28 -2.00 
36 LNDCTL070        0 F 34 NA NA 30 NA NA NA 30 0.00 
37 LNDADC031        1 F 44 75 4.8 22 21 21 23 17 -3.20 
38 PRGADC003        1 F 33 65 5.4 24 22 22 21 22 -2.00 
39 LNDCTL074        0 M 23 NA NA 30 NA NA NA 30 0.00 
40 PRGADC005        1 M 33 70 6.8 27 24 22 21 22 -5.20 
41 PRGADC017        1 F 33 79 0.2 21 20 17 19 21 -0.40 
42 PRGCTL011        0 F 33 NA NA 30 NA NA NA 30 0.00 
43 PRGADC025        1 F 33 75 1.9 24 16 20 19 19 -2.80 
44 PRGADC018        1 F 44 69 1.2 18 NA 16 19 16 -1.03 
45 PRGCTL032        0 M 33 NA NA 30 NA NA NA 30 0.00 
46 PRGADC026        1 F 34 68 9.0 16 16 15 16 11 -4.00 
47 PRGADC019        1 F 34 73 9.6 21 20 20 19 21 -0.40 
48 PRGCTL043        0 F 33 NA NA 30 NA NA NA 30 0.00 
49 PRGADC028        1 F 34 68 4.9 22 NA 22 23 17 -3.66 
50 PRGADC042        1 F 24 76 3.5 26 25 27 27 26 0.80 
51 PRGCTL048        0 F 33 NA NA 30 NA NA NA 30 0.00 
52 PRGADC031        1 F 34 72 -0.5 26 NA 27 24 22 -4.00 
53 PRGADC047        1 M 33 84 1.8 12 12 10 10 12 -0.80 
54 THSCTL016        0 M 23 78 0.2 30 NA NA NA 30 0.00 
55 PRGADC045        1 F 34 70 2.0 25 24 25 NA 19 -5.83 
56 PRGADC049        1 F 44 69 2.1 21 22 20 21 20 -1.20 
57 THSCTL019        0 F 34 NA NA 30 NA NA NA 30 0.00 
58 PRGADC046        1 F 33 75 7.3 17 16 NA 14 14 -3.20 
59 PRGADC053        1 F 33 80 -0.6 16 16 NA NA 15 -1.08 






No. Description Diagnosis Gender ApoE Age Of Onset (yrs) Disease duration (yrs) MMSE V1 MMSE V2 MMSE V3 MMSE V4 MMSE V5 MMSE decline regression 
61 THSADC002        1 F 44 66 2.4 12 12 7 NA 9 -3.66 
62 THSADC041        1 F 33 76 4.6 12 18 NA NA 10 -4.00 
63 KPOCTL009        0 F 23 NA NA 29 NA NA NA 29 0.00 
64 THSADC007        1 M 33 71 4.5 19 17 16 16 16 -2.80 
65 THSADC018        1 F 34 74 0.2 24 26 27 27 25 1.20 
66 TLSCTL720        0 F 34 NA NA 30 NA NA NA 30 0.00 
67 THSADC014        1 F 33 64 7.3 24 19 21 19 21 -2.40 
68 THSADC037        1 F 34 74 2.7 12 12 12 15 12 1.20 
69 LDZCTL002        0 F 33 NA NA 29 NA NA NA 29 0.00 
70 THSADC025        1 F 34 68 3.0 25 24 25 22 20 -4.80 
71 THSADC040        1 F 44 62 5.4 26 NA 26 26 26 0.00 
72 LDZCTL011        0 F 34 NA NA 29 NA NA NA 29 0.00 
73 THSADC034        1 F 33 69 6.8 22 17 12 7 2 -20.00 
74 THSADC049        1 M 33 68 3.6 25 23 22 NA 23 -1.71 
75 LNDCTL042        0 F 33 NA NA 29 NA NA NA 29 0.00 
76 THSADC042        1 M 34 76 4.6 12 8 7 NA 2 -10.00 
77 KPOADC035        1 F 44 66 1.9 21 26 28 29 20 0.40 
78 KPOCTL005        0 F 33 NA NA 29 NA NA NA 29 0.00 
79 THSADC043        1 F 33 67 5.2 17 NA NA 15 14 -2.92 
80 PRGADC004        1 F 34 67 5.8 22 28 24 17 21 -1.20 
81 THSCTL004        0 F 23 NA NA 29 NA NA NA 29 0.00 
82 THSADC046        1 F 34 71 2.6 17 8 10 10 3 -2.80 
83 TLSADC511        1 F 33 64 6.1 23 20 20 17 22 -2.00 
84 TLSCTL716        0 F 33 47 19.4 28 NA NA NA 30 2.00 
85 THSADC051        1 F 33 73 1.6 19 15 17 18 14 -0.40 
86 PRGADC009        1 F 34 73 7.4 18 20 16 14 17 -7.20 
87 PRGCTL022        0 F 33 NA NA 29 NA NA NA 30 1.00 
88 TLSADC505        1 F 34 60 1.9 19 13 15 11 11 -0.40 
89 THSADC035        1 F 33 68 2.4 17 15 11 14 15 -2.00 
90 PRGCTL053        0 F 33 NA NA 29 NA NA NA 30 1.00 
 
